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Endocrinology
THE SIGNIFICANCE OF THYROID-STIMULATING  
ANTIBODY (TSAb) IN THE MANAGEMENT 
AND PROGNOSTIC EVALUATION 
OF GRAVES DISEASE
A. L e ö v e y , К . K á l m á n , Gy . B a k ó , T. S z a b ó
F IR S T  D EPA R T M E N T OF M ED ICIN E, U N IV E R S IT Y  M ED ICAL SCHOOL, D E B R E C E N  
(R eceived: January 9, 1984)
S ix ty  six patients w ith Graves disease were followed up for the presence of 
TSAb at in tervals o f 4 to 12 weeks. Three d ifferent assays, the com petitive T SH  m em ­
brane-receptor assay (M RA), the cA M P-assay and the colloid droplet assay (CD) were 
used in parallel for dem onstration o f the antibod y.
In 17 o f the patients TSAb was dem onstrable also during rem issions. 11 of these  
patients relapsed w ithin  a year. T S A b -p ositiv ity  decline 1 to 4 m onths after 131I treat­
m ent. In case o f persisting TSAb p o s itiv ity  m I therapy or surgery should  be given  
preference to thyrostatic  m edication.
In gravidae followed up for T SA b, p o s itiv ity  not only persisted throughout 
pregnancy but even increased during th e  la st trim ester. After delivery all patients 
relapsed. One of the gravidae died of pregnancy toxicosis, the infant o f another woman 
was thyrotoxic  a t birth.
In pregnant wom en who have G raves d isease and are positive for T SA b, thyro­
static  or surgical treatm ent is recom m ended after the 2nd trimester ev en  in  cases o f  
minor severity.
Keywords: thyroid stim ulating an tib od y , Graves disease
Introduction
R ecent research has not on ly  given  closer insight into the role o f  thyroid  
stim ulating antibodies in the pathogenesis o f  diffuse thyrotoxic goitre, hut 
has been furnishing increasing evidence o f  their  predictive value as concerns 
the duration o f rem issions [3, 4, 6, 9, 13, 21, 22, 26, 29, 30, 32]. I t  has been 
found, indeed, th a t long-term  rem issions are unlikely to take place unless the  
TSAb dem onstrated earlier has disappeared from  the blood, otherw ise a relapse 
w ith in  a short tim e is to be expected. In  other words, TSAb p o sitiv ity  in  rem is­
sions indicates th a t, in spite of the clin ica lly  euthyroid state, the im m unological 
activ ity  o f the disease still persists.
The T SA b-assay m ay thus be regarded as an indicator of th e  duration o f  
therapy, as well as o f the therapeutic lines to  be followed in a g iven  case
[1 1 ,3 1 ] .
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R ecen t investigations relating to  the h istocom patib ility  genes h ave pro­
v ided  som e remarkable predictive clues to  the responsiveness o f the process 
and to  th e  duration of rem ission. McGregor et al. [19] studied the T S-im m uno- 
globulin  levels in association w ith  typ ing for h istocom patib ility  genes, after 
the determ ination  of th yrostatic  treatm ent. The results were found pred ictive  
w ith  a 95%  accuracy of the further course o f  th e  disease. More than  90%  of 
the D R g-positive patients w ho had been treated  w ith  carbimazole for six  
m on th s, relapsed w ithin  12 m onths, whereas in  case o f D R 3-n egativ ity  on ly  
55%  relap sed  i f  at the tim e o f drug w ithdraw al T SA b was dem onstrable. On 
the grounds o f  these findings, th e  authors regard H L A -D R 3-positiv ity  as in d i­
cative  o f  destructive therapy (131I) or thyroid surgery. A connection betw een  
suppressor T-cell activ ity  and p o sitiv ity  for H L A -R 8 antigen was found b y  th e  
present authors [1].
F u rth er inform ation on th e  relationships in  question was sought b y  a 
fo llow -up o f 66 patients w ith  Graves disease for th e  presence of TSA b, in  th e  
active as w ell as in the in active phase. The in terva ls between the assays were 
betw een  4 and 12 weeks.
M aterial and m ethods
52 fem ales and 14 m ales, aged 18 -6 4  years, were studied . Diagnosis was based on the  
C rooks-test expressing num erically th e  global clinical situ a tio n  and on the following laboratory  
param eters: T 3U , T 4, F T 4I, 13l I-retention  curve, T R H -T SH  stim ulation test, and T 3-suppres- 
sion te st .
F or th e  dem onstration of TSA b three m ethods were em ployed (Table I):
1. T he com petitive T SH  m em brane-receptor assay (M RA)
2. M easurem ent o f the cA M P-content in  hum an th yro id  slices (cAMP assay)
3. S tu d y  of the in ten sity  o f colloid droplet (CD) form ation  in  surviving hum an thyroid  
slices (C D -assay).
S ince Graves disease in  pregnancy involves d ifficu lt problem s [10, 16] including the  
role and clin ical im plications o f im m une factors which h ave y e t to be clarified, 4 gravidae  
were also inclu ded  in  the stu dy  and follow ed up from the f ir s t  m onth of pregnancy through out 
ts entire duration , beyond delivery and post-partum -period, for a total o f 12 m onths.
Table I
Demonstration o f human T S A b
a )  Com petitive TSH  membrane-receptor assay (M RA) according to the “radioligand” 
m ethod o f  Sm ith  and Hall [28]
b)  M easurem ent of cAMP concentrations of hum an thyroid slices, according to  O naya  
et al. [24] and McKenzie and Zakarija [20], w ith m odifications (Bordán et al. [5]).
c) Colloid droplet (CD) form ation, i.e. colloid p inocytosis of acinar cells o f surviving  
hum an thyroid  slices, examined by the m ethod of Onaya and Solom on [23] and Onaya e t  al. [24] 
m odified b y  L eövey et al. [14].
Results
F rom  am ong the 66 patien ts 47 were assayed  for TSAb on two occasions, 
16 p a tien ts  on three different occasions, three p a tien ts on 4, 6 and 7 occasions, 
resp ective ly  (Table II).
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It was rem arkable to find th a t in  17 o f the 66 cases T SA b -p ositiv ity  
persisted also during remissions o f  th e  disease. The results o f all three assays 
rem ained positive in  6, o f two assays in  7, o f  one in 4 cases. T he results have 
been analysed according to Table I I I .
U ntil com pletion  of the present report 11, that is 64%  o f  th e  patients 
relapsed w ithin a year. The average duration  o f remission had b een  6 m onths 
in these cases. I f  thyrostatic or radioiod ine treatm ent resulted in  rem issions 
o f a year or m ore, th e  TSAb-assays becam e negative w ithin 3 to  4 m onths 
(range 1-11 m onths).
N ineteen o f th e  66 patients w ere subjected  to radioiodine th erap y  with  
doses o f 5 to 8 mCi (185 to 296 M Bq), th is  allowed to follow up th e  response of 
TSAb in tim e w ith in  a period o f 1 -1 0  m onths. The different T SA b-assays
Table II
Global results o f  T S A b-assay  in 66 cases
N um ber 
o f cases
P ositive Negative
Number _____________________  ________________
of assays
percent percent
47 2 41 87.2 6
16 3 16 100 —
1 4 1 —
1 6 1 —
1 7 1 —
Table III
Persisting T SA b-positivity during rem ission o f Graves disease 
(Follow-up o f 66 patients)
Assays
N um ber 
of cases D uration m on ths
66 patien ts  
percent
MRA +  cAMP 4-  CD 6 2-10-8-6-10-5
MRA +  cAMP 3 6-7-5
MRA +  CD i 3
cAMP +  CD 3 10-3-17
MRA 2 2-1
cAMP 1 3
CD 1 6
Total 17 25.8
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show ed a decrease in 24 in stan ces, according to  th e  following distribution: 
M RA =  9 , CD =  8, cAM P =  7 (Table IV). N o d istin ct changes in the in itia l 
va lu es w ere found in  8 cases. (M R A  =  6, cAMP == 1, CD =  1) while an increase  
was n o te d  in  10 cases (cAM P =  5, MRA =  4, CD =  1).
Table IV
F ollow -up after 1311-therapy
A ssay
Decrease Increase No change
Values Tim e Values T im e Values Time
2 1 - 7 7 1 m onth 3 7 - 2 3 1 m onth 0 - 4 1 m onth
6 5 - 9 1 10 m onths 9 0 - 4 9 7 m onths 5 4 - 5 0 6 weeks
1 3 - 3 0 1 m onth 5 1 - 1 1 3 m onths 1 0 6 -8 3 3 m onths
1 8 - 6 8 6 m onths 5 7 - 2 2 1 m onth 1 7 1 -1 1 2 6 weeks
M RA 1 6 - 8 5 6 m onths 6 1 - 6 2 7 m onths
6 3 - 8 7 3 m onths 1 6 - 1 5 1 m onth
1 4 - 2 4 4 m onths
1 4 - 3 3 8 m onths
6 3 - 8 5 4 m onths
2 2 8 -1 0 0 6 weeks 1 5 0 -3 9 0 1 m onth 4 6 3 -4 5 0 1 m onth
9 0 0 -5 0 0 1 m onth 1 2 5 -2 5 7 6 m onths
2 2 1 -1 8 5 10 m onths 4 5 5 -7 0 0 3 m onths
cAM P 1 3 9 9 -3 1 1 7 m onths 2 0 0 -2 8 5 1 m onth
2 4 5 -1 4 0 6 weeks 2 0 0 -3 1 9 6 m onths
3 7 0 -3 1 0 7 m onths
2 9 0 -2 0 0 1 m onth
2 8 3 -1 2 8 1 m onth 128—311 1 m onth 100 — 124 6 weeks
1 8 2 -1 5 0 1 m onth
3 8 0 -3 1 0 1 m onth
CD 6 7 6 -4 7 6 10 m onths
5 9 5 -3 8 5 7 m onths
3 9 4 -1 2 8 1 m onth
3 1 1 -1 6 2 1 m onth
4 2 2 -2 5 4 m onths
n =  19
Discussion
On th e  grounds o f  th e  present find ings, T SA b-positiv ity  and clin ical 
a c t iv ity  persisting for 6 m onths or more under th yrosta tic  treatm ent is fe lt  
to  be in d icative of therapeutical destruction (131I) or surgical rem oval o f  th e  
th y ro id . In  our experience neither the type o f  assay  which has given the p o si­
t iv e  resu lt, nor the grade o f  p o sitiv ity  is o f any decisive  therapeutic im portance. 
I t  is , on th e  other hand, desirable to  follow up th e  cilinical course by parallel
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TSAb-assays o f different typ es, so as to  avoid  false-negative results and to  
increase diagnostic accuracy. In fact, n ega tiv ity  o f a single assay is in our 
view  by no means exclusive o f the p ositiv ity  o f  either o f the other tw o assays 
or o f both.
Global assessm ent o f  the constellation and prediction of the course in a 
given case would require the additional evidence o f histogenetic studies. To 
form a view  on th is question  we have, how ever, to  w ait until further evidence  
furnished by large-scale studies is forthcom ing.
Our observations w ith  131I-therapy are at variance w ith earlier results of 
Pinchera et al. [25] and w ith more recent reports o f Mukhtar et al. [21], McGre­
gor et al. [17], Fenzi et al. [8], Teng et al. [31] and Bech [3], according to  
whom  LATS, MRA and adenocyclase-cAM P increase after 131I-therapy. The 
general observation o f  these authors has been th a t the values rise in the course 
of the first 1 to 7 m onths, but gradually decline thereafter until the result had 
becom e negative, w hich is attained in the m ajority o f cases in 9 to 12 m onths 
after treatm ent. It is alleged as the main cause o f these findings that radioiodine 
causes gross dam age to  the epithelial cells o f the thyroid, thus giving rise to a 
release o f antigens w hich act at first as stim ulators o f the im m une system , 
including the form ation o f thyroid-stim ulating antibodies. It is further as­
sum ed by McGregor et al. [18] that the radioresistant helper T -lym phocytes are 
capable o f stim ulating the “ non-irradiated im m une cells” , endowing them  with  
the ab ility  of repopulation and autoantibody form ation. It seems obvious that 
during the first 3 or 4 m onths following upon 13lI-treatm ent when destruction  
of the thyroid parenchym a has run its course, the blood stream m ay be in vad ­
ed by antigen-com ponents, under the effect o f  w hich certain afferent and/or 
efferent subunits o f the im m une system  are activated  or hyperactivated . 
These considerations prom pted us to form separate groups from those 13 
patients who had been checked for TSAb during the first 1 to 4 m onths after 
treatm ent. The results are presented in Fig. 1. A decline o f the M RA-, cAM P  
and CD-values was found in 14 instances, an increase or no change in 7 instanc­
es each. Since, as it can be seen, we have found a decrease in the m ajority o f  
the cases, we fail to  confirm  the findings referred to above. It  might be assum ed  
for the interpretation o f these results th a t, in consequence of the destructive  
process involving the thyroid  parenchym a, certain antigen com ponents finding  
access in larger am ounts into the circulation m ay have bound and neutralized  
the thyroid-stim ulating im m unoglobulins in the form o f im m une com plexes [3].
In the 4 gravidae under study th yrotoxicosis was o f minor or m oderate 
severity  throughout the entire pregnancy, therefore, thyrostatic treatm ent 
involving certain hazards to  the fetus was dispensed w ith. D elivery w as, how ­
ever, invariably follow ed by a deterioration o f th yrotoxicosis requiring thyro­
static therapy in all o f the cases. All gravidae had beenT SA b-positive through­
out the entire pregnancy, and it is a point o f  interest that the T SA b-values
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Follow-up after 131l-treatment
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h ad  increased  during the la st trim ester. From  a single exception  apart, the 
o th er  laboratory values were in  conform ity w ith  these findings (Table У).
In  Cases 1 and 3, d elivery  was sm ooth, both  wom en gave birth to  full- 
term , h ea lth y  infants. On account o f  the clinical severity, m ethim azole treat­
m en t h ad  to  be started im m ed iate ly  after delivery in the first case, and three 
m o n th s later in  the other.
T h e infant of patient J . L . was thyrotoxic  at birth, w ith  a pulse rate of 
1 8 0 /m in , a T3U of 1.47 and T 4 283 o f nm ol/1. Tachycardia im proved on beta- 
b lockers and the clinical signs o f  th yrotoxicosis ceased spontaneously b y  the 
end o f  2 m onths. P lacental transm ission  o f  m aternal TSAb has been made 
resp on sib le  for the sym ptom s [7]. Congenital Graves disease m ay, how ever, 
p ersist for m onths or even years [12], in  w hich case not on ly  passive transm is­
sion  b u t involvem ent o f  im m unogenetic factors has also to  be considered.
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P atient A. I ., when 7 m onths pregnant, developed pregnancy to x ico s is  o f  extrem e 
severity  w ith nephropathy and excessive  hypertension. Premature delivery  o f  th e  fetus which 
had died in utero failed to produce a n y  relief. O wing to renal failure she w as m aintained on 
haem odialysis for tw o  m onths. D evelop m en t o f  the full-blown pregnancy to x ico sis  w ent hand 
in  hand w ith deterioration of the hyperthyroid  condition, parallel w ith an increase in  the TSAb 
value. She was started  on carbim azole, b u t died o f pulmonary em bolism  2 m onths after 
delivery.
Table V
Follow-up o f  pregn an ts w ith Graves' disease
M onth
N otes
* 3 6 9 12
1. P. z . F T 41 293 256 222 330 129 Full-term , h ea lth y  child
aged 23 MRA
Th.
31.5
0
42.6
0
54.3
0
39.5
Met. Met.
2. J. L. f t 4i 244 212 244 416 318 Full-term child , born with
aged 27 MRA 35.5 47.4 30 33.5 21.8 thyrotoxicosis. F T 4I =  416.
Th. 0 0 0 0 Met. 2 m onths la te r  euthyroid
3. K. L. F T 4I 311 189 280 197 343 Earlier ш 1, Carbimazol treat-
aged 32 MRA 57 31.6 48.6 26.5 71.4 ment. F ull-term , healthy
Th. 0 0 0 0 Met. child
4. A. I. FT4I 422 468 384 104 In the 7th m onth  pregnancy
aged 34 MRA
Th.
57.5
0
43.7
0
66.4
0
29
Met.
toxicosis. Prem ature delivery 
of dead fetus. Renal failure, 
haem odialysis, fatal pulmon­
ary em bolism . Previously on 
carbimazol
Met. =  m ethim azole
The present observations su ggest th a t T SA b-positivity in  th e  course of 
pregnancy indicates th at, unless adequate treatm ent is g iven , p o s it iv ity  will 
persist throughout th e  entire gesta tion  and increase during th e  la st trim ester, 
w hich heralds a relapse after delivery . For th is reason, T S A b -p ositiv ity  during 
pregnancy, even in hyperthyroidism  o f  m inor severity, calls for thyrostatic  
therapy or surgery in the second trim ester.
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CONCENTRATIONS OF ANDROGENS AND 
C19-STEROID SULPHATES IN ABDOMINAL SKIN  
OF HEALTHY WOMEN AND MEN
I. T ó t h , I. F a r e d i n
E N D O C R IN E U N IT , F IR ST  D EPA R T M E N T OF M E D IC IN E , U N IV E R S IT Y  M EDICAL SCHOOL,
SZEG ED , H UN G ARY
(R eceived: October 24, 1983)
Protein-binding assay and radioim m unoassay were used to determ ine th e  con­
centrations o f free androgens and C19-steroid su lphates in  suprapubic abdom inal skin  
slices obtained  from  healthy wom en and m en during appendectom y. It was found that 
the abdom inal skin of the wom en contained D H A  in  the highest concentration, follow ed  
in decreasing order by And., zf-d ione, Zl5-diol, T est, and DH T. The sequence w as the  
same for the m en, except that l'1-fi iont' preceded A nd. There was no significant difference  
in the concentrations of free androgens in abdom inal skin o f wom en and men; on ly  the  
concentration o f  zf-d ione was som ew hat higher in  the skin obtained from  m ales 
(P  <  0.05).
Of the Clg-steroid sulphates, And.-S was found in the highest concentration  in  
abdom inal skin o f fem ales, follow ed in decreasing order by D H A -S, zl5-diol-S and T est.-S . 
The corresponding decreasing sequence for the m en was D H A -S, And.-S, zls-diol-S and 
Test.-S . The concentration of D H A -S was sign ifican tly  higher (P  <  0.001) in m en than  
in wom en; in  the case o f zP-diol-S, only a slight degree o f significance could be observed  
(P  <  0.05).
Keywords: androgens and C19-steroid su lphates, hum an skin tissues
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Introduction
It is know n from  previous investigations th a t numerous free androgen  
steroids and C19-steroid sulphates can be detected  in  the lipid film  layer cover­
ing the hum an axillary and pubic hair [8, 9, 10]. I t  is also known th a t the  
accessory glands o f  the hum an skin, the apocrine sw eat glands, excrete a con ­
siderable qu an tity  o f  w ater-soluble steroids onto  th e  surface o f the skin [9, 12]. 
An intensive androgen m etabolism  occurs in th e  skin [4, 5, 6], and androgen  
receptors have been dem onstrated in  the sebaceous glands and in the skin  
[1, 11, 14, 15] and, accordingly, the hum an skin  is now adays regarded as a 
typical androgen target organ.
Send offprint requests to Dr. I. T óth, Dr. I. Faredin Endocrine U nit, First D epartm ent 
o f Medicine, U n iversity  Medical School, H -6701 Szeged, K orányi rkp. 8 . H ungary
Abbreviations : (zP-dione) =  4-androstene-3,17-dione; Androsterone (And) =  3a-hy- 
droxy-5a-androstan-17-one; Androstenediol (zP-diol) =  5-andres tene-3/i, 17/i-diol; D éhyd ro­
épiandrostérone (D H A ) =  3/3-hydroxy-5-androsten-17-one; D ihydrotestosterone (D H T ) =  
=  17jS-hydroxy-5a-androstan-3-one; T estosterone (T est) =  17/S-hydroxy-4-androsten-3-one; 
Déhydroépiandrostérone sulphate (D H A -S) =  3/S-sulphooxy-5-androsten-17-one; A ndrostene­
diol sulphate (zP-diol-S) =  5-androstene-3j8,17/S-diol-3-sulphate; Androsterone su lphate  
(And-S) =  3a-sulphooxy-5-a-androstan-17-one; Testosterone sulphate (Test-S) =  17/3-sulpho- 
oxy-4-androsten-3-one
Acta Mcdica Hungarica 42, 1985 
Akadémiai Kiadó, Budapest
14 TÓTH, I. and FAREDIN, I.
T h e suprapubic area is th e  one m ost exposed from the aspect o f  h irsu t­
ism . I t  appeared interesting to  exam ine how th e  concentrations o f free andro­
gens and  th e ir  sulphate esters vary  in th e  suprapubic abdom inal skin o f  hea lth y  
w om en and m en. We first elaborated a procedure for the sim ultaneous deter­
m in ation  o f  free androgens and their su lphate esters in abdom inal skin, and 
w ith  th is  procedure we studied  the concentrations o f the said steroids in 
ab dom inal skin excised from h ea lth y  w om en and men undergoing appendec­
to m y  under general anaesthesia. I t  was also studied  whether a sex  difference 
could  b e detected  in the androgen levels. An account o f these in vestigation s  
is p resen ted  here.
M aterials and m ethods
1. A queous solutions were prepared w ith  glass distilled water
2. T hin -layer chrom atography. The purity o f the authentic radioactive and “ cold” 
stero id s w a s checked, and the steroids extracted  from  skin were isolated on 5 X 28 cm  thin- 
layer p la te s  prepared w ith A120 3-G (E . Merck, T ype 60/E ) and silica gel G (E . M erck, nach  
S tah l) adsorbents. The following system s were used.
A lu m in a  plates.
TLC-“ G” : n-hexane — ethyl acetate — absolute ethanol — glacial acetic acid (120 : 130 : 1 : 2, 
v /v /v /v ) .
TLC-“ C2” : benzene — absolute ethanol (97 : 3, v /v ).
S ilica  gel G plates:
T C L -“ 3” : Chloroform-methanol (97 : 3, v /v ).
T L C -“ I ” : absolute ethanol-ethyl acetate-concentrated  A 11 ,0  U (50 : 50 : 10, v /v /v ) .
3. T he radioactive steroids used in  the stu dy  were as follows: [7-3H (N )] déhydroépi­
androstérone (spec. act. =  24 Ci/m m ol), [1/3, 2/S-3H ]testosterone (spec. act. =  44.6 Ci/mmol), 
[ la ,  2a (n )-3H ] dihydrotestosterone (spec. act. =  60 Ci/mmol) and [ l ,2 -3H (n)]4-androstene- 
-3 ,17 -d ion e . (spec. act. =  46 Ci/m m ol) were products o f  the Radio Chemical Centre (Am erham ), 
w h ile  [7-3H (N)]5-androstene-3/3, 17/S-diol (spec. act. =  20 Ci/mmol), [1,2-*H(N)J androsterone 
(sp ec . ac t. =  40 Ci/mmol) and the am m onium  salt o f [7-3H (N )]-dehydroepiandrosterone sul­
p h ate  (sp ec . act. =  24 Ci/mmol) w ere obtained from  N ew  England Nuclear (B oston ). Before 
use, th e  free steroids were purified  on a 4 g A120 3 colum n (E . Merck, B roockm ann III/IV  
a c t iv ity  [9] and their purity was th en  checked on A120 3-G thin-layer in  TLC-“ G” [9].
4. W e prepared [7-3H (N)]5-androstene-3/3, 17/S-diol-3-sulphate (spec. act. =  24 Ci/mmol) 
from  [7 -3H (N )D H A -S  by reduction w ith  N a B H 4. Before use, the tritiated  D H A -S  and the  
/15-d io l-3 -S  were purified on a 1.5 g florisil colum n (60/100 mesh, Floridin Co., Tallahassee, 
U S A ), and their purity were checked on silica gel th in-layer in  TLC-“ I”  [9].
5. T he non radioactive au th en tic  steroids were bought from Ikapharm  (R am at-G an, 
Israel). B efore use, they were purified  on a 4 g A120 3 colum n, and their purity w as checked on a 
th in -la y er  [9].
6 . Subjects and skin sam ples
T he abdom inal skin sam ples were obtained from  healthy wom en and m en in  the course 
o f a p p en d ectom y under general anaesthesia . These individuals did not suffer from  an y  endo­
crine or other disease. The abdom inal sk in sam ples were cleaned from  antiseptic  and from  
accessory  fa t tissues, and were processed w ithin 30 m inutes following surgery. The abdom inal 
sk in  sa m p le s  used contained both  derm is and epiderm is.
7. D eterm ination of concentrations o f free androgens and C19-steroid su lphates in ab­
dom ina l sk in  tissue. The concentrations o f free androgens (D H A , And., zl4-dione, zl5-dioI, Test, 
and D H T ) and the m ost im portant C19-steroid su lphates (And.-S, D H A -S, /T-dioI-3-S and 
T est.-S ) were determ ined sim ultaneously in  0.5—1.0 g quantities o f abdom inal skin.
0 .5—1.0 g o f the cleaned w hole sk in tissue w as cut into 15—20 fi slices in  a cryostat at 
— 20 °C and the slices were left to  stand for 24 hours in  10 m l 2 N N H 4OH at room  tem perature. 
D u rin g  th is  period the m ixture w as shaken in tensive ly . Subsequently it  was centrifuged for 
10 m in u tes a t 5000 r.p.m . in a cooled  centrifuge, and the supernatant (10 m l) w as transferred  
to  a ground-glass stoppered tube (F ig. 1).
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Fig. 1
A further 5 ml 2 N N H 4OH was added to the skin tissue residue, which was then tri­
turated strongly w ith  a glass rod. Centrifugation fo llow ed, and the supernatant (5 m l) was 
com bined w ith  the previous one (total 15 ml).
The skin tissue residue was next triturated w ith  4 X 5 ml m ethanol, and after centrifuga­
tion the m ethanol extracts were com bined (20 m l) and then evaporated to dryness in  vacuum  
at 30 °C.
Tritium -labelled variants o f the steroids to be measured (with known radioactiv ities: 
100,000-150,000 dpm ) were then added to the dry residue, followed by 15 ml 2 N N I1 ,0 H .
The com bined extract was half-saturated by the addition of 6 g crystalline (N H 4)2SO ,, 
and the m ixture was shaken with 4 x 1 5  ml ethyl acetate . After centrifugation, the com bined  
ethyl acetate extract (60 ml) was evaporated to dryness in vacuum  at 30 °C. W ater traces 
were rem oved by evaporation in vacuum  after the addition  of ethanol and benzene.
Separation o f  free and sulphate ester steroids
The crude extract was dissolved in 1 ml m ethanol, and the fractions of free steroids and 
sulphate esters were separated by chrom atography on a 1.5 g florisil colum n suspended in 
24 ml absolute benzene [16].
Isolation and determination o f  free  androgens
The fraction of free androgens was chrom atographed on a 4 g A120 3 colum n and separ­
ated into fractions I, II, III and IV.
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F raction  II contained th e  /I’-dionc, DH A and D H T ; fraction III, the And. and T est.;  
and fra ctio n  IV contained the /l5-diol.
F raction  II and the com bined fractions III and IV w ere chrom atographed in the TLC- 
“ G”  sy s tem , and the steroids w ith  different polarities were separated (Figs 2 and 3).
T he 17-ketosteroids (z f-d io n e  and And.) dissolved o u t o f the layer were purified  as 
T est, in  th e  TLC-“ G” system  after N a B H 4 reduction, as w as the 5a-androstane-3/?, 17/?-diol 
in  th e  T L C -“ C2” system .
A fter  being dissolved o u t o f  th e  layer, DH T and T est. (F igs 2 and 3) were further puri­
fied  on  a new  thin-layer in  th e  T L C -“ 3” system .
T h e  adsorbent containing th e  steroids was scraped o u t o f the thin-layer and collected  
in  sm a ll tu b es , and the m ixture w ith  the adsorbent was th en  transferred w ith 2 X 2 m l absolute  
b en zen e on to  a 1 g florisil colum n suspended in benzene (7.5 cm  high). The colum n was w ashed  
f ir s t  w ith  10 m l absolute benzene, and  then with 20 m l 0.5%  m ethanolic benzene. The steroids  
w ere e lu ted  from  the colum n w ith  10 m l 10% m ethanolic benzene. The eluate (10 m l) w as e v ­
a p orated  to  dryness in vacuum  a t a tem perature not higher than  30 °C. The dry residue was 
d isso lv ed  in  5 ml m ethanol, and radioactiv ity  o f  the steroid  was determined in  2 x 0 .1  m l 
a liq u o ts , so th a t a correction could  be made for the loss arising during the purification pro­
cedure.
T he individual steroids were determ ined in  aliquots o f  the remaining 4.8 ml m ethanolic  
so lu tio n . D H A  was determ ined b y  radioim m unoassay [13, 18], and the other steroids (z15-diol, 
T est., D T H  and 5a-ane-diol) b y  protein-binding assay [17]. The final result, corrected for the  
add ed  rad ioactiv ity , was g iven  in  u n its o f ng/g or nm ol/kg, referred to wet skin tissue w eight.
Isolation an d  determination o f  C ^-steroid  sulphates
T he sulphate ester fraction  w as evaporated to  dryness and then solvolysed w ith  30 ml 
1%  perchloric acid in ether at 37 °C for 16-20 hours. The solution was extracted w ith  5 ml 
5 N  N a O H , and finally w ith  2 x 5  m l distilled water. T he ether solution was evaporated to 
d ry n ess , and tritium -labelled varian ts of And. and T est, o f  known radioactivity (1 0 0 ,0 0 0 -  
150 ,000  dpm ) were added. The tr itia ted  DH A-S and zl5-diol-S were added to the extract during 
ex tra c tio n . The extract o f the so lvo lysed  steroids was chrom atographed on a 4 g A120 3 colum n, 
and th e y  were determined as free androgens as described above.
T he quantities of free androgens measured (D H A , Zl5-diol, And. and T est.) were con­
v erted  to  steroid sulphate esters, and the final result was given  in  units o f ng/g or nm ol/kg, 
referred to  w et skin tissue w eight.
R esu lts are expressed as m ean A  S.E.M.
Results
O f the free androgens in  the abdom inal sk in  o f  healthy males and fem ales 
(T able I), DH A  occurred in the greatest am ount (165 dr "78, and 80 dr 28 
n m o l/k g , respectively). W hereas And. was present in alm ost the sam e concen­
tr a tio n  in  the abdom inal sk in  o f males and fem ales (48 dr 25, and 55 dr 19 
nm ol/kg/respectively) th e  concentration o f zH-dione was significantly higher in  
m ales (101 dr 36 nm ol/kg) th an  in females (36 dr 8 nm ol/kg). Zl5-diol, T est and 
D H T  w ere found in decreasing am ounts in  th e  abdom inal skin, but all three  
androgen-active steroids w ere more abundant in  m ales than in fem ales.
O f the C]9-steroid su lphates (Table II), A nd.-S (132 dr 29 nm ol/kg) was 
p resen t in  the highest concentration  in the abdom inal skin of fem ales, whereas 
D H A -S  had the highest concentration (2162 +  406 nm ol/kg) in th at o f  m ales. 
A 5-d io l-S  and Test-S w ere found in lower concentrations in both m ales and 
fem a les , but here too there w as a difference betw een  the sexes: the concentra­
tio n  o f  D H A -S and d 5-diol-S  were sign ificantly  higher in  the males th an  in  the 
fem ales.
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D iscussion
The values o f the individual androgenic steroids determ ined in hum an  
abdom inal skin represent the androgen concentration  in the whole abdom inal 
skin; th is is due to  a com bination of the androgens reaching the skin v ia  the  
blood stream  and those formed in the skin . In  the results no d istinction  was 
m ade betw een androgens in the cytoso l, th ose  in the cell nucleus, and those 
hound to  receptors. The individual androgen concentrations in the w hole abdom ­
inal skin m ay be influenced by the quantities found in the various appendages 
of the skin: the hair follicles, the apocrine sw eat glands and the sebaceous 
glands.
Few  data are available in the literature concerning the steroid content 
of skin [7]. D eslypere et al. [2, 3] determ ined the concentrations o f  three andro­
genic steroids (T est., D H T  and 5a-A-3a, 17/3-diol) in the skin of m ales. E valua­
tion  o f  their results was hampered by th e  circum stance that th ey  obtained the 
skin sam ples from corpses, and the m etabolism  occurring before exam ination  
in the sam ples m ay have caused considerable changes in the ratios o f  individual 
steroids. In  sp ite o f th is, they dem onstrated th a t the androgen concentration  
was highest in scrotal skin, lower in pubic skin, and even lower in th e  skin 
excised  from the th igh . This means th a t th e  steroids can be com pared only  
in skin excised from a given area of the b od y . In  all cases, we carried out steroid  
analysis in skin from  the abdomen, and th u s the observed steroid concentra­
tions reflect the in v ivo  hormonal state  o f  abdom inal skin.
I f  the steroid concentration m easured in abdominal skin are com pared  
w ith  those o f peripheral blood, for each o f  the free steroids a su b stantia lly
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Table I
Concentration o f androgenic steroids in abdominal skin o f normal women and men (ng/g and nmol/kg)
Steroids
determined Concentrations No of cases
N orm al women 
Limits
(28 — 46 yr) 
Mean +  S.E.M. No of cases
Norm al men 
Limits
(2 8 -4 7  yr) 
Mean ±  S.E.M. P
DH A nmol/kg
n g /g
7 2 1 .5 -4 0 6 .0
6 .2 -1 1 7 .0
80.3 ±  28.15 
23.1 ±  8.11
5 4 3 .0 -4 6 5 .0
1 2 .4 -1 3 4 .0
165.2 ±  77.66 
47.6 ±  22.40
N. S.
And nmol/kg
“ g/g
6 5 . 5 -  111.1
1 . 6 -  32.3
54.7 ±  19.36 
15.9 ±  5.63
5 0 .5 -9 7 .0
0 .1 6 -2 8 .3
48.1 ±  24.95 
14.0 ±  7.28
N. S.
zl4-dione nmol/kg
ng/g
8 1 2 .9 -7 4 .3
3 .7 -2 1 .3
35.7 ±  8.07 
10.24 ±  2.31
5 3 7 .0 -2 3 7 .0
10.6 - 68.0
101.2 ±  35.55 
29.1 ±  10.19
P <  0.05 S.
Zp-diol nmol/kg
ng/g
6 6 .5 -9 2 .2
1 .9 -2 6 .8
29.80 ±  13.66 
8.70 ±  3.97
5 8 .0 -5 5 .0
2 .2 -1 6 .1
34.6 ±  7.54 
10.1 ±  2.23
N. S.
Test nmol/kg
ng/g
7 1 .7 -4 3 .7
0 .7 -1 2 .6
16.50 ±  6.06 
4.80 ±  1.73
5 1 7 .0 -6 5 .0
4 .8 -1 8 .6
34.8 ±  9.17 
9.9 ± 2 .6 3
N. S.
5a-DHT nmol/kg
ng/g
7 0 - 2 8 .5
0 - 8 .3
8.5 ±  4.03
2.5 ±  1-17
5 0 - 4 8 .0
0 - 1 4 .0
20.6 ±  9.28 
6.0 ±  2.69
N. S.
N. S. =  not significant 
S =  significant
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Table II
Concentration o f Cl9~steroid sulphates in abdominal skin o f  normal women and men (ng/g and nmol/kg)
Steroide
determined Concentrations No o f cases
N ormal women 
Limits
(28 — 46 yr) 
Mean ±  S.E.M. No of cases
Normal men 
Limits
(2 8 -4 7  yr) 
Mean +  S.E.M. P
DHA-S nmol/kg 6 7 .0 -1 8 6 .4 81.95 ±  26.71 5 9 7 6 -3 0 6 5 2 162± 406 P  <  0.001 s .
ng/g 2.6 - 68.8 30.30 ±  9.86 3 6 0 -1 1 3 1 7 9 8 ± 1 5 0
And-S nmol/kg 8 2 2 .1 -2 0 6 .3 132.2 ±  29.06 5 3 1 -3 6 4 2 0 4 ± 6 4 N. S.
ng/g 8 .2 -7 6 .4 49.0 ±  10.76 1 1 .5 -1 3 4 .8 75.5 ±  23.7
J M io l-S nmol/kg 6 1 5 .9 -6 2 .4 42.1 ± 7 .1 4 4 4 9 - 2 3 5 132.5 ±  41 P <  0.05 S.
ng/g 5 .9 -2 3 .1 15.6 ±  2.64 1 8 .3 -8 7 .0 49.2 ±  15.2
Test.-S nmol/kg 7 4 .3 -2 5 .7 14.2 ±  3.09 5 3 .5 -6 0 .0 22.1 ±  10.0 N. S.
n g/g 1.6—9.5 5.3 ±  1.14 1 .3 -2 2 .0 8.1 ±  3.69
N . S. =  not significant 
S. =  significant
ю
A
N
D
R
O
G
E
N
S A
N
D
 C
19-S
T
E
R
O
ID
 S
U
L
P
H
A
T
E
S
 IN
 A
B
D
O
M
IN
A
L
 S
K
IN
2 0 T Ó T H , I . and  FA R E D IN , I.
higher concentration  was found in the skin than  in  serum . Thus, free androgens 
accum ulate in  the skin. The situ ation  is different for the C19-steroid sulphates, 
the b lood  leve l of w hich is several orders o f m agnitude higher than th a t o f  
free stero ids. Under norm al conditions the values o f  these steroids were m uch  
lower in  abdom inal skin than  in  peripheral blood.
A n  increasing number o f  data support the assum ption  that the andro­
g en -sen sitiv ity  of tissues m ay be characterised b y  the number of androgen- 
receptors, th e  latter varying in  parallel w ith  the concentration  of androgens. 
T hus, th e  higher androgen concentration  found in  th e  hairy abdominal skin of 
m ales in d icates a higher level o f  steroid-binding proteins in  the skin. Confirm a­
tio n  o f  th is  w ill be a task  o f subsequent exam inations.
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STEROIDS EXCRETED RY HUMAN SKIN II. 
C19-STEROID SULPHATES 
IN HUMAN AXILLARY SWEAT
I. T ó t h , I. F a r e d i n
EN D O C R IN E U N IT , F IR S T  D E PA R T M E N T  O F M E D IC IN E , U N IV ERSITY  M ED ICAL SC H O O L,
SZ E G E D , H UN G ARY
(R eceived: O ctober 21, 1983)
B eside déhydroépiandrostérone sulphate and androsterone su lp hate , 5-andro- 
stene-3/j, 17/?-diol-3-sulphate and testosteron e sulphate were isolated and  identified  from 
the axillary sw eat o f sexually  m ature w om en and men. The qu an tities o f these four 
C19-steroid sulphates were determ ined ind ividually in the sw eat o f  e igh t healthy, 
sexually m ature wom en and men: dehydroepiandrosterone sulphate w as found in the 
highest am ount, it  was follow ed b y  5-androstene-3jS, 17/?-diol-3-sulphate and andro­
sterone sulphate. T estosterone su lphate occurred in the lowest q u a n tity , its  excretion  
am ounting to about one-thousandth  of that o f dehydroepiandrosterone sulphate. 
Study o f the C19-steroid su lphates excreted  by the apocrine sw eat glands perm itted  
an insight into  the steroid m etabolism  in hum an skin, which presum ably  is, closely  
connected w ith  the steroid horm ones o f peripheral blood.
Keywords: axillary sw eat, C19-steroid sulphates, human skin
Terms and abbreviations: A ndrostanedione (A-ane-dione): 5a-androstane-3,17-dione; 
Androstenedione ( / l4-dione): 4-androstene-3,17-dione; Androsterone (A nd.): 3a-hydroxy-5a- 
-androstan-17-one; Androstenediol (zl5-diol): 5-androstene-3/S, 17/9-diol; D ehydroepiandro­
sterone (D H A ): 3/?-hydroxy-5-androsten-17-one; D ihydrotestosterone (D H T ): 17ß-hydroxy-5a- 
-adrostan-3-one; T estosterone (Test.): 17/?-hydroxy-4-androsten-3-one; D ehydroepiandro-
steron sulphate (D H A -S): 3/?-sulphooxy-5-androsten-17-one; A ndrostenediol su lphate (zl5- 
-diol-S): 5-androstene-3/S, 17/S-diol-3-sulphate; Androsterone sulphate (A nd.-S): 3a-sulphooxy- 
-5a-androstan-17-one; T estosterone sulphate (Test.-S): 17/l-sulphooxy-4-androsten-3-one
Introduction
Our investigations on the steroid horm one content o f axillary hair dem on­
strated that the bulk of the C19-steroids detected  are to be found in  th e  form of 
water-soluble su lphate esters [14]. Our experim ents showed th a t  these ste­
roids can be extracted  from the hair b y  soaking [8, 14], and it  w as therefore 
assum ed th at the hair takes up the steroid sulphates from sw eat.
The q u an tity  o f C19-steroids determ ined in axillary hair does not how­
ever, give reliable inform ation on the am ount of steroid sulphates excreted  hy 
th e  human skin or the sw eat glands. An exact answer to this q u estion  can be 
given only b y  analysis o f axillary sw eat collected in a definite period o f tim e.
Send offprint requests to Dr. I. T óth , Dr. I. Faredin, Endocrine U n it F irst D epartm ent 
o f M edicine, U n iversity  M edical School, H -6701 Szeged, K orányi rkp. 8 . H ungary
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The present paper reports on quantitative exam inations o f  the four m ost im por­
ta n t C19-steroid sulphates excreted  in axillary sw eat: dehydroepiandrosterone 
su lphate (D H A -S), androsterone sulphate (A nd.-S), 5-androstene-3/3, 17/5-diol- 
-3-su lphate (zl5-diol-S) and testosterone sulphate (T est.-S ).
M aterials and methods
1. The chemicals and so lu tion s em ployed were of a n a ly tica l purity. The organic solvents  
were purified  by prescribed procedures, and distilled in a fractionating  column [8].
2. R adioactive steroids: [7-3H (N )] DHA-S (S. A .: 24 Ci/m m ol), [7-3H (N)]zl5-diol-S  
(S. A .: 24 Ci/mmol) and [1,2-3H (N )] A nd. (S. A.: 40 Ci/m m ol) were products o f New England  
N uclear (U SA ), while [Iß,  2/J(n)-3I l |  T est. (S. A.: 44.6 C i/m m ol) w as obtained from the R adio­
chem ical Centre (Amersham, E nglan d). These steroids were purified  on A120 3 column and on 
th in -layer  [8 ].
3. R ad ioactiv ity  was m easured w ith a Packard Tri-Carb L iquid Scintillation Spectrom ­
eter (M odel 3375) w ith correction o f  the quench effect. T he effic ien cy  of the instrum ent for 
3H in th e  case o f free steroids w as 45—48% , while in the case o f  steroid sulphates (where the  
sc in tilla tion  m edium  contained also 1 m l methanol) it  was 33—35% .
4. A fter thin-layer chrom atography, localization o f th e  sp ots o f the radioactive steroids 
w as perform ed with a Packard Radiochrom atogram  Scanner (M odel 7201).
5. T he free and sulphate ester steroids were separated on  florisil column (Florisil 60/100 
m esh; F loridin Co., USA) [12]. The free steroids of different polarities were separated on A120 3 
colum n w ith  benzene contain ing an increasing ethanol concen tration  gradient [8]. The free 
steroids o f  similar polarity w ere separated on A120 3-G (nach  S tah l, Merck, GFR) thin-layers 
w ith  th e  so lvent system  (n -h ex a n e-e th y l acetate — absolu te  ethanol — glacial acetic acid  
120 : 130 : 1 : 2 (v /v /v /v )) [8 ].
6 . Chemical reactions o f  C19-steroids
a. Reduction: the 17-ketone group can be reduced w ith  a m ethanolic solution of N a R H 4 
under appropriate experim ental conditions to yield a h y d ro x y  group [8 ].
b . A cetylation . W hen a cetic  anhydride is added to  a so lu tio n  of the Cl9-steroid in  pyri­
d ine, th e  hydroxy groups are a cety la ted  [8].
c. The steroid acetates are hydrolysed in alkaline m eth ano l, and the free steroids can  
be ex tra cted  w ith dichlorom ethane [8 ].
d. O xidation. The h yd roxy  groups of the C19-steroids can  be converted to ketone groups 
b y  o x id a tio n  w ith chromic acid [8 ].
e. T he C19-steroid su lp hates are solvolysed by perchloric acid [11].
7. Q uantitative d eterm ination  of the steroids. The am oun ts o f DH A-S and A nd.-S  
present in  sw eat were determ ined b y  means of the Z im m erm an and dinitrophenylhydrazine  
colour reactions [8, 11]. The am oun t of Г’-diol-S and T est.-S  were measured by protein­
binding assav. The serum o f w om en in the third trim ester o f  pregnancv was used as binding  
protein  [13, 14].
8 . Sw eat collection. G auze pads were used to collect th e  sw eat for quantitative exam ina­
tions. A  0.5 cm  thick layer o f  co tton -w ool was sewn b etw een  tw o  layers of gauze m easuring  
10 X 15 cm . The resulting pads were tied  onto the exam ined ind iv idu al by means of six  elastic  
tapes so th a t the arm rem ained free, b u t at the same tim e th e  arm pits were com pletely covered  
(F ig . 1). Sw eat was collected for 24 hours from both arm pits, th e  ax illary  hair having first  
been sh aved  off and the surface o f the skin cleaned w ith  cotton -w ool. The pads were then  
transferred to a glass-filter a ttach ed  to  a suction-bottle, and ex tra cted  w ith  3 x 1 5  ml m ethanol. 
The com bined m ethanolic so lu tion  w as evaporated to dryness in  vacuum .
9. Individuals exam ined . T hese were healthy w om en and m en, who were predom inantly  
laboratory  workers in our D ep artm en t, and performed their  norm al daily activities at the  
tim e o f  sw eat collection.
10. B rief description o f  determ ination  of C19-steroid su lp hates in  axillary sw eat. The 
course o f  our procedure is ou tlined  in  F ig. 2. [3H ]D H A -S and [3H ] /l5-diol-S of known activ ities  
were added to the crude ex tra ct obta ined  by m ethanolic d isso lu tion  from the sw eat collector, 
in order to  be able to correct for th e  loss arising during th e  iso la tion  procedure, and also to  
be able to  localize the steroids to  be determined during their  chrom atographic purification. 
The lip ids were removed b y  d efa ttin g  from the crude e x tra c t containing a large am ount o f  
contam ination  [8], and the fraction  o f  steroid sulphates w as separated  by colum n chrom atog-
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raphy on florisil as described previously [8, 12]. K now n quantities o f [3H ] And. and [3H] 
T est, were added to the ex tra ct o f the free steroids ob ta ined  after so lvolysis, and the m aterial 
w as chrom atographed on A120 3 colum n. Final isolation o f  th e  ind ividual steroids was performed 
on A120 3 thin-layer. The quantities o f steroid su lphates determ ined in  axillary sw eat were 
expressed in units o f  nm ol/24  h or pm ol/24 h. R esults are expressed as m ean ±  S.E.M .
Fig. 1. Collection of axillary  sw eat
Axillary s w e a t collector 
(g a u z e , co tton-w ool p ad  )
E xtraction  : w ith  m ethano l
C rude ex trac t | .  (3H )D H A -S ; [3H] û5-d io t - S
Partition ing  : m e th a n o l-n -h e x a n e
1 D efatted ex trac t |
F lorisil colum n c h ro m a to g ra p h y
1 S tero id  su lp h a te s  |
S olvolysis: Г/.Н С10*
1 Free s te ro id s  |*  [3H ]A n d .; [3H] Test.
A lumina colum n c h ro m a to g ra p h y
f----1 -----------J
DHA And »Test Д5-с
T ~r 1
A lum ina th i n - la y e r  ch rom atog raphy
Fig. 2 . D eterm ination  of C19-steroid sulphates in  axillary sweat: flow -sheet
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Results
1. I d e n t i f i c a t i o n  o f  A 5- d i o l - S  a n d  T e s t . - S
S in ce D H A -S and And. -S w ere identified  earlier in axillary sw eat [8], we 
deal here on ly  with the id en tifica tion  o f / l 5-diol-S and T est.-S .
A fter  chromatographic separation , th e  quantity  and rad ioactiv ity  of 
th e  in d iv id u a l isolated steroids w ere determ ined on aliquots, and their specific  
a c t iv ity  (S . A.) was calculated . In  the residual part Zl5-diol and T est, were 
su b jected  to  the chemical reactions shown in Tables I and II , respectively ,
Table I
Identification o f  Æ -diol-S isolated from  axillary sweat following solvolysis
S ubjec t
[7-3H ]J 8-diol-S 
added to  sweat 
extract
(S.A. =  24 Ci/mmol)
Chem ical
reac tions D erivatives
TLC
systems
S.A.
(dpm//tg)
A m ount of 
/ l 5-diol-S 
in  sweat 
(nm ol/24 h)
J .T . 535.752 dpm / 15-diol G 8850 165
25 yr A cetylation Zp-diol-diAc la„ —
m ale H ydrolysis Zl5-diol G 7764 186
B. T. 470.322 dpm zl5-diol G 6030 211
31 yr A cetylation Zl5-diol-diAc l a 0 —
fem ale H ydrolysis d 5-diol G 6391 200
T. I. 507.230 dpm Zl5-diol G 3800 359
43 yr A cetylation ,!5-diol-diAc la,, —
m ale H ydrolysis /l5-diol G 4180 327
S. A . =  Specific A ctiv ity  
T L C  s y s t e m s :
G =  A120 3-G, n -hexane-ethyl acetate-absolute ethanol-glacial acetic acid  
(120 : 130 : 1 : 2, v /v /v /v )
l a 0 =  silica gel G, c-hexane-ethyl acetate (80 : 20, v /v )
and th e n , after the individual step s, were chrom atographed in the appropriate 
th in -la y er  system . The chrom atogram s o f the different steroids, and th e  scanno- 
gram  o f  th e  labelled steroids running together w ith them , indicated  th a t  these  
tw o  stero id s isolated from sw eat were identical w ith  A5-diol and T est.
B esid es the qualitative proof, quantitative determ ination and S. A. 
m easu rem en t were repeatedly carried out after the chem ical reactions; these  
resu lts are also given in T ables I and II.
T h e tabulated date show  clearly th at the S. A. values obtained  after 
chrom atographic running o f th e  derivatives produced in th e  chem ical reac­
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tion s, and the quantities o f sw eat steroid calculated from th ese, did not differ 
essentia lly  from the results measured in itia lly . This unam biguously dem on­
strated the id en tity  o f  Zl5-diol-S and T est.-S , and showed th a t our procedure 
for their isolation and determ ination was exact and reliable.
Table II
Identification o f  Test.-S isolated from  axillary sweat following solvolysis
Subject
[l/?,2/3*-H] Test, 
added to  sweat 
ex trac t
(S.A. =  44.6 Ci/mmol
Chemical
reactions
D erivatives S.A.
(dpm/ng)
A m ount of 
Test.-S  in sweat 
(pmol/24 h)
Zs. J. 185.078 dpm Test. 358 1403
21 yr O xidation zJ4-dione —
female Reduction Test. 354 1417
T. I. 191.549 dpm ___ Test. 991 526
43 yr O xidation zl4-dione —
m ale Reduction Test. 1004 518
T. I. 191.549 dpm ___ Test. 393 1319
44 yr O xidation zl4-dione —
m ale Reduction Test. 420 1237
S. A. =  Specific A ctiv ity
2. A m o u n t  o f  C 19- s t e r o i d  s u l p h a t e s  e x c re te d  i n  2 4  h
The quantities o f C19-steroid sulphates excreted in the axillary sw eat of 
eigh t sexually m ature wom en aged 17-37 years and eight sexually  m ature men 
aged 17-44 years are listed  in Table III . As observed in a stu d y  o f the C19- 
steroid sulphates o f axillary hair [14], D H A -S was present in  the highest 
am ount in both sexes (wom en: 7 9 5 ^ 2 3 3  nm ol/24 h; men 1 0 6 3 ^ 1 8 9  nm ol/24 h. 
The am ount o f  And.-S in  axillary sw eat was substantially  low er (women: 
51 i  16 nm ol/24 h; men: 66 ^  13 nm ol/24 h). A difference could be seen be­
tw een  the mean values for the w om en (74 ±  24 nm ol/24 h) and th e  m en (152 i  
±  37 nm ol/24 h) as regards the excretion o f Zl5-diol-S, though th e  individual 
scatter was wide in both groups. O f the four C19-steroid sulphates exam ined, 
T est.-S  was excreted in low est am ount in axillary sw eat (wom en: 815 d: 
i  367 pm ol/24 h; men: 2055 939 pm ol/24 h).
The data in Table III  clearly revealed the large individual fluctuations  
for both wom en and m en. It could also be observed th at certain individuals 
(В . K . a 21-year-old wom an, and J . T., a 26-year-old man) in ten sively  excreted  
all four steroid sulphates, whereas lower than  average am ounts o f all four 
steroid sulphates were found in the sw eat o f others (M. Y. and T. I ., 20 and 37- 
year-old wom en).
Acta Medica Hungarica 42, 1985
26 TÓTH, I. and FAREDIN, I.
3. R a t i o s  o f  C 19- s t e r o i d  s u l p h a t e s
The constancy o f com position  o f the steroids excreted in sw eat was 
dem onstrated  in an experim ental series in which the quantities and ratios of 
the sw eat steroids excreted d aily  by tw o men were determ ined on several occa­
sions. T he data in Table IV  show  th at w ith the exception  o f T est.-S , the am ounts
Table III
Am ounts o f C19-steroid sulphates in axillary sweat o f  healthy women and men
Subject
Age
(years)
DHA-S 
nmol/24 h
And.-S 
nmol/24 h
J 5-diol-S 
nmol/24 h
Test.-S 
pmol/24 h
1. K. E . fem ale 17 505 38 46 288
2. T. M. fem ale 17 1688 148 70 934
3. T. M. fem ale 18 152 13 16 280
4. V. K . fem ale 19 901 65 111 —
5. M. V . fem ale 20 125 19 11 624
6. B. K . fem ale 21 1769 76 111 442
7. B . T. fem ale 31 982 35 208 2942
8. T. I. fem ale 37 242 16 19 195
Lim its: 1 7 - 3 7 1 2 5 -1 7 6 9 1 3 - 1 4 8 1 1 -2 0 8 1 9 5 -2 9 4 2
m ean i  S.E.M . 7 9 5 ± 2 3 3 5 1 ± 1 6 7 4 ± 2 4 8 1 5 ± 3 6 7
9. B . T. male 17 564 24 46
10. Sz. F . male 23 573 67 76 6339
11. J . L. male 25 1202 46 159 —
12. J . T. male 26 2217 132 386 1514
13. D . I. male 27 787 65 86 393
14. L. J . male 35 841 54 189 2915
15. T. J . male 42 1243 35 135 597
16. T. L. male 44 1077 105 138 573
Lim its: 17—44 564±2217 2 4 - 1 3 2 4 6 - 3 8 6 3 9 3 -6 3 3 9
m ean ^  S.E.M . 1063±189 6 6 ± 1 3 1 5 2 ± 3 7 2 0 5 5 ± 9 3 9
Table IV
A m ounts and ratios o f  Cl9-steroid sulphates in  axillary sweat collected from  healthy subjects
at various times
Subject D ate of 
sampling
DHA-S 
nm ol/24 h
And.-S 
nmol/24 h
J 5-diol-S 
nmol/24 h
Test.-S 
pmol/24 h
DHA-S
And.-S
J*-diol-S
And.-S
J .T . 24 Jan. 2217 132 386 1514 16.8 2.9
26 yr 26 Jan. 2252 135 486 1319 16.7 3.6
male 31 Jan. 2114 127 435 3981 16.6 3.4
T. I. 16 Nov. 1077 105 138 573 10.2 1.3
43 yr 18 Nov 2014 219 359 1189 9.2 1.6
male 22 Nov. 3297 321 418 4285 10.3 1.3
1 Dec. 2250 208 281 1319 10.8 1.3
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of C19 -steroid sulphates in the axillary sw eat of J. T ., a 26-year-old  man, varied 
scarcely at different tim es. For the second individual, T. I ., a 43-year-old man, 
how ever, the quantities o f steroids found in sweat differed su b stantia lly  in the 
repeated sw eat collections. The ratios o f the excreted steroids DH A-S/And.-S  
and A5-diol-S/A nd.-S were seen to  vary with the individual, b u t to  be fairly 
constant and characteristic o f each individual (D H A -S/A nd.-S  =  16.6-16.8  
and 9 .2 -10 .8 , and Zl5-diol-S/A nd.-S =  2 .9 -3 .6  and 1.3—1.6), independently of 
the am ounts of the ind ividual steroid sulphates and the tim e o f sam pling.
Discussion
W hen our steroid studies were extended from axillary hair [14] to axil­
lary sw eat, we could dem onstrate th a t, besides D H A -S and A nd.-S , a consider­
able am ount o f zJ5-diol-S too is excreted in human axillary sw eat. It is known 
th a t A5-diol occurs in peripheral blood not only as m onosulphate, but also as 
disulpliate [10]. It should be noted th at w ith our procedure we determ ined in 
sw eat /d5-diol-3-S, i.e. the m onosulphate form.
In earlier in v itro incubation exam ination we showed th a t A5-diol-S was 
present am ong the m etabolites when zl5-diol was incubated w ith  skin slices,
i.e . the d 5-3/?-hydroxysteroid-sulphokinase in hum an skin is able to form a 
sulphate ester not on ly  from D H A , but also from Zl5-diol [5, 6 ]. Thus, part of 
the zl5-diol-S excreted in sw eat m ay be zl5-diol-S from peripheral blood, while 
part m ay originate from the sulphate m etabolite formed in th e  skin.
L ittle is know n o f the physiological significance o f  T est.-S ; its plasma 
level was very low com pared to  those o f the other C19-steroid su lphates [4]. We 
have dem onstrated the id en tity  o f  T est.-S  found in sw eat, b y  m eans o f chemical 
reactions and chrom atographic m ethods. Its quantity  was on ly  one-thousandth  
of th at o f D H A -S in sw eat. During in vitro incubation w ith  skin slices, Test.-S 
form ation has never been observed.
Two types o f sw eat gland can be distinguished in hum an skin: the small 
eccrine and the larger apocrine glands. W e earlier showed th a t there was no 
m easurable am ount o f steroid in sw eat collected in the abdom inal area [8]. 
Since the apocrine sw eat glands occur in greatest num ber in th e  arm pit, and 
only  eccrine glands are found in the abdom inal skin, it has b een  concluded  
th a t the apocrine glands were responsible for the excretion  o f steroid esters, 
the eccrine sw eat glands p laying no role in this [2, 3]. T his assum ption was 
supported by our experim ents w hich indicated th at there w as no detectable 
am ount o f steroid sulphate in the axillary sweat of girls and boys before puber­
ty , when the apocrine glands are not y e t functioning.
Zlle-steroids (5a-androst-16-en-3a-ol, 5a-androst-16-en-3-one) with pro­
perties o f pherom ones have recently been found in axillary sw eat [1, 2, 9] but 
their quantities are far lower than those o f the steroid esters we have measured.
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T h e amounts of the exam in ed  C19-steroid sulphates varied betw een very  
w ide lim its  in the different in d iv id u a ls , and these d ifferences can he explained  
on ly  in  part by the individual p lasm a  steroid level. I t  is assum ed th at the extent  
o f ex re tio n  depends prim arily on th e  number and a c tiv ity  o f  apocrine sweat 
glands o f  the individual. This w as shown by the sw eat steroid  determ inations 
on d ifferen t days: the am ount o f  C19-steroid sulphates excreted  b y  the apo­
crine glands varied in tim e, depend ing on the state o f em otional stress of the  
in d iv id u a l [1], while the com p osition  of excreted steroids (as expressed by  
th e  ra tio s  DH A -S./A nd.-S and Zl*-diol-S/And.-S) was a lm ost constant at differ­
en t p o in ts  o f time. This varied  from  individual to in d iv id u al, but was charac­
ter istic  o f  a given individual, presum ably being determ ined b y  the individual 
plasm a steroid com position.
T he quantity o f CJ9-stero id  sulphates excreted in sw eat is so extensive  
th a t , togeth er with the excretion  o f  steroids in urine, th is  is one o f the m ost 
im p o rta n t routes of steroid elim ination . Its im portance does not, however, 
lie  in  th e  quantity; study o f th e  sw eat steroids g ives in sigh t in to  the steroid  
m etab olism  of human skin, w h ich  is closely connected  w ith  the steroids of 
peripheral blood.
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QUANTITATIVE CHANGES IN STEROID 
AND PEPTIDE HORMONES IN THE 
MATERNAL-FETOPLACENTAL SYSTEM BETWEEN  
THE 28th—40th WEEKS OF PREGNANCY
P. H e r c z
SECO ND  D E PA R T M E N T  OF O BSTETRICS AND GYNAECOLOGY, SEM MELWEIS 
U N IV E R S IT Y  M EDICAL SCHOOL, H-1082 —  BU DA PEST
(R eceived: April 25, 1983)
The role o f  steroid and peptide horm ones in  the m aintenance of pregnancy  and 
in the onset o f  labour was investigated  in th e  m aternal-fetoplacental system  betw een  
the 28th—40th  w eeks o f pregnancy. The data o f  151 pregnant women and 108 new borns 
was processed, and a total o f 2385 sam ples w as studied  b y  RIA.
R esu lts show ed th at betw een the 28th—40th  week there is an increase in  the  
prolactin lev e l o f  the um bilical arterial and ven o u s blood w ith a parallel increase in  the  
cortisol leve l o f um bilical arterial blood and a fa ll in the progesterone level o f  um bilical 
arterial and venous blood which betw een the 3 6 th  and 40th week results in  a rise o f the  
oestradiol/progesterone quotient. A t the sam e tim e the oestradiol concentration  rises 
in the m aternal circulation and in case o f prem ature labour the oestradiol/progesterone  
quotient a tta in s values twice as high as those found in normal pregnancies. T he al­
teration o f the horm onal environm ent exped ites the predom inance of the m echanism s  
stim ulating the a c tiv ity  o f the m yom etrium . T he horm one values in the u m b ilica l ar­
tery and vein  characteristically  differ from th o se  o f the maternal serum . T hu s, it  
m ay be assum ed th a t the fetus, though being in  close com m unication w ith  th e  m ater­
nal organism , is capable o f  independently m aintain ing its hormonal environm ent. 
The results in d ica te  that the fetus or more accu rately  the fetoplacental u n it p la y s a 
significant part in  the m aintenance o f pregnancy and in the initiation o f labour than  
it has been assum ed previously.
Keywords: m aternal-foetoplacental sy stem , in itia tion  of labour, horm onal levels, 
feto-horm onal independence
Introduction
It is know n th a t approxim ately 70%  o f  th e  deaths within the first week  
of life occur in preterm  infants. The rate o f  preterm  birth in H ungary has risen  
from  1950 to the seventies from 5% to  10 -12% . Owing to the high m orb id ity  
and m ortality  rate o f  preterm infants, in vestiga tion  of the causes inducing  
preterm  delivery and prevention o f these are essentia l tasks of obstetric m ed i­
cine, tasks requiring a closer insight into th e  norm al and abnormal processes 
of pregnancy.
Studies in the last tw o decades have resulted  in significant d iscoveries. 
We have the organ perfusion studies o f D iczfa lu ssy  [2] to thank for th e  recog-
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n iton  o f fetoplacental horm onal units. L iggins [3], Nathanielsz [5], Thornburn  
[6] and associates studied  th e  hormonal changes in  the course o f gesta tion  and 
at th e  onset of parturition b y  means o f a catheter inserted into th e  m other  
an im al and its fetuses, and found a sharp prenata l rise in the plasm a cortisol 
lev e l o f  sheep fetuses, parallel w ith a decline o f  the progesterone lev e l. Sub­
seq u en tly , the oestradiol and prostaglandin concentrations rose in th e  m ater­
nal serum .
D ata  relating to  hum ans and their in terpretation  are contradictory. Fetal 
and m aternal values have scarcely been considered together, and observation  
o f preterm  births is particularly rare in  th is  respect. It is m ainly at term  that  
th e  horm onal values in  m aternal and um bilical arterial and venous cord blood  
h a v e  been  studied. The m aternal values, how ever, provide indirect inform ation  
ab ou t th e  fetoplacental secretory a c tiv ity . On the other hand it  is precisely  
th e  horm onal activ ity  o f  th e  fetus w hich stu d ies of mixed cord blood fa il to  
disclose. For these reasons sam ples serving for the present study w ere taken  
from  th e m aternal cub ita l vein  and separately  from  the fetal um bilical artery 
and um bilical vein. This has allowed us to  s tu d y  in the m aternal-fetoplacental 
u n it, th e  horm onal changes forming part o f  th e  mechanisms responsib le for 
th e  on set o f labour. The studies included th e  stage of preterm labour as well. 
T he s tu d y  was concerned w ith  the fo llow ing questions.
1. W hat changes occur in  the horm onal levels of the sera of the m aternal 
v e in , th e  fetal um bilical ve in  and artery b etw een  the 28th -40th  w eek o f  preg­
n a n cy  ?
2. W hat differences are there in  the serum  hormonal levels in  normal 
gravidae and in prem ature parturients b etw een  the 28th-36th  week o f  preg­
n a n cy ?
Material and m ethods
D a ta  o f 151 gravidae parturients and 108 new borns were processed (Table I).
Table I
The clinical groups under study
Group I: Premature delivery (28 — 36 week):
74 parturients
74 prem ature newborns
Group II: Full-term  delivery (week 40):
34 parturients 
34 newborns
Group III: Normal gravidae (28 — 36 week) acting as controls:
43 gravidae
G ravidae and parturients, total: 151
108 newborns
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Of the parturients 74 gave birth to newborns w eighing 1001 to 2500 g betw een the 28th  
and 36th weeks of pregnancy.
The results obtained in prem ature parturition  were compared w ith  those o f 34 full- 
term  parturients. The serum horm one values o f th ese  parturients were com pared w ith  those 
found in the same week of norm al pregnancy in  43 gravidae. Premature parturients were not 
given  steroid prophylaxis, parturition did not begin  w ith  preterm rupture o f m em branes and 
intrauterine retardation was not perceived in any o f  the newborn. The m aterial was collected  
partly  at the Mother and In fant Protection R esearch Centre of the Soviet M inistry o f H ealth  
in M oscow, partly at the Second D epartm ent o f O bstetrics and G ynaecology, Sem m elweis 
U n iversity  Medical School in Budapest.
Samples were taken from the m aternal cubita l vein , the fetal um bilical vein  and the 
feta l um bilical artery separately , im m ediately after delivery, before expulsion o f the placenta. 
W e wished to exam ine, as far as possibilities perm itted , those horm one-producing organs w ithin  
the m aternal-fetoplacental-unit which, on the ev id en ce o f published data, are essentia l factors 
of th is system . Inform ation on pituitary function  w as provided by the prolactin leve l, on pla­
cen tal secretory a c tiv ity  by the progesterone and H P L  levels, on adrenocortical a c tiv ity  by 
D H A S  and cortisol and on the fetop lacental-unit b y  oestradiol and oestriol.
The serum horm one concentration was determ ined by RIA in a to ta l o f 2385 sam ples 
(T able II). Progesterone, oestradiol, oestriol, cortisol and prolactin concentration w as deter-
ТаЫе II
Number o f  hormone assays
Hormones M aternal vein U m bilical vein Umbilical a rtery
Progesterone 148 106 91
DHAS 149 106 100
Oestradiol 148 107 94
Oestriol 148 106 94
Cortisol 148 107 94
Prolactin 144 106 92
H PL 141 91 65
Total: 2385 assays
m ined in the hormone laboratories o f the Mother and In fant Protection Research Centre of the 
S o v ie t M inistry of H ealth in M oscow using the reagents o f the “ Steranti” firm  according to the  
W H O  protocol (London). D H A S levels were m easured at the Second D epartm ent o f O bstetrics 
and G ynaecology, Sem m elweis U n iversity  Medical School, Budapest, following the B uster and 
A braham  m ethod [1], and using the isotopes o f th e  Am ersham  firm and the A braham ’s anti­
serum . H PL  concentration was determ ined at th e  Frederic Joliot-Curie In stitu te  o f Radio- 
bio logy  and R adiohygiene, B udapest, follow ing the M ohári—Kocsár m ethod [4], using the  
reagents o f the U .S. Biochem ical Corp. In the determ ination of hormone concentration  the 
in terassay  variance coefficient and the intraassay variance coefficient values were as follows: 
Progesterone 7.8% , 12.5% ; oestradiol 4.6% , 9.1% ; oestriol 7.5% , 8.4% ; cortisol 5 .7% , 10.2% ; 
D H A S  7.2% , 14.5% ; H PL  9.8% , 9% , prolactin 6 .8% , 11.2%.
Through m athem atical processing of the d ata  the mean values and S.E .M . o f the 
ind iv idu al hormones were calculated and the results were subjected to analysis o f  variance in 
order to  establish whether the hormonal values were affected by the gestational age. On 
these  grounds the period betw een the 28th and 40th  weeks was divided in to  three groups: 
28—32th , 33—36th and 40th weeks. Then each analysis was carried out separately in th e  three 
groups. The serum horm one concentration in the m aternal vein, the um bilical artery and the  
um b ilica l vein were com pared, also by analysis o f variance. The two sam ple t-test w as used  
for com parison of the values found in normal gravidae versus premature parturients. All 
variants were correlated to each other. For these calculations a com puter ty p e  IBM  30/31 
belonging to the H ungarian A cadem y o f Sciences w as used with the aid of the “ B M PD  Sta­
tistica l Software 1981 ed ition” .
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Results
1. S e r u m  s t e r o i d  a n d  p e p t i d e  h o r m o n e  l e v e l s  i n  m a t e r n a l  v e n o u s ,  u m b i l i c a l  
v e n o u s  a n d  u m b i l i c a l  a r t e r i a l  b lo o d  b e tw e e n  th e  2 8 t h —4 0 t h  w e e k  o f  p r e g n a n c y .
F igure 1 shows the p r o g e s t e r o n e  concentrations. W hile in m aternal b lood  
a s ig n ifica n t rise occurred betw een the 28th and 40th  week, the progesterone  
con cen tration  of the cord blood rose only betw een  the 28th and 36th  w eeks 
and thereafter it fell s ign ificantly . The h ighest progesterone concentration was
F ig. 1. Progesterone concentration  in serum of m aternal vein , um bilical vein and um b ilica l 
artery betw een the 28th and 40th  w eeks1
found  in  the um bilical vein  but that of the um bilical artery was also s ign ifi­
ca n tly  higher than  the progesterone level in  m aternal blood (P <  0.01). W here­
as changes in  the horm one concentration in  th e  um bilical arterial or v e n ­
ous b lood  failed to correlate w ith those in m aternal blood, a close correlation  
w as fou n d  betw een the values of the unbilical vein  and artery (r =  0 .7783, 
P <  0 .01).
T he D H A S  l e v e l s  (F ig. 2) o f m aternal b lood showed a rising ten d en cy  
b etw een  th e  28th and 36th w eeks, and a sign ificant fall between the 36th  and
1 On the three-dim ensional diagram. The horm one concentrations have been sh ifted  on  
the perpendicular axis.
C olum ns representing the serum  horm one concentrations:
E m p ty  colum ns: m aternal blood “ M”
In terru pted  lines: um bilical vein  “ V ”
H a tch ed  lines: um bilical artery “ A ”
n =  num ber of cases. In  each fig u re :  x  =  mean; scatter: ;£ S.E.M .; s =  significance
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40th  week (P  <[ 0.01). A t the same tim e th e  values o f the um bilical vein  and 
the um bilical artery tended to increase. D H A S concentration in th e  um bili­
cal artery was sign ificantly  higher than in  m aternal blood (P <7 0 .01). W hile 
the m aternal D H A S concentration correlated only loosely w ith  the values 
for the um bilical vessels (M-Y: r =  0 .2951, P  < 0  .01) the correlation betw een  
those o f  the um bilical artery and vein w as very  close (r =  0.8432, P  <  0.01).
F ig. 2. D H A S concentration in  serum of m aternal vein , um bilical vein and um bilical artery
between the 28th  and 40th  week
T h e  o e s t r a d i o l  c o n c e n t r a t i o n  (Fig. 3) o f  m aternal blood rose sign ifican tly  
betw een the 28th  and 40th weeks (P <  0.01), whereas th at of the um bilical artery  
and the um bilical vein  increased only betw een  the 28th and 36th  w eek, to fall 
sign ifican tly  thereafter (P < 0  .01). Its  concentration  in m aternal serum  was 
sign ifican tly  higher than  either in the um bilical vein  or in the um bilical artery  
(P  <[ 0.01). W hile the oestradiol level in  m aternal blood correlated on ly  loosely  
w ith  the level in um bilical blood, there w as a close correlation betw een  the  
concentration in the um bilical venous and arterial blood (M-У: r =  0.2672,
0.01 M-А: r =  0.6462, P <  0.01).
T h e  o e s t r a d i o l - p r o g e s t e r o n e  q u o t i e n t  (F ig . 4) was studied n ex t. A rise of 
the quotient betw een the 28th and 40th  w eeks was confined to the um bilical 
vein  whereas in the um bilical artery it  rose betw een the 28th and 36th  weeks 
but it  (P  <7 0.01) failed to rise in m aternal blood.
T h e  o e s t r io l  c o n c e n t r a t i o n  (Fig. 5) in the m aternal blood rose sign ifican tly  
(P  <  0.05) betw een both periods of 28tli — 32th  and 33rd — 36th w eeks. The 
values o f the um bilical vein and artery also rose sign ificantly  betw een  
the 28th and 36th  week (P <  0.05) b u t fe ll to  half the original figures by
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the 4 0 th  w eek  (P  <  0 .01). The highest serum oestriol levels were found in  th e  
u m b ilica l v e in  (P <  0.01) but the values m easured in  the um bilical artery b e­
tw een  th e  28th  and 36th w eeks were also higher than  those of the m aternal 
blood (P  <  0.01). W hile the oestriol concentration  in  m aternal blood correlated  
only  lo o se ly  w ith  those in the feta l vessels (M-Y: r =  0.3677, P <  0 .01) there
F ig. 3 . O estrad iol concentration in  serum  o f m aternal v e in , um bilical v  in  and um bilical 
artery betw een the 28th and 40th  week
bilical artery betw een the 28th and 40th  week
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was a close correlation betw een the levels observed in the um bilical ve in  and 
artery (r =  0.7073, P <  0.01).
As regards the c o r t i s o l  le ve l  (F ig. 6) its  significant increase betw een  the  
28th and 40th  w eeks was confined to the um bilical artery (P <  0.01). Cortisol 
concentration was significantly higher in th e  m aternal blood than  in  th e  umbi-
Fig. 5. Oestriol concentration in serum of m aternal vein , um bilical vein  and um bilical artery
between the 28th and 40th week.
Fig. 6. Cortisol concentration in serum o f m aternal vein , um bilical vein and um bilical artery
between the 28th and 40th  week
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lica l v e in  and the um bilical artery (P < 0  .01). A  close correlation was observed  
b etw een  th e  maternal ven ou s and the um bilical arterial serum cortisol levels  
(M-У: r =  0.7165, P  <  0 .01; M-А: r =  0 .5952, P  <  0.01; Y-A:"r =  0.9126, 
P  <  0 .01).
A s to  the p r o l a c t i n  l e v e l  (F ig. 7) betw een  th e  28th and 40th w eek only  
in  th e  um bilical vein and th e  um bilical artery w as a significant rise (P  <7 0.01),
F ig . 7. P rolactin  concentration in  serum  of m aternal v e in , um bilical vein and um bilical artery
betw een  the 28th and 40th  w eek
found  b u t not in the m aternal blood. W hile betw een  the 28th and 36th weeks 
th e  p ro lactin  level o f m aternal blood was h igher th an  th at o f the um bilical 
artery  and vein , (P <7 0.01) betw een  the 33rd and 36th  weeks and during the  
40th  w eek . The blood o f th e  um bilical artery and vein  showed sign ifican tly  
higher va lu es (P <7 0.01) th a n  the m aternal b lood . The serum prolactin leve l 
of th e  m aternal vein did n o t correlate w ith  th a t in  the um bilical artery and  
on ly  lo o se ly  w ith that in  th e  um bilical vein  (r =  0.2152, P < 7  0.05). There w as 
a s lig h t correlation betw een th e  cortisol levels in  th e  um bilical vein and artery  
(r =  0 .4991 , P <  0.01).
T h e H P L  leve l  (F ig. 8) ten d ed  to  rise b etw een  the 28th and 40th  w eek  in  
the m atern a l blood, but fe ll sign ificantly (P  < 7  0.01) in the um bilical ve in , 
and artery  (P < 7  0.01). The serum  H PL concentration  o f m aternal blood failed  
to  correlate w ith that in  th e  um bilical vein  and artery, but the values in  the  
u m b ilica l vessels showed a close correlation P <7 0.01 r =  0.63996.
2 . C o m p a r i s o n  o f  th e  s e r u m  h o r m o n e  v a l u e s  o f  p r e t e r m  p a r t u r i e n t s  a n d  
th o s e  o f  n o r m a l  g r a v i d a e
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During the 28th -32n d  weeks and the 33rd -36th  weeks of pregnancy the 
preterm parturients had sign ificantly  higher values for D H A S, oestriol, the 
oestradiol/progesterone quotient (Figs 9 -10 ) and cortisol than did normal 
gravidae. On th e  other hand in normal gravidae the H PL  values were sign ifi­
cantly higher than  in preterm parturients (P  <  0.01).
Fig. 8. H PL  concentration in serum of m aternal vein , um bilical vein and um bilical artery,
betw een the 28th and 40th  week
Fig. 9. Concentration of D H A S oestriol and the oestradiol/progesterone quotient in  serum  of 
normal gravidae and o f preterm  parturients betw een the 28th and 36th week. 1st group: 
premature labour; 2nd group: norm al pregnancy
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F ig. 10. Concentration o f cortisol and H PL  in serum  o f  norm al gravidae and o f prem ature  
partu rien ts betw een the 28th  and 36th  week. 1st group: prem ature labour; 2nd group: normal
.'pregnancy
Discussion
A lthough  the horm onal changes accom panying the onset o f labour in  hu­
m ans are less spectacular th an  those found in  laboratory anim als, the processes 
th a t  ta k e  place in the m aternal-fetoplacental u n it are nonetheless typ ica l. B e t­
w een  th e  28th and 40th  w eeks o f pregnancy w e found an increase in  th e  pro­
la c tin  le v e l in the um bilical artery and vein  togeth er  w ith a high cortisol level in  
th e  um b ilica l artery. Parallel w ith  the rise o f  cortisol concentration, th e  con­
cen tra tio n  o f progesterone in  th e  um bilical vesse ls declined betw een the 36th  
and 4 0 th  weeks, thus th e  oestradiol/progesterone quotient rose during th e  2 8 -  
4 0 th  w eek  in the um bilical v e in  and during th e  28 th -36 th  week in  th e  um ­
b ilica l artery. A t the sam e tim e the oestradiol leve l increased in the m aternal 
c ircu la tion , and the oestradiol/progesterone q uotien t attained in the preterm  
p artu rien ts twice the va lue found in normal pregnancy.
W ith  the increase o f  th e  cortisol level in  th e  m aternal-fetoplacental unit 
th e  oestradiol/progesterone balance was shifted  in  the direction of oestradiol. 
T he activ a tin g  m echanism  o f  the m yom etrium  thus gained preponderance as 
a resu lt o f  changes in th e  horm onal environm ent.
T he hormone values found in the um bilical artery and vein differed charac­
ter is t ica lly  from those in  m aternal serum. T he changes in the concentration  
o f progesterone, prolactin and H PL  in um bilical cord blood failed to correlate 
w ith  th o se  in  the m aternal b lood, in other words the concentration o f these  
h orm on es changed in the fe ta l circulation in d ependently  of the m aternal organ­
ism .
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The sera o f the m aternal vein  and o f  the fetal vessels d isp layed  typ ical 
differences in the quantitative proportion o f  the hormone levels under study. 
W hile in the 8th to the 40th week the oestradiol, cortisol and H P L  and in the 
28th to  36th weeks the prolactin concentration  level was sign ifican tly  higher 
in the m aternal sera than in that o f the fetu s, in the 36th to 40th  week those 
of progesterone, D H A S, oestriol and prolactin  were significantly higher in the 
um bilical artery and vein . This typical proportion of the hormone values seems 
to  suggest th at the fetal organism, in sp ite  o f  its close com m unication  with  
the m aternal organism , is capable o f m aintain ing its hormonal environm ent 
independently.
On the basis o f  the present results th e  fetoplacental unit seem s to p lay a 
more independent, more active part in the m aintenance of pregnancy and in the  
in itiation  o f labour than it  has hitherto been assum ed.
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COMPARATIVE STUDY OF INTRAVENOUS 
ANAESTHETIC TECHNIQUES ADMINISTERED  
DURING SHORT-TERM GYNECOLOGICAL 
OPERATIONS
Á g n e s  K e r t é s z , G. F a l k a y , M. B o r o s
D E P A R T M E N T  O F A NA ESTH ESIO LO GY  AND IN T E N S IV E  T H E R A P Y  AND 
D EPA R T M E N T O F O BSTETRICS AND GYNAECOLOGY, U N IV E R S IT Y  M ED ICAL SCHOOL, 
H-6701 SZEG ED , P.O . Box 464 H U N G A RY
(R eceived: January 30, 1984)
The effects o f  nine intravenous anaesthetic techniques on serum cortisol level 
and circulatory param eters were studied in hea lthy  patients undergoing term ination  
o f pregnancy.
Considering the increased pre-operation values and those of the pregnant control 
group as w ell as diurnal variations, it  was found th a t the serum cortisol value changed  
during and after the procedure depending on the ty p e  of anaesthesia used. This m ight 
m ean that the optim al typ e  of anaesthesia for interruption could be designed by m ea­
suring the serum  cortisol level, assum ing th a t th is param eter was one o f the indicators 
of stress. The rating the different types o f anaesthetics, the circulatory param eters 
were also considered.
According to these criteria the best results were observed using m ethohexital 
in com bination w ith  fentanyl or diazepam .
Keywords: serum  cortisol, pregnancy term ination , intravenous anaesthesia,
stress
Introduction
It is well know n th a t operative procedures cause pain accom panied by  
an increase of adrenal function  [2, 5, 8, 14]. M any authors have studied the 
stress-effect during different types o f anaesthesia and surgical intervention  
[1, 2, 11, 15, 17]. The plasm a cortisol concentration , was found to increase 
during surgical stim u lation  and to rem ain higher than  the hasal value for a 
variable tim e after the operation [4, 7]. The serum  cortisol level is an accepted  
index for evaluating the degree o f surgical stress [2, 11, 14, 15].
Few data are available about the effect on the adrenal response during  
minor surgery o f  short-term  intravenous anaesthetics and their com binations 
w ith  analgetics or sedatives. In  the present stu d y  the differences in  this respect 
o f various short-term  anaesthetic techniques used for pregnancy term ination  
have been analysed.
Send offprint requests to  Agnes K ertész 6726 Szeged Vedres utca 12, H ungary
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M aterial and methods
H ea lth y  patients (n =  16) who underw ent term ination of pregnancy in the first tri­
m ester w ere studied after inform ed consent. Mean age was 29.0 ±  7.0 (m ean ; S .D .) years, 
m ean b od y-w eigh t 63.3 ±  12.7 kg and the stage o f pregnancy was betw een 5 and 14 weeks. 
All p a tien ts  were classified in  the A SA  I group. The operation were carried out betw een  11 a.m. 
and 1 p .m . and lasted 9—15 m in.
N in e  different groups were form ed on the basis o f the adm inistered intravenous anaes­
th etics analgetics and benzodiazepine (Table I).
Table I
P atien ts groups according to type and dosage o f  drugs administered fo r anaesthesia
G roups n
F en tany l
* ^g/kg
D iazepam
m g/kg
Propanidid
m g/kg
Thiobu tabarb ital
“ g/kg
M ethohexital
m g/kg
Propanidid 11 - - 18.6 ±  7.3* — -
F en tany l +  
Propanidid 10 1.65 ±  0.73 — 14.6 ±  4.1 — —
D iazepam  +  
Propanidid 14 — 0.16 ±  0.04 12.2 ±  3.9 — —
Thiobutabarbital 14 - - — 14.4 ±  4.4 -
F en tanyl +
Thiobutabarbital 14 1.21 ±  0.33 — — 12.4 ±  2.9 —
D iazepam  -|-
Thiobutabarbital 11 — 0.10 ±  0.04 — 11.2 ±  2.4 —
M ethohexital 10 - - - — 2.88 ±  0.69
F entanyl +  
M ethohexital 12 1.29 ±  0.43 — — — 2.58 ±  0.61
D iazepam  -f- 
M ethohexital 10 - 0.18 ±  0.02 — — 2.24 ± 0 .7 0
M ean ±  S. D.
P rem edication was not applied before interruption. The anaesthetic analgetic  fentanyl 
and benzodiazep ine (diazepam ) were adm inistered fractionally  until the patients had been  
slig h tly  sedated  and one o f the in traven ous anaesthetics propanidid, th iobutabarbita l and 
m eth o h ex ita l was injected until disappearance of the eyelid  reflex. Spontaneous respiration  
w as m ain ta ined  in all cases. D uring anaesthesia, 250-300 m l R inger-lactate so lution  was 
infused .
For estim ation of the serum  cortisol level, four blood sam ples were taken in  all cases 
from  th e  antecubital vein  before the in troduction  o f anaesthesia, during surgery, after aw aken­
ing (i.e . w h en  the patient was able to  respond adequately to questions), and at 6 hours p.m .
In  th e  control group (n =  10) blood-sam ples were taken at 6, 12 and 6 hours for the  
purpose o f  determ ining diurnal variations o f  cortisol in  the first trim ester o f pregnancy. The 
blood sam ples were centrifuged and the separated serum was stored at —30° u n til analysed.
Serum  cortisol was m easured b y  radioim m unoassay [18]. The antigen was cortisol-21- 
-hem isuccinate-B SA . The antibody titer  was: 1 : 21000, its specifity: cortisol 100% , cortisone 
25% , corticosterone 2.2% , 11-deoxycortiso l 40% , progesterone 0.5% , 17-alpha-hydroxy- 
-progesterone 10%, 11-alpha-hydroxy-progesterone 1% , the norm al range being 160—660 nm ol/1. 
The accu racy  o f this m ethod: in ter-assay  (variation  coefficient): ± 1 4 .2 % , intra-assay (v .c.): 
± 1 0 .8 % . B lood pressure and pulse rate were m easured at the tim e o f blood sam pling.
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The relative changes o f cortisol, blood pressure and pulse rate com pared to  th e  pre­
operation values were determ ined all drug-com binations. In view  of the m arked individual 
differences, the diurnal variations as well as the physiological distribution o f cortisol, relative  
changes were studied. In the course of statistical analysis cortisol levels m easured at different 
tim e were com pared to the pre-operation values.
Statistical analysis w as performed using the W ilcoxon test for estim ating differences 
o f  the various drug com binations, blood sam pling tim es and cortisol levels. The drug-com ­
binations were evaluated according to the param eters obtained and the rank o f the different 
ty p es o f anaesthesia was established using regression analysis. The results were expressed  
as m ean d: S .D .
Results
Before exam ination o f the different typ es o f  anaeshesia, it was established  
th a t the diurnal variation  o f serum cortisol in  the first trim ester o f  pregnancy  
w as sim ilar to  th at o f non-pregnant wom en, but at a higher concentration range 
(at 6 a.m. 582 dr 229 nmol/1, at 12 noon 351 dr 148 nmol/1 and at 6 p.m. 
266 dr 112 nmol/1), (F ig. 1). Therefore in th is stu d y  the cortisol values in preg­
nant wom en were considered as controls.
c o n t r o l  g r o u p
. (Щ n = 1 0 x î SD  1 2 w e e k  p r e g n a n t  
c o n t r o l  g r o u p
12 18 h
Fig. 1. Diurnal variation of serum cortisol level in pregnant and non-pregnant wom en
Serum cortisol values around 12 noon are considerably higher than  in 
th e  control group (603.3 dr 67 vs. 351 dr 148 nmol/1), a fact which could be 
explained by the excitem en t before interruption, as no prem edication was 
applied.
The relative changes o f the serum cortisol level during interruption and 
after anaesthesia are shown in Fig. 2, where m ean values are given.
The predicted variations o f cortisol values before, during and after inter­
ruption were com pared using the W ilcoxon test. S ignificant differences in 
th e  cortisol level betw een the pre-operation value and the value expected  after 
surgery were observed only in the diazepam  -(- propanidid and diazepam  -f- 
-|- thiobutabarbital groups (P <  0 .01). D uring further differentiation th e  cor-
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tiso l v a lu es  decreased during interruption in  the fen tanyl-m ethohexita l and 
diazep am  +  m ethohexital groups (Fig. 3). The values were unchanged or in ­
creased  in  approxim ately the sam e degree in th e  rem aining 5 groups.
In  th ose groups in w hich propanidid w as the basic agent (propanidid, 
fe n ta n y l +  propanidid, diazepam  +  propanidid), the cortisol level increased
A □  During surgery И  On awakening
F ig. 2 . Serum  cortisol level during interruption and on awakening as com pared to  pre-opera”
tion values
b u t th e  increase was sign ificant (P <[ 0.01) on ly  w ith  the diazepam  -)- propa­
n id id  com bination .
D uring  anaesthesia w hen the basic anaesthetic agent was th iobutabarbi- 
ta l, th e  cortisol level showed a decrease during interruption (— 2.6% ) and an 
increase on awakening ( +  5.8% ) when barbiturate was adm inistered as a single  
drug. N o  change was observed in  the cortisol values during anaesthesia com ­
pared to  th e  pre-operation va lu e when the barbiturate was com bined w ith  fen­
ta n y l (— 0.1% ). H owever, on aw akening the cortisol level increased in this 
group to o , but less (+ 3 .7 % ) than  w ith  th e  use o f th iobutabarbital alone 
( +  5 .8% ). The increase was also significant w hen the barbiturate was com bined  
w ith  d iazepam  (+ 7 .0 %  and 38.6% ), respectively .
T h e best results were m easured in  the groups which received m eth oh ex i­
ta l, in  sp ite  o f the fact th a t during anaesthesia w ith  m ethohexital alone the  
cortiso l lev e l increased ( +  8 .9% ), whereas on aw akening it  showed a decreasing  
te n d en cy  (+ 5 .9 % ). I f  m ethohexita l was com bined w ith  fentanyl or d iazepam , 
th e  serum  cortisol level decreased (fentanyl +  m ethohexital: — 1.2% , dia­
zep am  +  m ethohexital: — 6.7% ), and the decrease lasted when subsequently  
on ly  fen ta n y l was applied (— 3.7% ).
Com paring the 6 p.m . va lu es the cortisol level in the fentanyl +  m ethohe­
x ita l and  diazepam  +  m ethohexita l groups did not differ sign ifican tly  from  
the con tro l. In  the groups o f fen tan y l +  th iobutabarbital, diazepam  +  th iobuta-
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Ï  ig. 3. Cortisol level during interruption during adm inistration o f different anaesthetic
techniques
barbital and m eth oh ex ita l the cortisol levels differed sign ifican tly  (P <  0.05). 
W hen propanidid, fen tan yl +  propanidid, diazepam  propanidid and thio- 
butabarbital were used, the differences were even  more sign ificant (P <  0.01) 
com pared to the pregnant control group’s 6 p .m . cortisol values (F ig. 4).
Blood pressure decreased m oderately during in terruption and in the  
post-operative period in  all groups. The decrease ranged from  5 to  15% but 
statistica lly  the difference was not sign ificant (F ig. 5). The pulse rate increased 
b y  15% in the fen tan y l -|- propanidid, diazepam  -f- th iobutabarbital and 
m ethohexital groups (F ig. 6), but not during operative in terventions. A t 6 
p.m . the pulse-rates decreased except in  the fentanyl -f- propanidid and dia­
zepam  T* th iobutabarbital groups.
E valuation  o f the drug-com binations w as performed b y  calculating the 
regression co-efficien ts. From the drug-com binations the one which had a 
sm aller regression co-efficient was considered m ost effective. The best results
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were observed  w ith fen tanyl m ethohexital and diazepam  +  m ethohexital 
(Table I I ) .  In these cases the regression co-efficients were negative.
T h e doses of short-acting intravenous anaesthetics could be decreased if  
th e y  w ere combined w ith an algetics or sedatives.
MeaniSD
NS Non significant
F ig. 4. Serum  cortisol values a t 6 p .m . com pared to values at 6 p .m . in  pregnant control group
□  Duri ng surgery I On awakening □  6 p.m.
F ig . 5. Relative changes in b lood  pressure as compared to pre-operative values
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D  During surgery ■  On awakening 0  6 p.m.
Table II
R a n k  o f  d i f fe r e n t  a n a e s th e s ia  ty p e s  re la ted  to th e  c h a n g e s  o f  s e r u m  co r tiso l leve ls
Rank
of
groups
Narcotic-analgetic
drugs
Regression
coefficients
Significance 
between the 
regression 
coefficients
l . Fentanyl -j- 
M ethohexital 0.0254
NS p <  0.05
2. Diazepam  -f- 
M ethohcxital 0.0060
P < 0.05
3. Tliiobutabarbital 0.0266
4. M ethohexital 0.0271
5. Fentanyl +  Thiobutabarbital 0.0302
6. Fentanyl -f- Propanidid 0.0449 —
P <
П
0.05
7. Propanidid 0.0519
8 .
Diazepam -f- 
Propanidid 0.0839
9. Diazepam +  Tliiobutabarbital 0.1659
Equation of the analysed relation: y  - b x  -f- c
where:
y  =  In cortisol
X =  tim e of blood sampling (before, during and at the end of surgery) 
b , c =  parameters o f linear regression relation 
NS: non-significant
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Discussion
In  recent years for characterizing and q u antitating  the different stress- 
situ a tio n s , the serum catecholam ine and cortisol levels were m easured [1, 2, 5,
8, 17].
P lasm a cortisol has been found to rise during surgery and its changes to  
be sim ilar as those o f the b lood  sugar level [6, 15, 16] A parallel rise in  ACTH  
le v e l w as found and presum ably th is was responsible for the increase o f  cortisol 
[10], b u t th e  plasma ACTH concentration w as far higher than  th a t required  
to  produce a m axim um  adrenocortical response [13]. In addition, th e  norm al 
pitu itary-adrenocortical feedback  m echanism  is no longer effective as the  
con cen tration  o f both horm ones increases sim ultaneously . ThisA CTH adm in­
istra tio n  during surgery produces no further increase in plasm a cortisol, and  
corticostero id  adm inistration in  the postoperative period does not abolish  the  
A C T H -cortisol response [13].
A part from increased production, a rise in  plasm a cortisol could  also 
resu lt from  decreased breakdow n. A reduction in  hepatic blood flo w  during 
a n aesth esia  has been show n and the liver is responsible for the m etabolism  of 
h ydrocortisone by conjugation  [12]. The e lim ination  half-life o f cortisol in  the  
b o d y  ta k es approxim ately 2 hours, so that th is  factor would be of litt le  im por­
ta n ce  during the first hour o f  surgery. It seem s therefore more lik ely  th a t the  
p rod u ction  of cortisol is related  to the degree o f  surgical stress. A considerable  
rise o f  th e  plasm a cortisol lev e l has been show n during major surgery and a 
sm aller rise during minor operations [11]. The ex ten t of the rise th u s varies 
w ith  th e  ty p e  of surgery and anaesthesia.
A n x ie ty  and fear w hich  increase cortisol secretion and blood cortisol 
va lu es before an operation have been show n to  be influenced by prem edication  
and th e  sleep pattern o f the previous night [9]. In  the period after operation  
factors such as infection, prolonged bed rest, hypoxaem ia and even alterations 
in  th e  u su a l day-night physiological cycles all contribute to  the changes.
T he neuroendorcrine response to surgery m ay be altered in  different 
w a y s. T he purpose is the reduction  or abolition o f  the endocrine and m etabolic  
ch an ges th a t result from surgical stim ulation  [3].
T he neuroendocrine response to  traum a appears to have evolved  to  assist 
su rv iv a l in a prim itive environm ent by provid ing appropriate substrates to  
m a in ta in  the function o f v ita l organs. H ow ever, in  modern anaesthetic and 
surgical practice where severe physiological disturbances are prevented  or 
rap id ly  treated , and su itab le drugs and agents m ade readily availab le, the  
b en e fits  o f  the stress response are no longer apparent. The aim in  th e  future 
m u st be th e  safe prevention o f the adverse horm onal and m etabolic changes 
in d u ced  b y  surgical stress.
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The nine different drug-com binations adm inistered in this stu d y  had a 
sim ilar clinical b en efit, but could be ranked in respect of anaesthesia according 
to the serum cortisol value. On the basis o f  th is, estim ation o f the cortisol 
level related to  operations seem s to be an appropriate m ethod for characteriz­
ing the different anaesthetic techniques and to  suggest the optim um  drug- 
com bination for short-term  anaesthesia. The m easurem ent o f serum  cortisol 
levels could provide further details when new  anaesthetics are introduced into  
clinical anaesthesia.
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THE EFFECT OF SERA OF PATIENTS 
WITH SYSTEMIC LUPUS ERYTHEMATOSUS 
ON ARTIFICIAL IMMUNE COMPLEXES
A n i k ó  B á n y a i , G .  S z a b ó , *J. C s o n g o r , I l d i k ó  S o n k o l y , 
G y . S z e g e d i
T H IR D  D EPA R T M E N T O F M ED IC IN E AND »CEN TRA L RESEA RCH  LABORATORY, 
U N IV E R S IT Y  M ED ICAL SCHOOL, D E B R E C E N , MÓRICZ ZS. S TR EE T 6.
(R eceived: Decem ber 21, 1983)
The solubilization o f artificial im m une com plexes m ediated b y  com plem ents  
has been w ell-known since 1975. I t  is known th at the process is bound to  the in tegrity  
of the a lternative com plem ent pathw ay. The phenom enon o f solubilization  can be 
used in  the investigation  o f the function  o f the com plem ent system . W e have studied  
the solubilization of artificial com plexes containing BSA and 12äI labelled a n ti-B S A  on 
the effect o f sera of healthy subjects and those o f p atients suffering from  SL E . W e have  
observed th a t the solubilization capacity o f SL E  sera is significantly low er than th a t of 
healthy persons. The decrease is the m ost d istin ct at the time of the a c tiv ity  o f  the  
disease.
Keywords: com plem ent solubilization o f im m une com plexes, system ic  lupus 
erythem atosus
A bbreviations: B SA  — bovine serum album in; SL E  — system ic lupus eryth em atosu s;
CIC — circulating im m une com plexes; PEG  — polyethylen e glycol
Introduction
The solubilization of artificially produced im m une com plexes resulting on  
the effect o f fresh serum was described b y  Miller and N ussenzw eig [7]. In  
recent years th e  m echanism  o f the phenom enon has become clear even  in  its 
details. As an interaction o f the im m une com plexes and the serum  factors, a 
m olecule group o f C-3b-convertase a ctiv ity  jo ins w ith  the large-sized com plexes 
containing antigens and antibodies, ensuring first the incorporation o f C-3b 
in to  the com plex and then o f its effect breaking up o f the lattice structure into  
sm aller units [7, 9, 10]. The com plexes originating in this w ay differ from the  
starting com plexes in their biological features [6]. The phenom enon is bound  
to  the in tegrity  o f  the com plem ent alternative pathw ay, it postulates the pres­
ence o f  B , P , D  factors as well as a required quantity  o f C-3, it  is inh ib ited  by  
anti-B  serum w hile the presence o f anti-C-2 serum  or the absence o f  la te  com -
Send offprint requests to: Dr. Anikó B ányai Third Departm ent of M edicine, D ebrecen, 
Móricz Zs. Street 6., H -4004 Debrecen, P .O .B . 3, H ungary
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plem ent com ponents do not influence developm ent o f the reaction [9, 10]. 
The phenom enon o f so lubilization  presented an opportunity for elaborating a 
new  q u an tita tive  m ethod in  the in vestigation  o f th e  function o f the com ple­
m ent system  [1, 2, 7].
W hen the fresh serum o f healthy subjects is g iven to artificially produced  
radiolahelled  im m une com plexes, th ey  w ill show  a standard level w ith  sm all 
flu ctu ation s at different tim es, under con stan t experim ental conditions, 
w ith ou t d istinction  as to  sex and age [8]. A^decrease o f  the solubilization capac­
ity  o f  th e  serum w as, how ever, observed in th e  case o f patients suffering from  
autoim m une or im m unogenetic disease [1, 8]. A lthough no parallelism  was 
found betw een  the increase o f  circulating im m une com plex level and th e  de­
crease o f  the solubilization  capacity , a close correlation was observed betw een  
the decreased C-3 com plem ent level and the reduced solubilization capacity  [1].
In  our experim ents th e  solubilization cap acity  o f the serum sam ples o f  
p atien ts w ith  SLE has been investigated . Our aim  w as to  compare the results 
obtained  in  the active and inactive stages o f  th e  disease w ithin the patien t 
group as w ell as the values in  SLE nephropathy and those not due to  renal 
in vo lvem en t. In  som e patients the alterations o f  th e  solubilization cap acity  
were follow ed for several m onths.
Materials and m ethods
Serum  sam ples. T he serum  sam ples o f 25 h ea lth y  subjects and 65 patients, considered  
to suffer from  SL E  on th e  basis o f international criteria were studied . 45 out o f the 65 serum  
sam ples w ere obtained in  the inactive  stage of the d isease and 20 cases in the active  stage. 
17 sam ples originated from  patients w ith  nephropathy and 48 from patients w ith ou t renal 
in vo lv em en t. The blood w as allow ed to c lot at room  tem perature for one hour and then  at 
+ 4  °C for 2 hours. Thereafter the serum was separated b y  centrifugation. In the present 
experim ents the sera were used im m ediately  after separation , 1 ml o f each sam ple was in ­
activ a ted  at 56 °C for 30 m inutes and used as negative  control.
B SA -anti-B SA  com plex labelled w ith  U5I. L abelling the BSA (Calbiochem) w ith  125I 
was perform ed by the chloram ine-T  m ethod [5]. Cleaned rabbit IgG produced against B SA  
(M iles L ab .) was used for preparing the com plex. A t w eigh ing th e  labelled BSA w ith  an ti-B SA  
an app roxim ately  fourfold antibody excess was applied. T he reaction m ixture was incubated  
at 37 °C for 12 hours and the precipitate was separated b y  centrifugation at 1600 g  for 30 
m inutes. T he precipitate w as washed six  tim es in P B S  buffer (physiological NaCl so lution  
buffered w ith  phosphate, contain ing 0.15 mmol/1 Ca + + and Mg + + ions) centrifuged at 1600 g  
for 30 m inutes and dispersed b y  repeated sucking through a th in  cannule. The fina l concentra­
tion  o f th e  im m une com plex  was presented in such a w ay  th a t the standard sam ple produced  
from  m ixed  sera of h ea lth y  subjects should solubilize 20 //1 o f  the solution to 70% . A t th a t  
tim e there was approxim ately  2—3 /tg/20 /Л protein in  the so lution  containing IC.
Solubilization test. 400 /Л o f  the 1 : 2 dilution o f serum  was measured to 20 /il IC solu­
tion  in  duplicate. D ilu tion  o f serum  was perform ed w ith  P B S  containing Ca++ and Mg + + 
ions. T he m ixture was incub ated  a t 37 °C for 2 hours under gentle stirring, then the reaction  
w as stop ped  b y  adding 400 ц\ cold buffer. Segregation o f th e  n ot solubilized precip itate and  
the supernatant w as perform ed b y  centrifugation in  a cooled centrifuge at 1600 g for 30 
m inutes. A fter segregation o f the supernatant and precip itation  the activ ity  o f  each was 
m easured. For determ ining the degree o f spontaneous solubilization , the IC solution  was 
incub ated  w ith  P B S instead  o f serum. Calculation o f the rate o f solubilization was perform ed  
b y  the form ula
, , . a c tiv ity  o f supernatant
percent solub ilization  = ------ — -------г---------------------------=-------- — ------- X 100
a ctiv ity  of supern atant and precipitate
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Thereafter the value obtained was com pared to a standard sample prepared from  a 1 : 2 
dilution o f the m ixed sera o f healthy persons, considering the standard to  be 100% . The 
value o f spontaneous solubilization has been previously  substracted from the va lu es obtained. 
Sim ultaneously w ith the m easuring o f sam ples, the solubilization capacity o f h ea t inactivated  
parallel sera w as also determ ined; th is value has never exceeded 10%, sim ilarly to  the sponta­
neous solubilization observed beside the buffer.
A n ti-D N A  levels and com position o f  CIC in sera were m easured b y  m icro-E L ISA  
m ethod from  sera and 3.5%  PEG  precip itate o f  the sera, as described earlier [4].
S tatistica l analysis o f the results w as perform ed with Student’s tw o-sam ple t-test.
R esu lts were expressed as m ean ^  S .D .
R esults
In  Table I the m ean solubilization  capacity of 25 serum sam ples from  
h ea lth y  persons and th a t o f 65 serum sam ples with SLE are show n. T he solubil­
ization  capacity  of the serum o f SLE patien ts compared to  the standard  was 
sign ifican tly  lower than  th at o f h ea lth y  person (P <  0.001). The va lu es m ea­
sured in  the sera of patients were d ivided  in to  groups accordings to  w hether at 
the m om ent of blood sam pling disease w as in an active or in a ctiv e  stage. It 
was found that the m ean solubilization  capacity  of the patients show ing sym p­
tom s o f  activ ity  was sign ificantly  low er than  of those in the in a ctiv e  stage 
(P  <[ 0 .001), although the m ean value at the tim e of in activ ity  fell short o f  the  
m ean o f healthy persons. R esults are illustrated  in Table II.
Table I
Solubilization capacity o f  serum  (mean i  S.D.)
Sera of healthy persons 
N: 25
Sera of SLE patients 
N: 65
97.72 ±  9.33%
P <  0.001
50.91 ±  13.92%
N  =  num ber of patients
Table II
Solubilization capacity o f  S L E  serum  (mean ±  S.D.)
SLE
inactive •
N: 45 69.42 ±  14.95%
P <  0.001
SLE 32.40 ±  12.90%
active
N: 20
number of patients
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In  Table III the results were divided in to  groups from the point o f  v iew  
o f  renal involvem ent. The m ean  solubilization cap acity  o f  serum from 17 SLE  
néphropath ie patients w as significantly weaker th an  th at of SLE patients  
w ith o u t any renal in vo lvem en t (P <  0.001).
In  Table IY the va lu es o f  néphropathie p atien ts were divided into groups 
according to the active or in active  stage o f th e  d isease at the tim e o f blood  
sam pling . In the active stage th e  mean solubilization  capacity  was sign ificantly  
low er th an  that of néphropath ie SLE patients in th e  inactive  stage o f the d ise­
ase.
Table III
Solubilization capacity o f  serum o f  néphropathie SL E  patien ts and those without any renal
involvement (mean i  S .D .)
SLE
with nephropathy
N: 17
SLE
without nephropathy
N: 48
39.35 ±  21.56%
P <  0.001
64.56 ±  18.80%
N  =  number of patients
Table TV
Solubilization capacity o f  serum  o f  néphropathie S L E  patien ts in the active and inactive 
stages o f  the disease (mean i  S .D .)
SLE
active
with nephropathy 
N: 10
SLE
inactive
with nephropathy
N: 7
24.52 ±  11.90%
P <  0.001
60.57 ±  11.58%
N  =  number of patients
In  Table V, anti-D N A  levels, im m unoglobulins and C3 contents o f CIC 
m easure w ith  ELISA are illu strated  in the sera o f  a ctive  and inactive groups o f  
p a tien ts  and controls. W e could  find no correlation betw een solubilization  
ca p a c ity  and anti-D N A  titre  and im m unoglobulin contents o f com plexes. In  
th e  a ctive  stage the m ean C3 content was sign ifica n tly  decreased (P <  0.05).
In  Table VI data o f  th e  follow-up of 3 p atien ts are shown.
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Table V
Comparison o f  an ti-D N A  levels, components o f  PEG precipitates and solubilization  
capacity o f  sera (m ean -  S.D .)
3.5% PEG  precipitates o f sera
P atien ts level Imm unoglobulin
contents C3 contents
capacity
SLE
active  
N: 20
SLE
37.27 ±  7.86 176.71 ±  24.62 0.93 ±  0.63 32.40 ±  12.90
inactive  
N: 45
H ealthy
31.02 ±  16.46 157.02 ±  20.10 1.51 ±  1.18 69.42 ±  14.95
persons
N: 25
19.5 ±  5.42 10.54 ±  1.62 n. m. 97.72 ±  9.33
A nti-D N A , im m unoglobulin and C3 contents: /<g/rnl serum  
n. m. =  not measured 
N  =  number o f patients
Table VI
Solubilization capacity o f  sera o f  SL E  patients at follow-up
Solubilization
capacity
A ctiv ity Patients
89 inactive
1 . Sz. I. (with  
nephropathy)
1982.09.01.
17 active 12.08.
17 active 12.14.
46 inactive 1983.02.16.
26 inactive
2. N. J. (with
nephropathy)
1982.10.13.
23 active 1983.02.02.
25 active 02.14.
48 inactive 05.25.
43 inactive
3. N. E. (without
nephropathy)
1983.01.02.
35 active 02.02.
31 active 02.23.
46 inactive 05.25.
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Discussion
R ely in g  upon data in th e  literature, we have w orked out a m ethod th at 
is su itab le  for the in vestiga tion  o f com plem ent m ediated  im m une com plex  
so lu b iliza tion  by a great num ber o f serum sam ples. In  accordance with other 
authors, on the basis o f num erous preliminary experim ents the method was 
found to  be suitable for standardization  and reproduction. The results of the  
m ethod  show ed that the a b ility  o f  sera of SLE p atien ts to  solubilize im m une 
com p lexes considerably decreased  as compared to  th a t  o f  healthy persons. 
The degree o f decrease w as m o st distinct in the a ctive  stage of the disease, 
32.4%  o f  th a t of healthy controls. The mean solubilization  capacity of patients  
w ith  SL E  nephropathy w as also considerably lower th a n  th e  capacity of those  
w ith o u t an y  renal involvem ent. T he low value o f the m ean was however due to  
th e  low  values of patients sh ow in g sym ptom s o f a c tiv ity .
F rom  our follow-up in vestiga tion s the data o f  3 p a tien ts’ are indicated. 
A lth ou gh  up to now we had o n ly  a small number o f cases in  addition to those  
w here w e succeeded to fo llow -up  an essential alteration  o f the sym ptom s, it 
was observed  that the decrease o f  the solubilization ca p a c ity  precedes the clin i­
cal sym p tom s of activ ity  and after the remission it  reaches the starting level 
gradually , during several w eek s. Am ong the data w e h ave not indicated the  
values o f  th e  five  serum, sam ples where there was an acute bacterial infection  
in th e  p a tien ts at the tim e o f b lood  sampling. The va lu es obtained at that tim e  
reached th e  level characteristic o f  healthy persons. T he phenom enon has been  
observed  b y  other authors as w ell [8] but its cause has never been clarified.
T he decrease of in v itro  im m une com plex solub ilization  capacity in SLE  
and other diseases of im m une pathogenesis shows a correlation first of all w ith  
the low  serum  C3 level. One m igh t suppose the presence o f  inhibitory materials 
or com plem ent consum ption as a cause of the decrease [8] Consumption of 
com p lem en t factors in these d iseases m ay be the consequence o f in v ivo interac­
tion  o f  im m une com plexes b e in g  produced in great q u a n tity .
C3 contents were sig n ifica n tly  decreased in active  stage CIC: Decreased  
C3 co n ten ts  and reduced solubilization  capacity in d icated  the presence o f  
in co m p lete ly  solubilized im m u n e com plexes in the c ircu lation  of SLE patients  
as it  has been reported by B aatru p  et al. [3].
In  sp ite  of the close correlation  between the decrease of the C3 com ple­
m ent lev e l and of the so lu b ilization  capacity, we m u st em phasize that the  
p henom enon  o f solubilization is th e  result o f a com pound m echanism  dependent 
not o n ly  upon the C3 level b u t also on other factors and th a t is w hy one cannot 
dem onstrate a complete parallelism  in all, the cases. T he aim  o f further in vesti­
gations w ill be clarify how  th e  m easurem ent o f the solubilization  capacity o f  
serum  could  be em ployed for follow ing-up the clin ical sta te , the activ ity  and 
in a c tiv ity , and possibly also th e  effect o f therapy.
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SERUM IgE LEVEL
IN SYSTEMIC LUPUS ERYTHEMATOSUS
K a t a l i n  M i k e c z , I l d i k ó  S o n k o l y , ‘ C s i l l a  M é s z á r o s , G y . S z e g e d i
T H IR D  D EPA R T M E N T O F M ED IC IN E AND 'D E P A R T M E N T  O F DERM ATOLOGY AND V EN ERO LO GY , 
U N IV E R S IT Y  M EDICAL SCHOOL, D E B R E C E N , MÓRICZ ZS. U. 6.
(R eceived: March 14, 1984)
The serum to ta l-Ig E  level has been studied in system ic lupus erythem atosus 
(SL E ), in order to obtain  data concerning the significance of IgE  antibodies in the 
appearance o f SL E  sym ptom s. In m ost patients the serum IgE  content was significantly  
higher in the active stage of the disease than during rem ission. The find ings indicated  
a specific statistica l distribution due to the m ultiple factors influencing IgE  produc­
tion  and so an augm ented IgE  level cannot he regarded as a reliable feature of SLE  
activation .
Keywords: IgE , system ic lupus erythem atosus, skin, allergy
A bbreviations: CD LE — chronic discoid lupus erythem atosus; IgE  — im m unoglo­
bulin E; SL E  — system ic lupus erythem atosus
Introduction
An im portant feature o f system ic lupus erythem atosus (SL E ), one o f the 
representative autoim m une diseases, is the increase o f polyclonal im m unoglo­
bulins produced as a result o f im m unoregulatory disorder. In  their 26 SLE 
patients, R ebhun et al. [15] found a correlation betw een clinical a c tiv ity  of the 
disease and the serum  IgE  content.
Mészáros et al. [13], too , have shown th at, when com pared w ith  normal 
IgG, IgA  and IgM concentrations, the IgE  level was very high in  CDLE pa­
tients.
An im portant concept concerning the regulation o f IgE  production was 
th at o f Marsh et al. [12], who postulated the role o f double genetic regulation  
in  the allergen-specific and non-specific IgE  production.
B y  studying the serum  tota l-IgE  level in 95 SLE p atien ts, we searched 
for an answer to  the follow ing questions, a) Is the increased im m unoglobulin  
production observed in SLE valid  for the IgE  class ? b) does the serum  IgE con­
ten t show an upward trend in the clin ically  active stage o f  S L E ?  c) is the 
quantitative developm ent o f the IgE  level in  SLE similar to th a t of other 
im m unoglobulins? d) can the appearance o f  certain SLE skin sym ptom s be 
brought into connection w ith  the serum IgE  concentration? e) how  does the
Send offprint requests to: Dr. K atalin M ikecz, Third D epartm ent o f M edicine, Debrecen, 
Móricz Zs. u. 6 ., P .O .B . 3, H -4004 Debrecen, H ungary
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IgE  le v e l o f  the patients develop  during follow-up in vestigations ? f) can any  
change o f  th e  IgE  level be observed  in SLE patients in connection  w ith  allergic 
m an ifesta tion s ? 1 И i f F
F rom  the results we h a v e  tried  to conclude to  th e  possible role o f IgE  
a n tib od y  in  the appearance o f  SL E  sym ptom s and th e  course o f th e  disease.
M aterials and methods
A  stu d y  was performed on 95 patien ts w ith SLE and 25 control subjects. SL E  was 
diagnosed  on  the basis of the 1982 rev ised  A R A  criteria [18]. The active  and inactive  stages 
of th e  d isease  were defined on basis o f  th e  clinical signs and th e  laboratory param eters. In  the  
period o f  th e  first exam ination 54 S L E  patients were in rem ission and 41 in  the active  stage. 
The ex a m in a tio n  was later repeated in  46 patients on one or m ore occasions (follow -up exam in a­
tions). Spontaneous (atopic) allergy and  drug allergy were d iagnosed basis o f  the h istory as 
w ell as c lin ica l observations (the allergen-specific  IgE  level has n ot been measured).
T he classification of SL E  sk in  sym ptom s was perform ed on the basis o f  h istological 
and im m unohistochem ical processing o f skin biopsy m aterials in  addition to evaluation  of 
the c lin ica l evidence.
T h e  control group was se lected  from  persons of corresponding age and sex, not suffering 
from  auto im m un e, allergic, in flam m atory  or tumourous disease.
Q uan tita tive  determ ination o f  th e  serum total-IgE  leve l was performed b y  the m ethod  
of Ceska and Lundkvist [2] b y  m ean s of paper-disk radioim m unosorbent test (IgE  PR IST , 
P h ad eb as, Pharm acia, Sweden) and o f  the serum im m unoglobulins (IgG , IgA , IgM) b y  Man- 
cin i’s rad ia l im m unodiffusion [10].
On account of the w ell-know n w ide distribution and the so-called lognorm al d istribu­
tion  o f  th e  Ig E  level, logarithm ic transform ation of the va lues was also performed and geo­
m etric m eans were calculated [7]. W e accepted the IgE  lev e l as decidedly increased i f  the  
va lue  w as above the geom etric m ean  +  2 gSD  ( =  295 kU/1) o f control sera [9].
S ta tistica l analysis w as perform ed by the U -test, S tu d en t’s t-test and the x 2-test.
Results
T h e distribution o f th e  serum  IgE levels observed in our m aterial is 
illu stra ted  in  Fig. 1 and th e  resu lts o f m easurem ents are sum m arized in Table I. 
T aking th e  arithm etic m eans as the basis, the IgE  level o f the SLE patients  
proved  to  be significantly h igher than  the average IgE  level o f the control 
su b jects. The mean IgE  lev e l m easured in the active period o f the disease was 
s ig n ifica n tly  higher than  th a t  o f  patients in rem ission. The average IgE  con­
cen tra tion  o f the patients in  rem ission approxim ately equalled the m ean o f  
th e  h ea lth y  controls. The exam in ation  was repeated in 17 patients a later  
period o f  the disease. In  th is  group, during the active period o f the disease 
th e  m ean  IgE  level was in sign ifican tly  higher th an  the value in the inactive  
stage and significantly h igher as compared to the control value (Table I). Con­
sidering th e  wide scattering o f  th e  serum IgE leve l in  th e  healthy  adult popu­
la tio n  (7) and the lognorm al d istribution  of the va lues different from the norm al 
s ta tis t ic a l distribution [7, 17], their logarithmic transform ation was performed 
and th en  the difference b etw een  the geometric m eans proved to  be significant 
o n ly  for the patients in th e  clin ica lly  active stage (Table I).
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□ZU SLE active 
V ///Á  SLE inactive 
■  control
20 50 100 200 300 500 800 1000 kU/l
F ig. 1. D istribution  o f serum to ta l-IgE  levels in healthy and SL E  population  (n =  120) 
(a, b, c: geom etric m eans; a = SL E  inactive, b =  control, c =  SL E  active)
Table I
Serum tolal-IgE  concentration in SL E
Diagnosis n
A rithm etic mean -f- SD 
(kU /l)
G eometric m ean +  gSE 
(kU/l)
SLE
"■(independent
Total 95 177.6 ±  243.8 
p <  0.01 total 
to the control
61.8 ±  1.18
N S
exam inations) Inactive 54 119.5 ±  194.1 41.0 ±  1.23
Active 41 254.2 ±  290.5 
p <  0.001 active  
to the control 
p <  0.01 active  
to the inactive
1 0 5 .9 ±  1.26 
p <  0.02 active  
to the control 
p <c 0.01 active  
to the inactive
SLE Inactive 17 168.3 ±  208.8 74.6 ±  1.42
* ’ (parallel
exam inations)
Active 17 231.0 ±  257.7 
p <  0.01 active  
to the control
94.9 ±  1.47
Control 25 78.2 ±  80.5 53.9 ±  1.18
* the exam ination was performed in different patients 
** the exam ination was performed in the same patients in the active and inactive periods 
of the disease
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In  SL E  patients w ith  a h igh  (> 2 9 5 k U /l )  IgE lev e l, the concentration of 
other im m unoglobulins w as also elevated  as compared to  th a t o f  patients w ith  
a low  Ig E  leve l (Table II). The d ifference, however, was not sign ificant. Figure 2 
illu stra tes th e  results obtained b y  correlating three d ifferent SLE skin sym ptom s 
and th e  Ig E  level. In the group o f  patien ts w ith fixed  erythem a more displayed  
a h igh  Ig E  level than in the group w ithout any skin sym ptom s. In spite of 
th e  exp ectation s among th e  p a tien ts  w ith  urticaria few  had an IgE  level above 
295 kU/1. The differences b etw een  th e  geometric m eans were not significant 
s ta tis tica lly .
F ollow -up exam inations w ere performed in 46 p atien ts. In half o f them  
p erm an en tly  low IgE levels w ere measured; in tw o p atien ts the low IgE  level
Table II
Q uantitative relations o f serum immunoglobulins in SL E  patien ts with low and high IgE  levels
A verage concen tration  o f immune(globulins +  SD (g/1)
Ig E  level <  100 kU/1 IgE level >  295 kU/1
IgG 16.96 ±  6.07 17.85 ±  3.56
IgA 2.61 ±  2.20 2.71 ±  1.29
IgM 1.18 ±  0.49 1.53 ±  1.39
n 55 21
skin symptoms urticaria skin lesions erythem a 
Geometric
mean: 43.0 709  108.0 130.1 кU/l
F ig. 2. Percentage of normal and v ery  high serum IgE  levels in  SL E  patients w ithout and
w ith  skin sym ptom s
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•was com bined w ith  a lack o f IgA (Table I I I ) . A perm anently high IgE  level 
was found in seven  patien ts and in three p a tien ts th is was associated w ith  a 
perm anently high IgA  level.
Table III
Serum IgE  level in SL E  patients, fo llow -up examinations
IgE  level
Perm anently
low
Perm anently
high Fluctuating
(k U /l) 0 .5 -1 0 0 3 0 0 0 -1 0 0 0 0.5 — 1000
n 23 7* 16**
* perm anently high IgA  level in 3 patients 
** allergic history in  14 patients
The serum IgE  level o f 16 patients varied  w ithin  wide lim its and the  
variations did not show  any correlation w ith  a c tiv ity  o f the disease. W hen  
looking for the exp lanation  o f this phenom enon, it  was found th at a top y  or 
(more often) drug allergy was m entioned in th e  h istory of all but tw o o f the  
patients. Am ong the 30 patien ts with a stead y  IgE  level, 12 patients were 
allergic.
Out o f the 46 SLE patients participating in  the follow-up exam inations, 
allergic phenom ena were found in  26 patients (Table IV) in the form o f exan ­
them a, urticariform skin sym ptom s, rarely allergic rhinitis and angioneurotic  
oedem a (we had no asthm a patients). Some drug m ay have been the exciting  
agent in 20 cases, pollen or house dust in 2 cases, parasitic infestation in 1 case 
and no exogenous cause could be detected in 3 cases. In the allergic SLE patients  
the mean variation  o f th e  IgE  level was found to  be sign ificantly  higher than  
in the non-allergic p atien ts. In some cases the appearance o f allergic phenom ­
ena showed a correlation w ith  the increase o f  th e  IgE  level.
Table IV
Serum IgE  level in allergic SLE  patients, fo llow -up examinations
P a tien ts  Arithmetic mean o f G eom etric mean of
group difference of «extrem e aifiVrencc +  gSE
values -f- SD
Allergic group 
n =  26
213.0 ±  287.5 
NS
67.1 ±  1.41 
p <  0.05
Non-allergic group 
n =  20
92.8 ±  150.8 12.6 ±  2.22
* extrem e value: m axim um  and minimum IgE  concentration measured in the sam e 
patient (kU/1)
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D iscussion
In  system ic autoim m une disease entities including SLE IgE  m a y  be in 
excess due to  the increased an tib od y  production o f the patients and th e  chronic 
course o f  th e  disease [5, 8, 16]. Som e authors attribute a subordinate [14], 
others a significant role [3] to  IgE  in  the pathom echanism  o f autoim m une  
diseases. T he high concentration  o f serum  im m unoglobulins m ay be an im por­
ta n t sign  o f  activation o f the d isease [5], but it  does not always unam biguously  
refers to  th e  role played b y  a g iven im m unoglobulin  in  the course o f  auto im ­
m une disease.
In  aggreem ent w ith  other authors [9, 15], we have observed a w ide scat­
ter in g  o f  th e  serum IgE con ten t and so we assum ed th at an increased Ig E  level 
in  SL E  w as a sign o f the clin ical activation  o f the disease in  m any p atien ts. 
S till, as an expressed increase does not appear in  every patient, the d iagnostic  
v a lu e  o f  a high serum IgE lev e l is lim ited .
T h e production of IgE  m ore or less differs from that o f other im m uno­
g lob u lin s. A t the same tim e, in  som e cases we have observed a lack o f IgA  in 
th e  presence of a perm anently low  IgE  level as w ell as a high IgA  concentration  
in  th e  presence of a perm anently  high IgE  level. This observation supports the 
th eo ry  o f  a genetically determ ined regulation o f IgE  production [12], and 
raises th e  possibility o f regulatory disorders being present [1].
W e found higher IgE  levels in the background of fixed  erythem a accom ­
p an ied  w ith  basic m em brane degeneration and in SLE urticaria, sim ilar in 
appearance to an allergic sk in  m anifestation . A topy occurred rarely, while 
drug a llergy  very often in  our SLE patients. Goldman et al. [6] m easured low  
Ig E  concentrations in the blood o f allergic SLE patients. During our follow-up  
exam in ation s of allergic p atien ts we observed a capricious flu ctu ation  of the 
Ig E  lev e l. These data support the idea of an independent genetic regulation  
o f  allergen-specific IgE  production  [12], and at the same tim e th ey  indicate a 
regu la tory  disorder o f allergen-specific IgE  production in SLE. On th e  other 
hand, all this m ay refer to  the fact th a t it  is not reagin-dependent reactions 
th a t can  be found in the foreground o f the clinical picture at the tim e o f acti­
v a tio n  o f  the basic disease and o f the appearance o f local and system ic sym ­
p tom s.
Several authors have raised the possible role o f im m une com plexes con­
ta in in g  IgE  in the induction  o f diseases associated w ith im m une com plexes 
[3, 4 , 8, 11]. It m ight be assum ed th a t IgE  antibodies, produced during the  
course o f  SLE like other antibodies, would develop circulating im m une com ­
p lex es  causing system ic and local tissue dam age. The local consequences of 
reagin-dependent reactions induced by im m une com plexes contain ing IgE  spe­
c if ica lly  linking to the surface o f  basophils and m ast cells m ay m anifest them ­
se lv es  in  an typical form  in  som e cases, in  so far as the vasoactive  m ediator
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m aterials form ing the main link o f th e  reaction chain are consum ed for the 
deposition of loca lly  accum ulated im m une com plexes [4].
As to  the role o f IgE antibody in  im m une com plex d iseases there are 
several alternatives; the question w ill have to  be settled experim entally . In 
the present stu d y  we have only a ttem p ted  to find  an explanation for the chang­
es o f  the IgE  level in SLE from the clin ical point of view.
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THE CLINICAL VALUE OE THE HIS-BUNDLE  
ELECTROGRAM IN INTRAVENTRICULAR 
CONDUCTION DEFECTS
G. V e r e s s , J. B o r b o l a , L. S z a t m á r i
NATION A L IN S T IT U T E  OF CARDIOLOGY, 1450 BU D A PEST, HÁMÁN KATÓ STR . 29. 
(R eceived 17 O ctober 1983)
A stu dy  concerned w ith the clinical significance of the H is-bundle ECG was 
carried out in  association w ith upper atrial stim ulation  in 20 patients w ith  intraventric­
ular conduction defect. On the ground o f the results the H is-bundle ECG is regarded 
as a procedure o f diagnostic value in  intraventricular conduction defects by contri­
buting to the accuracy of inform ation on the severity  and ex ten t o f the lesion. In the 
framework of published observations, including the present findings, questions relating  
to prognosis and to the necessity for pacing in  bifascicular block are discussed.
Keywords! bifascicular block, H is-bundle ECG, H-V interval, atrioventricular
block
Abbreviations: IY DC: intraventricular conduction  defect; H PS: H is-Tawara Purkinje 
system ; H B E : H is-bundle ECG; PA interval: intraatrial conduction tim e; А Н -interval: A-V 
nodal conduction tim e; H-Y interval: conduction tim e d istally  to the H is-bundle
Introduction
The various intraventricular conduction  defects (IVCD) m ay affect one 
or more sections o f  the H is-Tawara-Purkinje system  (H P S), in  other words, 
the block m ay in vo lve the bundle o f H is, the right bundle o f Tawara, the stem  
o f the left bundle o f Tawara, its anterior or posterior fascicle, and the peripheral 
Purkinje-system  [14, 15].
The various typ es o f bundle and fascicular block m ay be diagnosed by 
the conventional 12-lead surface ECG. The form, w idth and axis position of  
the Q R S-com plex provide valuable diagnostic inform ation on IVCD, hut the 
traditional ECG lacks the necessary accuracy for any closer defin ition  either 
of the degree o f  the conduction disturbance, or o f the num ber and extent o f  
the lesions in case if  IVCD involving the H P S .
It has been reported in recent years th a t the H is-bundle ECG (H B E ) 
greatly contributes to  the diagnostic accuracy in IVCD involv ing  the H PS,
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and e v e n  allows to identify  lesions eluding diagnosis by the traditional sur- 
face-E C G  leads [2, 3, 7, 16, 17, 18, 19, 20, 21, 22, 23, 26, 28, 29, 30, 31].
T heoretically , a prolonged H -У interval o f the H B E , in the presence of 
a bundle-branch  block, predicts th e  progression o f th e  conduction disorder to  
co m p le te  AY-block. Production  o f com plete heart block and sudden death  
p reced ed  b y  these signs have been  reported b y  num erous authors [10, 18, 25, 
29]. T h e  significance of the H -V  interval in the diagnosis o f  IYCD is, how ever, 
s till op en  to  controversy and requires further electrophysiological and clinical 
ev id en ce . The present stu d y  has been concerned w ith  the significance o f  th e  
H -Y  in terv a l in cases o f bundle-branch block.
P atien ts and methods
In  th e  period 1977/78 100 H B E  were performed in our In stitu te . The investiga tion  
w as p ro m p ted  in  the majority o f th e  cases b y  sick sinus syndrom e, W P W  and LGL syndrom es, 
su p raven tricu lar tachycardia, atrioventricu lar and intraventricular conduction disturbances  
[32]. T h is  report is confined to th o se  cases in which the presence o f IYCD was accessible to 
ECG diggn osis. The H B E  was recorded under conditions described earlier [30, 31].
U p p er  atrial stim ulation w as app lied , subsequently the bundle o f H is was stim ulated  
in  order to  bring the His-bundle p o ten tia l in to  display [21]. E xhaustion  of the conduction  
sy s tem  b y  m eans of stim ulation o f  increasing frequency (100—180/m in) allowed to stu d y  the  
beh av iou r  o f  th e  AV-node (A -H -in terval) and of the H is-Purkinje—Tawara system  (H -Y interval)  
[5]. T h e  H -V  interval was m easured from  the peak of the H -deflection  to the earliest QRS- 
d e flec tio n  appearing on the sim ultaneous ECG-tracing, 2 or 3 surface-ECG-leads being re­
corded sim ultaneously  w ith the H B E . In  order to study  the H -V -interval more closely, 0.02  
m g/kg bod y-w eigh t of atropin w as adm inistered intravenously  prior to  atrial stim ulation , 
w ith  th e  a im  o f eliminating the balan cing  function of the AV-node [23]. After abrupt d iscon­
tin u a n ce  o f  upper atrial stim ulation  th e  sinus node recovery tim e (SN R T ) was m easured  
to g e th er  w ith  its corrected value. In  a few  cases 0.5 to  1 m g/kg body w eight o f A jm alin was 
a d m in istered  i.v . for the study of th e  behaviour of the H -V -interval [8, 27]. The tracings were 
reg istered  b y  a direct-writing S iem ens—E lem a 1600 or a H eilige 363-type at a paper speed  
of 25—50—100 mm/sec.
Results
T w e n ty  H BE had been prom pted  by clinical m anifestations associated  
w ith  IV C D . The patients ranged in  age from 11 to 66 years. D istribution o f the  
various ty p e s  of IVCD and th e  values of the electrophysiological param eters 
are sh o w n  in Table I. The IV C D  were associated w ith  AV conduction distur­
bances in  6, by sino-auricular b lock  in  2 cases. The presenting sym ptom s were 
dizziness in  6, syncope in 4, p a lp ita tio n  in 5, w eakness in  3 cases, bradycardia íd 
one case . A  patient with right bundle-branch block -|- 1st degree AV-block, in  
w hom  periodic 3rd degree A V -block had been noted earlier, had now no com ­
p la in ts. I n  the present cases th e  P -А interval ranged from  25 to 50 m s, the  
A -H -in terv a l from 50 to 120 m s and the H-V in terval from  35 to 255 ms. The 
H -V -in terva l was abnormal in  7 cases. In 3 o f the 4 patients w ith syncope it 
was abnorm ally  increased. I ts  excessive  increase to  255 and 155 ms in tw o p a ­
tien ts w ith  le ft bundle-branch b lock  (L B B B ) suffering from  vertigo confirm ed
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the diagnosis of a bilateral bundle injury. An increase in  the H -V interval by 
more than  5 ms was dem onstrable in response to upper atrial stim ulation  in 4 
cases, to  stim ulation under the effect o f atropine in 9 cases. T w o patients of 
the la tter group developed a block distal to  the bundle o f H is, one patient an 
intra-H is block. In the m ajority , lengthening o f the А -H in terval w as elicited  
by stim ulation  (100 to 150/m in), no such response having been obtained in 4 
cases. The SNRT ranged from  650 to  8000 ms, exceeding the norm al value in 
5 cases. A perm anent pacem aker was im planted in 7 cases, tem porary  pacing 
was required in one case (case No. 20) because o f asystole subsequent to 
ventricular fibrillation. In  4 o f these cases bilateral bundle branch block, in 3 
cases, the sick sinus syndrom e had been the primary factor responsib le for the 
sym ptom s. In the follow ing som e illustrative cases are reported, th e  respective 
serial numbers being listed  in Table I.
Case 1. K . I., a fem ale aged 61 w as adm itted  w ith  dizzines and fa inting . T he ECG was 
typ ica l o f  a L B B B  +  lst-degree AV-block. The H B E  revealed an excessive ly  prolonged H-Y 
in terva l (255 ms) and a normal А -H  interval (F ig . 1). A perm anent pacem aker w as im planted.
Case 4. S. K ., a fem ale, aged 48, had experienced recurrent episodes o f  m om entary  
unconsciousness over the last w eeks. The ECG revealed, in addition to an in term itten t LBBB  
and L A H B , a frequently recurrent sino-auricular block. The intervals o f th e  H B E , in  both  
the L B B B  as well as in the L A H B  beats, were found normal (F ig. 2) and rem ained unchanged  
in response to stim ulation. The SN R T  attained, how ever, 3150 ms. A fter im p lan ta tion  of a per­
m anent pacemaker she was discharged sym ptom -free.
HV :255ms
Fig. 1. K. L., 61-year-old fem ale patien t L B B B  +  prolonged H-V interval 
(incom plete bilateral bundle-branch block)
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Table 1
Electrophysiologic data in patients with intraventricular conduction disorders
о
H -У in terval
Serial
ECG
No
R-R P-A A-H H-V SNRT W enckebach poin t stim ulation 
1 0 0 -1 8 0  
per min.
atropine +  
stim ulation
PM
im plant
1. LBBB +  AV-I 860 35 75 255 1600 120 255 260 +
2. L B B B  +  R B B B  +
premat. c. 800 50 50 35 1100 120 35 50 —
3. R B B B  +  LAHB 1070 40 70 50 1180 100 50 60 —
4. L B B B  +  LAHB +  S-А Ы. 1820 40 50 60 3150 100 60 60 +
5. R B B B  +  LAHB +  AV-Ь I. 760 40 120 70 1300 120 70 70 +
6 . R B B B  +  LAHB 680 50 70 50 8000 120 50 60 +
7. Interm. LBBB 4- LAHB 700 45 75 45 1300 120 45 45
8 . R B B B  +  AV-Ы. I. +
premat. v .  c . 950 40 170 50 1110 100 50 50 —
9. LBBB -f- interm. LAHB 700 50 50 155 2000 — 155 155
AV-bl. dist. to H
+
10. R B B B  +  LAHB 780 40 80 55 780 100 55 55 —
11. LBBB 660 35 60 45 650 — 50 occasional bl. 
dist. to H
—
12. L B B B 780 40 50 45 650 120 50 Intra-
His-bl.
—
13. LAHB +  R B B B  +  AV-b I. 780 50 75 115 1400 150 115 120 +
14. LBBB +  S-A-bl. 1260 25 100 75 2800 120 75 80 +
15. R B B B 760 40 130 40 1200 120 40 40
16. R B B B  +  AV-Ы. I. +
interm. AV-bl. III. 780 50 170 45 1150 100 45 45 —
17. LAHB +  AV-bl. I. 900 50 110 65 1200 150 70 70 —
18. LBBB 800 50 30 50 1200 — 50 50 —
19. LAHB 660 35 80 45 650 — 50 45 —
20. interm. LAHB +  LAHB - f
prem. atr. contr. 680 40 70 40 820 retrograde
conduction
40 — temporary
V
E
R
E
SS, G
. et al.
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Case 12. S. P ., a fem ale aged 56, had been on digitalis and diuretics because o f circulatory  
failure for years, and had been noticing occasional slowing of heart rate. T he surface ECG 
showed a typical L B B B  w ith normal A V -conduction. The intervals o f th e  H B E  were normal. 
H igh right atrial stim ulation  at 125/m in fa iled  to  elicit any change in  the H -Y  interval, but 
after i.v . atropine, production of an intra-H is b lock w as registered during stim ulation  (176/m in). 
No perm anent pacing was required (F ig. 3).
Case 13. P. T ., a fem ale patien t aged 65, hypertensive for 14 years, w as adm itted for 
recurrent brief spells o f unconciousness experienced lately . The surface leads revealed , in addi­
tion  to  a LAH B -f- R B B B  a 1st degree A V -block w ith  the PQ m easuring 0 .24 sec. The H-V 
interval of the H B E  was prolonged (115 m s), thu s confirm ing that, in addition  to  the bifascic- 
ular block, conduction by the posterior, fascicle, was also affected (trifascicular block). The 
H-V interval rem ained unchanged upon upper atrial stim ulation (Fig. 4). A fter im plantation  
o f a perm anent pacem aker the patient was discharged symptom-free.
100 mm/sec
HBE
AH :50ms AH :50ms
HV :60ms HV :60ms
Fig. 2.\ S. H ., 48-year-old| fem ale patient. In term itten t LAH B and L B B B  (norm pl tim e-
intervals)
After atropine
100mm/sec S t-S t  :480ms S t-S t:3 4 0 m s
Fig. 3. S. P., 56-year-old fem ale patient L B B B  w ith  normal tim e-intervals. U pper atrial 
stim ulation under the effect o f i .v . atropine elicits an intra-H is block
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100 mm/sec
St - A : 80 m s _____ _
A - H : 75 ms 
H -V :115 ms
F ig. 4. P. T., 65-year-old fem ale p a tien t. Upper atrial stim ulation  leaves the AH and HV
intervals unchanged
Discussion
W hile 6 to 10% o f p a tien ts  w ith bifascicular block are liable to develop  
a com p lete  AV-block w ith  A dam s-Stokes attacks at som e later tim e [4, 12, 13, 
24, 2 6 ), th e  majority rem ain free from this com plication  [3, 7, 32]. D elim ita ­
tio n  o f  a homogeneous group in  which this is bound to  occur is, obviously , 
im p ossib le  on the basis o f conventional leads. The H B E , whose H -У interval 
is accessib le  to  accurate m easurem ents, does, how ever, allow to separate the  
tw o  groups, according to  w h eth er  the conduction tim e o f the still functioning  
branch  is normal or prolonged. The significance o f  th is lies in the possib ility  
o f p red ictin g  the clinical course, possibly o f recom m ending arteficial pacing  
beforehand , so as to prevent th e  production o f a com plete heart-block and o f  
th e  A dam s-Stokes syndrom e [11]. A close electrophysiological investigation  o f  
th is k in d  has also the ad van tage o f  making unnecessary pacing avoidable i f  it  
show s a norm al profile o f  th e  conduction system  in  patien ts w ith bifascicular  
or bundle-branch block, experiencing spells o f dizziness or syncope, particularly  
in  ad van ced  age. In the presence o f a normal H -У interval the last-nam ed  
sy m p to m s point to a neurological or cerebrovascular, rather than to a cardiac, 
origin [6, 32]. In our IVCD p a tien ts  the H B E  has been  o f substantial d iagnos­
tic  aid . T he abnormal H -У in terv a l supported the diagnosis o f bilateral bundle  
lesion  in  3 out of 4 patients w ith  sym ptom s o f syncope, and in 2 of these the
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presence o f the sick sinus syndrom e was also confirm ed on the ground of an 
abnorm al SNRT.
Perm anent pacing was applied in three cases, tem porary pacing in the 
fourth case o f the syncope-group. In another three cases (patients 1, 5, 9) 
bilateral bundle lesion, confirm ed by an abnorm ally increased H-Y interval, 
ju stified  in accordance w ith  the clinical sym ptom s the im plantation  of a per­
m anent pacem aker. E xhaustion  o f the conduction system  b y  atrial stim ulation  
m ay disclose eventual concealed conduction defects [5, 17, 19, 21, 28]. In  the 
m ajority of the present cases an increase in the А -H  interval w as dem onstrable 
in response to  upper atrial stim ulation . The function o f the conduction  system  
distal to  the bundle o f H is is d ifficult to study, owing to  th e  screening role of 
the AY node. For th is reason, stim ulation  failed to produce any significance 
change in the H-V interval. Atropine is, however, capable o f  inhibiting the 
balancing function o f the AV node. A lengthening o f the H -V  interval was 
indeed dem onstrable, in 9 o f  our cases in response to stim ulation  under the  
effect o f atropine. In 2 o f these, production of a block distal to  the bundle 
o f H is (Cases Nos 9 and 11), and in one case (No. 12) an intra-H is block 
was noted.
A classic bundle-branch block dem onstrable by conventional ECG leads 
associated w ith other conduction  disorders is a sign o f  ex ten sive  damage to 
the conduction system . It is , how ever, often im possible to  te ll from the ECG 
alone, whether the A V -conduction disorder associated w ith  a bundle-branch 
block was reflecting a lesion o f the AV-node, either one near the H PS, or one 
distal to  the node o f  H is. In  6 o f the present cases a lst-degree AV-block asso­
ciated w ith I VCD was show n b y  the surface ECG. On the evidence o f the 
H B E  the lesion responsible for the AV-block was d istal to  th e  bundle of His in 
4 (N os 1, 5, 13, 17), and proxim al to it  in in 2 (Nos 8, 16) cases. Sim ilarly to  
the lst-degree block, the 2nd-degree-block m ay also have a lesion  o f the con­
duction  system  proxim al or d istal to the bundle o f H is as its  site o f  origin. It is 
the exact location o f the lesion rather than its typ e, th at determ ines the prog­
nosis [17]. In our Case N o. 9 2 : 1  AV-block in association w ith  a L B B B  was 
noted. On the evidence o f  the H B E , the site o f the block was d istal to  the bundle 
o f H is. I f  in patients com plaining o f  dizziness the H B E -in tervals were found 
n egative, unnecessary pacem aker im plantation could be avoided , in view  of  
the reliab ility  o f  this diagnostic procedure. In Case No. 20 a concealed retro­
grade conduction o f A V -junctional prem ature contractions o f  bigem inal arrange­
m ent had been responsible for a gradual increase in the А -H  in terval in the 
sinus beats following upon the prem ature contractions and th u s, for the pro­
duction  o f W enckebach periodicity. A similar case by surface ECG has been 
reported by D am ato and Lau [1], but to our knowledge before our Case No. 
20 no observation o f th is uncom m on rhythm  disturbance id entified  by H BE  
has been published [33].
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T h e length of the H -V in terva l in IYCD has been related by numerous 
authors to  the production o f com p lete  heart block and to  sudden death at some 
later t im e . Scheimann et al., fo llow ing up 39 cases o f bundle-branch block w ith  
H -V  in terva ls longer than  75 m s for an average period o f 18 m onths, noted  
th e  production  of 2nd or 3rd-degree block in 7 cases; 13 patients died, 5 of 
th em  suddenly . In the 14 p a tien ts  o f  Vera et al. [29] w ho had bundle-branch  
block  in  association w ith  syn cop e, 2nd or 3rd-degree A V -block, the H-V interval 
w as in var iab ly  longer than  65 m s. In the 10 patients o f N arula et al. [17] who  
had L A H B  -f- RBB in associa tion  w ith  H-V intervals exceeding 55 m s, the  
m o rta lity  in  a year was 61 percent. Perm anent pacing o f  patien ts w ith  asym p­
to m a tic  bundle-branch b lock  w as advocated b y  th ese authors if  the H-V  
in te r v a l was longer than  70 m s. Dhingra et al. [7] found  H -V intervals over 
80 m s in  not more than  18 (5% ) out o f 388 patients w ith  bundle-branch block. 
P ro d u ctio n  of a 2nd or 3rd-degree AV-block was confined  to  one (6%) o f the  
p a tie n ts  during an average fo llow -up period of tw o years. The death figure in 
th e ir  p a tien t material w as 33% , as opposed to 61%  reported b y  Narula et al. 
[17 ]. I t  has however to  be n o ted  th a t the study o f D hingra et al. [7] was 
p ro sp ectiv e , the patients w ith  confirm ed AV-block or episodes of syncope 
a ssoc ia ted  with the bundle-branch block having been excluded at the onset. 
On th e  other hand, the figures o f  Scheim ann et al. [25], N arula et al. [18] and 
V era e t al. [29] were based on  retrospective studies w ith  no selection on the  
b asis o f  the criteria referred to  above.
From  the present observations the H B E  em erges as a procedure suitable 
for th e  study of patients w ith  IVCD. It should be perform ed in all cases in 
w h ich  IVCD are associated w ith  dizziness, syncope or bradyarrhythm ia. Abnor­
m al electrophysiological fin d in gs, in particular a H -V in terval exceeding 75 ms 
or an abnorm al SNRT, call for preventive im plantation  o f a pacem aker [11]. 
N e g a tiv e  H B E  intervals in  p atien ts w ith bundle-branch block com plaining  
o f d izziness exclude the p o ssib ility  of A dam s-Stokes attacks and allows to 
a v o id  unnecessary pacing. O bviously , neurological in vestigations for the pos­
sib le  causes of the sym ptom s are required in these cases.
Periodic follow-up stu d ies should be made in  sym ptom  free cases of 
bundle-branch block, but electrophysiological investigations are not necessary.
R E F E R E N C E S
1. D a m a to , A. N ., Lau, S. H .: C oncealed and supernormal atrioventricular conduction. Circu­
la tion  43, 967-970 (1971)
2. D én es, P ., Dhingra, R. C., W u, D ., Chuquimia, R ., A m at-Y -L eon , F ., W yndham , C., Rosen,
K . M.: H-Y interval in  p a tien ts  w ith  bifascicular block and le ft anterior hem iblock. Am. 
J . Cardiol. 35, 23-29  (1975)
3. D én es, P ., Dhingra, R. C., W u , D ., W yndham , C. R ., A m at-Y -L eon , F ., Rosen, K. M.:
Sudden death in patien ts w ith  chronic bifascicular block. Arch. Intern. Med. 137, 
1005-1010 (1977)
A d a  Medica Hungarica 42, 1985
HIS-BUNDLE ELECTROGRAM IN INTRAVENTRICULAR CONDUCTION DEFECTS 75
4. DePasquale, N . P ., Bruno, M. S.: Natural h istory o f com bined right bundle branch block
and left anterior hem iblock (bilateral bundle branch block). Am. J. Med. 54, 297-303  
(1973)
5. Dhingra, R. C., R osen , K . M., Rahim toola, S. H .: Norm al conduction intervals and re­
sponses in s ix ty -on e  patiens using H is bundle recording and atrial pacing. Chest 64, 
55-59 (1973)
6. Dhingra, R. C., D énes, P ., W u, D ., Chuquimia, R ., Am at-Y -L eon, F ., W yndham , C.,
Rosen, K. M.: Syncope in patients w ith chronic bifascicular block. Significance, causative  
m echanism s and clinical im plications. Ann. Intern. Med. 81, 302-306 (1974)
7. Dhingra, R. C., D énes, P ., W u, D ., W yndham , C.: P rospective observations in patients w ith
chronic bundle branch block and marked H -V prolongation. Circulation 53, 600-604  
(1976)
8. D ekov, E ., Veress, G., Borbola, J ., Szatm áry, L.: A His-Tawara-Purkinje rendszer electro-
physiológiai v izsgá la ta . (E lectrophysiological stu d y  o f the H is-Tawara-Purkinje-sys- 
tem .) Proc. M eeting o f the Hungarian A ssociation  o f Cardiologists, B alatonfiired (1979)
9. Ferrer, M. I.: The sick sinus syndrom a. Circulation 47, 635-641 (1974)
10. Gupta, P. K ., L ichstein , E ., Chadda, K. D.: Follow -up studies in patients w ith  right bundle
branch block and left anterior hemiblock: S ignificance o f H-V interval. J . Electrocardiol. 
10, 221-228 (1977)
11. H aft, J. I.: The H -V interval and patients w ith  bifascicular block. J. Electrocardiol. 10,
1-3 (1977)
12. K ulbertus, H ., Collignon, P .: Association of right bundle branch block w ith  left superior or
inferior intraventricu lar block. Its relation to com plete heart block and A dam s-Stokes 
Syndrome. Br. H eart J . 31, 435-440 (1969)
13. Lasser, R. P ., H aft, J . I., Friedberg, C. K.: R elationship  o f right bundle branch block and
marked left axis deviation  (w ith left parietal or peri-infarction block) to com plete heart 
block and A dam s-Stokes syndrome. Circulation 37, 429-437 (1968)
14. Lenegre, J.: E tio logy  and pathology of bilateral bundle branch block in relation to com plete
heart block. Prog. Cardiovasc. Dis. 6, 409-444  (1964)
15. L ev, M.: The norm al o f  the conduction system  and its pathology in atrioventricular block
Ann. NY. Acad. Sei. I l l ,  817-822 (1964)
16. L evites, R ., and H aft, J . I.: Significance of first degree heart block in bifascicular block.
Am. J. Cardiol. 34, 259-264  (1974)
17. Narula, 0 .  S.: H is B undle E lectrography and Clinical E lectrophysiology. F . A. D avis Co.,
Philadelphia (1975)
18. Narula, O. S., Gazi, N ., Sam et, P ., T olentino, A .: Ten year prospective observation based
an H-V interval in  patien ts w ith  right bundle branch block (R B B B ) and left axis devia­
tion (LAD). Proc. 51st Annual Scientific Session o f the Am erican H eart A ssociation. 
Dallas (1978)
19. Rosen, K. M., R ah im toola , S. H ., Chuquimia, R ., L oeb, H. S. and Gunnar, R. M.: Electro-
physiological significance of first degree atrioventricular block w ith intraventricular  
conduction disturbance. Circulation 43, 491-502  (1971)
20. R osen, K. M., E hsani, A. E ., R ahim toola, S. H .: H -V intervals in  left bundle branch block
clinical and electrocardiographic correlations. Circulation 46, 717-723 (1972)
21. R osen, K. M.: E valuation  o f cardiac conduction in  th e  cardiac catheterization laboratory.
Am. J. Cardiol. 30, 701-703  (1972)
22. R osen, K. M., R ah im toola , S. H ., Bharati, S., L ev, M.: Bundle branch block w ith  intact
atrioventricular conduction. Electrophysiologic and pathologic correlations in three 
cases. Am. J. Cardiol. 32, 783-793 (1973)
23. R osen, K. M.: Personal com m unication. (1978)
24. Rosenbaum , M. B ., E lizari, M. V., Lazzari, J. O.: The H em iblocks. Tam pa Tracings, Old-
smar, F la . (1970)
25. Scheim an, M., W eiss, A ., K unkel, F.: His bundle recordings in patients w ith bundle branch
block and transient neurologic sym ptom s. Circulation 48, 322-330 (1973)
26. Spurrel, R. A. J ., Sm ithen , C. S., Sow ton, E.: S tu dy o f right bundle branch block in asso­
ciation w ith either left anterior hem iblock or left posterior hem iblock using H is bundle 
electrograms. Br. H eart .1. 34, 800-806 (1972)
27. Szatm áry, L., Borbola, J ., Veress, G.: A jm alin-test alkalm azása klinikai szívelektrofizioló-
giai vizsgálatokban. (U se of Ajm alin-test in electrophysiological investigations o f the 
heart.) Proc. M eeting of Hungarian A ssociation o f Cardiologists, Balatonfiired (1979)
28. Tenczer, J., L ittm ann, L ., Molnár, F ., Fenyvesi, T ., Zsám olyi, K ., K ékes, Е.: Elektrofizioló-
giai vizsgálatok bifascicularis blockban. (E lectrophysiological studies in bifascicular  
block.) Magy. B elorv. Arch. 31, 276-280 (1978)
Ada Medica Hungarica 42, 1985
76 VERESS, G. et al.
29. V era, Z ., M ason, D. T ., Aw an, N . A ., Silva, O.: Prolonged His-Q interval in bifascicular
b lock . E vidence for im pending com plete trifascicular block. Clin. Res. 23, 212-218  (1975)
30. V eress, G ., Szatm áry, L.: A llis -k ö teg  E K G  jelentősége bifascicularis blockban. (The signif­
ican ce  o f  the bundle o f H is in bifascicular block.) Cardiol. H ung. 4, 253-263 (1977)
31. V eress, G ., Borbola, J ., Szatm áry, L.: A pplication o f H is bundle recording to stu dy  disor­
ders o f  atrioventricular conduction . A cta Med. Acad. Acad. Sei. H ung. 36, 167-175 (1979)
32. V eress, G.: Kamrai ingerü letvezetési zavarok. (Intraventricular conduction defects.)
T h esis, B udapest (1979)
33. V eress, G.: Concealed retrograde A -V  nodal conduction in  a case of in term itten t fascicular
b lock . Am . Heart J. 5, 934-936  (1981)
Acta Medica Hungarica 42, 1985
Acta Medica Hungarica, Volume 42 (1 2), pp. 77 — 84 (1985)
Laboratory
PRODUCTION AND PROPERTIES OF ANTISERUM  
FOR RADIOIMMUNOASSAY OF SERUM CONJUGATED 
CHENODEOXYCHOLIC ACID AND ITS 
PREUIMINARY APPUICATION
É v a  C. O r b á n , J. P .  P a l l o s ,
L. T. K o c s á r
“ F R É D É R IC  JO L IO T -C U R IE ”  NATIONAL R ESEA R C H  IN ST IT U T E  FOR R A D IO B IO LO G Y  AND 
R A D IO H Y G IE N E , H-1221 B U D A PEST, P E N T Z  KÁROLY U. 5., H UN G ARY
(R eceived: 3 February, 1984)
Sensitive tritiated  radioim m unoassay was developed for conjugated  chenodeoxy- 
cholic acid, using im m unogen prepared b y  the m ixed anhydride m eth od . The obtained  
molar bile sa lt-B SA  ratio in  the im m unogen was 19 : 1. The d istin gu ish in g  features 
o f the im m unization procedure were a prelim inary vaccination of the an im al w ith  anti- 
tubercular vaccine (V D S), and the adm inistration of very sm all doses o f  im m unogen  
(50 fig). A ssay sen sitiv ity  for this bile salt fell in the picom ole range w ith  the standard 
curve extending from  1.5 to 150 pmol. Specificity  o f the antiserum  w as com pared with 
th a t of the com m ercially available “ G lycochenodeoxycholic acid R IA  k it”  (Nordiclab  
O y, Oulu, F inland), and proved to be satisfactory. Fasting serum  conjugated  cheno- 
deoxycholic acid concentration in 25 hea lthy  subjects and 15 patien ts w ith  cirrhosis 
was 0.63 jtimol/l and 43.05 /tmol/1, respectively. The assay was perform ed on  unextracted  
sera.
Keywords: bile salt, radioim m unoassay, antiserum , conjugated chenodeoxy- 
cholic acid
Introduction
The interest in serum  bile acid determ ination has considerably increased  
recent years. Of the blood tests used routinely to  assess liver fu n ction , none 
is ideal. Only som e o f them  can be used to measure hepatocyte fu n ction  and 
even  th ey  are rather insensitive. N o doubt, there is a need for b etter  tests. 
The synthesis and excretion  o f bile belong to  the fundam ental fu n ction s of the 
hepatobiliary system . The hepatocytes synthesize bile acids b y  microsomal 
hydroxylation  o f cholesterol. A num ber o f studies have shown th a t serum  bile 
acid concentration is a sensitive indicator o f liver function and th a t highly 
increased bile acid levels are seen in  the sera o f patients w ith  hepatobiliary  
diseases [6, 9]. The early m ethods used for the m easurem ent o f  serum  bile 
acide were insensitive, tim e and m oney consum ing [4, 8]. The problem  was
Send offprint request to Dr. É v a  C. Orbán, “ Frédéric Joliot-Curie”  N a tio n a l Research 
In stitu te  for Radiobiology and R adiohygiene, H -1221 B udapest, Pentz K ároly u. 5,
Acta Medica Hungarica 42, 1985 
Akadémiai K iadó, Budapest
78 ORBÁN, C. ÉVA et al.
reso lved  w hen the first bile sa lt  radioim m unoassay w as reported by Sim m onds 
et al. [14] allowing a sen sitive  assay of large num bers o f  samples. A lthough  
during th e  past ten years a great number of m odifications o f the above m ethod  
w as p u b lish ed  [5, 7], the prob lem  o f insufficient sp ec ific ity  of the prepared  
an tiseru m  still exists and th e  a ssa y  o f sera requires tim e and labour consum ing  
ex tra ctio n s.
T h e  present study describes a rapid, sen sitive  radioim m unoassay o f  
u n ex tra cted  serum for chenodeoxycholic acid conjugates. Chenodeoxycholic  
acid w as chosen because its  serum  concentration is th e  highest o f all th e  bile  
acids.
M aterials and methods
B ile  acids were purchased from  Sigm a, P-L B iochem icals, Calbiochem; purity was an a­
ly sed  b y  H PL C , using V A R IA N  m od el 8500 liquid chrom atograph equipped w ith  V A R IA N  
series 634  U V -spectrophotom eter as a detector, H E W L E T T -P A C K A R D  3380 A integrator, 
25 c m X 4 .6 m m I .D .  K N A U E R  H PL C -colum n packed w ith  LiChrosorb R P-18 5 fim . The 
so lv e n t sy stem  was a m ixture o f  H PLC -grade m ethanol (M E R C K ) — 0.005 mol/1 K H 2P 0 4 
buffer (80  : 20, v/v), the pH  w as ad ju sted  to 2.0 w ith concen trated  H 3P 0 4. F low  rate was 
1.0 m l/m in . UV  detection w as perform ed at 215 nm. 3H -chenodeoxycholylg lycine (specific  
a c t iv ity  85.1 GBq/mmol) was o b ta in ed  from New England N uclear Co., Boston, Mass. B ovine  
serum  albu m in  (fatty  acid-free) w a s supplied by Sigma, F reun d’s com plete adjuvant from  
D ifco  Laboratories Ltd. V D S (S a lv io li Diffused Vaccine) w as a g ift o f Ghimas, Spa, B ologna, 
I ta ly . T ri-N -butylam ine and isobutylch loroform ate were ob ta ined  from Fluka AG, B uchs, 
S w itzerlan d , Scintillation liquid  w as a Triton X -100-(Serva)-based flu id . Other chem icals used  
in  th e  experim ents were o f a n a ly tica l grade.
Preparation of im m unogen. B ile  acid-albumin im m unogen was prepared by covalently  
coup ling  bovine serum album in (B S A ) to hapten (chenodeoxycholylg lycine) by the m ixed  
an h yd rid e  technique [3]. The cou p lin g  procedure was a m odifica tion  using fa tty  acid-free 
b o v in e  serum  albumin. The a lbu m in -b ile  acid com pound w as separated from unconjugated  
bile a c id  b y  dialysis against 0.01 m ol/1 phosphate buffer pH  7 .4  a t  4°C  for 72 h. 3H -labelled bile 
acid  w a s added to determine th e  conjugation  efficiency. T he radioactive content o f an aliquot 
(1% , v /v )  o f the initial reaction  m ixtu re  was determ ined w ith  the aliquot (5%  v /v )  o f the  
d ia ly sed  fraction, and the b in d ing  w as calculated. Im m unogen  was diluted to protein  con­
cen tra tio n  o f 100 jUg/ml w ith  0 .9%  sodium  chloride and em ulsified  w ith an equal volum e of  
F reu n d ’s com plete adjuvant u n til a  s t if f  w ater in oil em ulsion w as obtained.
Preparation of antiserum . T hree rabbits were in jected  intraderm ally w ith  0.75 m g of 
V D S on  th e  inside of the th igh . Im m unization  began 6 w eeks after vaccination. Intraderm al 
in jec tio n s  were given to 10 a b d om in a l sites at a dose of 50 //g  o f  im m unogen per rabbit. This 
tr ea tm e n t was repeated 3 tim es in  w eek ly  intervals and th en  a booster dose (50 ftg) was given  
m o n th ly .
T he antigenic response o f  th e  im m unized animals w as determ ined by the O uchterlony  
dou ble-d iffu sion  technique and d ilu tio n  of the serum th a t w ou ld  bind 50% of 10 000 cpm  
3H -chenodeoxycholylg lycine. T he h igh est titres were those for antisera collected 20 weeks 
after  th e  in itia l im m unization. A fter  separation, sera were stored  at —20 °C and a suitable  
d ilu tio n  w as prepared w hen required.
A ssa y  procedure. A n tiserum , tracer and samples were d ilu ted  w ith 0.02 mol/1 phosphate  
bu ffer  p H  7.4 containing 0.6%  sod iu m  chloride, 0.1% bovine serum  albumin and 0.1%  sodium  
azide. T he tracer solution co n ta in ed  about 10 000 cpm /0.1 m l 3H -chenodeoxycholylglycine  
in  b u ffer  solution. Antiserum  w as d ilu ted  w ith albumin buffer so th a t the final d ilution  used  
in  radioim m unoassay gave 50%  bou n d  antibody. The standard curve consisted of 0.1 m l bile 
acid  so lu tio n  containing 1.5, 5, 15, 50, 150 pmol. First, 0.2 m l buffer solution, 0.1 m l standard  
or th e  unknow n serum (diluted  1 : 10 or 1 : 50, according to  th e  supposed concentration), 0.1 ml 
tracer so lu tion  and 0.1 m l d ilu ted  antiserum  were added to  th e  test tubes. The tubes were 
m ix ed  on Vortex and left a t room  temperature for 1 hour. Saturated am m onium  sulphate  
(0 .5  m l) w as added to the tu b es , thoroughly mixed, equilibrated  at 4 °C for 45 m inutes and
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centrifugated at 1500 g for 20 m inutes at 4 °C. An aliquot o f the supernatant (0.5 ml) was 
m ixed w ith 7 ml o f scintillation m ixture. Sam ples were counted w ith  a Packard Tri-Carb 
Model 3375, the quenching proved to be constant.
Test sera were obtained after a 12 h fast. Blood was allowed to c lo t a t room  temperature, 
and the serum was separated by centrifugation and im m ediately deep frozen until assayed. 
R esults were expressed as means i  S.E .M . The significance of difference o f m ean values was 
tested  by Student’s t test.
Results
The m ixed anhydride reaction gave a hapten (chenodeoxycholylglycine)- 
protein ratio o f  19 : 1.
Figure 1 shows the antigenic response determ ined by O uchterlony dou­
ble-diffusion technique. F ive w eeks after the beginning o f im m unization , the 
serum  obtained from rabbits m ixed w ith  bovine serum album in in  excess and 
centrifuged (to rem ove anti-B SA  antibodies) showed no precip itation  by diffu­
sion against bovine serum album in in the double-diffusion te s t  whereas a 
single precipitation line was obtained by diffusion against chenodeoxycholyl- 
gylcine-bovine serum album in conjugate.
Figure 2 shows the highest antibody dilution capable o f  binding 50% of 
a tracer dose (10 000 cpm /tube) o f 3H -chenodeoxycholylglycine p lo tted  against 
th e  tim e of im m unization, in three rabbits. 26 weeks after vaccin ation  by YDS, 
antibody titres were 1/2500, 1/3000 and 1/3500, respectively.
Cross-reactivity o f  antisera to  other 13 bile salts was determ ined accord­
ing to Abraham [1]. Table I illustrates the specificity  o f  our antiserum  in 
com parison w ith  com m ercially available R IA  kit antiserum  exam ined by 
Nordiclab [7] and K ällberg et al. [5]. The specificity  o f antiserum  determined  
b y  the m anufacturer and K ällberg et al. was not the sam e. Our antiserum  
and Nordiclab’s antiserum  (determ ined by Källberg) had a lm ost the same 
sen sitiv ity  to both conjugates o f  chenodeoxycholic acid, but a low er sensitiv ity
B SA
BSA
Fig. 1. Ouchterlony double-diffusion test o f bovine serum albumin and chenodeoxycholyl- 
glycine-bovine serum albumin com pound against antiserum to cbenodeoxycbolylg lycine
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F ig . 2. T im e course of antibody titre  in  rabbits after im m unization  w ith  chenodeoxycholyl-
glycine
Table I
Relative cross-reactivity ( percent) o f different bile acids w ith two antisera
Bile acid
Cross-reactivity , percent
Our antiserum
A ntiserum  of N ordiclab 
R IA  k i t  exam ined by 
M anufact. K ällberg e t al. [5]
Chenodeoxycholylglycine 100 100 100
Chenodeoxycholyltaurine 90 50 90
Chenodeoxy cholic acid 20 100 33
Cholic acid < 0 .1 0.1 0.4
Cholylglycine 0.4 0.8 0.3
Cholyltaurine 0.5 0.4 0.6
Deoxycholic acid < 0 .1 < 0 .1
Deoxycholylglycine 0.1 < 0 .1
Deoxycholyltaurine < 0 .1 < 0 .1
Lithocholic acid 0.3 0.6 _*
Lithocholylglycine 0.5 8.0 _*
Lithocholyltaurine 0.5 1.5
Sulphated lithocholylglycine < 0 .1 < 0 .1
* N ot examined
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to unconjugated chenodeoxycholic acid and low  sensitivity to cholic acid and 
its conjugates. C ross-reactivity o f our antiserum  to other bile salts e.g. 
lithocholylglycine and lithocholyltaurine seem ed to have som e advantage over 
the “ G lycochenodeoxycholic acid R IA  k it” antiserum  according to  the data  
given by the m anufacturer.
Figure 3 show s the standard curve for chenodeoxycholylglycine. Each  
point represents the m ean ^  SD calculated from  five  triplicate analyses. Thus, 
the standard curve range was set a t 1 .5 -1 5 0  pmol.
1.5 5 15 50 150(pmol/tube)
I Dilution of sera: 1:10 __________________
0.15 05 15 5 Ï5(pmol/l)
I Dilution of sera : 1:50 __________________
0.75 2.5 7.5 25 75(pmol/l)
Chenodeoxycholylglycine
Fig. 3. Standard radioim m unoassay curve for chenodeoxycholylglycine. The curve reflects 
a log it transform ation of B/B0 v s. log dose concentration
The least detectable am ount o f  chenodeoxycholylglycine, defined  as 
mean -f- 2 S .E .M . o f the value for zero dose, was 1.5 pm ol/tube. The intra­
assay precision at a low  serum concentration  o f chenodeoxycholylglycine  
(0.6 jUmol/1) proved to  be 8.5%  and at a higher serum concentration (20 fx m o ljl)  
11.0%  (coefficient o f  variation). The in terassay  precision determ ined by sub­
jecting the sam ples to  6 different assays, w ere 13.4% and 14.7%  (coefficien t 
o f variation). R ecovery  estim ated by adding various am ounts (5, 15, 50, 100 
pmol) o f chenodeoxycholylglycine to  pooled serum ranged betw een  91 and 
108% .
Serum values o f 25 control subjects w ith  no evidence o f  liver disease and 
15 patients w ith  cirrhosis confirmed b y  liver biopsy are show n in Table II. 
Mean concentration were 0.63 /tmol/l and 43.05 jumol/1, respectively.
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Table II
Serum  concentration of chenodeoxycholylglycine in normal subjects and patients with cirrhosis
(m ean ±  S.E.M .)
Chenodeoxycholyl­
glycine /tmol/1
Controls 0.63
(n =  25) ± 0 .0 6
Cirrhosis 43.05*
(n =  15) ± 9 .9 6
*P < 0 .0 0 1
Discussion
T he advantage of using fa tty  acid-free b ovine serum albumin m ade the  
m ixed  anhydride reaction attractive  and gave a higher hapten-protein ratio  
th a n  th e  12 : 1 observed b y  th e  other authors [10, 11], who used the m ixed  
an h yd rid e procedure too. The question of the optim um  bile salt-protein ratio  
has n o t been settled. I t  is how ever, generally accepted th at it is favourable  
i f  am on g  59 terminal am ino groups of lysine residues o f BSA, 15-30 could  
be con ju gated  to bile acids [13].
I n  th e  present work, w e applied a pretreatm ent o f  the animals w ith  a 
n on -sp ecific  adjuvant (Y D S). This material contains tuberculosis bacilli o f  
h u m an  and bovine origin, k illed  and m ixed w ith  hyaluronidase to facilita te  
sp read in g  from the site o f  in jection  to the lym p h  nodes. Bachiega et al. [2] 
and R od a  et al. [12] stressed  the beneficial result o f this pre-inoculation. 
P ro b a b ly , the effect differs from  Freund’s com plete adjuvant and plays a role 
m a in ly  in the first part o f  im m unization. A nother im portant factor in our 
im m u n iza tion  schedule w as th e  use of 50 f ig  o f  an tigen  in contrast to  other  
authors [1 0 ,1 4 ], who applied 1—2 mg of the antigen. The result of these im m u n ­
iza tio n  conditions was th a t th e  titre and sp ec ific ity  o f  our antisera proved  
to  b e su ffic ien t. Higher titre  as reported b y  other authors [12] m ight be due 
to th e  application of lower tracer activ ity .
R adioim m unoassay reports agree th a t antisera to  bile salts are specific  
for th e  bile salt structure b u t show variable sp ecific ity  to other bile sa lts. 
Our antisera , similarly as th ose  o f others [7, 14], cannot discriminate betw een  
g ly c in e  and taurine conjugates, but a ffin ity  to  unconjugated bile acids is 
o n ly  20%  of that for conjugates, moreover the free chenodeoxycholic acid is 
o n ly  a sm all part of the serum  to ta l chenodeoxycholic acid content. Therefore, 
w e ca ll our method “ R IA  for conjugated chenodeoxycholic acid” .
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The sen sitiv ity  o f our R IA  allows to  determ ine picom ole am ounts in 
serum . As bile acids are present in nanom ole/m l concentrations, the assay  is 
convenient for m easuring normal as well as pathologically  increased values.
The com m ercially available R IA  k it has the disadvantage o f  needing a 
previous extraction  o f bile acid w ith ethanol. U sing our assay conditions no 
serum  effects were found, so that extraction  o f serum prior to assay  was un­
necessary.
According to  the literature [7, 14] in  fasting normal subjects the serum  
levels o f conjugated chenodeoxycholic acids are less than 1 jumol/1. In  hepato­
biliary disease the concentration o f bile acids is significantly higher than  in 
the controls several hundred fold increases m ay be found in serious cases. 
N orm al sera were diluted 1 : 50 w ith  assay  buffer, to  bring the concentration  
to  the range o f the standard curve. Our data  for the fasting bile acid concentra­
tion  showed a significant difference betw een  the means o f the tw o  groups. 
W ith  one exception , in the control group all bile acid values w ere below  1 
jUmol/1. In the cirrhotic group all patients show ed increased concentrations of 
conjugated chenodeoxycholic acid. Since th e  group was heterogeneous, it  is 
suggested th at the bile acid level m ay be influenced  by the stage o f  cirrhosis. 
Further studies o f a large number o f sam ples are required to elucidate the 
biologic variab ility  and to  obtain inform ation about physiological and p ath o­
logical events.
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Book reviews
C a n c e r  M o r t a l i t y  b y  O c c u p a t i o n  a n d  C la s s  1 9 5 1 - 1 9 7 1  
Logan, W. P. D. IARC Scientific P ublications N o. 36.
International A gency for Research on Cancer, L yon , 1982. 253 pages, w ith num erous tables 
and figures. Price: Sw. fr. 6 0 .—
The la test volum e issued by the International A gency for Research on Cancer (IARC) 
is o f the usual standard, both  in content and in production . B y  providing an im pressive body  
of inform ation it  offers valuable aid to all those engaged in cancer research. T he various rela­
tionships and data relating to distribution and prevalence are made accessible to  the reader 
by tables o f clear arrangem ent, accom panied b y  short, instructive explanatory n otes con­
centrating on essentials.
The are six  chapters. The Introduction and Chapter 1 offer general exp lanations. Chapter
2 entitled “The present study: classification and in d ices” , falls into the follow ing subdivisions: 
Social classes and sub-classes; Socio-econom ic groups; O ccupation orders; O ccupation units; 
Classification o f causes o f  death (on the ground o f  th e  International Classification o f D iseases 
of W HO; M ortality ind ices), the indices and form ulae necessary for the calculations. Chapter
3 covers the second h a lf o f  the nineteenth century, g iv in g  a brief survery of the m ain events. 
Chapter 4 a Com m entary on the tables 1911-1977, w hich occupies 71 pages, thu s m aking 
up a substantial part o f the book, deals w ith cancer m ortality  and w ith its various aspects 
organ by organ, on the basis o f the International C lassification  of Diseases o f  W H O . Chapter
5 on socio-econom ic relationships, is o f particular in terest b y  covering the situation  in  Australia, 
Finland, France, H ong-K ong, Japan, Northern Ireland, Norway, Scotland, U S A . Chapter
6 includes a sum m ary, recom m endations, as also a classified  bibliography w ith  200 references. 
There are fiv e  appendices w ith  tables.
L. C s e l k ó
C a n c e r  I n c i d e n c e  i n  th e  U S S R ,  74 pages: published  as the 48th volu m e o f the 
IARC, Scientific  Publications series No. 48 . (in English)
Price: Sw. fr. 3 0 . -  IA R C , WHO
The book is a publication of the M inistry o f  H ealth  o f the USSR, D epartm ent o f Medical 
Statistics, Petrov Research In stitu te  o f O ncology, L eningrad, and of the International Agency  
for Research on Cancer (IA R C ) issued as a su pp lem en t o f the internationally  w ell-know n
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IA R C  Cancer Incidence in  F ive C ontinents. The editors o f  th e  version published in  the U S S R  
are, N . P . N ap alk ov , G. F . T serkovny and V. M. M erabishvili. The editors of the book published  
in  L y o n  in  th e  English language are, D . M. Parkin, M. Sm ans and C. S. Muir. Vol. 3. T he aim  
o f th e  p u b lica tio n  — as drafted in  th e  preface by the d irector o f IARC — is to m ake th e  d ata  
o f cancer pattern s in  the U S S R  availab le to sc ien tists unable to read the original R ussian  
litera tu re . T h e  book is divided in to  6 chapters. The first, introductory chapter contains data  
on th e  geographical features, pop u lation  and m edical fac ilities o f the U SSR . Chapter 2 fa m il­
iarizes th e  registration technique o f  cancer diseases. T he registration  of cancer cases and m orta l­
i ty  is  th e  responsib ility  o f the oncological dispensaries serving catchm ent areas through out  
th e  S o v ie t  U n ion . The registration is  based on a fo llow -up  card introduced in 1975*76, con ­
ta in in g  31 item s. The 8th  version o f  th e  International C lassification of Diseases (IC D ) is  used  
for th e  grouping of cancer cases. G reat im portance is a ttrib uted  to the grouping o f co llected  
d ata  accord ing  to reliability (ind icatin g  the data based  on  histological verification  and the  
d ea th  cer tifica te). These are analysed  in  Chapter 3. The n e x t  chapter provides data  on  age- 
-sp ec ific  m orb id ity  rates by sex  and tum our sites for th e  15 republics o f the U SSR . The editors 
present th e  data  of the tables, broken down according to  republics, in  a layout id en tica l to  
th a t u sed  in  Volum e 3 of Cancer Incidence in F ive C ontinent, to facilitate on In ternational 
com parison . Chapter 5 com prises age-standardized rates concerning the 15 republics o f  the  
U S S R . H ere  th e  publication o f data  differs from the m anner used in Cancer Incidence in  F iv e  
C on tin en ts, where the date are ca lcu lated  using fiv e-year  age groups. The data in  th e  present 
book w ere com plied according to  ten -year age groups. Chapter 6 is the m ost in terestin g  
one, in  w h ich  — according to th e  various regions o f  th e  U S S R  — the editors dem onstrate  
differences in  the incidence o f the various cancer d iseases, as well as the changes observable  
in th e  freq u en cy  of occurrence since 1965. It is in terestin g  th a t the incidence o f  oral and  
ph aryn gea l cancer is higher in  th e  Central Asian republics and Azerbaijan than  elsew here. 
There are also great variations betw een  the different republics in  the rate for oesophageal 
cancer. T h e  data concerning the incidence of stom ach and lung cancer indicate im portant  
ch anges. W hile  in  1969 and 1971, stom ach cancer w as th e  m ost frequent in  both  sexes in  
th e  S o v ie t  U nion , in 1980 lung cancer in males had th e  h ighest incidence. A n increasing  
te n d e n c y  w a s observed regarding breast cancer cases betw een  1965-1980, particularly in  the  
B a ltic  rep ub lics. Related to the w hole Soviet Union, how ever, the incidence of breast cancer  
is still lo w er  than in the W estern  countries, and its  incidence is the low est in  the A sian  
rep ub lics, w here breast cancer is less frequent than in  Japan .
I t  can  be seen, therefore, th a t  th is book is a repository o f extrem ely abundant m ateria l, 
com p iled  w ith  attentive critique. T he publication is usefu l for epidem iologists, sp ecia lists in  
the f ie ld  o f  public health and oncologists.
K . L a p i s
T h e  P r o m o t i o n  a n d  D e v e l o p m e n t  o f  T r a d i t i o n a l  M e d i c i n e
T ech n ica l R eport Series, 622. W H O , Geneva 1978. 41 pages, 2 figures. Price: Sw . fr. 5 .—
A  W H O  Meeting on the Prom otion and D evelop m en t of Traditional M edicine was 
held  in  G en eva  from 28 N ovem ber to  2 D ecem ber, 1977, in  conform ity w ith the fo llow in g  
agenda:
— T raditional m edicine in  h ea lth  care Reasons for th e  prom otion of traditional m edicine
— U tilization  of trad itional m edicine in national hea lth  care system
— Integration of trad itional m edicine and m odern m edicine
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— M anpower developm ent for traditional m edicine
— Research prom otion and developm ent in  traditional m edicine
— R ecom m endations.
In  order to discuss the actual subjects, an agreem ent had to be reached on the basic 
defin itions such as “ traditional m edicine” , “ health  care system ” and on their integration.
Som e of the subjects at issue receive a particularly thorough coverage, first o f all, the  
nature, goal and scope of traditional m edicine, illustrated  by accounts from  som e m em ber  
countries (Sri Lanka, Sudan, E gypt, G hana, India). The possibilities, problem s, w ays and 
m eans o f integrating traditional m edicine and m odern m edicine are considered in  all their 
aspects.
D iscussion o f manpower developm ent, exem plified  by the Cameroonian m odel, is also 
o f interest. The part on research prom otion and developm ent is based on research prom otion  
and developm ent is based on experience in  three countries (M exico, N igeria, China) and points 
to the possibilities o f traditional m edicine in  various fields, such as hum an reproduction, 
tropical m edicine (w ith  the exception  o f m alaria, schistosom iasis, filiariasis, leprosy, try­
panosom iasis, leishm aniasis), drug dependence (where acupuncture has been found o f potential 
benefit), cancer chem oteraphy, rheum atoid arthritis and som e other diseases (cardiovascular  
diseases, diabetes, burns, acute abdom inal a ilm ents, bone fractures, k idney stones, gall­
stones).
The book closes w ith theoretically  w ell-founded practical recom m endations.
L. C s e l k ó
V a c c i n a t i o n  C e r t i f i c a t e  R e q u i r e m e n t s  f o r  I n t e r n a t i o n a l  T r a v e l  a n d  H e a l t h  A d v i c e  
to  T r a v e l l e r s  1 9 8 3 .
W H O , Geneva 1983. 70 pages w ith  1 figure, 2 ta b les  and 3 m aps. Price: Sw. fr. 12.—
The la test publication in this annual series is alm ost com pletely identical, even  as 
concerns the num ber o f its  pages, w ith  its predecessor. The introductory notes on the necessity  
o f international vaccination  certificates (IYC) are follow ed by inform ation on the follow ing  
topics: IVC requirem ents in  the various countries, risk factors grouped according to  continents  
and countries, and practical recom m endations in  th e  in terest o f prevention. The data reflect  
the situation  of 1 January, 1983.
In  the volum e 210 countries are represented. The situation  has changed since the last 
year as in  65 countries no vaccination certificates are required. As to the other 145 countries, 
IVC for yellow  fever is required in 114, for ye llow  fever -|- cholera in 29, for cholera in  2 coun­
tries. V accination  certificates for typhoid , sm allpox and poliom yelitis are no longer required  
in  any o f the countries. On the other hand, accounts o f  the hazard and/or incidence of malaria 
have com e th is year from 102 countries.
The closing chapter on the prevention o f  diseases is very useful and m ore exhaustive  
than in the previous publications (food- and w ater-borne diseases, rabies, tetan u s, b ites by 
insects and other anim als, chem oprophylaxis o f  m alaria, sexually transm itted diseases, etc.).
The volum e contains excellent tables and m aps showing the distribution o f diseases.
L. C s e l k ó
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I n t e r n a t i o n a l  H e a l t h  R e g u l a t i o n  ( 1 9 6 9 )  Third A nnotated  Edition.
W HO, G eneva 1984. 79 pages. Price: Sw. fr. 11 .—
T he In ternational H ealth R egulations adopted b y  the second World H ealth A ssem bly  
on 21 J u ly , 1969, represent a revised and consolidated version  of the previous International 
San itary R egulations.
T he publication  includes 9 sections and 4 appendices. Som e of the sections are sub­
divided in to  chapters.
S ection  I g ives definitions. In  Section II notifications and epidem iological inform ation  
are foun d. Section  III  deals w ith  health  organization. Section  У gives the regulations for 
plague, ye llo w  fever and cholera. The strict m easures concerning plague and yellow  fever  
are g iv en  in  close detail, in  the fram ework of 11 papers each. The measures against cholera  
are dea lt w ith  in  4 papers. It is em phasized th at these three diseases represent a major threat 
and call, b y  th is fact, for perm anent alertness. Sections V I—IX  provide inform ation on health  
docum ents, charges, various provisions. In A ppendices 1—4 w e find  forms for various declara­
tions and certificates, e.g . vaccination  against yellow  fever, revaccination, M aritime D eclara­
tion  o f H ea lth  and the health  part o f  the A ircraft General D eclaration . The sanitary standards 
of air and m aritim e traffic  are found in  the subsequent appendices. The volum e is very  well 
indexed.
L .  C s e l k ó
S e v e n t h  G e n e r a l  P r o g r a m m e  o f  W o r k , c o v e r i n g  th e  p e r i o d  1 9 8 4 - 1 9 8 9 .
W H O , G eneva. 153 pages. Price: Sw. fr. 8. —
T his publication , the 8th volum e in  the series “ H ealth  for All” , gives a program m e in  
the form  o f a close tim e-table o f the essential tasks.
S ection  1 contains introductory notes on the general lines, ends and m eans o f the pro­
gram m e. Section  2 takes a retrospective look at the results of the previous program m e. 
Section  3 g ives a sum m ary of the global strategy o f H ealth  for All. Sections 4—5 provide  
in form ation  on the roles, processes, functions, structures, general programmes and fram e­
work o f  W H O . Section 6 outlines the m ain trends of th e  programmes and determ ines 
the priorities. Section 7 presents a program m e outline in accordance w ith  the classified lis t o f  
program m es, in  a practical form. In  chapter A of th is section  questions of m anagem ent and  
coord in ation  are discussed. Chapter В on the infrastructure o f health system s, concentrates  
on th e  develop m en t and organization of health  system  based on primary health  care and on  
in form ation  and healt education of the population. In Chapter C the following topics are 
dealth  w ith  in  the framework o f health seciences and technology: research prom otion and  
develop m en t; general health protection; protection and prom otion of m ental and environ­
m enta l hea lth ; disease prevention and control. In Chapter D the tasks involved by program m e  
support are form ulated in  close detail. In  Sections 8 and 9 im plem entation  of the program m e  
including m onitoring and evaluation , is outlined, Section  10 g ives a brief sum m ary. There is  
an app en d ix  and an index  at the end of the volum e.
• L .  C s e l k ó
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P l a n  o f  A c t i o n  f o r  I m p l e m e n t a t i o n  o f  the G lo b a l  S t r a t e g y  f o r  H e a l th  f o r  A l l  a n d  
i n d e x  o f  th e  “ H e a l t h  f o r  A l l ” s e r ie s  N o s  1 - 7 .
W HO, Geneva. 1982. 55 pages. Price: Sw. fr. 6. —
This brochure has been published as No. 7. in  the series “ H ealth  for All” , on the basis 
of the plan of action approved and accepted by the W orld H ealth General A ssem bly. I t  also 
contains an index  for N os 1—7.
After a brief introduction  and general com m ents, Chapter 2 sum s up the strategies and 
plans o f action, outlin ing the general tasks of the m em ber states, the regional com m ittees, 
the executive  board, the W orld H ealth Assem bly and the directorgeneral. Chapters II  to  Y  
bearing the titles D evelop ing H ealth System s, Prom otion and Support, Generating and M obil­
izing Resources and M onitoring an E valuation, set o u t the tasks outlined in  Chapter I in  
detail to all those concerned (i.e. the m ember states, the regional com m ittee, etc.). Chapter Y I, 
the longest and the m ost concrete part o f the book, g ives a fairly realistic tim e-tab le for im ­
plem enting the global strategy , in a clearly arranged, tabu lated  form , in  chronological order 
(from  M ay, 1981, to  M ay, 1978) for the Member S ta tes, the W HO governing bodies and the  
W HO Secretariat. On stu dying  the tables one cannot help being im pressed by the im m ense  
scope and the thoroughness o f the activities of W H O  disp layed in the interest o f the im ple­
m entation of its global strategy. A t the end of the book there is an index and a very  useful 
list o f references.
L. C s e l k ó
E d u c a t i o n  a n d  T r a i n i n g  i n  O c c u p a t i o n a l  H e a l t h ,  S a f e t y  a n d  E r g o n o m i c s .  T e c h n i ­
c a l  R e p o r t  S e r i e s  6 6 3 .
W HO, G eneva 1981. 48 pages. Price: Sw. fr. 3 ,—
The Jo in t ILO /W H O  Com m ittee on O ccupational H ealth  m et in  G eneva from  2 to  9 
March, 1981, to discuss education and training in occupational health, safety and ergonom ics. 
This volum e sum s up the work achieved by the A ssem bly, in  six  parts. Part I gives an outline  
of the tasks, clearly in the spirit o f  the objective o f W H O  “ H ealth  for all by  the year 2000” . 
Part II on the needs for education and training in occupational health  safety and ergonom ics, 
deals w ith  the m ultiple aspects o f these issues and g ives a great deal o f practical inform ation. 
Part III  discusses the policy  in education and train ing in  occupational health and safety , 
and, after general com m ents, em phasizes the necessity for purposeful activ ities a t a national, as 
well as international, level. P art IV, o f practical orientation , gives an excellent coverage o f the 
objectives and problem s o f education and training, discussing first the general objectives, 
subsequently the objectives by persons who require training. Part V covers various issues 
of technology, m ethodology and training programmes. P art V I sum s up the recom m endations.
In view  of its  h igh practical inform ative va lue  and its clear arrangem ent, th e  book  
excels even  am ong the other members in  this series, all o f high standard. I t  closes w ith  a list 
of 23 references.
L. C s e l k ó
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P r i m a r y  P r e v e n t i o n  o f  E s s e n t i a l  H y p e r t e n s i o n .  Technical R eport Series 686.
W H O , G eneva 1983. 40 pages. Price: Sw. fr. 4 .—
T he W H O  Research Group on  the Prim ary Prevention of H ypertension m et in  G eneva 
from  20 to  24 Septem ber 1982. A n  account of the m eeting is given in  th is volum e.
In  th e  introduction the b asic  objectives and m otivations are pointed out. In  Section  1, 
tw o  possib le  approaches to  prim ary prevention o f hypertension, i.e. high-risk stra tegy  and 
m ass stra teg y , are outlined. Section  2 is  on the natural history o f blood pressure elevations, 
d iscu ssin g  hypertension in  childhood , adolescence and old age, as well as the pathophysio logy  
o f  ea r ly  hypertension. Section 3 covers the genetic aspects in consideration of evidence for 
g en etic  factors, o f the m ode o f inheritance and o f  the fam ilial predictors o f hypertension. 
S ec tio n  4 o f  outstanding practical va lu e , deals w ith  th e  environm ental influences in th e  follow ­
ing  order: body-w eight, sa lt and other dietary factors, alcohol, physical activ ity , psychological 
socia l an d  other influences. Section  5 provides a sum m ary and offers recom m endations form ul­
a ted  in  10 poin ts, all highly realistic. In  poin t 7 the need for a flexib le adaptation of th e  health  
serv ices in  the countries o f rapidly changing life sty le  to  the prevailing requirem ents is stressed. 
T he v o lu m e  closes w ith a list o f  130 references.
L .  C s e l k ó
L e g i s l a t i v e  A c t i o n  to C o m b a t  th e  W o r l d  S m o k i n g  E p i d e m i c :  R o o m e r , R .
W H O  G eneva 1982. 131 pages, 9 tables. Price: Sw. fr. 17 .—
T he present study, the first W H O  publication on the regulatory control o f  sm oking  
p u b lish ed  since the establishm ent o f W H O ’s Program m e on Sm oking and H ealth , 1980, 
in c lu d es 3 sections. I t  falls in to  15 chapters.
Section  1 is subdivided in to  the following chapters: The sm oking epidem ics and action  
b y  W H O ; T he role and evolu tion  o f legislation to  control sm oking; types o f  legislation. 
A n ex h a u stiv e  and highly in teresting  analysis is  provided by the chapters o f Section  2, 
“ L eg is la tio n ” . The m ost in teresting topics include drowing and processing of tobacco, public­
ity ,  com p lete  and partial prohib ition , health  warning and statem ent of tar and n icotine con­
te n ts , contro l o f harmful substances in  tobacco, restriction  of sales to adults, prevention  in  
ju v e n ile s  and children, restriction o f  sm oking in public places and in the w orkplace, sm oking  
and healt-ed u cation  (beginning a t  school!), fiscal and econom ic m easures, m ultipurpose sta t­
u te s  in  N orw ay, France, Bulgaria, F in land. Section 3 has tw o chapters: Challenge to  devel­
op in g  countries; H ighlights and com m ents. This is follow ed by a list o f 218 references. In 
th e  A p p en d ix  we find he legislations of the various countries; the W HO decrees 33 and 35, 
and th e  recom m endations o f the W H O  E xpert C om m ittee. The practical orientation of the  
s tu d y  is  one o f its  essential m erits.
L. C s e l k ó
Acta Medica Hungarica 42, 1985
BOOK REVIEWS 91
T h e  T r a d i t i o n a l  B i r t h  A t t e n d a n t  i n  S e v e n  C o u n t r i e s  : C a se  S t u d i e s  i n  U t i l i z a t i o n  
a n d  T r a i n i n g
M angay-M aglacas, A ., Fizurki, H . Public H ealth  Papers 75. W HO, G eneva 1981. 211 pages 
w ith  31 tables, 7 figures and 5 annexes. Price: Sw. fr. 15 .—
A world congress on primary health  care w as held by WHO in A lm a A ta  in  1978. 
This volum e includes the elaborates o f  seven countries on the problems o f the trad itional birth 
atten dan t (T B A ), centred on the follow ing issues:
1. Ecuador: TB A  training program me, supervision , evaluation and fo llow -up services.
2. H onduras: A dm inistrative arrangem ents for linking the TBA with the form al health  system .
3. Philippines: D evelopm ent and use of the national registry of traditional b irth  attendants.
4. Sierra Leone: Practices o f untrained T B A s and support for TB A  training and utilization .
5. Sri Lanka: E xploring the use of the T B A  as a low -cost means for fam ily hea lth . 6 . Sudan: 
Replacing T B A s by village m idwives. 7. Thailand: U tilization  of T BAs in  fa m ily  planning  
and m aternal and child care.
A n y com parison betw een the reports o f the various countries w ould be fu tile , since 
their problem s and results are view ed against their own background. The o b jec tiv ity  o f in­
form ation is, how ever, com m on to all. I t  g ives particular interest to the elaborates th a t the 
facts are considered in their com plexity , from  m ultip le angles o f approach.
In the closing part the problem s of perspectives are sum m ed up and various aspects 
are pointed  out. This part o f practical orientation  w ill be of particular use.
L. C s e l k ó
P r e v e n t i o n  o f  L i v e r  C a n c e r .  Report o f a W H O  Meeting
Technical R eport Series, No. 691, W HO, G eneva 1983. Price: Sw. fr. 3 .—
In view  o f the practical im portance of the questions connected w ith  th e  prevention of  
liver cancer and o f the recent results achieved in  th is field , a WHO m eeting w as held on this 
subject in  G eneva, in  January, 1983. Though the proportion of hepatitis В -virus (H B V ) 
carriers is relative ly  low  in H ungary, it  none the less involves considerable hea lth  problems 
in  th is country too . In various regions o f Africa and Asia earlier infections o f the population  
w ith  H B V  atta in  nearly 100% and the proportion o f carriers approxim ates 15% . The causal 
relationsh ip betw een  the HBV-carrier sta te  and prim ary hepatocellular carcinom a has been 
confirm ed b y  num erous epidem iological studies. On the evidence of a prosp ective  study, 
conducted in  T aivan  on the largest scale h itherto  known, the HBV-carrier sta te  involves a 
223-fold prevalence o f hepatom a. According to  various estim ates, H B V -infections account 
for 80%  o f all hepatom as, thus H B V  as a carcinogenic risk is second only to  sm oking. The 
cause o f  the h igh carcinogenecity o f  H B S-virus m ay lie in the integration tendency  o f the 
virus in  the D N A  of hepatocytes. Integrated D N S  or its  essential viral fragm ents are iden­
tifiab le  in the hepatom a cells in practically  all cases o f  primary hepatocellular carcinoma. 
Interesting evidence has been furnished by studies o f the life-cycles o f som e anim al viruses. 
In the course o f the reproductive cycle a com plem entary RNA-sequence o f v iral D N A  was 
identified . This is  assum ed to be a step , com prising a reverse transcriptase reaction , in  the 
reproduction o f  the virus. The hepatitis-viruses thu s resem ble RN A  tum our viruses in  some 
of their properties.
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T he results achieved in  H B Y -vaccination  represent a hallm ark in the prevention of  
H B V -h ep atitis . Since it  has not been possible to obtain  the v irus from  tissue cultures, carrier 
plasm a has rem ained the on ly  source o f H B sA g. Standardization  o f the preparations is crucial, 
for th is reason a H B sA g-preparation o f know n concentration  has been developed by W H O . 
In order to  check the preparation for im m unogenicity, a m ouse strain of known hap lotype H2 
has been  recom m ended b y  W H O . In  v iew  o f their sources, th e  preparations have to be checked  
for sa fe ty  before release, in  accordance w ith  existing regu lations. Research for safer H B sA g  
sources s in  progress. There are som e in itia l results o f  cloning m ethods, but em prim ents a t the  
use o f b io log ica l vectors seem  still m ore prom ising. I t  is sou ght to  integrate the D N A -sequence  
o f H B sA g in to  vaccina-virus or in to  non-pathogenic enteral bacteria.
In  regions where H B Y -infections are endem ic, vertica l in fections are of major im por­
tance. T he p lacen ta  being im perm eable to the virus, th e  in fections occur in  the perinatal period. 
Som e red uction  in  the incidence o f perinatal infections has been  a tta ined  b y  hepatitis-B  im m uno­
globulin (H B Ig ). 90%  in  in fants having received H B sA g after  b irth reveal im m une bodies at 
6 m onths, w h ich  is a rem arkably h igh proportion at their age. In  Japan, 90 to 98%  of in fants  
up to th e  age o f 12 m onths were im m une after com bined im m unisation  w ith  H B Ig  and H B sA g. 
The e ffic ien cy  o f vaccination  was n ot affected by sim ultaneous passive im m unization. In v iew  
of the va ry in g  proportions o f H BsAg-carriers in  the various countries, the preventive m easures 
recom m ended b y  W HO also very  from  country to country. For countries w ith a high or m oder­
ate proportion  of carriers a general neonatal com bined a ctiv e  -j- passive im m unization , for 
those w ith  a low  proportion, a selective im m unization o f th e  groups which are at the h ighest  
risk o f in fectio n  (health  workers, e tc .) is recom m ended. In  th e  closing part useful guidelines, 
are g iven  for the evaluation  of the effic iency  of im m unizations.
T his slender volum e o f 30 pages m ay be recom m ended to  gastroenterologists, v irologists, 
ep idem iologists, neonatologists, oncologists alike. In add ition  to  its  practical value, it  m akes 
fascinating  reading by providing inform ation on various recen tly  disclosed facts about the  
biology o f H B v .
J. F e h é r
P r e v e n t i o n  o f  C o r o n a r y  H e a r t  D i s e a s e .  Report o f a W H O  Committee.
T echnical R eport Series N o. 678. W H O , G eneva 1982. Price: Sw . fr. 5 .—
T he W H O  E xpert Com m ittee on the Prevention o f Coronary H earth Disease held a 
m eeting in  G eneva, in  D ecem ber, 1981. The subject-m atter on  th e  m eeting is covered b y  th is  
publication  o f 54 pages.
T he m orta lity  figures reflecting the situation in  26 countries are highly instructive. 
W hile in  a num ber o f industrialized countries the m ortality  figures in the m iddle-aged popula­
tion  have  show n a considerable decline in  the course o f the seven ties , this is, regrettably, not 
the case in  som e other countries including H ungary. I t  is  th e  prevalence of vascular disease  
which accou nts for the high death-figures. The WHO m eeting w as convened in order to elabor­
ate a un iversa l preventive strategy tak ing the generally know n risk-factors into  account. I t  
is regarded as fundam ental to  extend  the preventive m easures to  the whole population, sta r t­
ing from  childhood , so at to  be able to  select the high-risk ind ividuals and to subject them  
to an in ten sified  prevention. In  fact, in  the industrialized countries the high-risk group accounts 
for 20%  o f  the population, and nearly 50%  of m yocardial infarctions occurs in  th is group. 
The p rev en tiv e  strategy has proved successful, and even  post-in farction  prevention has been  
found rew arding. For the develop ing countries ind ividual strategies are recom m ended. In  
opposition  to  earlier practice, the objective  is not to copy th e  sty le  o f life o f  the industrialized
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countries but rather, w ithou t neglecting th e  p ositive  avenues of develop m en t, to m aintain  
those traditional custom s which are in keeping w ith  the prevention o f coronary disease.
The LDL-cholesterol level is regarded as the m ost im portant risk-factor. Its  approxim a­
tion to the total cholesterol level is su ffic ien t for practical purposes. I t  is  desirable to attain  
average values below 5.30 mmol/1 but it  is in  th e  region of 4.14 mmol w here coronary disease 
is  m ost uncom m on in the population. I t  is  an encouraging fact that in  th e  U S A  the average 
cholesterol level has fallen from  6.09 to 5.44 mmol/1 since 1950. Preference o f  proteins o f veget­
able to those of anim al origin, reduction o f da ily  cholesterol intake to  less th a n  300 m g, en­
hancem ent of energy utilization , increase in  th e  proportion of com plex carbohydrates in nutri­
tion , belong to the m ain recom m endations. On the other hand, therapeutic use o f unsaturated  
fa tty  acids, regarded b y  m any as e ffic ien t, lacks sufficient foundation. A ntihypertensive  
m easures p lay a central part in the prevention  o f coronary disease. In  a g iv en  population a 
lowering of blood pressure has been atta ined  b y  low -salt diet. The daily  in ta k e  o f salt should 
be less than  3 g.
Sm oking belongs to the essential risk-factors. Nicotine-poor cigarettes carry the same 
hazards as do the traditional brands. P hysica l a c tiv ity  has diverse beneficial effects, therefore 
it  is recom m ended by the Com m ittee beyond its  dem onstrable benefits. T he necessary measures 
in  case o f  overw eight and diabetes are also o f m ajor importance. T hough am ong moderate 
alcohol-consum ers the figures o f coronary disease are relatively low, y e t  th e  dem onstrable 
protective  effect o f alcohol is too sm all, w h ile  its  tox ic  effects are too grave, to  m ake its con­
sum ption recom m endable. I t  is rem arkable th a t, contrary to com mon belief, th e  incidence of 
coronary disease is little  affected by the ty p e  o f  personality or by social stress. Therefore, this 
factor receives no major consideration b y  the C om m ittee, least it  should d ivert a tten tion  from 
the essential hazards including those of m etab olic  nature. Use of oral contraceptives in the 
industrialized countries should be confined to  non-sm oking, low-risk w om en. E fficien t pre­
vention  o f coronary disease can be inp lem ented  on ly  at a governm ental leve l. E du cation  of the  
com m unities, training o f health workers, m odification  of the general n u trition a l structure, 
prom otion of physical ac tiv ity , anti-sm oking m easures, belong to the m ain lin es o f prevention.
In  view  of the general im portance o f the question , this publication m ay  be recommended  
not on ly  to those d irectly  concerned w ith  th e  subject but to every p h ysician . The reasons 
for the recom m endations are given in a clear, concise form. The essential da ta  are backed by  
an exhaustive  list o f references.
J. F e h é r
I n t e r f e r o n  T h e r a p y .  Report of a W HO Scientific  Group
Technical Report Series 676. W H O, G eneva, 1982. Price: Sw. fr. 3 .—
T his publication o f 28 pages covers th e  m aterial of the m eeting held  b y  the WHO  
E xpert Com m ittee in G eneva, March 1982. T he d iscovery that in cell cu ltures, under the effect 
o f viral and bacterial infections, chem ical stim u li, antiviral protective su b stan ces, acting also 
as im m une m odulators, are formed, dates som e three decades back. T hese substances have, 
how ever, not ye t been adopted for current therapeutic use. Three m ain ty p e s  o f  interferon 
are known: according to the producing ce ll-typ e, the alpha, beta and gam m a types. The 
interferons of the tw o latter types are m ade up  o f polypeptide chains o f id en tica l sequences, 
whereas the 12 chains o f group alpha are o f  s ligh tly  different sequences. T he m ethods for the 
production of interferon are no longer confined to buffy-coat, lym phoblast or fibroblast cell­
line induction . The D N A  recom binant techniques b y  which interferon o f h igh  pu rity  can be 
obtained, have been gaining increasing practical im portance.
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B efore clinical trials the in terferon  preparation to be te sted  has to be checked for sa fety  
w hich, in  case o f  pooled bu ffy-coat or lym phoblast cultures, poses m ajor problems. In certain  
experim ental system s high interferon doses have displayed considerable neurotoxic and hepato- 
to x ic  e ffec ts. In  hum an therapy side-effects o f this kind are less com m on and of lesser gravity . 
In  v iew  o f the difficulties o f com paring interferons from  d ifferent sources, standard prepara­
tions h a v e  been developed recen tly  b y  W H O. I t  seems prom ising to  induce endogenous in ter­
feron b y  m eans of chemical inducers a lthough the results o f  an im al experim ents are not neces­
sarily applicable to humans.
Sporadic clinical trials w hich interferon have been in  progress for more than a decade. 
Liberal supplies o f standardized preparations enable regular tr ia ls, including phase II , to  be 
carried out. Side-effects greatly  depend  on the purity o f  the preparation , but even interferon  
obtained b y  the recom binant im m unosorbent techniques are n o t entirely  pyrogen-free. The 
side-effects include granulocytopenia, transitory liver fun ction  disorders and, at high dose- 
levels, reversib le damage to the n ervous system , e.g. convulsions. In  a certain proportion of the  
patien ts, form ation of neutralizing antibodies is dem onstrable.
L ocal or system ic application  o f  interferon has been foun d  o f benefit in  viral infections 
o f the upper respiratory passages. In  herpetic infections, as also in  keratitis, it  has proved of  
therapeutic  value. Responses o f  som e degree were noted in  cytom egalovirus infections, bu t 
in  the first place after transp lan tation  and in chronic liver  d isease , particularly if  interferon  
was used  in  alternation w ith  other antiv iral agents. Success is u su a lly  transitory, bu t i t  has 
been possib le to eradicate the v iral genom e in chronic hepatitis. T he results obtained in  juvenile  
laryngeal papillom a offer the m ost prom ising exam ple o f th e  a c t iv ity  o f interferon against 
papillom a viruses. Transitory b e n e fit has been obtained in  m yelom a and acute leukaem ia, 
partial rem issions in 12 out o f  40 cases o f m etastating breast-cancer. Local application o f  
interferon has given favourable resu lts in  cases of m alignant m elanom a, bladder cancer and  
recurrent gliom a. Interferon has b een  also used w ith ben efit as an  adjuvant in  osteosarcom a. 
Its sy stem ic  application in  m elan om a and in non-m icrocellular pulm onary carcinom a is, 
how ever, o f  no benefit.
In  conclusions, the n ecessity  for further trials w ith  stan dardized  preparations has been  
em phasized b y  the Com m ittee, and atten tion  is drawn to  th e  s till unexplored avenue o f ap­
proach to  th e  prevention o f m align an t disease by m eans o f interferon .
J . F e h é r
M e t h o d s  f o r  C o h o r t  S t u d i e s  i n  C h r o n i c  A i r f l o w  L i m i t a t i o n :  € .  du Florey, S. R. 
Leeder
W H O , R egional Office for Europe, Copenhagen .European Series, N o. 12. Price: Sw. fr. 19. —
T his account of the m eth ods for the study of the ep id em io logy  o f chronic respiratory  
disease, issued  by the R egional O ffice o f WHO for Europe, has been  w ritten by an Australian  
and a B ritish  author. It is d iv ided  in to  five  chapters. Chapter 1 describes the various typ es  
of ep idem iological m ethods, po iting  o u t their advantages and  drawbacks. As the title  o f the  
book ind icates, the cohort stu d ies , w hich are actually screening tests  on large groups, are 
best su ited  for the study of the epidem iology  of chronic resp iratory disease by linking up cause  
and e ffec t, even though being m ore costly  than other m ethods em ployed  for this purpose. In  
order to  m ake the m ethod effic ien t, th e  group under stu dy  m u st be kept intact, therefore its  
m em bers should be prevented as far as possible from dropping out. Planning as well as im ­
p lem en tation  of the study m ust ta k e  this point into consideration . Chapter 2 points to the
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epidem iological characters o f the population sam ples to be studied and discusses th e  various 
difficu lties o f approach, e.g. spirom etry in young children, etc. Inform ation provided  on the 
selection  of groups and optim alization of their size, w ith  a clear, concise s ta tis tica l analysis, 
w ill be o f  particular interest to all those engaged in  epidem iologic research. T he m eth od  based  
on the use o f questionnaires is dealth w ith  in Chapter 3 in close detail. This m eth od  has not 
y e t  found general acceptance although in som e countries it  is part of h istory-tak ing  on adm is­
sion to hospital. The questionnaire of the M edical Research Council represents a hallm ark of 
historical significance in th is respect. I t  was originally  elaborated in  E ngland and  b y  not it 
has been adopted in  a m odified form all over the world. On the surface, th e  questionnaire  
m ethod seem s sim ple but, as pointed out b y  the authors on the faith of their experience, its 
effic ien cy  rests on those who ask the questions. Curiously enough, physicians, ow in g  to their 
directive attitude, are in general less su ited  for th is task  than non-m edical persons. Anyone 
to  be entrusted w ith it, receives a thorough train ing before, in  the form of a tra in in g  course of 
8 days, a t the end of which he or she m ay be received or rejected, according to his or her ability. 
Chapter 4 supplem ented by the A ppendix, provides exhaustive inform ation on data-processing  
and statistica l analysis. Chapter 5 is on the pertinent docum entation m ethods. In th e  A ppendix  
an excellent sum m ary of the histam ine provocation  te st is given by one o f the authors.
As a source of inform ation m eeting the h ighest standards, the book m ay be recom m ended  
to epidem iologists and pulm onologists alike.
J. F e h é r
N o n g o n o c o c c a l  U r e th r i t i s  a n d  O th e r  S e l e c t e d  S e x u a l l y  T r a n s m i t t e d  D i s e a s e s  o f  
P u b l i c  H e a l th  I m p o r t a n c e
Technical Report Series 660. WHO G eneva 1981. 142 pages w ith 14 tab les and 5 figures. 
Price: Sw. fr. 9 .—
T he volum e contains the procedings o f a m eeting held by the W H O  R esearch Group 
on nongonorrheal urethritis and other sexu a lly  transm itted  diseases in G eneva from  20 to 
25 N ovem ber, 1978. It includes 15 chapters, a lis t o f  references and an app endix .
B y  w ay of introduction, Chapter 1 points to  the broadening spectrum  o f  sex u a lly  trans­
m itted  (s .t .)  diseases. In fact, venereology o f our days is no longer confined to th e  f iv e  “ classic”  
V D  (syphilis, gonorrhoea, chancroid, lym phogranulom a inguinale, donovanosis), b u t has to 
deal w ith  num erous other diseases whose sexual transm ission had been unknow n u n til recently. 
The aetiological classification, sym ptom atology  and com plications of these d iseases are also 
included in this chapter. Chapters 2 to 7 provide inform ation on s.t. diseases according to the 
in fective  agent (Chlamidia trachom atis, H erpes viridae, H epatitis virus ty p e -B , U reaplasm a  
urealyticum  and M ycoplasm a hom inis, H aem ophilus ducreyi, Cytom egalovirus), in  the follow­
ing order of succession: pathogen, epidem iology, clinical features, laboratory d iagnosis, m an­
agem ent, prevention. Chapter 8 to 15 describe the following conditions in  th e  sam e order of 
succession: trichom oniasis, donovanosis, other im portant infections (caused b y  H aem ophilus 
vaginalis, ectoparasites, s .t. enteric agents, group-B  streptococcal infections, gen ita l warts), 
non-gonococcal urethritis, epididym itis, v u lv ovag in itis , cervicitis and urethritis in wom en, 
genital ulcer, pelvic inflam m atory diseases. Chapter 16 gives a summary sta tem en t o f infertility  
and s.t. diseases, Chapter 17 a sum m ary sta tem en t on maternal and infant m o rta lity  and s.t. 
diseases. In Chapter 18 the necessary steps for program me developm ent are ou tlin ed . This is 
follow ed by a list o f 195 references. In A ppendices 1—5 recom m endations for th e  therapy of 
som e im portant s.t. diseases (urethritis, vu lvovag in itis  and cervicitis, genital u lceration , acute 
salp ingitis), are offered. L. C s e l k ó
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F i e l d  G u i d e  to the D e t e c t i o n  a n d  C o n tro l  o f  X e r o p h t h a l m i a .  Second E ddition . 
A. Som m er
W H O  G enova, 1982. Price: Sw . fr. 10 .—
T his WHO publication discusses the ophthalm ic m anifesta tions of vitam in A deficiency, 
from  hem eralopia to to ta l destru ction  of the cornea.
T his deficiency causing grave consequences occurs a t present alm ost exclusively in  the  
d evelop in g  countries, particu larly  in  those of Africa, A sia and  th e  W est Pacific. Isolated  en­
dem ic areas exist in  the Carribean, L atin  American and E ast-M editerranean countries. A ccord­
ing  to  recent figures, 5 m illion  children are affected yea rly  in  A sia and 250,000 lose their  
ey esigh t.
T he hook gives am ple in form ation  on the signs and sym p tom s, epidemiological aspects, 
m anagem en t and prevention o f  v ita m in  A deficiency. T he 32 colour illustrations serve the  
diagnosis o f xerophthalm ia. For exam ination and diet prin ted  form s are recommended.
M a r g i t  V a r g a
C o n t r o l  o f  V i t a m i n - A  D e f i c i e n c y  a n d  X e r o p h t h a l m i a .  Report of a Joint W HO  
U N IC E F  (USAID) H elen  K eller International (IVACG) Meeting, 1980.
Price: Sw . fr. 7 .—
T his brochure of 70 pages w ith  colour illustrations, instructive tables and graphs 
com prizes the material o f th e  m eeting  held by the above organizations is Jakarta betw een  
13 and  16 October, 1980.
А -vitam in deficiency is a grave nutritional disorder causing  xerophtalm ia and blindness, 
ev en  m arasm us and death in  y o u n g  children.
In  th e  Introduction th e  advances in  research concerned w ith  the biochem istry of v ita -  
m in-A  and carotine are sum m ed u p . After its absorption, v ita m in  A  is stored in  the liver  in  
th e  form  o f  retinol ester. B ind in g  and release result from  com p lex  processes, which for the  
greatest part have been clarified . V itam in-А deficiency is  h ard ly  ever an isolated syndrom e; 
i t  is practica lly  always associated  w ith  protein m alnutrition  (PE M ).
E valuation  of v itam in  A  deficiency, its biochem istry , diagnostic criteria, ocular and  
extraocular signs, public h ea lth  aspects and the m ethods o f  supervision receive thorough  
consideration .
F in ally , statistical figures relating to the prevalence o f  v itam in  A deficiency in  som e  
regions o f Asia, Africa, L atin  A m erica  and the Caribbean island s are presented. P reventive  
and therapeutic  recom m endations are given.
M a r g i t  V a r g a
L u m i n e s c e n c e  i n  B i o l o g y  a n d  M e d i c i n e .  Editors: L. S z a l a y  and S. D a m j a n o v i c h
P ublish in g  H ouse of the H un garian  Academ y of Sciences, B ud ap est, 1983. 421 pages, w ith  
200 figures. Price: 135.— F t
T he book deals w ith  th e  th eo ry  and practice o f the c lassica l and new methods o f lum in­
escence analysis applied in  b io logy  and medicine.
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The first three chapters represent a com prehensive introduction to th e  basis o f molecular 
ligh t absorption and light em ission, the m ethods o f lum inescence m easurem ent and the appli­
cation  of lum inescence in m olecular b iology.
The fourth  chapter discusses the m olecular luminescence m ethods for investigation  
of cell structure. The topics o f fluorescence m icroscopy and im m unofluorescence are treated  
som ew hat too briefly . In spite o f th is, th is chapter will be of aid to  researchers working in 
this field .
This book will be popular am ong scien tists interested in the field  o f  biom edicine and 
is recom m ended to all those who apply lum inescence analysis in diagnostics.
D . S z a b ó
W H O  E x p e r t  C o m m i t t e e  o n  B i o l o g i c a l  S t a n d a r d i z a t i o n
T hirty-second R eport. Technical R eport Series, W H O , Geneva 1983. Price: Sw . fr. 12 ,—
The objective  o f the work com m enced in  1982 was the elaboration o f standards for 
countries where there are none, or where th e  standardization of biological com ponents had 
ju st started . An essential prerequisite w ould be the organization of laboratories in  each country, 
w hich, in  possession of international standards, m ight be able to produce standards for the 
given  country. The desirability o f a central e laboration  o f the working standards is  em phasized, 
bu t the costs are prohibitive. R ecom m endations are offered for clinical chem ical standards, 
v itam in s and sensitiv ity  tests, vaccines and pyrogens.
In a separate chapter the standards for the various antibiotics, an tibod ies, antigens, 
blood preparations, endocrine substances, are defined. The standardization requirem ents for 
pertussis, poliom yelitis, R :ft V alley fever and m easles vaccines are given.
In the 7 chapters of the A nnex, the requirem ents for the above vaccines, furthermore 
for diphteria toxo id , com bined and viral vaccines, as well as for the su scep tib ility  test, are 
listed  under the following headings: m anufacturing-national control requirem ents; require­
m ent for hum an diploid cells used for virus vaccine production; summary protocol o f  produc­
tion  and testing.
K . J o b s t
W H O  E x p e r t  C o m m i t t e e  on  B i o l o g i c a l  S t a n d a r d i z a t i o n
T hirty-third report. Technical Report Series, N o. 687. W HO, Geneva 1983. 184 pages. Price: 
Sw. fr. 13 .—
Standardization of biological substances invo lves the interest and th e  activ ities of 
various agencies o f W HO, as well as o f num erous scientific societies, in various countries. 
This im plies th a t activ ities in this sphere are often  concurrently em ployed. Por th is reason, 
and also in the in terest o f the best possible use o f  the lim ited material resources, W H O  seeks 
to coordinate these activities. W ith th is purpose an information register o f  the substances 
being investigated  has been issued. Inform ation on the prevailing situation is g iv en  and recom ­
m endations are offered under the follow ing headings: test organisms rot an tib io tic  assay; 
shake venom  and antivenom s; the potency o f adsorbed tetanus toxoid; heparin; S P I; throm bo­
plastins; louse-borne human typhus vaccine; oral poliom yelitis vaccine; interferons; pro­
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insulins; standardization of m onoclonal antibodies, recom binant D N A -technology. In a separ­
ate chapter the criteria for th e  reference substances and gu idelines for the elaboration o f new  
in ternational standards are given . T he requirements specified  here concern antibiotics, an ti­
bodies, an tigens, blood preparations, endocrine and related preparations, some biologic sub­
stances, ty p h u s vaccine, throm boplastin  for tests m onitoring anticoagulant therapy, polyo- 
m yelitis vaccin e , antim icrobic su scep tib ility  tests.
In  th e  tw o appendices o f  149 pages, which form  th e  bu lk  o f this small volum e, the  
criteria o f  standardization are set o u t in  the form of a protocol, and the successive steps of  
standardization  are described in  close detail. For interferon standardization  and characteriza­
tion of assays, reference antiserum , neutralization assay, im m unoassay , the various standards 
(H u IF N -a lp h a , beta, gam m a) and their calibration, for the poliom yelitis vaccines m anu­
facturing and national control requirem ents are considered. Preparation and calibration of 
throm boplastin  are described and th e  part played by coum arin and factor V II in the assay  
is po in ted  out. The book, predom inantly  o f technical character, provides essential, up -to-date  
aid to all in stitu tion s dealing w ith  th e  standardization o f  b io log ica l substances.
K .  J o b s t
L a b o r a t o r y  B i o s a f e t y  M a n u a l
W H O, G eneva 1983. 123 pages. Price: Sw. fr. 14.—
T his publication has been in tended  for heads and supervisors o f laboratories, as also 
for b io sa fe ty  inspectors, bu t also contains inform ation for sc ien tists and public authorities 
responsible for the safety o f laboratories in  the various countries. The pertaining regulations 
w ith  regard to  organization as w ell as to handling of p ath ogen s, have varied from country  
to country  un til recently. This m anual assembles the b iosa fety  recom m endation applicable  
at an in ternational level.
T he in fective  m icroorganism s are divided into risk groups I—IV , on the basis of ind ividual 
and com m u n ity  risks. The laboratories are also classed in to  four risk groups.
Inform ation and recom m endation on three m ain issues are provided under the headings
1. basic standards o f laboratory operation, design and equipm ent;
2 . procedures for safe laboratory practice; safety  train ing programmes, safe sh ipm ent 
of specim ens, em ergency procedures;
3. Selection  and use o f essentia l biosafety equipm ent.
T he dangerous laboratory chem icals and the sa fe ty  equipm ents are dealt w ith  in  a 
separate chapter. There are 24 in stru ctive  illustrations and 6 tab les. The volume, of particular  
use to  m icrobiologists, is w ell referenced.
K . J o b s t
L a b o r a t o r y  D e c o n t a m i n a t i o n  a n d  D e s t r u c t io n  o f  C a r c in o g e n s  in  L a b o r a t o r y  
W a s t e s :  s o m e  P o l y c y c l i c  A r o m a t i c  H y d r o c a r b o n s
IARC Scien tific  Publications N o. 49. Lyon 1983. 81 pages. Price: Sw. fr. 18.—
B iom edical research concerned w ith chemical carcinogens goes hand in hand w ith  the  
contam ination  of various m ateria ls w ith  carcinogens. N o t o n ly  the carcasses o f laboratory  
anim als, b u t also the laboratory instrum ents and the prem ises o f  th e  experiments are contam i­
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nated . A special program me for the destruction o f carcinogen-contam inated laboratory wastes 
has been elaborated, and is being regularly published by IARC, under the sponsorship of NIH. 
This volum e, the third in  the series, concerns the polycyclic aromatic hydrocarbons, i.e. b e n z ­
anthracene, bcnzo(a)pyrene, 7-brom om ethylbenz(a)anthracene, d ibenz(a,h)anthracene, 7,12- 
-dim ethylbenz(a)anthracene, and 3-m ethyl-chlolanthracene. The m ethods found suitable for 
these com pounds are presum ably also applicable for the elim ination o f  other arom atic carbo­
hydrates and their derivatives.
For the degradation o f these products, chem ical and physical m ethods such as oxida­
tion  w ith  ozone and hydrogenation have also been applied in addition to  biodegradation. 
These have been sum m ed up in A ppendix B . Three m ethods of an e ffic ien cy  over 99%  are 
recom m ended by the working group, i.e. treatm ent w ith acid K -perm anganate, w ith  concen­
trated  sulphuric acid, w ith saturated aqueous K -perm anganate. The m ethods, as w ell as tests 
for their efficiency, are described in  detail. The physical and chemical constan ts o f  the chemicals 
in question are listed  in  the appendix. The m ethods described here and in A p pend ix  В are 
supported by an exhaustive bibliography.
K. J o b s t
L a b o r a t o r y  D e c o n t a m i n a t i o n  a n d  D e s t r u c t i o n  o f  C a r c in o g e n s  i n  L a b o r a t o r y  
W a s t e s :  S o m e  N - n i t r o s a m i n e s
\R C  Scientific Publications N o. 43. Lyon 1982. 79 pages. Price: Sw. fr. 2 0 .—
The occurrence o f N -nitrosam ines and o f its  precursors in the environ m en t has been 
on the increase, to begin w ith foodstuffs, liquor, tobacco. Various chem icals, pestic id es, rubber, 
leather, m etal industries provide potentia l sources. These compounds result from  nitrification  
o f m ainly secondary, but partly also of prim ary and tertiary, am ines and o f  quaternary am­
m onium  salts. Though the causal relationship betw een exposure to N -n itrosam ine and human 
cancer have ye t to be conclusively proved, on the ground of experim ental evid en ce the exis­
tence of such relationships m ay be none the less taken into consideration. T his requires partic­
ular precautions not only in the course of m anufacture or preparation, hu t also o f experim ents 
and m akes necessary the destruction o f various w astes including those from  anim al sources.
This sm all volum e describes the procedures enabling the chem ical carcinogens contam i­
nating laboratory instrum ents to be decom posed or inactivated 8 com pounds, i.e . N-nitroso- 
dim ethylam ine, N-nitrosodipropylam ine, N -nitrosodibutylam ine, N -n itrosopiperid ine, N-nitro- 
sopyrolidine, N-nitrosom orpholine, and N ,N ’-dinitrosopiperazine have been  tested . The 
m ethods described in the book are regarded as su itab le for the neutralization o f  practically  all 
other com pounds of th is type.
The earlier degradation procedures o f  questionable value, (N a  hyp och lorite, chromo- 
sulphuric acid, cuprochloride HC1) are critically  reviewed. The recom m endations are, denitri­
fica tion  w ith hypochrom ic acid in  glacial acetic  acid, photolytic degradation b y  ultraviolet 
irradiation, oxidation  w ith  K -perm anganate in a m edium  of sulphuric acid, handling w ith a 
K -hydroxylated  nickel-alum inium  alloy, etc. are given. Each procedure is described in detail.
The other (e.g. biological) degradation procedures published in  the literature and the 
chem ical and physical constants o f the eight com pounds listed above have been  sum m ed in 
the A ppendix. There is a list o f more than 100 references.
The book provides im portant aid to industrial m edicine, laboratories and in the first 
place to specialists concerned w ith  environm ental health.
K. J o b s t
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10th EUROPEAN CONGRESS 
OF PERINATAL MEDICINE
Leipzig, German Democratic Republic 
August 12-16, 1986
DEAR COLLEAGUES
You are  cordially invited to participate 
in the 10th European Congress of 
Perinatal Medicine to be held in Leip­
zig, German Democratic Republic, from 
August 12th to 16th, 1986.
This Congress is being organized by the 
“ Gesellschaft für Perinatale Medizin der 
Deutschen Demokratischen Republik” 
in Cooperation with the “ European So­
ciety of Perinatal Medicine” .
The aim of the Scientific Programme is 
to give participants the opportunity to 
present the results of their most recent 
work, to exchange ideas and experiences, 
to take part in discussions and to estab­
lish contacts with foreign colleagues. It 
is ou r  intention to invite selected special- 
sts to Main lectures, Symposia and 
Workshops. All scientific problems rele­
vant to the central themes but also Free 
Papers will be covered during the 
Congress.
Poster presentations and other scientific 
expositions will be of g rea t importance 
and the Organizing Committee is dedi­
cating special attention to them. An 
exhibition of technical equipments and 
pharmaceutical products, of medical and 
bel I etristic books will be held in con­
junction with our Congress.
We do hope to have the opportunity of 
welcoming you in Leipzig in 1986.
Klaus Jährig 
Chairman
Hans-Joachim W araschk 
Secretary General
Waldemar Rumler 
Treasurer
COMM UNICATIONS
Languages
The official languages of the Congress 
will be English and German. Simulta­
neous interpretation will be provide for 
Main lectures and Symposia.
Accommodation and Travel
All the accommodation facilities will be 
provided, a number of categories from 
5-star-hotels to university hostels has 
been reserved.
For those participants who wish to take 
the opportunity of spending a few extra 
days in the German Democratic Repub­
lic, post-congress tours can be arranged.
Social Program m e
An extensive social programme is 
planned for all participants of the 
Congress and for accompanying per­
sons.
Second Announcement
A second circular containing more 
detailed information on the Congress, 
programme, abstract and registrations 
forms and other instructions will be 
available in September 1985. To re­
ceive a copy, please complete and 
return the attached form to the Secre­
tariat.
Congress Secretariat:
10th EUROPEAN CONGRESS  
OF PERINATAL MEDICINE
Frauenklinik im
Universitäts-Klinikum Kröllwitz 
Ernst-Grube-Straße 40, P.О.В. 63 
DDR-4010 Halle (Saale)
Phone: (0046)-672323 
Telex: 04 353 uni hal dd
AG 1181110184 -  IV-26-7
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I N T E R N A T I O N A L  C O N F E R E N C E
OCCUPATIONAL AND 
ENVIRONMENTAL SIGNIFICANCE 
OF CHEMICAL CARCINOGENS
B ologna, Ita ly  
O ctober 8 —10, 1985
Palazzo della  Cultura e dei Congressi 
Bologna
P R E L IM IN A R Y  PROGRAM
M A J O R  C O N F E R E N C E  T O P I C S
A . C auses o f human cancer; w h a t is known and w hat is knowable
B . A n im al carcinogenesis testin g : underlying concepts, advantages and contra
C. M echanism s of carcinogenesis
D . Short-term  tests; relevance for hum an cancer risk
E . R ecen t laboratory studies in  chem ical carcinogenesis
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER 
World Health Organization 
Lyon — France
FELLOWSHIPS FOR RESEARCH TRAINING IN CANCER
1985 —1986
Applications for training fellowships in 1985—1986 are invited from junior 
scientists wishing to be trained in those aspects of cancer research related to the 
A gency’s own program m e: epidemiology, biostatistics, environmental and viral 
carcinogenesis and mechanisms of carcinogenesis.
Applicants should be engaged in research in medical or allied sciences and intend 
to pursue a career in cancer research.
Fellowships are  awarded for one year and are tenable at the Agency or in another 
suitable institution abroad. Fellows will, in general, be selected from applicants with 
some postdoctoral research experience related to cancer in medicine or the natural 
sciences. They must have an adequate knowledge, both written and spoken, of the 
language of the country in which their fellowship is tenable.
Applications cannot normally be accepted from people already holding fellowships 
enabling them to study abroad.
Stipends will vary according to the cost of living in the country of study. The cost of 
travel for the applicant, and in certain circumstances, that of one dependent will be met.
VISITING SCIENTIST AWARD 
1985-1986
This award — one per year — is intended for established cancer research 
workers, with a minimum of five years postdoctoral experience, who wish to 
spend one year at IARC, working on the implementation of a collaborative  
research project related to the A gency’s own programmes: epidemiology, 
biostatistics, environmental and viral carcinogenesis and mechanisms of carcino­
genesis.
Applicants must belong to the staff of a university or a research institution. They must 
provide a written assurance that they will have a position to return to at the end of 
the period of award.
Candidates should submit their applications after consultation with an IARC scien­
tific staff member. Applications will be reviewed by the Fellowships Selection Committee 
each year.
Fellowship application forms and more detailed information are available from: 
Chairman of the Fellowships Selection Committee 
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER 
150 cours Albert-Thomas, 69372 Lyon Cedex 08 
France
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EFFECT OF THYMECTOMY IN IMMUNE DISEASES 
OTHER THAN MYASTHENIA
A. S z o b o r  and J . M o l n á r
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HUNGARY
(R eceived  Septem ber 27, 1984)
In th e  course o f thym ectom y of p a tien ts w ith  m yasthenia gravis, surprising  
data concerning the recovery or considerable im provem ent of other im m une disorders 
have been observed. A m ong these disorders rheum atoid  arthritis figured in  s ix  in ­
stances, im m une throm bocytopenia in tw o cases, po lym yositis and psoriasis in one 
case each. T hym ectom y as a powerful im m unosuppressive procedure m ay h ave a role 
in the therapeutic m anagem ent of some im m une disorders other than m yasth en ia  
gravis.
K eywords: im m une disorder, m yasth en ia  gravis, thym ectom y, rheum atoid  
arthritis, im m une throm bocytopenia, p o lym yositis, psoriasis
Introduction
It is w ell know n th a t m yasthenia gravis (MG) m ay be associated  or 
com bined w ith  other diseases such as rheum atic, skin and visceral disorders, 
haem atologic conditions, d iseases of the th yro id  gland, m yopathy, etc . These  
associations exceeded the exp ected  incidence o f  these rare diseases, hence th e  
idea has been raised o f som e possible connection  or o f  a com m on origin. The  
observations o f  these associations did not go beyond  registration, esp ecia lly  
concerning MG on the one hand, and thyroid disorders and m yopathy on the  
other. The im portance o f  d isease-associations has becom e evident, and th e  
presentation o f  such cases has becom e in teresting  after in MG the p o ssib ility  
o f an im m une or autoim m une pathom echanism  had been suggested, and later  
successfully proved [5, 19, 32, 41, 51, 54, 55]. In  addition to experim ental 
and theoretical data, it w as th e  d isease-associations which have provided  
a considerable argum ent for th e  immune pathom echanism  of MG, th en  S im p­
son [51, 52] stressed the opinion, that MG should  be considered a sp ecific  
m anifestation o f  the general or polysystem ic im m unopathy localized in  the  
neuro-m uscular junction  o f the motor synapsis.
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I t  w as only natural th a t atten tion  has been directed in  the fir st  line 
tow ard  th ose  disease-associations in  w hich an im m une or autoim m une patho- 
m ech an ism  has been proved or at least suggested . Such diseases are p o ly ­
m y o s it is , derm atom yositis, system ic lupus erythem atosus, rheum atoid  arthri­
t is , scleroderm a or progressive sclerosis, in  a wider sense som e o f th e  haem o- 
p o etic  disorders (e.g. im m une or id iopath ic  throm bocytopenia, pernicious 
an aem ia , haem olytic anaem ia), som e visceral diseases (e.g. im m une glom erulo­
n ep h ritis , Goodpasture syndrom e, im m une pneum onitis, distress syndrom e), 
and sk in  disorders such as psoriasis, lichen  ruber, candidiasis, som e form s o f  
p em p h igu s and eczem a [1, 2 , 3, 6, 7, 9, 10, 11, 13, 14, 15, 16, 18, 23, 24 , 26, 
27, 2 8 , 30, 31, 35, 36, 37, 38, 39, 40, 42, 43, 44 , 45, 46, 47, 48, 49, 50, 56, 58, 
60, 61 , 65, 66, 67].
In  th e  course o f  33 years we have observed associations o f  MG w ith  other 
disorders in  a num ber o f cases. The m ost im portant associations could  be 
su rv ey ed  on the basis o f  750 m yasthenic p atien ts observed and follow ed-up  
p erson a lly  b y  us. The association  o f MG and thyroid  disorders has been  dis­
cu ssed  in  a previous paper [60]. The num ber and percentage o f  th e  diseases 
associa ted  w ith  MG are show n in  Table I  w here only diseases w ith  certain  or 
su ggested  im m une origin have been included . There was no sign ifican t differ­
ence concerning associated diseases betw een  the patients having th ym om a  
(15 .7% ) or thym ic hyperplasia (78.2% ). T he diseases associated w ith  MG had  
ex isted  prior to th ym ectom y for MG, there w as only a single case w here th y m ­
e c to m y  was followed b y  rheum atoid arthritis after six years. A  m ultifold  
associa tion  o f thym om a, MG and chronic m yelom onocytic leukaem ia in  an
Table I
Number and percentage o f  imm une diseases associated with 
myasthenia gravis in  750 cases
A ssociated diseases No. Percentage 
o f patien ts
Thyroid disease 44 5.86
Rheum atoid arthritis 22 2.93
Polym yositis, derm atom yositis 21 2.8
System ic lupus erythem atosus 7 0.93
Local (discoid) lupus 2 0.27
Diffuse progressive sclerosis 4 0.53
Raynaud phenom enon 3 0.4
Sjögren syndrome 3 0.4
Immune throm bocytopenia 2 0.27
Pernicious anaem ia 2 0.27
Psoriasis 4 0.53
Eczem atous skin disease 2 0.27
Hodgkin lym phom a 2 0.27
Multiple sclerosis 4 0.53
M yelom onocytic leukaem ia 1 0.13
Total 123 16.4
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old patient was observed and published elsew here [23]. In tw o cases MG was 
associated with H od gk in  lym phom a [59] and in  four instances w ith  m ultiple  
sclerosis [57].
In spite o f  th e  large literature on the diseases associated w ith  MG and 
th e  w ell-established results o f th ym ectom y in  MG, one can hardly find  any 
report on the effect o f  th ym ectom y on the associated diseases. In  our material 
353 patients were treated  by th ym ectom y v ia  m edian stern otom y. In  two  
fem ale patients w ho had MG and rheum atoid arthritis, surprising im provem ent 
w as observed not o n ly  in  MG but also in  rheum atoid  arthritis. A fter th is first 
observation we started  to  collect data am ong our m yasthenic p a tien ts sub­
jected  to  th ym ectom y or to large (destructive) dose o f  thym ic X -ra y  irradia­
tion .
Report of cases
1. T. E. a 27 year old woman had developed generalized MG w ith  ocular, bulbar, facial 
and skeletal sym ptom s after an airway in fection  at th e  age o f 18 years. A t th e  onset cholin­
ergic drugs were usefu l, th e  course of MG was rem ittant and benign, but after repeated infec­
tions and a pregnancy, exacerbations occurred for 9 years. R heum atoid arthritis started at 
the age of 23 years; w as progressive in nature and needed constant active therapy. W hen an 
active  thym us gland (47 g , hyperplasia II I )  was rem oved, MG im proved rapid ly  and after 
a year her rheum atoid arthritis also im proved, so th a t she did not need steroids or other 
therapy since. During 15 years of postoperative observation  MG had to  be trea ted  only for 
short periods, the rheum atoid  arthritis w as in com plete rem ission.
2. C. B. a 22 years old woman. A t 19 years o f  age arthritis developed on  her hands, 
w rists, knees and ankle jo in ts  after prolonged exposition  to  cold. The arthritis caused joint 
deform ities in a short tim e, during steroid therapy her condition  becam e worse. In  th e  fifth  
m onth  of penicillam ine therapy generalised MG w ith  dom inant bulbar and respiratory sym p­
tom s developed. MG rem ained progressive after th e  cessation  of penicillam ine therapy for 
over six  m onths, and she did not tolerate an y  form  o f steroid treatm ent. A very  active  thym us  
gland (43 g, hyperplasia o f  degree III) w as rem oved b y  sternotom y. In  the m uscle sample 
fibre degeneration and regeneration, furtherm ore lym photic  infiltrations were seen. After the  
operation both MG and rheum atoid arthritis im proved quick ly, the patien t w ho up to  then  
unable to  m ove started  to  walk, her pains ceased. D uring th e  n ex t 10 years she needed 120—  
180 m g pyridostigm ine daily , gave life to  tw o healthy  children, her rheum atoid arthritis had 
n ot to  be treated at all.
3. C. Z. a 56 years old male patien t had been suffering from  typ ical rheum atoid  arthri­
tis  for 20 years. F in a lly  he was given penicillam ine therapy, in  the fourth  m on th  o f which 
MG developed w ith dom inan t bulbar sym ptom s. MG rem ained unchanged in th e  e igh th  m onth  
after cessation o f pen icillam ine therapy, furtherm ore th e  patient needed m ore and more 
cholinergic drugs. T h y m ectom y revealed an active gland (36 g, hyperplasia II ) . A fter the 
operation both MG and rheum atoid arthritis im proved significantly . During th e  n ex t 5 years 
th e  patient could be k ep t in  remission w ith  low  doses o f  prednisolone and 120— 180 m g/day  
o f pyridistigm ine.
4. V. P . a 14 years old girl. From th e  age o f 9 years she had been treated  on account 
o f juvenile  rheum atoid arthritis w ith steroids, azathioprine and penicillam ine. A t 12 years 
she had developed u lcerous colitis and tw o  years later MG w ith  skeletal sym p tom s, then  later 
w ith  bulbar, ocular and respiratory ones. After tw o  years o f  ceasing penicillam ine therapy  
MG still existed, furtherm ore it progressed into  a crisis-endangered state . A t surgery, the  
thym u s gland was large and histologically active (48 g, hyperplasia III). A fter th e  operation  
MG im proved gradually, th e  patient becam e sym ptom free and did not need an y  cholinergic 
drug. R heum atoid arthritis and colitis have  also becom e sym ptom free w ithout therapy and 
in  th e  n ext five years she has been well.
5. R . J . a 35 years old man had been suffering from  rheum atoid arthritis for 7 years. 
In  the sixth m onth o f  penicillam ine therapy generalized and progressive MG developed. 
After discontinuation o f  th e  penicillam ine therapy th e  rheum atoid arthritis becam e worse and
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MG rem ain ed  unchanged for seven  m onths. Large dosage X -ra y  irradiation ( 1 0 x 1 7  cG) was 
app lied  to  th e  thym ic area. M yasthenic  sym ptom s decreased gradually then  ceased, and the  
rh eu m a to id  arthritis im proved considerably. During the n e x t 10 years no treatm ent was 
n ecessa ry , the patient was able to  return  to  his original job.
6. V. B . a 38 years old m ale  patien t after 5 years o f  rheum atoid arthritis had been  
g iv en  penicillam ine. After 5 m onth s MG had developed w ith  facia l, bulbar, ocular and skeletal 
sy m p to m s. These decreased after pen icillam ine therapy had been interrupted, but still con­
tin u ed  to  ex is t for over six  m on th s. D estructive dosage X -ra y  treatm ent on the th y m ic  area 
resu lted  in  a quick rem ission o f  MG and in a gradual im provem ent of rheum atoid arthritis. 
The fo llo w -u p  period has in  th is  case  been 5 years, during w hich only  tem porary treatm ent 
w ith  sm a ll doses of steroid or indom ethacine was necessary.
7. P . A .  a 15 years old girl had  been suffering from  th e  age o f 10 from psoriasis on her 
w hole b o d y  and resistant to  an y  th era p y , and from tem porary acute psoriatic arthritis. H alf 
a year after  thym ectom y —  perform ed on account of serious generalized MG w hich endangered  
th e  resp iratory  functions, to o , —  her psoriasis and arthritis ceased and have not relapsed in  
th e  n e x t  f iv e  years. The th y m ic  g land  in  th is case was hyperactive containing a large num ber 
o f germ in ative  centres.
8 . K . K .  a 35 years old fem ale  had been treated w ith  steroid for over 11 years because 
o f im m u n e  throm bocytopenia. A t th e  age o f 33 years she had  developed MG w ith  progressive  
generalized  sym ptom s, including respiratory troubles. A t thym ectom y a very large and active  
th y m u s g land  was found (46 g, hyperplasia  III). After th yem ectom y no steroid treatm ent was 
necessary  during 6 years.
9. V. P . a 28 years old fem ale  had taken steroids regularly from  the age o f 19 years 
on  a cco u n t o f immune throm bocytopenia . MG had begun at 26 years w ith ocular, bulbar and 
sk ele ta l sym ptom s. T hym ectom y revealed  an active gland (27 g, hyperplasia II I)  w ith  num er­
ous germ in ative  centres. A fter th y m ecto m y  no cholinergic or steroid treatm ent has been  
necessary  in  the last 5 years.
10. L . L . a 29 years old m ale had had MG since the age of 24 years; it  progressed into  
a v ery  serious form w ith bulbar, sk eleta l and respiratory sym ptom s. In  addition a progressive 
p o ly m y o sitis  also developed in  h is lim bs and oesophagus, corroborated by EMG and h isto­
log ic  exam in ation  of m uscle sam ples. H e had to be treated  in  IP P R  because o f respiratory  
crisis. B y  sternotom y a very  large th y m u s gland w as rem oved (48 g, hyperplasia II I )  w ith  
num erous germ inative centres and lym phoblastic  transform ation. After the operation, MG 
im proved  gradually and sym p tom s o f  polym yositis disappeared. N o treatm ent has been  
necessary  in  12 years.
Discussion
T he effect of th y m ecto m y  on MG was established by B lalock et al. [8] 
and K eyn es [29] more th an  four decades ago and th e  benefit o f the operation  
has b een  proved through fo r ty  years. Only the local (ocular) form o f MG has 
been  considered an excep tion , in  which th ym ectom y has rem ained a m atter  
o f  d eb ate  [22, 25, 68]. In  our associated  cases th ym ectom y resulted in  recovery  
in  th ree  instances, and in  sa tisfactory  rem ission o f m yasthenic sym ptom s in 
th e  o th er seven cases. In  f iv e  cases MG was caused or provoked b y  penicill­
am ine therapy [56, 58]. It is an open question w hether penicillam ine-D  would  
cause a dose-dependent m yasth en ic reaction w hich then vanishes after dis­
con tin u ation  of the drug, or it  could cause MG w hich should be considered  
a tru e m yasthenic disease, or w ould make m anifest a m yasthenic process, 
la ten t or unknown till the tim e  o f penicillam ine treatm en t [58]. This question  
can o n ly  be answered on th e  basis o f collected cases in the future. Our cases 
seem  to  suggest the third p ossib ility , as do also som e data on the acetylcholine  
recep tor antibodies [17, 21 , 53 , 62, 63, 64].
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In addition to the results achieved in  MG by th ym ectom y, th e  associated  
or connected diseases supposin gly  o f im m une origin and nature im proved in 
a considerable w ay and in  a sign ificant degree; thus, in four cases o f  rheuma­
toid arthritis we saw long-lasting rem issions where no treatm ent w as necessary, 
in two instances the condition  im proved and sm all dose o f steroid  treatm ent 
was necessary only tem porarily . T otal and lasting remission fo llow ed  thym ec­
tom y in  tw o patients w ith  im m une throm bocytopenia, th e  you n g  female 
patient suffering from resistant psoriasis recovered com pletely , and a male 
patient suffering from polym yositis becam e sym ptom free.
The role of the th ym u s gland in MG has been well known, th e  data  being, 
nevertheless, in the m ajority  o f  the cases empiric. The lym p h o cy tes  under 
thym ic control can produce antibodies against acetylcholine receptors either 
inside the thym us or in the blood [33, 34]. These antibodies bound to  the post- 
synaptic (m uscle) mem brane (acetylcholine receptor site) m ay cause a partial 
or tota l neuro-m uscular b lock w ith the consequence know n as m yasthenic  
fatigue. The thym us can be considered the m ain regulator organ o f immune 
processes, hence th ym ectom y is a powerful im m unosuppressive procedure. 
Our observations call a tten tion  to the possible role o f the th y m u s in the 
pathom echanism  of other disorders o f know n or suspected im m une (auto­
im m une) origin and nature. H ence th ym ectom y m ay be considered an im­
m unosuppressive treatm ent in  im m une diseases other than MG, in  spite of 
the fact th a t the role o f th e  thym us is even less clarified in  th ese  diseases 
than in MG. In this connection  som e results achieved by th y m ecto m y  in 
id iopathic polym yositis [4] and m ultiple sclerosis [12, 20] m ay also be quoted. 
I t  seem s to  be worth-w hile to  collect further data about the effect o f  thym ec­
tom y on various im m une disorders and for th is purpose the large MG case 
m aterial thym ectom ies seem  to  be the best solution.
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LYMPHOCYTE MARKERS IN PATIENTS 
WITH PROGRESSIVE SYSTEMIC SCLEROSIS
L. C z i r j á k , K atalin  D a n k ó , Ildikó S o n k o l y ,
E dit B O D O LA Y  and G y. SZ EG ED I
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(R eceived  J u ly  30, 1984)
18 patients w ith progressive system ic  sclerosis were investigated . A n absolute  
lym phopenia and a decrease in  the num ber o f  E -rosettes and early E -rosette  form ing  
cells were found. The number o f Ту cells w as reduced as compared to  th e  control values. 
N o dim inution w as found in th e  num ber o f  h istam ine receptor bearing cells b u t the  
num ber o f T lym phocytes capable o f  recognizing autologous red blood cells  w as con­
siderably decreased. The num ber and the ratio o f these T cell subpopulations rem ained  
relatively  stable even after 6 m onths in  th e  p a tien ts w ith progressive system ic sclerosis. 
N o individual correlation was found betw een th e  clinical findings and th e  ratio o f 
T cell subpopulations.
Keywords: progressive system ic sclerosis (scleroderm a), T lym p h ocyte  m arkers, 
T  у  cells
A bbreviations: H -binding receptors —  h istam ine binding receptor, PSS —  progressive  
system ic sclerosis, Ту —  T lym phocyte bearing IgG  F c receptors on their surface.
Introduction
Progressive system ic sclerosis (PSS) is characterized by in flam m atory , 
fibrotic and degenerative changes in vo lv in g  the skin and certain internal 
organs. The m ajority o f investigators found a depressed cell-m ediated im m u­
n ity  in patients w ith  PSS. A bnorm alities in  the distribution o f T lym p h ocyte  
subtypes [1, 7, 10], the num ber o f E -rosette  form ing cells [2, 8 ], leukocyte  
m igration inhibition  [9] and antibody dependent cell-m ediated cy to to x ic ity  
[4] have been described.
Studies on the im m unoregulatory helper/suppressor-cytotoxic T cell 
subpopulation have shown conflicting results [1, 7, 21]. Abnorm alities o f T cell 
subsets defined b y  m onoclonal antibodies have recently been described [13, 
21]. The m ajority o f observations suggest th a t the im balance o f th e  im m uno­
regulatory T cell subpopulations is caused b y  the dim inution of th e  suppressor  
T cell subset in patients w ith PSS [10, 13, 21].
Som e o f the T lym phocytes bear h istam ine (H )-binding receptors on 
their surface. Cells w ith  H -receptors have been found within the O K T8 positive
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population  and com prised approxim ately 50%  o f the T cell subpopulation  
having F c receptors for IgG [14].
A m ong the very  heterogeneous T cells there is a lym phocyte subpopula­
tion  capable o f  recognizing autologous antigenic structures [15, 16]. The ly m ­
ph ocytes form ing rosettes w ith  autologous erythrocytes represent a precursor 
T cell population  in  w hich functionally  n on-com m itted  lym phocytes are also  
represented [15]. T hese post-thym ic precursor cells m ay play an im portant 
role in im m unoregulation . The number o f T lym p h ocytes capable o f  recog­
nizing autologous red blood cells were found to  be reduced in  patients w ith  lupus  
erythem atosus [3].
In  our study th e  E -rosette form ing cell, T cell subpopulation w ith  Fc  
receptors for IgG and T cells bearing H -binding receptors were investigated  in  
p atien ts w ith  PSS. H a lf a year later som e p a tien ts  were reinvestigated  so as 
to  stu d y  th e  individual variab ility  in  the T cell subsets discussed above.
There is no single diagnostic te st for P SS. A bnorm alities in the num ber 
of T cell subsets m ay, how ever, be helpful in  understanding the pathogenesis  
o f th e  disease. This report extends these observations to  the in vestigation  o f  
autologous E -rosette form ing cells in patien ts w ith  scleroderma.
A lso  it  is not clear w hether im m unoregulatory abnorm alities represent 
a relevan t factor or an epiphenom enon in th e  etio logy  o f PSS.
Patients and m ethods
E ig h teen  fem ale p atien ts w ith  PSS were investigated . Their m ean age was 45 ± 1 5  years 
(31 to  64) w ith  a m ean h istory of 9 .2 ± 8 .3  years. A ll p a tien ts  had proxim al scleroderm a and  
R aynaud phenom enon, 15 had internal organ m anifestations; all fulfilled the prelim inary  
diagnostic criteria for scleroderm a [18]. In  treatm ent, D -penicillam ine, prednisone and/or  
nifedipine were applied (Table I).
Table I
Clinical profile  o f  patients with progressive system ic sclerosis (P SSJ
PSS w ith  diffuse scleroderma (No.) 18
Age (m ean) 4 5 ± 1 5
Duration o f disease (mean) 9 .2 ± 8 .3
Number of patients w ith Raynaud phenom enon 18
Number o f patients with
R aynaud phenomenon 18
Pulm onary involvem ent 12
Oesophageal dysfunction 8
Cardiac involvem ent 4
Renal involvem ent —
Other m anifestations 4
Num ber of patients receiving
D-penicillam ine (300— 1000 m g/day) 5
Prednisone (15 m g/day or less) 4
Nifedipine (30— 50 m g/day) 11
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Peripheral m ononuclear cells were separated on Ficoll-Urom iro gradient. E -rosette  
forming T cells were determ ined by th e  standard m ethod  [11]. The number of th e  early E- 
rosette forming cells w as investigated b y  the m ethod  o f Y u et al. [20]. Т у  cells were dem on­
strated by IgG -type rabbit antibodies against ox eryth rocytes as described by G upta et al. [6]. 
H -Binding receptors on  T lym phocytes were determ ined by the m ethod of Saxon  [17] and 
Kedar [12] w ith  slight m odifications [19]. The h istam ine receptor-bearing cells were detected  
by m eans of rosette  form ation w ith h istam ine-coated  erythrocytes.
The rosette  form ing capacity o f  lym p h o cy tes w ith  autologous erythrocytes w as de­
term ined as described elsewhere [3]. B riefly , 2 x lO G peripheral blood m ononuclear cells and 
3 x l 0 7 autologous erythrocytes were m ixed , centrifuged and before counting incub ated  at 
4 °C over 24 hours.
50 hea lthy  controls were also studied . The resu lts w e expressed by m eans ±  S .D .
The differences betw een groups were eva lu ated  b y  Student’s t-test.
Results
E ighteen patients were in vestigated . The absolute lym phocyte count 
and the num ber o f E-rosette form ing T cells were decreased as com pared to 
the control va lu es (Table II). N o d im inution  was found in the num ber of 
histam ine receptor bearing cells (Table II ) . The num ber and the ratio o f  Т у  
cells were decreased in patients w ith  PSS as com pared to the control values  
(Table II) and th e  number of T lym p h ocytes capable o f recognizing autologous 
red blood cells w as also considerably decreased (Table III). The peripheral 
blood m ononuclear cells bearing IgG  on their  surface were unchanged.
Table II
T  cell subsets in patien ts w ith P SS
P atien ts Controls P  by l-tes t
Number 18 50
Absolute lym phocyte count, m m -3 1 6 3 0 ± 6 7 0 2490 ± 6 7 5 0.001
E-rosette forming cells, per cent 4 5 ± 1 4 .5 *
(7 8 0 ± 3 4 0 )
6 3 ± 1 2 .8
(85 0 ± 4 2 0 )
0.001
Early E-rosette form ing cells, per cent 2 2 .5 ± 1 5 .0  
(368 ± 2 8 8 )
34.0 ± 8 .4  
(850±420)
0.001
Ту cells, per cent 4 .3 5 ± 3 .5 1 *  
(78 ± 7 4 )
1 0 .4 ± 1 .5  
(140 ± 4 0 )
0.001
Cells w ith H -binding receptors, per cent 8 .6 ± 5 .7 3  
(160 ±  134)
9 .6 ± 1 .3
(1 5 0 ± 3 0 )
NS
* In parentheses: Absolute number o f  cells in 1 p i  blood
Six m onths later 10 patients w ith  P SS were reinvestigated so as to 
evaluate again their  T lym phocyte subsets. A s show n in Table IV , the num ber  
of T cell subpopulations remained rela tively  stab le during the 6 m onth period. 
No correlation w as found betw een the clin ical findings and the ratio o f  T cell 
subpopulations.
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Table III
Autologous rosette form ing T  cells in  patien ts with P SS
P atien ts  Controls {»test
N um ber 18 30
A u tologou s rosette 9.23 ± 8 -50*  20.4 ± 3 .1  0.001
form ing T  cells, per cent (1 6 6 ± 1 8 2 ) (5 1 0 ± 1 4 )
* In  parentheses: Absolute num ber of cells in 1 pX blood
Table IV
T  cell subpopulations reinvestigated 5 .7 ± 1 .2  months later in patients with P S S
First Second
investigation
N um ber 10
A b solu te  lym phocyte count, m m ~3 1610±840 155 4 ± 8 1 2
E -rosette  forming cells, per cent 48 .5±18 .9*  
(828 ± 4 2 4 )
4 1 .4 ± 2 1 .0
(6 6 9 ± 3 4 6 )
E arly  E -rosette forming cells, per cent 28.7 ± 1 4 .5  
(451 ± 3 0 2 )
1 5 .7 ± 1 6 .3  
(214 ± 1 7 1 )
Т у  cells, per cent 4 .9 ± 4 3  
(85 ± 9 0 )
5 .5 ± 5 .3  
(94 ± 9 2 )
A utologous E-rosette forming cells, per cent 8.2 ± 6.0 
(140 ± 1 0 0 )
1 1 .1 ± 5 .5  
(198 ± 136)
* In  parentheses: Absolute num ber of cells in  1 p \  blood
Discussion
In  m ost studies like in  the present one an absolute lym phopenia was 
observed  [2]. P atients w ith  PSS showed a reduction  in the num ber o f  E- 
ro sette  form ing T lym p h ocytes [2, 8 ], as found also in the present. R ecen tly  
no sig n ifica n t decrease has been shown w hen OKT3 m onoclonal antibody was 
used  to  d etect the num ber o f T lym phocytes [21]. The discrepancy was not 
surprising in  v iew  o f the fact th a t tw o different, partially overlapping T ly m ­
p h o cy te  subpopulations were in volved  in  th e  studies.
T he absolute num ber and the ratio o f early E-rosette forming cells e x ­
h ib ited  a reduction in  the patien ts w ith  PSS [2], as dem onstrated also in  the  
present investigation .
S tu d ies of the helper/suppressor-cytotoxic T cell subpopulations in  
p a tien ts  w ith  PSS showed conflicting  results. Norm al Ту cells and decreased  
Т ц  ce lls  [1] or increased Ту cells and decreased Т ц  cells [7], and decreased
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Ту cell subpopulations were reported [10]. R ecent studies w ith m onoclonal 
antibodies have show n a T cell im balance in sclerodermic patients [13, 21]. 
The elevated  ratio o f O K T4/OKT8 cells has been  attributed to the dim inution  
o f OKT8 positive cells [21].
In  our stu d y  a m arked decrease in  th e  num ber o f y  cells w as show n. 
The dim inution in  the num ber o f E -rosettes, early E-rosette form ing cells and 
y  lym phocytes m ay have contributed to th e  depressed cellular im m u n ity  in  
patien ts w ith  PSS.
H istam ine-binding T lym phocytes w ere found to  be present in  50%  of 
the Ту cells but not in  th e  T cell subpopulation  bearing receptors for IgM  [14]. 
In contrast, the histam ine-binding T lym p h ocytes were not decreased in  PSS  
as com pared to  the control patients.
In our study a reduction in the autologous E-rosette-form ing cells was 
dem onstrated in scleroderm ic patients. To our know ledge this d im inution of 
autologous E -rosette form ing cells has n o t been described previously. The 
reduction in the p ost-th ym ic precursor cells m ay provide one of the factors 
for the altered im m unoregulation in p a tien ts w ith  scleroderma.
H a lf a year later 10 patients w ith P S S  were reinvestigated. The ratio  
and the num ber o f E -rosette, early E -rosette  form ing cells, Ту lym p h ocytes  
and autologous E -rosette form ing cells show ed a relative stab ility  during the  
6 m onth period.
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DEMONSTRATION OF THE EFFICIENCY OF 
SPECIFIC MUCOUS MEMBRANE DEFENSE BY 
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Gastric juice and b ile  fractions A , B , C of 143 patients, vag ina l secretion and 
cervical mucus of further 257 patien ts, and th e  sera of all patien ts, w ere studied for 
IgG , IgA , IgM, com plem ent C3, album in and transferrin, together w ith  acid ity  tests 
and m icrobiological stu d y . The data thu s obtained, nearly 10 000 in  num ber, were 
subjected to  autom ated (factor) analysis. This revealed certain concealed  relationships 
w hich has been superim posed b y  the m anifestations: the specific defense o f  th e  mucous 
m em branes resulting from  th e  a c tiv ity  o f  th e  secretory im m une sy stem  takes effect 
only  under special cond itions. T he local secretory im m une factors, togeth er  w ith  the 
effects connected w ith  ac id ity  and proteolytic  a c tiv ity , are deployed o n ly  in  th e  stomach  
and duodenum  at th e  first level o f m ucous m em brane defense. For th e  defense of the 
genital m ucous m em branes —  in the period o f sexual activ ity  and reproduction  —  the 
transudative factors o f  th e  serum  resulting from  hormonal ac tiv ity  are responsib le, and 
on ly  if  these factors are affected  does th e  specific defense m echanism  o f  the mucous 
m embranes take action.
Keywords: secretory im m une system , acid ity , gastroduodenal ju ice , vaginal 
secretion, cervical m ucus, factor analysis
Introduction
Bacteria, fungi and viruses are direct constituents o f  our intrinsic and 
extrinsic environm ent. T he antigenic environm ent o f the m ucous membranes 
differs, therefore, w idely from  th a t o f the general im m une system . For instance, 
the alim entary tract is an abundant source o f live and inan im ated  antigens: 
the m ucous m em branes are in  constant com m unication w ith  m an y  thousands 
o f various substances actin g  as im m une stim ulants or im m une m odulators.
The antigens m ay pass across the m ucous membranes a tiv e ly  or passively  
and gain access to  the im m unocom petent lym phocytes w hich th e y  stim ulate, 
or controversely, in w hich th ey  induce tolerance as a result o f  com plex regu­
latory m echanism s [13].
Studies of the m icrobial colonization o f the mucous m em brane, o f the 
regulation o f the m icroflora and o f the relationships betw een th ese  processes, 
have been attracting increasing in terest. The organism has m u ltip le  defense 
m echanism s against antigen ic invasion o f the integum ent [3, 5, 7, 14].
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T he discovery o f th e  sp ec ific  defense system  (secretory im m une system ) 
a llow ed  to  confirm various h ith erto  unexplained fa cts , e.g. nasal or enteral 
im m u n ization . This gave food  to  the tendency o f incrim inating specific, rather 
th a n  th e  well-known n on -sp ec ific , factors for th e  m anifestations o f certaiu  
p h en om en a , and m ay have accounted  for confusing data  relating to the body- 
f lu id s , as illustrated b y  th e  fin d in gs concerning th e  genital secretions [15]: 
th ere  are findings confirm ing th e  predominance o f  IgG  on the one hand [15], 
and o f  IgA  [16], on the oth er . W hile, according to  som e authors the gastric  
ju ice  conta ins no im m unoglobulins [14], according to  others it  does contain  
p rotein s o f  a highly variable pattern  [6].
R esearch in the la st yea rs has been lending increasing support to  the  
sign ifican ce  of the non-specific  defense m echanism s o f  the body [1, 5, 7]. The 
n ecess ity  for considering n o t o n ly  the specific, b u t also the non-specific im ­
m u n e factors in studies o f  th e  defensive a c tiv ity  o f  th e  mucous m em branes 
w as, therefore, self-evident.
F or the explanation o f  th e  above relationships, the literature has little  
to  offer. This is because no m ajor progress in research concerning the im m uno­
lo g ica l barrier of the m u cou s membranes has been  achieved until the last 
d eca d es .
W e have, therefore, undertaken  a com plex stu d y  o f the defense m echa­
n ism s o f  the mucous m em branes, lim iting the dem onstration  o f the phenom ena  
in  q u estio n  to two m ucous m em brane regions o f  derm atological relevance, 
w h ich  g ive  fairly easy access to  the clinician and w hich  are the sites o f a high  
a n tig en ic  activ ity  even under physiological cond itions. On these grounds we 
h a v e  selected  two m odels for th e  study of th e  essen tia l factors o f  m ucous 
m em brane defense, sam ples o f  duodenal ju ice co llected  b y  gastroduodenal 
tu b e , and  vaginal secretions. T here is a particular factor interfering w ith the  
d efen se activ ity  of the m u cou s membrane barrier o f  either region, i.e. the  
reservoir character o f th e  stom ach  and the cavity-character o f the vagina. 
M oreover, the factors in v o lv ed  in  mucous m em brane defense operate at a high  
in te n s ity  even under norm al, and  still more under abnorm al, conditions.
T he material for dem onstration  of m ucous m em brane activ ity  was pro­
v id ed  b y  gastroduodenal ju ice  samples obtained from  selected patients who 
had som e indications o f en teral dyshacteria in  their h istory , and vaginal secre­
tio n s obtained  from leukorrhoeic patients o f H arkány H ospital.
Our former observations in  a number o f cases belonging to the sam e 
p a tie n ts  material have been  reported earlier [10]. I t  has been also dem on­
stra ted  th a t though the p rote in  concentration in  th e  secretions is lower in  the  
s tim u la ted  than in the restin g  sta te , protein tran sflu x  (volum e X  concentration) 
q u an tifiab le  from the sam ples is  practically id en tica l [11]. W e found it, th ere­
fore, su ffic ien t from the p o in t o f  view  of com parability  to  take into account 
th e  p rote in  concentrations m easured in the sam ples.
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The study o f the specific and non-specific  factors has provided us w ith  
a v a st b od y  o f data, evaluation o f w hich required an autom ated technique. 
The conventional b iostatistical m ethods were supplem ented by th e  analysis 
o f background factors. Factor analysis allow ed to  disclose the responsible  
background variables factors o f  a m u ltivariety  system  [12]. The basic idea 
w as th a t the m ajority o f our observations and correlation studies registered  
m erely m anifestations o f the phenom ena, w ith ou t being able to  d isclose the  
essentia l background variables. On th e  other hand, the m ultivariate system , 
in  v iew  o f its collinearity, allowed to  describe a set o f factors in term s o f one 
or more single com m on factor. Therefore, m any variables can be replaced  
b y  very  few  factors which include all th ese variables. For the num ber of 
th ese factors tw o criteria have to  be considered, first that the num ber of 
factors m ust be sufficient for m atching the factor m odel to the set o f  variab les, 
and it  m ust also be suitable for proper in terpretation . R ecognition  o f  the 
variables being at the background o f the cluster o f phenom ena, d efin itio n  of 
their num ber and their num erical expression offer the m ost rew arding line  
o f research.
Material and m ethods
D uodenal ju ice  sam ples o f 143 patients w ith  skin diseases, 75 m ales and 68 fem ales, 
of a m ean o f  age 40.3 years, were studied. Only th e  data  o f those cases were considered from  
w hich 4 sam ples (gastric ju ice, bile fractions A, B , C) could be obtained. Thus a to ta l o f  572 
sam ples w as studied . Sam ples o f vaginal secretion and o f cervical m ucus w ere stu d ied  in 
257 gynaecological p atien ts o f m ean age 34.4 years, 78%  being aged between 21— 40 years. 
A to ta l o f  514 sam ples was studied. The sera were studied  in  all o f the cases.
T he bodyflu ids were subjected to  m icrobiological (bacteriological, m ycological, parasito­
logical) stud ies, and their pH  was also estim ated.
Im m unological methods : IgG, IgA , IgM , com plem ent C3, transferrin and album in  
according to  Laurell [8], and M ancini et al. [9], respectively . On reproduction o f  th e  assays 
the variations rem ained w ithin 10%.
B iosta tistica l methods. The objective o f  au tom ated  processing was to  ev a lu a te  th e  data  
o f m easurem ents, nearly 10 000 in  num ber. T he sta tistica l sources were provided  b y  the  
q u antifiab le  inform ative data of th e  patients (e .g . age, sex , pH , etc.) and b y  th e  results o f  
th e  m easurem ents. The data were collected on code-sheets and transferred to perforated  hands, 
su bseq uently  to m agnetic p lates. I t  was after form ulation  of the theoretical con cep t th a t  the  
basic inform ation required by the studies was selected . T he data were evaluated b y  com puter  
T ype R 22 (M. Pollack U niversity o f  Technical Sciences, Pécs), in  accordance w ith  program  
B M D P (1978, H ealth  Science Computing F a cility , U n iversity  o f  California, L os A ngeles), 
P  4 M chapter F actor Analysis.
T he evaluating program furnished the follow ing results: 1: mean values w ith  S .D . of 
all param eters, th e  m inim um  and m axim um  values o f  m easurem ents; 2: the degree o f  correla­
tio n  b etw een  the paired param eters; 3: results o f  th e  F -te s t  and two-sam ple t-test for all para­
m eters in  tw o  arbitrary groups including th e  degree o f freedom  and the com puted  «-values; 
4: factor analysis. T he present report deals w ith  th e  results o f factor analysis. T h e  data  thus 
outlined is perm it to  disclose the correlations betw een  th e  original variables and factors. 
Factor loading expresses the correlations betw een th e  variables and the factors. Therefore, 
th e  prim ary task  o f factor analysis was to determ ine factor loading. According to  th e  concept 
o f  factor analysis, the individual variables are occupied , m ore accurately sh aped , b y  the  
various factors, the degree o f which is reflected b y  th e  factor load. The variance o f  each  factor  
in  th e  w hole set o f  variations is expressed in  the cum ulative  proportion of to ta l variance in 
per cents. On theoretical grounds there is no correlation betw een the factors, since so long  
as th ey  are correlated, th ey  have a com m on factor (up to  the lim it o f correlation), and the  
system  is still open to further “factorization” .
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Table I
Results o f  factor analysis
I .
G astroduodenal juice 
n  =  143
II.
Vaginal secretion 
n  =  257
com mon factor* loading** common factor* loading* *
I. I.
local Ig A  and IgG factor vaginal transudable factor
A -IgA 0.844 F-IgG 0.790
B -Ig A 0.806 F-transferrin 0.718
A -IgG 0.800 F-C3 0.689
C-IgA 0.782 F -album in 0.697
C-IgG 0.743 F-IgM 0.608
B -IgG 0.723 F -IgA 0.581
G -IgA 0.711
G -acid ity 0.561
G -IgG 0.554
G -m icrobial content 0.548
II. h .
complement factor cervical transudable factor
C-C3 0.922 C-transferrin 0.839
B-C3 0.921 C-albumin 0.765
A-C3 0.898 C-C3 0.745
III. h i .
album in factor serum fac tor
B -album in 0.845 S-IgG 0.773
A -album in 0.723 S-IgA 0.740
C-album in 0.689 S-IgM 0.617
IV. IV.
transudable factor local Ig A  factor
G-C3 0.880 C-IgA 0.680
G-IgM 0.643
G -IgG 0.554
V. V.
serum fa c tor p H  and age factor
S-IgA 0.594 F -pH 0.793
S-IgG 0.572 age 0.604
S-C3 0.502
Com m entary :
1. ty p e : G: gastric juice  
A: A bile 
В : В  bile 
С: C bile 
S: serum
1. ty p e :  F: vaginal secretion 
C: cervical mucus 
S: serum
* common factor : unit influencing a set o f observed variables 
** factor loading: degree o f loading of the com m on factor by the variable
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Results
The difference in  the results o f factor analysis, as far as th e  order of 
succession of th e  protective factors o f  th e  tw o  mucous m em brane surface 
(gastroduodenal, and vaginal) under s tu d y  w as concerned, m ay im p ly  that 
th e  defense a c tiv ity  o f  the im m unoglobulins produced locally  in  th e  mucous 
m em branes asserts itse lf  only under particu lar conditions. Table I  represents 
the com m on factor derived from the com puterized  data o f th e  tw o  groups, 
and the factor loadings b y  the observed variab les included in th e  individual 
factors. Table II  show s the cum ulative proportion of tota l variance o f  5 factors 
in  each o f the tw o groups classified on th e  basis o f the respective data .
Table II
Interpretation o f  the results o f  factor analysis
I.
G astroduodenal juice 
n =  143
I I .
Vaginal secretion 
n -  257
common factor %* common factor %•
I. I.
local IgA  and IgG factor 26.7 vaginal transudable factor 30.5
II. и .
complement factor 38.0 cervical transudable factor 41.2
h i . III.
album in factor 46.2 serum  factor 49.2
IV. IV.
transudable factor 54.1 local IgA  factor 56.3
V. V.
serum factor 61.4 p H  and age factor 62.7
Commentary :
*%: cum ulative proportion of total variance
In  the g a s tr o d u o d e n a l  sam ples th e  fir st  four factors were provided  by  
local factors dem onstrable in the b odyflu ids. Factor V was provided b y  serum  
factors.
The elem ents o f  Factor I were form ed b y  IgA  and IgG w ith  a h igh  factor 
loading. In  addition , non-specific factors (p H , microbes) were also present. 
The factor b y  itse lf  w as responsible for th e  m anifestation o f 26 .7%  o f the 
phenom ena.
Factor II included the factors o f  com plem ent C3 of the duodenal juice, 
w ith  a very high factor loading. The first tw o  factors together accounted  for 
the m anifestation  o f 38%  of the phenom ena.
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F a cto r  III  com prized th e  albumin factors m easured in the gastroduo­
denal ju ice . The three factors together accounted  for 46.2%  of the m an i­
festa tio n s .
F a cto r  IV was con stitu ted  b y  com plem ent C3, IgM and IgG d em on ­
strab le in  th e  gastric ju ice. T he four factors togeth er  accounted for 54.1%  of  
th e  m anifestations.
F a cto r  V was form ed b y  protein com ponents IgA , IgG and com plem ent 
C3 m easured  in the serum . T he f iv e  factors to g eth er  accounted for nearly  tw o  
th ird  (61.2% ) o f the m anifestations.
In  th e  f e m a le  g e n i t a l  t r a c t  the first th ree factors were provided b y  
tran su d ab le  proteins originating from the serum . Factor IV included IgA  
secreted  b y  the cervical m ucosa.
T h e  elem ents o f F actor I  were prevalently transudable proteins d em on ­
strable in  vaginal secretion, i.e . IgG, transferrin, com plem ent C3, album in, 
IgM  and  IgA . The factor b y  its e lf  accounted for 30.5%  of the m anifestations.
F a cto r  II  was also form ed b y  transudable proteins, transferrin, a lbum in, 
co m p lem en t C3 and IgM, w ith  a high factor load ing . The first two factors were 
resp on sib le  for 41.2%  of th e  phenom ena.
F a cto r  I I I  was form ed b y  IgG, IgA  and IgM  measured in serum . The 
three factors together accounted  for 49.2%  o f th e  m anifestations.
Ig A  m easured in  the cervical secretion w as on ly  fourth in  order, form ing  
F actor IV . The four factors together accounted for 56.3%  of the m an ifesta ­
tion s.
F a cto r  V comprized th e  p H  and age. The f iv e  factors together accounted  
for n ear ly  tw o thirds (62.7% ) o f  the m anifestations.
Discussion
T h e fiv e  gastroduodenal factors, as w ell as th e  five vaginal factors, 
accou n ted  for tw o thirds o f  th e  m anifestations o f  th e  respective phenom ena.
T h e antibodies released as a result o f sp ecific  a ctiv ity  m ight have been  
ex p ected  to  p lay a prim ary part in m ucosal defense. The results o f  factor  
an a lysis , as far as the order o f  succession o f th e  involvem ent of the defense  
factors w as concerned, how ever, not identical for th e  two mucosal surfaces 
under stu d y . This seem ed to  suggest th at th e  specific  factors o f m ucosal 
defense m anifest them selves o n ly  under particular conditions.
T h e first line o f  gastroduodenal m ucosal defense is formed, side b y  side  
w ith  lo ca l im m unoglobulins (specific factors), b y  non-specific factors, i.e . p H  
and proteo lysis (Factor I). As it  is known, proteo lysis o f  antigens and o f  a n ti­
bodies o f  protein character proceeds in  the stom ach  and duodenum also under  
ph ysio log ica l conditions (norm acidity, proteo ly tic  activ ity). In add ition , 
gastric HC1, by virtue o f its coagulants, bactericid ial and bacteriostatic a c t iv ­
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ities, m ay play a m ajor part in the elim ination o f antigens [1, 5, 7]. I t  seems, 
therefore, obvious th a t Factor I  includes, side b y  side w ith  th e  local im m uno­
globulins IgA  and IgG, the chem ical reaction and the antim icrobial factors. 
The possibility o f  a com plem ent activation  by a classic or an alternative  
m echanism  alike [12] m ay account for the finding that the elem ents o f Factor 
II  are com plem ent factors dem onstrable in  the bodyflu ids. These are produced 
b y  the m acrophages (prevalently  in  the liver), thus a tta in in g  the mucosal 
surfaces as a result o f transudation , i.e . through vascular p ath w ays.
Factor I I I  was form ed b y  album in com ponents dem onstrated  in the 
gastric juice. A lbum in is produced in  the liver, therefore it  is on ly  v ia  the 
circulation (as a result o f  transudation) th at it  attains th e  m ucosal surfaces. 
The presence o f the com plem ent (II)- and of the album in (I ll) - fa c to r s  con­
firm , in addition, th a t in the course o f  an inflam m atory process elicited by  
som e local antigenic stim ulus, general im m une reactions (related  to  the circu­
lating  antibodies) m ay also take part in the elim ination o f  antigens. This 
im plies that the general im m une response also represents a factor o f immune 
defense. Factor IV  was also form ed b y  transudable proteins: com plem ent C3, 
IgM  and IgG o f the duodenal ju ice. Factor V comprized factors IgA , IgG and 
com plem ent C3 originating from  serum . This finding is con sisten t w ith  the 
possib ility  o f a vascular origin (blood or lym ph) o f certain proteins, as pointed  
out above.
In the defense m echanism s o f the f e m a le  g e n i ta l  s y s te m  th e  transudative  
factors and those originating from  the serum predom inate; in th eir  background  
horm onal factors m ay be assum ed. As it  is known, th e  sparse im m unocytes 
o f the vaginal lam ina propria are unable produce im m unoglobulins in any 
significant qu an tity , m oreover, the non-keratinizing squam ous ep ithel cells 
fail to produce th e  glycoproteins o f  transport function, ind ispensab le for the 
form ation of secretory im m unoglobulins [3, 4, 14]. The cond itions are thus 
adverse to  the production  o f secretory im m unoglobulins. T he protein com ­
ponents identified  in  the vaginal secretion have none the less been  shown by  
factor analysis to  belong, despite the anatom ic situation , to  F actor I. This 
m ust be attributed to  vascular, rather than  to local, specific factors, resulting  
in  all probability from  transudative processes attributable to  vascular reac­
tions. In  the period o f sexual m aturity  exem plified b y  the present cases the 
vascular reactions are subject to  horm onal regulations. The fin d in gs that the 
cervical tissues b y  its  anatom ic structure is capable to  produce im m uno­
globulins in substantia l am ounts and th a t, as shown b y  factor analysis, Factor 
II  also includes transudable proteins, transferrin, album in, com plem ent C3, 
IgM (m ajority o f  these proteins form ed in  the liver), are con sisten t w ith the 
role o f vascular reactions resulting from  hormonal regulatory m echanism s.
The role and significance o f  the first tw o transudative factors is high­
lighted by the find ing th a t the con stitu en ts o f Factor III  orig inate from  serum.
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IgA  o f  loca l cervical prod u ction  belongs to F actor IV . F actor У includes, in  
a d d itio n  to  the factors re la ted  to  the pH , the elem ent o f  age. The chem ical 
rea ctio n  is  primarily age-rela ted  (hormonal a c tiv ity ). The age-factor m ay  
re fle c t  m enopausal changes.
F a cto r  analysis has th u s  allow ed to disclose certa in  relationships which  
had b een  concealed b y  th e  m anifestations. These m a y  be sum m ed up as 
fo llo w s. T he local specific im m u n e factors take e ffec t, together w ith  factors 
o f a c id ity  and proteolysis, o n ly  in  the stom ach and duodenum , thus form ing  
th e  f ir s t  line of defense. T he defense of the gen ital m ucous m em branes, at 
lea st  in  th e  period of reproduction , rests prim arily on vascular factors resu lt­
ing  fro m  transudative processes involving a horm onal a c tiv ity . Though here 
to o , th e  specific mucous m em brane defense is s ign ifican t (local factor IgA ), 
its  s t im u la tio n  into action requires particular circum stances, e.g. a m alignant 
p rocess.
T h e results of factor an a ly sis  have throw n som e lig h t on certain new  
a sp ects o f  the com plex d efen se  m echanism  o f th e  m ucous membranes. It  
em erges from  the facts d isc lo sed  b y  the study th a t  th eir  defense, sim ilarly  
to  th e  horm onal regulations, resu lts  from the in terp lay  o f  various specific and  
n o n -sp ec ific  factors and m echan ism s operating at d ifferent levels.
In  conclusion, the fu n c tio n  o f the secretory im m une system  m ay be 
regarded  as an activ ity  in  its  ow n  right serving th e  in teg r ity  o f  the body. Its  
p o ten tia l com pensatory role in  various chronic processes adds to its sign ifi­
can ce.
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IgE LEVEL IN SOME DERMATOLOGICAL DISEASES
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The to ta l IgE  level was m easured b y  radioim m unosorbent te s t  (P hadebas RIST, 
Pharm acia) in  blood samples o f 454 derm atological patients and 26 b lood  donors aged 
14— 70 years. The results showed different Ig E  values in the sam e groups o f  diseases. 
E levated  serum  IgE  values were observed in  atopic derm atitis, drug allergy, discoid 
lupus erythem atosus and chronic derm atom ycosis. In drug allergy th e  average non­
specific IgE  lev e l o f patients reacting w ith  im m ediate reaction w as higher than the 
norm al value.
T ested ind ividually w ith  P en ic illoy l G RAST no strong correlation  could be 
dem onstrated betw een the qu antity  o f  specific  and non-specific IgE .
Keywords: Serum IgE ,—  R IST  —  Derm atological diseases.
Introduction
The IgE  m olecule is similar in structure to  the other im m unoglobulins 
b u t has som e different characteristics as w ell. It has an unusual a ffin ity  to  
basophils and m ast cells, that is w hy it  is deposited in certain tissu es (“ shock 
organs” ). The serum  IgE level is considerably  lower than that o f  o th er im m uno­
globulins and show s a high variab ility  according to age and gen etic  constitu ­
tion . IgE , discovered by Ishizaka [5] and Juhlin  [6] played a prom inent role 
in  clarifying its structural and b iochem ical properties. In v iew  o f  its  a low  
serum  level isotope m ethods are used  for detecting IgE.
In a previous paper we have show n th a t the serum Ig E  lev e l m ay be 
elevated  in  som e skin disorders and in  im m ediate type drug h y p ersen sitiv ity  
[9, 10, 11, 12]. In  the present paper w e report on our work perform ed in  the  
period 1974— 1982.
Material and m ethods
The serum  IgE  level was determ ined in 480 subjects: 454 had various sk in  disorders 
and 26 were hea lthy  blood donors. T hey ranged in  age between 14 and 70 years; m ales and 
fem ales were in about equal number.
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T he radioim m unosorbent te s t  (R IST) (Phadebas R IST  Ig E  kit) was used to  d etect  
IgE  as described previously [9]. V alues were given in  kU/1. A s th e  serum IgE levels do not 
fo llow  th e  G aussian d istribution  and show a high variance, h o t  th e  arithmetical and geo­
m etrical m eans had to be know n since [17] only on th e  basis o f  th e  latter could th e  sign ifi­
cance be calculated as it  is seen  T able I. To compare th e  v a lu es o f patients and controls, 
S tu d en t’s i-te s t  was perform ed.
Results
T he arithm etical and geom etrical means o f  th e  to ta l IgE  levels m easured  
in p a tien ts  and controls and th e  statistical ca lcu lations are shown in T able I.
Table I
Serum  Ig E  values in skin diseases
Diagnosis
N
kU/1
X  ±  SE GEOM X P
Drug allergy 130 1 7 7 0 .8 4 ± 1 4 9 .8 4 689.36 * * *
Lupus erythem atosus disc. 63 1 3 8 5 .7 1 ± 2 0 2 .3 5 929.81 * * *
Photoderm atosis 47 1566.38 ± 3 0 8 .1 4 933.83 * * *
Chronic derm atom ycosis 73 1 1 8 9 .1 8 ± 1 5 2 .6 2 662.36 * * *
Contact eczem a 18 590.00 ±  84.57 464.76 *
A topic derm atitis 44 2850.22 ± 3 7 4 .9 2 1765.85 * * *
Chronic urticaria 14 637.86 ± 2 3 7 .0 2 367.45 N S
Other derm atoses 65 1 8 0 0 .6 2 ± 1 3 7 .0 2 485.20 * * *
Control 26 3 1 5 .0 0 ±  38.18 265.66
I t  can  be seen th a t a lm ost in  every skin d isorder th e  serum IgE lev e l w as  
elevated . I ts  mean va lu e revealed  big differences am ong individuals in  every  
disease group. The ind iv id u al and m ean values w ere extrem ely high in  atopic  
derm atitis and sign ifican tly  above normal in  drug allergy, discoid lupus  
erythem atosus, photoderm atoses and chronic m ycoses. The values were low est  
in co n ta ct eczema and chronic urticaria. The va lu es in  th e  “ other derm atoses”  
group w ere heterogeneous.
T he individuals exam in ed  could be d ivided  in to  three groups according  
to  th e ir  to ta l IgE  level.
Group I. <C 400 kU/1
Group II. 400— 2000 kU/1
Group III. >  2000 kU/1
The percentage o f these groups is dem onstrated in  F ig . 1. It can be seen th a t  
the d istribution  of the va lu es w as different in  th e  various groups. A  m edium  
level w as m ost frequent in  drug allergy, lupus erythem atosus discoides, p h o to ­
derm atosis, chronic urticaria and other disorders. In  contact eczema th e  IgE  
leve l w as found m ostly  low  or medium while in  atop ic  dermatitis, m edium  
or h igh .
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Drug LED
a lle rg y ^  ,
Group: I
□  < 400 kU/1
Photoder-Chrome Contact Atopic Chr.urti- Other  ^
m ato s is jm y c o s is^ je c z e m a ^ d e rm .^ c a r ia  ^  d e r m .^
I 4 0 0 -2 0 0 0  к U /1
Fig. 1. Percentage d istribution  o f IgE  levels
Values under 400 units were m easured in  several cases o f  co n ta ct eczema, 
w hile on ly  a few  in atopic derm atitis. A n elevated level occurred in  every  
p atien t group, but in no subject in  th e  control group where th e  h ighest IgE  
va lu e was 820 kU/1.
D iscussion
Barsoum  and K uwert [2] found high IgE  levels in the h ea lth y  population  
and his work drew our attention  to  the im portance of dividing th e  values into 
three groups. The actually  m easured serum  to ta l IgE level is in flu en ced  by  
age, genetic and environm ental factors. T he antigen-specific and  to ta l IgE  
lev e l is regulated b y  different genes and th e  genetically determ ined IgE  levels 
are m odified  b y  environm ental (allergen exposition) and internal (effector and 
suppressor) factors. The actual IgE  lev e l is th e  resultant o f  th ese  factors, the 
v a r iab ility  o f w hich has been proved [8].
E levated  IgE  levels were determ ined  in  both healthy ind iv id u als and 
th ose  suffering from  skin diseases. The leve ls  were highest in  h yp er IgE  syn­
drom e and in  atopic diseases [3, 4 , 5, 6, 14, 16]. Parallel to IgE  determ ination  
w e also detected  the IgG , IgA  and IgM  levels in every case u sin g  M ancini’s 
radial im m unodiffusion m ethod The m ean values of these globulins were w ith­
in th e  norm al range in every case.
In  certain disease groups we determ ined T-cell count b y  th e  E-rosette  
m ethod  [11, 13]. E xcept in  contact d erm atitis, the E-rosette cou n t was lower 
in every  disease group o f negative correlation was found b etw een  th e  average 
IgE  level and the E -rosette form ing cell count.
Specific IgE  detection by R A ST  w as performed only in  penicillin  sen­
sitiv e  patients and we could not find  an y  close correlation betw een  th e  specific  
and to ta l IgE  values [12].
In the light o f the present in vestiga tion  and data in th e  literature an 
elevated  IgE  level cannot be considered pathognom onic.
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T LYMPHOCYTE SUBPOPULATIONS IN PROGRESSIVE 
SYSTEMIC SCLEROSIS DEFINED BY MONOCLONAL
ANTIBODIES
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T w enty tw o patients w ith  progressive system ic sclerosis were studied b y  m onoclonal 
antibodies to detect OKT4 and O K T8 positive  cells. The absolute number of OKT4 and O K T8 
cells was not altered as compared to control values. The ratio of T4/T8 cells slightly  increased  
w ithout statistical significance. The num ber o f E -rosette form ing T-cells was reduced in patients  
w ith  progressive system ic sclerosis. S ix  m onths later  11 patients were reinvestigated , and 
sim ilar results were obtained for the T-cell subsets and the ratio o f T4/T8 p ositive  cells. Indi­
vidual data showed marked variab ility  in the tw o periods o f investigation  w ithout how ever, 
any correlation to the clinical findings. The scleroderm ic patients had a long disease duration  
and showed no im m unoregulatory T-cell im balance.
Keywords: Progressive system ic sclerosis, m onoclonal antibody, helper cell, 
suppressor cell
Abbreviations: PSS — progressive system ic sclerosis 
T,y cells — IgG Fc receptor bearing 
T lym phocytes
T^ cells — IgM Fc receptor bearing 
T lym phocytes
Introduction
Progressive system ic sclerosis (PSS) is characterized by fibrotic, degenera­
tiv e  and inflam m atory changes in volv ing  the skin and certain internal organs. 
The cause o f PSS is unknown but a dysfunction  o f the im m une system  m ay have  
been involved . There is no characteristic laboratory test for PSS. The im balance  
in  the ratio o f helper/suppressor cy to tox ic  T-cell subsets m ay have a p ath o­
genetic im portance. The im m unoregulatory OKT4/OKT8 T-cell subsets were 
described previously in PSS [1, 4, 5, 7], but these studies gave conflicting  
results. In  a previous study we found a sign ificant decrease in the ratio o f  Ту 
cells in PSS. Abnorm alities o f T-cell subpopulations defined by m onoclonal 
antibodies have recently been described [3, 8, 12].
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Our stu d y  was designed to determ ine th e  OKT4 and OKT8 positive  
T -cell subpopulations in  patients w ith  PSS. One úa lf year later tue patients  
were re investigated , to  stu d y  the individual variab ility  in the number o f T-cell 
subsets.
Patients and m ethods
T w en ty  tw o fem ale p atien ts w ith  PSS and 10 volunteers were studied. Their m ean age 
was 43.7 +  13.7 (31 to 61) years. The m ean disease duration w as 9.1 +  8.3 years. A ll patients  
were in  a stab le condition, 19 had m anifestation(s) o f  internal organ(s). Pulm onary involve­
m ent w as detected  in  15, oesophageal dysfunction  in  12, cardiac involvem ent in  6 cases. M ani­
festation  o f  other internal organs was found in 4 p atien ts. One patient had renal disease. All 
patients fu lfilled  the prelim inary diagnostic criteria scleroderm a (10). B asic therapy included  
nifedipin in  15 patients, D-penicillam ine in 7 and prednisone in 2 cases. No drugs were adm in­
istered 24 hours] before th e  investigation . E leven  patien ts were reinvestigated 6 m onth  later. 
E -rosette  form ing T-cells form  peripheral blood m ononuclear cells were determ ined b y  the  
standard m ethod.
T -cell subsets were investigated  w ith  OKT4 and O K T8 m onoclonal antibodies (Ortho 
P harm aceutical Inc., R aritan , N . J .) by indirect im m unofluorescence technique as described  
previously  [11]. The results are expressed as m ean +  S.D .
Results
In  th e  22 patien ts w ith  PSS the absolute lym phocyte count and the  
num ber o f  E-rosette form ing T-cells were decreased as compared to  the controls 
(Table I).
Table I
T-cell subsets in  patients with P S S
Absolute 
lym phocyte 
count (m m -3)
E-rosette forming 
cells, per cent
OKT4 
p e r  cent
OKT8 
per cent
T4/T8
ratio
P atients  
(n =  22)
1630+670* 4 6 + 1 4 .5 *
(780+340)**
3 8 .7 + 1 2 .7
(7 0 0 + 3 4 0 )
14 .9 + 7 .7  
(400 +  300)
2 .9 + 1 .4
Controls 
(n =  10)
2 190+ 520 7 0 + 1 5 .1
(1 530+ 330)
4 4 .6 + 1 0 .7
(9 6 0 + 2 6 0 )
1 9 .5 + 4 .7
(4 1 0 + 7 0 )
2 .4 + 0 .5
* p <c 0.001 by Student’s t test
** the absolute num ber of cells (mean +  S .D .) in 1 p i  blood are in parentheses
T he ratio o f O K T4/O K T8 cells was sligh tly  increased but this augm enta­
tion  w as not sign ificant statistica lly  (Table I). In  accordance w ith  other authors 
[8], w e found that the patien t group exh ib ited  a m uch wider scatter o f  data than  
did th e  control values for T4 and T8 markers.
N o alterations were found in the num ber o f OKT4 and OKT8 positive  
cells as com pared to  the control values (Table I).
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Six m onths later 11 patients were reinvestigated  to determ ine their T-cell 
subsets. As show n in T able II , no changes in  the ratio and the num ber o f T-cell 
subpopulations were found as compared to  the control values.
Table II
T-cell subsets in  patien ts with P SS reinvestigated 5.7 +  1.2 months later
Investigation
Absolute 
lym phocyte 
count (m m -3)
E-rosette forming 
cells, per cent
OKT4 
per cent
OKT8 
per cent
T4/T8
ratio
First 1600 +  800 51.6 +  20.2 
(890+550)*
36.7 +  16.9 
(670 +  399)
13.2 +  8.0 
(23 0 + 1 6 0 )
2.95 +  1.7
Second 1550 +  770 43 .6+ 21 .2
(700+ 340)
31.5 +  16.0 
(500 +  220)
15.2 +  8.5 
(25 4 + 1 5 5 )
2.33 +  1.7
* the absolute num ber of cells (mean +  S .D .) in  1 /(1 blood are in parentheses 
11 patients w ith PSS were investigated. Their age was 43.1 +  16.9 years. The mean 
duration of the disease was 10.0 +  9.1 years.
The num ber o f E -rosette forming T -cells rem ained stab le during the 6 
m onth period but the individual data o f OKT4 and OKT8 subsets showed a 
marked variab ility  at the tw o different periods o f investigation . N o individual 
correlation was found betw een the clinical find ings and the ratio o f T-cell 
subpopulations.
Discussion
In m ost studies and in  the present one an absolute lym phopenia has been  
found in PSS [2, 4, 6] together with a reduction  in  E -rosette form ing T ly m ­
phocytes [2, 4 , 5, 12]. The latter deficiency was show n also in our previous 
study [4], but no sign ifican t decrease w as show n when OKT3 m onoclonal 
antibody was used to  detect the number o f T -cells [8, 12].
Studies reporting on the cytotoxic-suppressor/helper T-cell subpopula­
tions in patien ts w ith  PSS showed conflicting results. Norm al T^ w ith decreased  
T^ cells [1], increased T Y cells w ith decreased T^ cells [5] and decreased T7 cell 
populations were reported [7]. Our previous stu d y  also showed a significant 
decrease in  th e  ratio o f  T Y cells in PSS [4].
R ecent studies have shown aT-cell im balance in  PSS determ ined by m ono­
clonal antibodies [3, 8, 12]. The elevated ratio o f  OKT4/OKT8 cells has been  
attributed to the d im inution in the num ber o f OKT8 cells, which remained  
stable during a 1 year period [12]. No correlation was found betw een the e levat­
ed ratio o f O K T4/O K T8 cells and the in v itro  suppressor function  o f these cells 
[12]. In  another report an increased helper function  in vitro was dem onstrated
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in  p a t ie n ts  w iht PSS [9]. In  one o f  th e  studies the m ajority o f  the p atien ts w ith  
an e le v a te d  ratio of O K T4/O K T8 cells were found to  be generally younger and  
to  h a v e  a short disease duration  [8].
In  th e  present study, scleroderm ic patients w ith  long disease duration  
had n o  im m unoregulary T -cell im balance. The 11 patients reinvestigated  one 
h a lf y e a r  later showed the sam e resu lt w ith m arked variab ility  o f  the num ber  
and ra tio  o f  T4/T8 cells. The decreased number o f E -rosette form ing cells rem ain­
ed s ta b le  during the tim e o f  in vestiga tion . P atien ts w ith  an e levated  ratio  
o f O K T 4/O K T 8 cells were n o t c lin ica lly  distinguishable from  the other p atien ts.
T h e  discrepancies in  th e  fin d in g  o f T-cell subsets could he explained  by  
d ifferen ces in the duration o f  th e  disease, the sm all num ber o f p atien ts in ­
v e s t ig a te d  and the wide geographic variations in  the populations studied .
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Endocrinology
EFFECT OF DOMPERIDONE ON SERUM TSH AND  
GROWTH HORMONE IN THYROID PATIENTS
J. F ö l d e s , C s . B á n o s , P . L a k a t o s , J. T a k ó
F IR S T  D EPA R T M E N T O F M ED ICIN E, SEM M ELW EIS U N IV E R S IT Y  MEDICAL SCHOOL, B U D A P E S T ,
H U N G A RY
(R eceived February 23, 1984)
In  euthyroid fem ale patients, the release o f TSH  from the p itu ita ry  increases 
in response to  dom peridone, a dopam inergic-receptor blocking agent o f  peripheral 
action. The rate o f increase varies w ith  th e  functional state o f the th y ro id , as con­
firm ed b y  results obtained in cases o f euthyroid ism , primary hyp othyroid ism , sub- 
clinical hypothyroidism  and subclinical hyperthyroidism . Observations su ggest th a t the  
more vigorous feedback-m echanism  m odu lates th e  dopaminergic regu lation  o f  TSH - 
secretion at a h igh degree of sensitivity. S tim u la tion  w ith 1-dopa in tensifies th e  release 
o f grow th horm one from  the p itu itary w h ich  is, how ever, o f lesser degree in  hyperthyroid  
or hypothyroid  than  in  euthyroid ind ividuals. The GH-response to 1-dopa is enhanced  
b y  adm insitration  o f propranolol, but th e  m axim um  serum GH levels in  response to 
stim ulation  w ith  1-dopa are significantly low er in  hyperthyroid than in  euthyroid  in­
dividuals. A dm inistration of dom peridone leaves the serum GH levels u n affected  in 
euthyroid and hyperthyroid subjects, bu t causes a significant increase in  a num ber of 
p atien ts w ith  prim ary hypothyroidism .
The results suggest that the dopam inergic system  plays a part in  th e  regulation  
of T SH  and GH secretion, asserting itse lf  partly  as a direct effect on th e  p itu itary , 
and th a t the dopam inergic regulation m ay  be affected by thyroid d y sfu n ction .
Keywords: Serum TSH level, grow th  horm one level, dom peridone, thyroid
disease.
Introduction
The therapeutic use of dopam ine-receptor blocking agents has been  
gaining ground in  recent years. These drugs are m ainly used for th e  control 
o f nausea or vom itin g  and in  disorders o f  in testinal m otility . T h ey  also act 
on th e  central nervous system , prim arily as stim ulants of prolactin  secretion. 
A  particular group o f these drugs (m etoclopram ide, sulpiride) is m arked by  
a central nervous and hypophyseal a c tiv ity  [, 32], whereas those o f  th e  other 
group (dom peridone) fail to  pass the blood-brain-barrier and exert th eir  action  
at th e  periphery on the em inentia m ediana and directly on the p itu ita ry  [8, 
32].
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T he aim of the present study was to  exam in e the secretory responses 
o f  T S H  and o f growth horm one (GH) to stim u la tio n  w ith dom peridone in  
variou s sta tes o f thyroid  function .
M aterials and m ethods
F em ale  patients aged 25— 50 years, w ith euthyroid ism , untreated Graves’ disease, sub- 
c lin ica l hyperthyroidism , subclin ical and m anifest, prim ary hypothyroidism  were stu d ied . 
H y p erth yro id ism  was confirm ed in  each case, in  add ition  to  th e  clinical features, b y  th e  in ­
creased  serum  thyroxine (T 4) and tri-iodothyronine (T3) leve ls . The material o f  subclin ical 
h yp erthyroid ism  com prized p a tien ts  w ith  autonom ous adenom as. In the patients o f  th is  
group, a ll o f  whom  were euthyroid , th e  scintiscan had revealed  a “ hot”  nodule in th e  thyroid . 
Serum  to ta l T 4, T3, “free”  T 4 and TBG  had been found norm al. The patients were d iv ided  
on  th e  b a sis o f  prelim inary studies [20] into two groups. In  Group “A ” the serum-“ free” -T 4, 
T 4/T B G , T 3/TBG  were norm al and serum-TSH increased in  response to T R H  stim ulation  
(200 /ig  i.v .);  in  Group “ B ” th e  va lu es o f “free” -T4, T 4/T B G , T 3/TBG showed a slight increase  
w ith in  th e  norm al range and there was no TSH -response to  T R H  stim ulation. The p a tien ts  
belon g in g  to  Group В were considered to  have subclin ical hyperthyroidism .
In  all cases o f prim ary hypothyroid ism , serum  to ta l T 4 was less than 40 nmol/1 and  
serum -T SH  in  excess o f  30 mU/1. T he patients w ith  su bclin ica l hypothyroidism  were c lin ically  
eu th yro id , th e  values o f serum -total T 4 and T3 were norm al and th e  serum TSH value exceed ed  
5.0 m U/1.
T h e  various stim ulation  te s ts  were performed a t 8 h  in  the morning after an ov er­
n ig h t’s fa st. 5 euthyroid patien ts w ere stim ulated w ith  an  i .v . dose of 200 /ig T R H , and b lood  
sam p les w ere taken for T SH  m easurem ent at 0, 20, 60 and 120 m in. 7 days later th e  te s t  w as 
rep eated  b y  adm inistering 10 m g dom peridone i.v . 30 m in  before TRH -stim ulation.
T h e  dose for the dom peridone test was 10 m g i .v . (M otilium , Gedeon R ichter L td ., 
B u d a p est), for the sulpiride te s t  100 m g of the drug i.m . (In stitu te  o f  Pharm aceutical R e ­
search , B ud apest). B lood sam ples were taken in all cases a t 30 m in and im m ediately before  
adm in istra tion  o f the drugs, th e  average of the two resu lts being  taken as baseline va lu e , and  
su b seq u en tly  at 30, 60, 120 and 180 m in.
F or th e  1-dopa test the p a tien ts received 500 m g 1-dopa (D opaflex, EGYT, B u d ap est)  
b y  m o u th . The samplings were done as above. In a num ber o f  cases the test was repeated  
during propranolol (Chim im port, Bucharest) treatm ent w ith  daily  doses o f 4 tim es 40 m g  
( =  160 m g/day) for 6 days, and th e  1-dopa test was rep eated  on  the morning o f the sev en th  
day.
T he follow ing determ ination  m ethods were used: T 4 (H ungarian Academ y o f Sciences, 
Iso to p e  In stitu te; R K -12; norm al range: 70— 160 nm ol/1); T 3 (Hungarian A cadem y o f  S c i­
ences, Isosop e In stitute; R K -11; norm al range: 1 .2— 3.0 nmol/1; TSH  (B yck-M allinckrodt, 
R IA -m a t-T S H , normal range: < 1 .2 5 — 3.8 mU/1); “free” T 4 (RCC; normal range 9.7— 24.0 pmol/1 
T B G  (H oech st; normal range: 12— 28 mg/1); GH (Serono; norm al range: 0— 5 ng/m l; 1 ng =  
2 /лТТ W H O  66/217); prolactin (Serono Prolactin-TER; norm al range: 5— 25 ng/m l; 1 ng P R L -  
T E R  standard  =  23 /tU  W H O  75/504; cortisol (B io-R ad; Q uantim m une Cortisol R IA , norm al 
range: 4 .5 — 18 /ig/dl =  0 .12—0.50 /rmol/1).
In  consideration of the episodic character o f p itu ita ry  GH secretion [15], th e  increase  
in  G H  concentration  in  response to  stim ulation te st could  n o t  be regarded as p ositive  un less  
A G H  (difference betw een m axim um  serum GH and baseline va lue) was in excess o f  5 ng /m l.
T he sam ples were stored a t — 20 °C until use, and th e  serum samples o f each p a tie n t  
w ere assa y ed  sim ultaneously. T he tab les represent th e  m ean values w ith the standard errors 
(S .E .M .). For statistical analysis, S tu dent’s t-test w as used .
Results
F igure 1 represents th e  TSH  response to  T R H  (200 ц g i.v .) and to  
dom peridone (10 mg i.v .)  +  T R H  (200 f ig  i .v .)  in  5 euthyroid patients. On th e  
ev id en ce  o f  the find ings, th e  response o f T S H  to  T R H  was considerably en ­
h an ced  b y  previous adm inistration  of dom peridone.
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Fig. 1. R esponse of serum  T SH  level to T R H  and to  dom peridone (10 mg i.v .)  ±  T R H  (200 fig 
Î .V .) ,  in hea lthy  fem ales. ----------  T R H ; - - - - - - -  dom peridone +  T R H ; =  p <  0.01
As it  can be seen, on Table I tb  response o f  T SH  to  dom peridone stim u ­
lation in subclin ical hypothyroidism  (7 .1 2 ± 1 .4 8  vs. 1 .5 7 ± 0 .1 5 1  mU/1 A  TSH ; 
p <  0.01), and in  m anifest prim ary hypothyroid ism  (3.48 ± 0 .5 4  vs. 1 .5 7 ± 0 .151 
mU/1 A T SH ; P <C 0.01) was more marked th an  in  eu thyroid  p atien ts. A lso, 
after adm inistration  o f dom peridone, serum T S H  show ed a greater increase in  
subclin- ical than  in m anifest prim ary hypothyroid ism  (7.12 ± 1 .4 8  vs. 3.48 ±  
0.544 m U /1 A  T SH ; P <  0.05).
Table II  lists the results o f thyroid function  tests in euthyroid patients  
w ith  autonom ous adenom a. These corresponded in both  Group A and Group 
В to  euthyroid  values. A lthough in Group В th e  values o f free-T4, T 4/TBG  and 
T3/TBG w ere w ithin  the normal range, th ey  were sign ificantly  (P  <  0.05) 
above the corresponding values o f Group A.
Table I
Response to domperidone (10 mg i.v .) o f serum T S H  level in  fem ale patients w ith euthyroidism  
subclinical hypothyroidism  and prim ary manifest hypothyroidism  ( mean ±  S .E .M .)
Serum TSH  mU/1 basal value A  TSH
Euthyroidism  
n =  12 P cO .O l
" 1 .5 3 ± 0 .3 2 ~
P < 0 .0 1
“ 1.57 ± 0 .1 5 “
Subclinical hypo­
thyroidism  
n =  9 P <0 .001
112.81 ± 3 .0 8 -  P < 0 .0 0 1 I7 .1 2 ± 1 .4 8
Primary, m anifest 43.41 ± 3 .9 7 _ P < 0 .0 5 _ 3 .4 8 ± 0 .5 4 _
hypothyroidism  
n =  14
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F ig. 2 . R esponse of serum T SH  lev e l to  dom peridone (10 m g i.v .)  in  two groups of euthyroid
p a tie n ts  w ith  autonomous adenom a (see tex t). ----------  Group A; ------- -- - Group B ; ............
. . .C ontrol group treated w ith  physiological NaCl
Figure 2 represents th e  response o f T SH  to  dom peridone stim ulation  in  
su b clin ica l hyperthyroidism . W hile in Group A the response o f T SH  was 
sim ilar to  that found in th e  controls, in  Group В the serum T SH  leve l failed  
to  r ise in  response to dom peridone.
Subsequently the role o f  dopam ine regulation in GH release w as exam ­
in ed . U nder the effect o f 1-dopa (500 mg b y  m outh), a significant increase in
Table II
Results in two groups o f  pa tien ts  with euthyroid autonomous adenoma (  see text )
T4
nmol/1
T ,
nmol/1
Free-T6
pmol/1
t 4/t b g
nmol/mg
T 3/TBG
nmol/rag
Group A , n  =  5 1 0 2 .2 ± 6 .5 1 .6 5  ± 0 .0 9 1 6 .2 2 ± 1 .0 5 4 .7 1  ± 0 .3 1 0 .8 6  ± 0 .0 0 5
Group B , n  =  5 1 2 8 .2 ± 7 .8 2 .3 2 ± 0 .1 2 2 2 .3 0 ± 2 .1 7 5 .8 6 ± 0 .4 8 0 1 .0 8  ± 0 .0 0 7
P: A  vs. В N .S . N .S . < 0 .0 5 < 0 .0 5 < 0 .0 5
N orm al lim its 7 0 — 1 6 0 1 .2 — 3.0 9 .7 — 2 4 .0 4 .3 0 — 5.90 0 .0 8 0 — 0 .1 1 0
Table III
Response o f  serum  GH  level to 1-dopa (500 mg orally)
A GH ng/ml
Éuthyroidism  (n =  5) 2 .0 6 ± 0 .7 2  "1
Phys. NaCl P < 0 .0 1
Euthyroidism(n =  6)* * * 2 0 .8 0 ± 4 .1 1  J
1-dopa
Hyperthyroidism (n =  10)** 6 .2 5 ± 1 .8 5  П
1-dopa P < 0 .0 1
Pr. hypothyroidism (n =  7)**~ 7 .1 6 ± 2 .1 9  J
1-dopa
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Fig. 3. Response of serum  GH level to 1-dopa alone ( ---------- ), 1-dopa after previous adm inistra­
tion  o f propranolol in euthyroid and hyperthyroid female patients
the serum GH level occurred, but A  GH w as sign ificantly lower in th e  hyper­
thyroid and the hypothyroid  than in th e  euthyroid group (6.25 ± 1 -8 5  vs. 
2 0 .8 0 r b 4 .ll , and 7 .1 6 ± 2 .1 9  vs. 2 0 .8 0 ± 1 1  ng/m l; P < 0 .0 1 ) .
The data presented in  Fig. 3 in d icate th a t pretreatment o f  euthyroid  
subjects w ith  propranolol (160 m g/day) w as follow ed by an enhanced GH- 
response to  1-dopa. This was also valid for th e  hyperthyroid group. Y e t , at 
the tim e o f propranolol treatm ent the m axim um  GH-response to  1-dopa was 
sign ificantly  weaker than  in the controls (P  <  0.01).
In the euthyroid  group (n =  12) the increase in scrum GH concentration  
in response to sulpiride stim ulation was n o t significant. On individual exam i-
ТаЫе IV
Response o f  serum GH  and prolactin level to su lp ir ide  (100 mg i.m .) ( n =  11)
Sulpiride
basal value
Time (min) 
30 60 120
GH ng/m l 1 .6 4 ± 0 .2 7 6 3 .2 2 ± 1 .2 9 6 2 .19±1.305 1 .4 1 ± 0 .4 1 7
Prolactin ng/m l 8 .8 ± 1 .4 3 2 3 5 .7± 24 .62 148.1 ±17.51 7 9 .0 ± 1 2 .0 1
Table V
Response o f serum GH level to dom peridone (10 mg i.v.)
in euthyroid and hyperthyroid fem ale patients
Serum -G H  (ng/ml)
Domperidone Euthyroidism H yperthy  roidiem
(n =  14) (a  = 1 0 )
1 .8 4 ± 0 .6 7 2.17 ±0 .51
30 min 1 .72± 0 .75 1.42 ± 0 .35
60 min 1 .2 5 ± 0 .3 0 1 .32± 0 .34
120 min 1.50±0.41 2.45 ± 0 .5 2
180 min 1 .0 4 ± 0 .3 9 2.67 ± 0 .5 2
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n a tio n  o f  th e  controls a sign ifican t increase in  th e  serum GH level in response  
to  su lp ir id e  was found in  2 o f  our 12 cases, A  G H  being in excess o f  5 n g /m l, 
w hereas in  the other cases th e  change failed to  ex ceed  5 ng/ml. The serum  P R L  
con cen tra tio n  increased sign ifican tly  after adm inistration  of sulpiride in  all 
of th e  cases.
F ig. 4 . R esp onse  of serum GH lev e l to dom peridone (10 m g i.v .) in female patien ts w itu
prim ary hypothyroid ism
D om peridone (10 mg i.v .)  failed to a ffect th e  serum GH level to  an y  
s ig n ifica n t degree either in  th e  euthyroid (n =  14) or in the hyperthyroid  
(n =  10) group. In the controls the GH le v e l show ed a slightly declin ing  
ten d en cy , whereas in  the hyperthyroid  group a transitory decrease w as fo l­
low ed  b y  a slight increase. T he changes in  serum  GH were, how ever, n ot  
s ig n ifica n t in  any o f the groups and A  GH rem ained  below 5 ng/m l.
A ccording to Fig. 4 , dom peridone caused a significant increase in  th e  
serum  G H  level in 4 out o f  9 patien ts w ith prim ary hypothyroidism .
Discussion
I t  h as been confirm ed in  recent years th a t  th e  control o f T SH -secretion  
in v o lv e s , in  addition to  T R H -stim ulation  and feedback m echanism , also  
a dopam inergic regulation [33], m anifested w ith  an inhibition of tonic charac­
ter o f  T S H  secretion, in  all probability  by enhancing the negative feedback  
regu la tion , and affecting th e  circadian variations o f  TSH secretion [36]. T he  
fin d in g s according to  w hich th e  release o f T S H  from  the pituitary increases  
in resp on se  to  dopam ine receptor blockers and th a t the responses v a ry  in  
in te n s ity  w ith  the functional s ta te  o f the th yro id  [16, 34] are consistent w ith  
a dopam inergic inhibitory m echanism . Correspondingly, adm inistration o f  
th ese drugs is followed b y  a sligh t increase in  serum  TSH  even in eu th yro id  
su b jects, b y  a more m arked increase in m an ifest primary hypothyroid ism ,
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and the reaction has been found to atta in  its m axim um  in subclin ical hypo­
thyroidism . These earlier observations have been supported b y  th e  present 
find ings, according to  w hich the increase in  th e  serum TSH  lev e l in  response 
to  T R H  stim ulation  w as more marked in  the subclinical than  in  th e  m anifest, 
prim ary form o f hypothyroid ism .
Since we lack any inform ation on the m echanism  by w hich acute dop­
am ine inhibition operates in subclinical hyperthyroidism , we h ave extended  
our studies to clinical cases of th is type. This group was form ed b y  euthyroid  
patien ts w ith autonom ous thyroid adenom a, in  whom  serum  tota l T 4 and T3 
were norm al, w hile th e  values o f “ free”  T 4 and o f the T 4/TBG- and T 3/TBG- 
quotients, though still w ith in  the normal range, were sligh tly  increased, and 
T R H  failed to elic it a TSH -response. In  all these cases dom peridone failed 
to  affect the serum  T SH  level. This seem s to  suggest th a t, sim ilarly  to the 
absence of the T R H  —* TSH -response, the response o f TSH  to  dopam ine- 
blocking agents also fa iled  to appear even though the serum th yro id  hormone 
levels are but sligh tly  increased w ithout exceeding the norm al range. 
A ll th is dem onstrates th a t the dopam inergic regulation o f T SH  release is 
m odulated by th e  in ten sified  negative feedback-m echanism  at a high level of 
sen sitiv ity .
The present results seem ed to confirm  earlier findings [14, 29] in that 
the dopam inergic system  m ay influence TSH  secretion also b y  acting directly  
on the pitu itary. This is supported by the observation th at dom peridone which 
fa ils to pass the blood-brain barrier, enhanced TSH  release from  the pituitary  
in  v ivo , and that previous adm inistration o f dom peridone results in  an in ten­
sified  TSH  response to  T R H . R ecent experim ental results in  v itro  also point 
to  a direct dopam inergic regulation o f the p itu itary. In agreem ent w ith  these  
findings the presence o f  hypophyseal dopam ine receptors has been dem on­
strated [21], m oreover, on the evidence o f  studies in v itro, dopam ine has been 
found to  reverse the stim ulating effect o f  T R H  on TSH  secretion [3]. These 
observations are, how ever, by no means exclusive o f the part p layed  by the 
central, dopam inergic m echanism  in the regulation o f TSH  secretion.
The pitu itary release o f GH is under the control o f tw o hypothalam ic  
horm ones, the stim u latin g  G H R F (growth horm one releasing factor) and the  
inh ibitory som atostatin  [23]. For the form ation o f GH, thyroid  horm ones are 
also required [39]. Certain observations suggest, though, th at T 4 and T3 act 
as suppressors o f  GH secretion. The dopam inergic neurotransm itter system  
also takes part in the physiological regulation o f GH secretion. U nder physio­
logical conditions dopam ine (DA) seems to  p lay  a com plex part in  th is process: 
while stim ulating basal GH secretion, it  depresses the enhanced GH secretion  
elicited by various stim uli [3, 4, 28, 38]. Changes in thyroid  function  are 
accom panied by m odifications in the num ber o f pituitary D A -receptors [21]. 
I t  is, therefore, uncertain  in what m anner dopam ine regulation affects the
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secretion  o f GH in hyperthyroid ism  and also in hypothyroidism . W e have  
a ttem p ted  to  answer th is q u estion  in  a further series o f  studies by stim ulation  
te s ts  w ith  the dopam ine agon ist 1-dopa, and w ith  th e  dopam ine receptor  
blocker o f  “ peripheral” action , domperidone, w ith  subsequent follow -up o f  
th e  serum  GH level. One o f th e  reasons w hy studies relating to  GH have been  
deem ed o f  im portance, is con n ected  w ith the generally  know n fact th a t both  
hyperthyroid ism  and hypothyroid ism  are associated w ith  disorders o f  glucose  
m etab olism . Abnorm alities o f  th e  secretion and m etabolism  o f insulin  and  
g lucagon  in  these conditions h a v e  been dem onstrated in  earlier studies [18, 19] 
and, as indicated  b y  recent ev idence, elevation o f  th e  serum GH level even  
w ith in  th e  physiological range affects the peripheral a c tiv ity  o f insulin  [7].
L -dopa after oral adm inistration  is converted in  the CNS and at the  
periphery to  dopam ine, su b seq u en tly  to norepinephrine, and in  normal in d iv id ­
uals i t  enhances p itu itary G H  secretion [5]. A ccording to our studies, the  
increase in  the serum GH lev e l in  response to  1-dopa is slighter in  both  hyper­
th y ro id  and hypothyroid th an  in  euthyroid fem ale subjects. If, therefore, the  
fu n ction  o f  the thyroid is a ffected , the GH response to  1-dopa is weaker than  
in  n orm al subjects, in a sim ilar m anner as the GH response to  hypoglycaem ia  
or to  stim ulation  w ith arginine [8, 9, 22, 25]. Various explanations accounting  
for th e  abnorm al GH response m ay be offered, n am ely , im paired absorption  
or m etabolism  o f 1-dopa, changes in the central trop-horm one functions, 
changed  responsiveness to  dopam ine, and possib ly an im paired hypophyseal 
GH production , which m ight be partly  attributed to  th e  increased serum  T 4 
and T 3 levels.
Propranolol is known to  in ten sify  the post-hypoglycaem ic GH response 
[30, 4 0 ] . According to the present study, propranolol enhances the G H  re­
sponse to  1-dopa in  hyperthyroid ism  in the sam e w a y  as under norm al condi­
tion s, probably  because the stim u latin g  activ ity  o f  th e  central norepinephrine 
sy stem  on  GH secretion, tak in g  effect via the alpha receptors, is enhanced [27]. 
I t  has been  found, on the other hand, that in case o f  treatm ent w ith  beta- 
blockers th e  m axim um  serum  G H  level in response to  1-dopa is sign ificantly  
low er in  hyperthyroid than  in  euthyroid subjects, these findings being con­
s isten t w ith  earlier observations in hypoglycaem ia -|- propranolol adm inistra­
tion . A ll th is  suggests th at in  th is  disease it is not possib le to  stim ulate p itu itary  
GH secretion  in the same degree as in  normal subjects. According to  our fin d ­
ings, th is  is in  no w ay connected  w ith  feedback-processes elicited b y  the in ­
creased serum  GH level, since th e  basal serum GH concentration o f hyper­
th yro id  patients corresponds to  th a t of healthy subjects. The potentia l role 
o f so m atosta tin  in the production  o f the deficient GH response has none the  
less to  be taken into account, since, according to  earlier studies [6], the in ­
crease in  the concentration o f  th yro id  hormones provides in itse lf a stim ulus 
to  th e  intensification  of the hypothalam ic secretion o f som atostatin .
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It  is easier to  account for the im paired GH response elic ited  by 1-dopa 
in hypothyroidism , since it has been shown in anim al stud ies th a t in hypo­
thyroidism  the hypophyseal GH concentration is lower th an  the control 
value [37].
Subsequently the effect o f dopam ine receptor blockers on GH secretion 
was exam ined. First, the question  was studied whether su lpiride, o f identical 
site o f  action as m etoclopram ide (MCP), having also a central action, and 
dom peridone o f a peripheral site  o f  action, affected h yp op h ysea l GH excre­
tion  in  a similar m anner. Earlier data concerning the question  how  pituitary 
GH secretion was affected b y  MCP are inconsistent [2, 10, 11, 35]. According 
to  our findings, sulpiride le ft the scrum GH level unaffected  in  10 out of 
12 cases. This was clearly at variance w ith the results o f  Chiodera et al. [10], 
according to which the serum  GH level o f healthy fem ales rises significantly  
in response to  MCP.
Seeking to  explain the confusing results, it was suspected  first that the 
sulpiride used m ight have been ineffic ien t. This possib ility , how ever, had to 
be rejected , since the serum prolactin  level increased in  response to  sulpiride 
in all o f  the cases. In  fact, the results o f the tests m ay be affected  b y  individual 
features o f the patients and b y  differences in  the cond itions o f  the study. 
Some data indicate for instance th a t the effect of dopam ine receptor blockers 
on GH secretion is m odulated b y  the oestrogen/androgen ratio , a mechanism  
w hich m ay involve the biphasic effect of the oestrogens on G H  release [1]. 
I t  has also been show n th at m otor a c tiv ity , for instance w alk ing , m ay increase 
the serum  GH level in fem ales, particularly in the lu tea l phase. In  order to 
elim inate interfering factors o f  th is kind, only hospitalized, endocrinologically  
norm al, non-users o f oral contraceptives were studied. T he questions posed 
b y  the inconsistency o f the results have y e t to  be clarified b y  further studies.
Sim ilarly to  sulpiride w hich has also a central action , dom peridone left 
the serum  GH level unaffected in  all euthyroid and hyperthyroid  patients with 
the exception  o f a single one, w hile it  caused a sign ificant e levation  of the 
serum GH level in a num ber o f patients w ith  primary hypothyroid ism . This 
response pattern is unrelated to  any stress factor, since stim ulation  with 
dom peridone left the serum cortisol level unaffected.
The abnormal response o f GH secretion to stim ulation w ith  domperidone 
in hypothyroidism  is rem iniscent o f  the effect of T R H . In  opposition  to eu­
thyroid  subjects, in  hypothyroid  patients the serum GH lev e l in  response by 
T R H  is increased [12, 24]. On the evidence o f recent stu d ies, in  vitro altera­
tions o f  p itu itary responsiveness m ay alone account for th is  response pattern 
[37]. Our studies w ith  dom peridone, are also suggestive o f  a direct effect on 
the p itu itary. On the other hand, involvem ent of som atostatin  in the produc­
tion  o f the GH response has also to be considered, since prim ary hypothyroid­
ism  is associated not only w ith  a low  hypothalam ic concentration  of soma-
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to s ta t in , b u t also with an im paired  responsiveness o f  som atosta tin  release [6]. 
To te s t  th ese  hypotheses fu rth er  studies will, how ever, be required.
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THE EFFECTS OF BENZODIAZEPINES AS ANAESTHESIA 
INDUCING AGENTS ON PLASMA CORTISOL LEVEL IN 
ELECTIVE HYSTERECTOMY
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The effects o f anaesthesia inducing benzodiazepines (diazepam , flunitrazepam , 
m idazolam ) on serum cortisol level, blood pressure and pulse rate were exam ined in 
patients undergoing elective hysterectom y. D iurnal variation o f serum  cortisol was 
established tw o days before operation.
E ither form  o f benzodiazepine provided good suppression of the cortisol response 
to stress during anaesthesia and surgery. The endocrine response to surgical stress was 
more pronounced at end of the operation in all three groups.
Considering the relative changes o f cortisol compared to the pre-operative values 
the sm allest differences were seen in the group receiving m idazolam . A t 6 p.m . on the 
day of operation the cortisol level decreased in the flunitrazepam  and m idazolam  groups. 
Especially in the patients who received m idazolam  at 6 a.m. on the follow ing day the 
values did not differ from those observed in the control group.
On the basis o f  these exam inations i t  w ould appear that to prevent adverse 
stress-induced effects there is a slight advantage in using m idazolam  for induction of 
anaesthesia.
Keywords: cortisol, stress, anaesthesia induction, benzodiazepines, hysterec­
tom y
Introduction
The im portance o f stress occurring in  response to a surgical stim ulus, and 
the role o f  anaesthetics in suppressing th is  have received m uch attention  
[1, 3, 20, 21].
It is clear th a t events such as endotracheal intubation, surgical incision, 
and intra-abdom inal pelvic surgery cause a release of catecholam ines and cor­
tiso l in anaesthetized  patients and m any o f th ese stim uli can be a ttenuated  by  
various anaesthetics and autonom ic b locking agents [11, 19]. Various ap­
proaches to  “ stress free” anaesthesia are being popularized in an a ttem pt to 
m inim ize p oten tia lly  harm ful hormonal and m etabolic changes caused by ex ­
cessive surgical stress [8, 9, 14, 16].
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Benzodiazepines are w id e ly  used for inducing anaesthesia. Follow ing  
stu d ies on the m etabolism clin ical use of diazepam  and Ro-21-3981 exten d in g  
over m a n y  years, the stud ies h a v e  been continued using midazolam [4, 6, 21]. 
M idazolam  is a new benzodiazepine which differs basica lly  from diazepam  and  
flu n itrazep am  in that it  is w ater  soluble and has a shorter half-life [4, 6].
T h is study exam ined th ree different kinds o f  benzodiazepines concerning  
th eir  stress attenuation during the same surgical procedure. The response to  
stress w as assessed by m onitoring plasm a cortisol, blood pressure and heart 
rate, m idazolam  was com pared to  diazepam  and flunitrazepam  for stress­
low erin g  effect.
M aterial and methods
T hree benzodiazepine d er iva tives were investigated  in  37 ASA class 1 (The c lassification  
o f  p h y sica l status adopted b y  the A m erican Society o f A naesthesiologists, Class 1— 5) p atien ts  
u n d ergo in g  general anaesthesia. T he patients were scheduled for elective hysterectom y b y  
la p a ro to m y  due to fibrom yom as.
T h ey  were divided into three groups which each received a different benzodiazepine as an 
a n aesth esia  inducing agent. A few  im portant clinical data aresum m arized n T able I.
Table I
Clinical data o f  patients who underwent hysterectomy
G roups benzodiazepines 
num ber of patients
Age
(yr)
from  —  to
W eight
(kg)
D uration of
surgery anaesthesia 
min.
Diazepam  
n =  14
29 — 52 
45.1 ±  1.79 66.89 ±  2.95 79.57 ±  4.70 99.86 ±  4.07
Flunitrazepam  
n =  12
33 — 54 
44.5 ±  1.98 65.75 ±  3.93 81.83 ±  7.08 107.66 ±  8.86
M idazolam  
n =  11
33 — 55 
45.54 ±  1.95 63.3 ±  2.39 87.72 ±  7.78 107.27 ±  8.29
mean i  S.E.M.
Prem edication, induction o f  anaesthesia and dosage of different drugs were standardized  
according  to  body-weight (Table II ) . The evening before operation  the patients were prem e­
d ica ted  w ith  glutathim ide (N o x y ro n E) and diazepam (SeduxenE). On the morning o f the opera­
tio n , d iazepam  (0.16 mg/kg) w as adm inistered and 30 m in before surgery, pethidine (D olarganE) 
(0 .80  m g /k g ) and atropine (0.0080 m g/kg), intram uscularly. A naesthesia was induced betw een  
8 and  10 a.m . and endotracheal in tu b ation  was facilitated b y  succinylcholine 1 m g/kg. A n aesthe­
sia w a s m aintained w ith a 4/2 n itrous oxid/oxygen m ixture. Pancuronium  bromide (Pavulon®  
0.06 m g /k g ) was given w hen necessary. Adequate v en tila tion  was m aintained b y  artificial 
resp ira tion . Arterial blood pressure and heart rate were m onitored throughout.
F rom  the group w hich received  diazepam , four blood-sam ples were taken, tw o  days  
before operation  at 6 a.m ., 12 noon , 6 p .m ., and the next m orning for the purpose of determ ining  
diurnal variation  of the cortisol lev e l. These values served as controls during the day o f opera­
tio n .
M easurements were carried o u t on venous sam ples drawn at 6 a.m.; prior to ind uction  of  
an aesth esia ; following in tubation; 5 m in after skin incision; a t the end of operation; after  
ex tu b a tio n , i.e. when the patien t w as able to  respond to  questions; at noon; 6 p.m .; and 6 a.m .
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Table П
Dosages o f  different benzodiazepines and narcotic-analgetic drugs adm inistered  
fo r  anaesthesia induction
Groups
benzodiazepines 
num ber of 
patien ts
D iazepam
m g/kg
Flunitrazepam
mg/kg
Midazolam
mg/kg
F en tany l 
/Щ1kg
Thiobutabarbital
mg/kg
Diazepam  
n =  14
0.23 ±  0.03 - - 3.97 d b  0.67 3.93 ±  0.43
Flunitrazepam  
n =  12
— 0.015 ±  0.001 — 2.14 ±  0.21 2.84 ±  0.32
Midazolam  
n =  11
— - 0.29 ±  0.038 4.42 ±  0.52 -
m ean ±  S.E.M.
n ex t morning. The sam ples were centrifuged and the serum was stored a t — 30C° until analysed. 
Cortisol was m easured b y  radioim m unoassay [22].
A ll three groups were com parable concerning the anaesthetic m anagem ent. Results 
presented in the te x t, T ables and Figures are expressed as m ean values +  SEM . The data were 
analysed by different tests; P  <  0.05 was considered statistically  significant. S tudent’s t and d 
as well as W ilcoxon’s non-param etric test were used for com parison o f  paired data. Among 
several groups the exam ination o f expectab le cortisol values were carried out using the Krus- 
kal— W allis test and one-w ay analysis o f  variance. The relative changes o f cortisol compared 
to  the starting values were exam ined b y  qu otient-test. K ruskal— W allis te s t  and variance 
analysis were also used to  analyse the relative changes of cortisol characteristic o f  the same 
intra-operative tim e in  the different benzodiazepine groups.
Results
The cortisol level on the day before operation exh ib ited  characteristic 
diurnal variation w ithin  the norm al range (F ig. 1). The values at 6 a .m ., 12 noon 
and 6 p.m. in  th e  control group corresponded to  th ose in  th e  literature 
and (391.2 51.29,226.0 34.78, 146.5 ^  12.63 nmol/1, respectively).
Fig. 1. D iurnal variations in plasm a cortisol level in 9 w om en
4 Acta Medica Hungarica 42, 1985
1 4 8 KERTÉSZ, ÁGNES et al.
I n  F ig. 2 are shown th e  cortico l concentrations in  the three series during 
th e  en tire  anaesthesia and op era tive  periods. Cortisol va lu es m easured before 
in d u c tio n  o f anaesthesia w ere ta k en  as 100% and values during anaesthesia  
and operation  were com pared to  th is .
□  f » i 1 ime, nCont ro l  n = 9 УЛ F luni tr azepam^  n = 12
^  Diazepam n = 14 Midazolam n = 11
F ig . 2 . Cortisol level during an aesth esia  and surgery w ith  th e  adm inistration of different
benzodiazepines
T h e cortisol level increased  sligh tly  (106.7 ^  9.4% ) follow ing intubation  
in  th e  diazepam  group. V alu es m easured 5 min after skin-incision differed 
m o d era te ly  (131.6 +  14.6% , P  -< 0.05) but at the end o f operation (202.2 ^  
i  2 0 .8 % ) and after ex tu b a tio n  (199.6 ^  22.7% ) considerably (P <C 0.001), 
from  th e  pre-induction va lu es (F ig . 2).
I n  th e  flunitrazepam  group th e  plasma cortisol decreased after intubation  
(91.7  зк 6.7% ), which con tin u ed  5 min after incision (85.5 i  5.6% ) and this 
d ifferen ce was slightly s ign ifican t (P  =  0.05) com pared to  the starting value. 
A t th e  end of operation (218 .2  ±  29.7% , P <  0.01) and follow ing extubation  
(230 .7  i  27.7% , P <  0 .001), h igh  cortisol values were observed (F ig. 2).
In  the group which rece ived  m idazolam (Dorm icum r) the cortisol level 
s lig h tly  decreased after in tu b a tio n  (96.7 ^  3.9% ). Túe values after incision  
w ere sim ilar to that m easured before induction of anaesthesia (100.8 ^  10.8% ). 
A t th e  en d  o f operation and fo llow in g  extubation (189.1 23.4% ) a significant
(P  <  0 .01) increase (207.6 ^  28 .9% ) was noted (F ig . 2).
P lasm a cortical levels a t  12 noon were considerably higher (P  <  0.001) 
in  all th ree groups (diazepam  717.00  i  51.47, flun itrazepam  794.08 ^  70.58, 
m id azo lam  825.36 ±  128.99 n m ol/1 ) than the control va lues (F ig. 3).
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Fig. 3. Cortisol values on the morning of the day o f  operation, after surgery at n oon , 6 p.m .,
and next m orning
A t 6  p .m . the cortisol values further increased in the d iazepam  group 
(785.78 3 t; 54.37 nmol/1), but in  the other tw o  groups a decrease w as observed  
(flunitrazepam  610.08 ^  51.07, m idazolam  656.0 A: 72.75 nmol/1). T he differ­
ence w as sign ificant (P  •< 0.05) when the diazepam  and flunitrazepam  groups 
were com pared.
Cortisol levels m easured at 6  a.m. on th e  follow ing day (diazepam  483.433t; 
±  37.49, flunitrazepam  481.91 3 (3 42.39, m idazolam  435.36 ±  44 .35  nmol/1) 
alm ost corresponded to the values at 6  a.m . before operation, and th ese  values 
were w ith in  the normal range (391.2 3 (3  51 .29  nmol/1), (Fig. 3).
B enzodiazepines were adm inistered according to body-w eight. F en tan yl 
was fractionally  given until narrowing o f th e  pupil had set in. It w as fou n d  that 
the required dose o f fen tanyl for causing th is  sign was different in  th e  three 
groups. The sm allest dose was necessary in  th e  patients receiving flun itrazepam . 
For disappearance o f  the eyelash reflex no thiobutabarbital was required in  the 
m idazolam  group.
B lood pressure and pulse rate were com pared to values m easured before 
induction  ofanaestúesia. Considering th a t a change o f 10 mm Hg (resp ectively  
1 0 (min) cannot be considered a difference, deviation  from 1 0  o f th e  absolute  
values o f  changes were presented ( A  b lood pressure, A  pulse rate), (F ig . 4).
The m ost sign ificant decrease in blood pressure approxim ately 20  m m H g  
was observed after in tubation. A t the end o f  th e  operation blood pressure was
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En*) 5 mi n  af t er  inci sion ^  Fol l owi ng ext uba t i on
x p < 0. 05 Me a n  ± SEM
F ig . 4 . B lood  pressure and pulse rate  during anaesthesia and  surgery w ith the adm inistration
o f  different benzodiazepines
in creasin g  but its increase did not exceed 20 m m H g, even in  the m idazolam  
group.
P u lse  rate show ed no sign ificant decrease in  any o f the three groups.
In  th e  postoperative period, blood pressure and heart rate were stab le  
in  a ll three groups.
Discussion
Surgical procedures evok e an endocrine response which results in  su b ­
stra te  m obilization, a change in  m etabolism  tow ards catabolism  w ith  a n ega­
t iv e  n itrogen  balance and retention  of salt and  w ater. The m agnitude o f  th is  
resp on se  is proportional to  th e  severity o f the operative trauma [3, 17]. Major 
su rg ica l procedures in  hum an beings result in  an increase in plasm a cortisol 
[2, 5 , 8 , 12]. The on ly  kn ow n  physiologic stim u lu s for adrenal secretion  o f  
co rtiso l is ACTH and h tis trophic hormone has b een  found to be e levated  b y  
o n e -b a lf  hour after beginning o f surgery [5].
T ue m ost im portant em otions in the pre-operative period are a n x iety , 
depression  and astgenia. T h ey  are part o f hu m an  stress reactions w hich  also  
in v o lv e  horm onal (ACTH, cortisol, etc.) and sym p ath etic  activ ity . A  rise in  
p lasm a cortisol is seen in  stress situations su ch  as pelvic gynaecological or 
in d eed  any major surgery, thus docum enting th a t  it  is an im portant stress  
p aram eter.
There are few  data availab le about how benzodiazepines influence surgical 
stress and w ithin  th is adrenal cortisol production  during major surgery. To 
e v a lu a te  stress a ttenuation  during anaesthesia, m easurem ent o f stress horm ones
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(cortisol, catecholam ines) has been established to be reliable param eters [1, 
3, 11, 15, 22]. The sym pathetic nervous system  is activated  b y  a v a r ie ty  of 
even ts w hich occur during anaesthesia and surgery. Most plasm a noradrenaline  
com es from  sym pathetic nerve term inals and m ost adrenaline from  th e adrenal 
m edulla. These and the cortisol produced b y  the adrenal cortex are principal 
hum oral markers o f  the m ultiple stresses o f  anaesthesia and surgery.
A naesthesia w ith  fentanyl, oxygen  and nitrous oxide is currently a popu­
lar technique and an alternative to  halogenated  agents. Stanley at al. [18] have  
proposed the use o f large fentanyl doses to  prevent liberation o f catecholam ines  
and cortisol. The present paper reported on th e  cortisol response m ajor gyneco­
logical surgery during anaesthesia induced w itú  benzodiazepines adm inistered  
iv . in  clin ically  used  doses.
B enzodiazepine derivatives are w id ely  used for a variety  o f  clinical 
ind ications [7, 10]. The characteristic effects o f  the benzodiazepines are their 
anticonvulsant, anxiolytic, sleep-inducing, m uscle relaxant, and sedative  
actions. M idazolam  is a new benzodiazepine which, when com pared w ith  its 
predecessors diazepam  and flunitrazepam  has several advantages [4, 6, 13]. 
The im idazole ring confers to the m olecule a higher basicity, a h igh stab ility  in 
solution  and a short duration o f action. M idazolam is w ater-soluble and has 
been studied  as an anaesthesia induction  agent [4, 6]. It could also be used as a 
com ponent o f balanced anaesthesia to  provide sedation and am nesia as w ell as 
to  prevent the stressinduced adverse horm onal and m etabolic changes. Since 
diazepam  and flunitrazepam  have been used for all these purposes, com para­
tiv e  observations were conducted on the effects of these benzodiazepines on the  
plasm a cortisol level.
Clinical and endocrine investigations have dem onstrated th e  expected  
effectiven ess and advantages o f  benzodiazepines in anaesthesiology [4, 13]. 
M easurem ent o f  the cortisol level could provide further details w hen new  
anaesthesia inducing agents are introduced in to  practice.
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POST-EXERTION CHANGES IN LEFT VENTRICULAR 
SYSTOLIC TIME INTERVALS IN PATIENTS 
WITH PRIMARY HYPERTENSION TREATED  
WITH HYDROCHLOROTHIAZIDE, BINAZINE, AND
PROPRANOLOL
K .  M a r k i e w i c z , L .  G ó r s k i , M . Ch o l e w a
F IR S T  CLIN IC  O F IN TER N A L D ISEASES, IN S T IT U T E  O F IN TER N A L M ED ICINE, M ED IC A L ACADEMY,
E Ó D 2, PO LA N D
(R eceived  A pril 16, 1984)
The stu dy  involved 13 p a tien ts  w ith  prim ary hypertension w ho exercised on 
a bicycle ergom eter w ith in tensity  increasing up to subm axim um  lev e l. The exercise 
was carried out in four stages: before trea tm en t (1st study), follow ing one w eek treat­
m ent w ith  50 m g hydrochlorothiazide daily  (2nd study), after one w eek  treatm ent 
w ith  th e  sam e dose o f hydrochlorothiazide and 120 mg binazine daily  (3rd stu d y), and 
after one w eek treatm ent w ith hydrochlorothiazide and binazine, and 60 m g o f propra­
nolol daily  (4th  study). U sing the approach o f W eissler et ah, left ventricu lar systolic  
tim e intervals were analysed at rest, after exercise and up to the 90th  m inute of restitu ­
tion . H ydrochlorothiazide and binazine treatm ent decreased sy sto lic  and diastolic 
blood pressure, the total electrom echanical systo lic  time index (Q S2I) and the left 
ventricular ejection tim e index (L Y E T I), and increased the P E P /L V E T  ind ex  at rest 
and after exercise. Addition o f propranolol did not augment the h yp o ten siv e  effect, 
w hile the left ventricular systolic  tim e  in tervals returned to  the va lu es observed before 
treatm ent.
Keywords: hypertension, ph ysica l effort, left ventricular dynam ics.
A bbreviations: Ps: systolic blood pressure, Pd: diastolic blood pressure, QS2I: electro­
m echanical systo lic  tim e index, LVTI: left ventricular ejection tim e ind ex , P E P : preejection  
period.
Introduction
H aem odynam ic disturbance accom panying system ic hypertension  con­
tin u e to  attract much interest. I t  has been found that in  th e  early phase of 
hypertension  an increase in  cardiac o u tp u t and stroke volum e tak es place w ith  
the to ta l vascular resistance rem aining unchanged [4, 6, 12, 24 ]. I t  is believed  
th a t cardiac contractility  during th a t tim e increases or rem ains unchanged,
Send offprint requests to K. M arkiewicz, 90549 Lódz, ul. Zerom skiego 113, Poland.
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w hile le ft  ventricular end-d iastolic  volum e and pressure increase [6, 18]. Stable  
system ic  hypertension in v o lv es  increased peripheral resistance, decreased  
cardiac output, gradual hypertrophy of the heart m uscle, and decreased le ft  
ventricu lar diastolic vo lu m e and pressure [6, 12, 23 , 24]. The literature con ­
ta ins conflicting reports on th e  inotropic sta te  o f  th e  hypertrophic heart 
m uscle [19, 25]. D isturbed contractility  has been  observed primarily in  p a ti­
ents w ith  stable system ic hypertension  after th e y  had  performed some physical 
effort [1, 29]. Over th e  la st several years ergom etric te sts  have been applied  
for diagnosing the early phases o f hypertension [15, 22], to  assess physical 
effic ien cy  [2, 17], and to  s tu d y  the effectiveness o f  hypotension treatm ent 
w hich , i t  is thought, should  prevent an excessive  rise o f pressure during  
p h ysica l exertion [9, 10]. T he aim  o f the present s tu d y  was to investigate the  
changes in  post-exertion  le ft ventricular dynam ics in  th e  course of hypotension  
trea tm en t in  patients suffering from primary hypertension .
M aterial and m ethods
The stu dy  involved 13 p a tien ts  w ith  primary hyp ertension . The diagnosis and the  
in vestig a tio n s were carried o u t under clinical conditions. T he group consisted of 7 w om en  
and 6 m en aged 42 to 68, m ean age 51.5 ± 7 .8  years, all o f  w h om  w ere found to be in the second  
period (according to the W H O  classification) o f stab le sy stem ic  hypertension. On adm ission  
th e  p a tien ts  had a m ean sy sto lic  b lood  pressure of 173.1 ± 1 5 .1  m m  H g and a diastolic pressure
Table I
General characteristics o f hypertensive patien ts who exercised on bicycle ergometer before treatm ent
( 3 ) ,  and hydrochlorothiazide,
No. Name Sex Age Height,cm
Body w eight, 
k g Minnesota code
l . D . Cz. M 57 165 87.7 i i - i
2. G. E. M 68 168 72.0 II - l;  IV-1; IX-3
3. K . M. M 57 173 72.5 II -l;  V-3
4. P. F. M 50 173 98.0 VII-4; IX-1
5. Z. M. M 47 172 76.0 I I - l;  III-l
6. H. K. F 53 157 70.8 I I - l;  IV-3
7. N . T. M 52 167 72.6 II I - l;  IX-3
8. G .T . F 49 146 62.0 V-3
9. J .T . F 48 158 89.1 0
10. 0 .  B. F 45 160 67.0 I I - l;  IV-3; V-3
11. Ch. J. F 42 167 85.4 IV-2
12. Z. W. F 44 158 77.7 I I - l;  IV-3; V-2; IX -3
13. S. W. F 58 162 74.0 II - l;  V-3
mean 51.5 163.5 77.3
± S D 7.8 8.1 10.8
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of 103.1 ± 1 2 .0  m m  H g. They received no drugs for at least seven days prior to  th e  study. 
F ollow ing that th ey  exercised on a Zim m erm ann bicycle ergometer (G D R ) at 60 revolutions  
per m inute (1st study). In itial in ten sity  o f the exercise was 30 W att (W ) and th is  was in­
creased b y  30 W every fiv e  m inutes. The successive phases o f the exercise were separated  
b y  3-m inute intervals during w hich polycardiogram s were m ade. The in ten sity  o f  th e  effort 
w as from  30 to 120 (m ean 7 8 .5 ± 2 7 .1 )  W  and the work performed ranged from  8976.1 to  
89761.4 Joule (m ean 46952.1 ± 2 4 3 1 6 .3  Joule). H eart rate (H R ) acceleration w as from  116 to 
180/m inute, m ean 146.2 ± 1 9 .3 /m in u te . E xercise w as discontinued when subm axim al H R  was 
atta ined . In  tw o cases the exercise w as d iscontinued earlier when sym ptom s o f  m yocardial 
ischaem ia were noted in the electrocardiogram .
Follow ing the first study, hypotension  treatm ent was applied according to  th e  follow ­
ing schedule: hydrochlorothiazide 50 m g daily  (2nd study), hydrochlorothiazide 50 m g and 
binazine (P olfa , Poland) 120 m g daily  (3rd stu dy), and hydrochorothiazide 50 m g, binazine 
120 m g, and propranolol 60 m g daily  (4th  study). E ach phase o f the treatm ent la sted  seven  
days. O wing to earlier norm alization o f arterial blood pressure, 12 p atien ts were qualified  
for th e  third study, and 11 for the fourth . F ollow ing  each phase of treatm ent th e  subjects 
perform ed physical exercise the in ten sity  o f  w hich w as identical to th a t perform ed before 
treatm ent. H eart rate acceleration in  th e  2nd stu dy  w as from 120 to 188/m in, m ean 150.5 ±  
20 .5; in  th e  3rd study, 140 to  174/m in, m ean 1 4 9 .0 ± 1 0 .2 ;  and in the 4th , from  96 to  156/min, 
m ean 1 3 3 .1 ± 1 6 .3  (Table I).
U sing a three-channel ECG apparatus (M ulticard -— 3 M) and w ith  the patien ts lying, 
synchronous records o f the 2nd ECG lead , phonocardiogram  from  the cardiac apex in  the  
70 H z band, and o f carotid pulse curve were m ade before exercise (A), after each phase of 
th e  exercise (B , C, D ), and in the 5th  (E ), 10th (F ), 20th (G), 30th (H ), 60 th  (I), and 90th  (J) 
m inute of recovery. From  the polycardiogram s obtained, left ventricular sy sto lic  tim e inter­
va ls were calculated using the m ethod o f W eissler et al. [28]. In  order to exclu d e  th e  effects 
o f heart rate on to ta l electrom echanical systo lic  tim e (Q S2) and left ventricular ejection  tim e 
(L V E T ) we corrected them  according to  our own linear regression equations, calculated  for 
each phase o f the stu dy , and then  th is tim e intervals were presented as indices (Q S ,I, LVETI) 
independent o f  HR.
The num erical results obtained were subjected  to  statistical analysis using S tudent’s 
paired 1 test and considering differences o f P  <  0.05 to  be statistically  significant [20].
( study 1 ) ,  after one week o f treatment w ith hydrochlorothiazide (2 ) , hydrochlorothiazide and binazine  
binazine, and propranolol (4 )
Ps/Pd, 
mm Hg
Maximum
load,
W att
Work perform ed, H eart rate  acceleration
Joule 1 2 3 4
190/120 90 53 856.8 148 152 156 144
150/80 90 53 856.8 116 120 — —
155/100 90 53 856.8 116 148 148 —
180/100 120 89 761.4 148 160 140 156
160/100 90 53 856.8 152 144 140 132
170/90 30 8 976.2 128 136 140 96
180/100 120 89 761.4 152 156 156 120
190/100 30 8 976.2 164 168 140 140
170/110 90 53 856.8 140 144 152 130
175/120 90 53 856.8 180 188 174 150
200/120 90 53 856.8 132 136 148 128
170/105 60 26 928.4 164 156 144 140
160/95 30 8 976.2 160 148 150 128
173.1/103.1 78.5 46 952.1 146.2 150.5 149.0 133.1
15.1/12.0 27.1 24 316.3 19.3 20.5 10.2 16.3
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Results
S ysto lic  blood pressure (Ps) at rest before treatm en t was 173.1 ± 1 5 .1  mm  
H g, in  th e  second stu d y  —  1 4 8 .5 ± 1 8 .3  mm  H g (P  -< 0 .0 0 1 ), in the third  
stu d y  —  142.9 ± 2 0 .5  mm  H g (P <  0.001), and in  the fourth study it  was
145.5 ± 1 6 .3  m m  H g (P <  0.001). Exercise produced significant increase o f  Ps 
values in  the successive studies b y  4 5 .0 ± 2 0 .5 , 3 5 .1 ± 2 3 .9 , 3 5 .4 ± 2 2 .5 , and
35.5 ± 1 8 .0  mm H g (P  <  0.001) respectively. The ex ten t o f Ps increase was 
in  each  case similar and non-significant (P  >  0.05). A fter exercise, Ps tended  
to  decrease and the decrease continued throughout th e  entire recovery period 
(P  <  0 .05). D iastolic blood pressure (Pd) at rest in  th e  first study was 103. 1 ±  
12.0 m m  H g, and it  decreased b y  8.5 ± 1 3 .7  in  th e  second study (P > 0 .0 5 ) ,  
by 1 1 .9 ± 1 2 .1  in the third stu d y  (P <  0.05), and b y  9 .8 ± 9 .3  in the fourth  
stu d y  (P  <  0.05). Pd values increased non-sign ificantly  in  all studies during 
exercise (P  >  0.05), and decreased during restitu tion . This decrease was m ost 
pronounced at 30 and 60 m inute after th e  exercise and was sta tistica lly  
sign ifican t in  the 2nd and 4 th  studies (P  <  0.05) (F ig. 1).
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Fig. 1. S ysto lic  (Ps) and d iastolic  (P d) blood pressure at rest (A), following exercise w ith  
a load  o f  30 W  (B ), and 60 W  (C) after subm axim al effort (D ), and in  the 5th (E ), 10th  (F ), 
20th  (G ), 30th  (H ), 60th  (I), and 90th  (J) m inute o f restitu tion . 1 —- [ j  —  control s tu dy; 
2 —  [7/3 —  after one week o f treatm ent w ith  50 m g/day  o f hydrochlorothiazide; 3 —  Ixxl —  
after one w eek of treatm ent w ith  50 m g/day of hydrochlorothiazide and 120 m g/day o f  bina- 
zine; 4 —  JJ]j —  after one w eek o f  treatm ent w ith  50 m g/d ay  hydrochlorothiazide, 120 m g/day  
of b inazine, and 60 m g/day o f propranolol. * — P <  0.05 and ** =  P  <  0.001 in intergroup
comparisons
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T otal electrom echanical systo lic  tim e index (QS2I) at rest in the 1st 
stu d y  was 5 7 5 .7 ± 2 3 .3  ms, and it decreased to  5 3 4 .3 ± 2 1 .0  in  th e  2nd study, 
to  504.1 ± 2 3 .8  in the 3rd study (P  <7 0 .001), and in the 4 th  stu d y  it was 
5 7 4 .5 ± 1 9 .0  ms (P  > 0 .0 5 ) .  The m ost pronounced decrease o f  QS2I occurred 
after suhm axim al exercise by 2 4 .0 ± 1 8 .7 , 2 0 .9 ± 2 4 .1 , 3 4 .4 ± 1 6 .9  and 18.5 ±  
15.3 ms respectively  in the four studies (P  <  0.05). The degree o f  QS2I decrease 
w as similar in all studies (P >  0.05). In  the course of restitu tion  th e  lowest 
QS2I values were observed in th e  2nd and 3rd studies (P  < / 0 .001) (Fig. 2).
Fig. 2 . T otal electrom echanical systolic tim e ind ex  (Q S2I) in 13 primary h y p erten sive  patien t  
at rest (A), after exertion  w ith loads of 30 W  (B ) and 60 W (C), after su bm axim al effort (D ) 
and in  the 5th  (E ), 10th (F ), 20th (G), 30th  (H ), 60th  (I), and 90th (J) m in u te  o f  restitu tion  
in th e  control stu dy  (1 — | j), after one w eek  treatm ent w ith 50 m g/day o f  hydrochloro­
th iazide (2 —  (23), after one week treatm ent w ith  50 m g/day of hydrochlorothiazide and 
120 m g/day of binazine ( 3 — Ixxil, and after one w eek treatm ent w ith 50 m g /d a y  o f hydro­
chlorothiazide, 120 m g/day of binazine, and 60 m g/day  of propranolol (4 —  1ГЩ). From  top 
to  bottom : QS2I values obtained at rest and during exercise and restitu tion  in  each study, 
values obtained in th e  successive stages o f  the studies; differences between th e  resu lts obtained  
during exercise and restitu tion , and the in itia l ones. Statistical com parisons: о  —  P  <  0.05 
(for th e  dynam ics o f changes w ithin the stu dies), and * P <  0.05 and ** P  <  0.001 (for com ­
parison of the results betw een  the studies)
Left ventricular ejection tim e in d ex  (LVETI) at rest in  th e  fir st study  
w as 422.9 ± 2 3 .4  m s, and it decreased to  391.2 ± 1 5 .2  in the 2nd stu d y  and to 
3 8 3 .7 ± 2 1 .9  in the 3rd (P < / 0.001). In  th e  4 th  study the L Y E T I va lu es was 
4 2 5 .3 ± 1 8 .2  ms (P  >  0.05). After exercise w ith  an intensity o f 60 W  and after 
subm axim um  exertion  the LVETI va lu es in the successive studies were higher,
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F ig. 3. L eft ventricular ejection  tim e  index (LYETI) in 13 hypertensive patients during 
exercise and recovery, before and after treatm ent. Sym bols as in Fig. 2
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Fig. 4 . P reejection  period (P E P ) a t rest, during exercise, and during recovery in hyp ertensive  
p a tien ts, before and in  th e  course of hypotension trea tm en t. Sym bols as in Fig. 2
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and in the 20th , 30th, 60th, and 90th  m inutes of restitution low er, than  the 
value obtained at rest (P <  0.05) (F ig . 3).
The preejection period (P E P ) at rest was in the 1st s tu d y  131.6 ± 1 7 .0  
ms; in  the 2nd study, 1 2 9 .2 ± 1 3 .4  ms (P  > 0 .0 5 ) ;  in the 3rd stu d y , 128 .Id; 
16.4 ms (P  > 0 .0 5 ) ;  and in the 4th  stu d y , 1 3 1 .0± 10 .1  ms (P  > 0 .0 5 ) .  In  all 
studies after exercise the P E P  values sign ificantly decreased b y  41.2 ± 1 5 .3 ,  
2 7 .8 ± 2 3 .6 , 2 8 .8 ± 2 0 .6 , and 2 8 .2 ± 1 2 .0  m s, respectively (P  <  0.05). The 
degree o f  changes in P E P  values in  the 2nd, 3rd, and 4th  stud ies was less 
pronounced than  in the 1st stu d y  (P  <  0.05). In  the recovery period the P E P  
values were similar in all studies (P  >  0.05) (Fig. 4).
The PEP/LY ET ratio at rest w as in  the 1st study 0 .4 8 5 ± 0 .0 8 6 ;  in the 
2nd, 0 .5 6 6 ± 0 .0 9 1  (P <  0.05); in  th e  3rd, 0 .5 2 7 ± 0 .0 7 3  (P >  0 .05), and in the 
4th  stu d y , 0 .4 8 6 ± 0 .0 8 5  (P  >  0.05). Exercise decreased the P E P /L V E T  values 
in the successive studies, hut on ly  in  the 1st study was the 0.061 ± 0 .0 6 1  de­
crease sign ificant statistica lly  (P  <  0.001). Im m ediately after th e  exercise and 
in the restitution  period the P E P /L Y E T  values in the 2nd and 3rd studies 
were sta tistica lly  sign ificantly  low er than  in  the 1st study (P  <  0.05). The 
dynam ics o f  PE P/L V E T  changes was sim ilar in  all studies (P  >  0.05) (F ig. 5).
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Fig. 5. P E P/L V E T  ratio in hypertensive patients at rest, during exercise, and during re­
covery, before and in the course o f hypotension treatm ent. Sym bols as in  Fig. 2
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Discussion
T reatm ent w ith hydrochlorothiazide applied in  a dose o f 50 m g/day for 
7 days produced a sign ifican t decrease in systo lic  b lood  pressure and som e­
w h at less pronounced decrease o f  diastolic pressure. A t the same tim e we 
observed  changes in  th e  le ft  ventricular systo lic  tim e intervals: the to ta l 
electrom echanical systo lic  tim e  index and the ejection  period index decreased, 
w hile th e  PE P/L V E T  ratio increased. The unchanged  behaviour of the pre­
ejection  period and the sign ifica n tly  decreased ejection  period index suggested  
th a t th e  basic effect o f  d iuretic treatm ent w as a decreased flow  of blood to  
the heart [3, 13].
A pplication  together w ith  the diuretic o f  b inazine in the com m only  
used dose o f  120 m g/day, caused  a dilatation o f peripheral blood vessels and 
brought about a further sligh t decrease of systo lic  and diastolic arterial blood  
pressures and of the QS2I  and LY ETI values. There w ere no significant changes 
in  th e  preejection period, and the PE P/L V E T  ratio  continued to be non- 
sign ifica n tly  larger than  th e  in itia l value. Such a behaviour of the systolic  
tim e in tervals indicated th a t  le ft ventricular d ynam ics continued to  be dis­
turbed  in  the case o f com bined hydrochlorothiazine-binazine treatm ent. It  
w as fou n d  th at drugs w hich  cause dilatation o f arterioles give rise to  heart 
rate, increased plasm a renin  activ ity , and increased sym pathetic nervous 
system  a ctiv ity  and w hen used  alone, an increase in  cardiac output [5, 8, 11, 
14]. For th is  reason it  is recom m ended that in  such cases drugs blocking the  
beta  adrenergic receptors should  be adm inistered [7, 26, 27]. In  the present 
stu d y , adm inistration o f 60 m g o f propranolol da ily , in  addition to th e  pre­
v io u sly  adm inistered hydrochlorothiazide and b inazine, arrested the decrease 
of b lood  pressure, and le ft ventricular systolic tim e intervals returned to  the  
levels  observed before th e  stu d y .
T he research o f M artynov et al. [17], and Chalev et Kairov [2], shows 
th a t th e  physical effic ien cy  o f  hypertensive p a tien ts substantially  decreases 
in  th e  early  stages o f  th e  condition . Follow ing exercise, the patients w ith  
prim ary hypertension show ed an increased systo lic  pressure, which decreased  
during th e  recovery period. Ps values were low er th an  a t rest even in the 90th  
m in u te o f  restitution. This behaviour o f the systo lic  b lood  pressure was sim ilar 
as th a t  observed in h ea lth y  subjects following exercise [16]. Exercise decreased  
th e  to ta l electrom echanical systo lic  tim e in d ex  and th e  preejection period, 
increased th e  ejection period index , and decreased th e  PEP/LV ET ratio. W e 
m ay th u s conclude th a t such  a behaviour o f the le ft ventricular systolic tim e  
in terva ls constitutes evidence o f  proper adaptation  o f  th e  heart to effort [16]. 
B etw een  the 10th and 30 th  m inute o f restitution  a sligh t deterioration o f the  
left ventricu lar systolic d ynam ics occurred.
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The direction o f changes in systolic and diastolic blood pressure and in 
left ventricular systolic  dynam ics during exercise and restitution  in the course 
of hypotension  treatm ent was similar as before treatm ent. Exercise decreased 
the QS2I, P E P , and P E P/L Y E T  values, and increased the LY ETI values. 
It follows th a t in  th e  course o f hypotension treatm en t the adaptation  to  effort 
rem ained norm al [16]. The in tensity  o f the applied exercise did not produce 
any im pairm ent o f  heart function  during hypotension  treatm ent th a t included  
adm inistration o f drugs blocking the beta adrenergic receptors. Sim ilarly as 
during rest, treatm ent w ith  diuretic and arteriole-d ilating drugs during exercise  
produced a substantia l decrease o f the ejection  tim e index. Such a behaviour  
o f the ejection  index  was advantageous because it  prevented the excessive  
accretion o f  blood pressure during exercise. A ddition  o f  a sm all dose o f  pro­
pranolol caused the systolic  dynam ics to  return to  the pretreatm ent level, with  
the blood pressure stabilizing at a lower level.
During hypotension  treatm ent, the degree o f post-exertion  m yocardial 
hypodynam ia observed before treatm ent w as d istinctly  lowered. This m ay  
have been related to  the lower pressure values and the decreased afterload  
due to  treatm ent.
Conclusions
1. Combined treatm ent w ith hydrochlorothiazide, binazine and propra­
nolol prevented excessive post-exertion increm ent o f systolic and diastolic  
blood pressure.
2. In  com parison w ith  the initial stu d y , treatm ent w ith  hydrochloro­
thiazide, hydrochlorothiazide and binazine decreased the tota l electrom echa­
nical systolic  tim e index  and the left ventricular ejection tim e index  and 
increased the PE P/L Y E T  ratio at rest and follow ing exercise: on the addition  
of propranolol, the left ventricular systolic  tim e intervals returned to  the 
values observed before treatm ent.
3. In  patien ts w ith prim ary hypertension, a disturbance o f le ft ventricu­
lar systolic  function  occurred during recovery. H ypotensive treatm ent pre­
vented  the m yocardial hypodynam ia syndrom e after physical exercise.
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Gastroenterology
THERAPEUTICAL EXPERIMENTS IN ULCERATIVE 
COLITIS AND CROHN’S DISEASE
Gy. N a g y , G. P r ó n a y , L. Ú j s z á s z y
COUNTY HOSPITA L, M ISKOLC, HUNGARY
(R eceived M ay 7, 1984)
In th e  period  1963— 82 am ong the patien ts w ith  aspecific inflam m atory bowel 
disease, the incidence o f u lcerative colitis w as 3.1 per 100 000 per year, while the fre­
quency of Crohn’s disease has doubled during th e  observation period and now  its  
incidence is 0.58 per 100 000 per year. D uring th e  past 20 years, 404 p atien ts w ith  
ulcerative co litis were treated . The average fo llow -up of the patients lasted  for 6.6 years. 
During this period , 40%  of the patients could he kept in  balance perm anently w ith  
salicylazosulfapyridine (SA SP) m onotherapy. A  further 34%  reacted to  SA SP  plus 
steroid. The ra te  o f regression was increased b y  a further 14% w hen the com bination  
was occasionally  com pleted w ith a short-term  antibiotic or prolonged azathioprine  
therapy. The inestim able cases and those refractory to  treatm ent m ade up the other 
12% and am ong them  are also the 23 colectom ized patients. D uring the tw o decades 
40 patients w ith  Crohn typ e  ileocolitis were treated . SA SP adm inistration by itself 
was su fficien t in  only one case am ong them . In  6 cases steroid, in 4 antib iotics, in  7 aza­
thioprine and in  2 cases m etronidazole treatm ent had to be introduced com plem en- 
tarily. The fa c t th a t 21 o f the 40 patients had to  be subjected to  bow el resection in 
som e phase o f  th e  disease, shows how im possib le it  is to evaluate th e  different thera­
peutic interventions.
K eywords: u lcerative colitis, Crohn’s d isease, salicylazosulfapyridine, steroids, 
azathioprine.
A bbreviation: SA SP  =  salicylazosulfapyridine.
Introduction
The occurrence o f  inflam m atory bow el disease, especially o f Crohn’s 
disease, is increasing throughout the world. Since despite widespread research 
and therapeutical trials the pathogenesis and so the causal treatm ent o f these  
conditions rem ains unknow n, in flam m atory bow el disease is one o f  the greatest 
problem s o f m odern gastroenterology. In th e  follow ing we shall sum up our 
20 years clinical experience.
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P atien ts and methods
In  our Gastroenterological D ep artm en t and E ndoscopy Clinic, system ic care o f  colitis 
p a tien ts  h as been performed since 1963.
T h e  diagnosis of u lcerative co litis  w as based in  all cases besides the clinical sym ptom s 
on rec to sco p ic  and biopsy findings. E arlier, th e  extension o f the process was usually evaluated  
from  rad io log ica l descriptions, w h ile  since 1977 m ost o f the diagnostic inform ation has been  
o b ta in ed  from  colonoscopy.
E v a lu a tio n  of the clinical ty p e s  o f ulcerative colitis w as done according to  R o th  [30]. 
T he p a th o lo g ica l activity o f the d isease  w as evaluated according to  the h istological d ivision  
o f M atts [18 ]. In  judging the clin ical a c tiv ity  and the grade of severity , we used four categories 
(T able I).
Table I
Clinical severity and activity grade o f ulcerative colitis
F u lm in an t
Severe
M oderate
Mild
Sepsis with >  39 °C fever, profuse purulent-sanguineous diarrhoea, anaem ia—  
hypoproteinaemia
Toxic sym ptom s, fever, m ucosanguineous diarrhoea >  10 per day, anaem ia  
Moderate toxic sym p tom s, subfebrility, m ucosanguineous faeces <  10 per day
Mild general sym ptom s, subfebrility, m ild m ucosanguineous faeces <  5 per day, 
sometimes obstipation
F o r  therapy salicylazosulfapyridine (SA SP) (Salazopyrin , Pharm acia, U ppsala) was 
a d m in istered  as the basic drug in it ia lly  in  large doses (4— 6 g per day) then 2 g per day as 
a p reserv in g  dose. Since 1978 we h a v e  been using m ostly  Salazopyridazine (M edexport, Mos­
cow ) in  a  3 g  per day therapeutical or 1.5 g per day preserving dose. In refractory cases or 
w ith  p a t ie n ts  who originally had had  severe sym ptom s, the basic m edication w as com bined  
b y  lo ca l steroid  treatm ent for a fe w  w eeks and in case o f ex ten sive  disorders b y  system ic  
steroid  th era p y  for months. The in itia l large doses e.g. 40 m g o f oral or 100 m g of parenteral
Table II
A c tiv ity  index o f Crohn's disease 
(B est et al. [4])
1. Liquid or very soft stoo ls-n um b er in 1 week X  2 =
2. Quantity of abdom inal pains weekly  
(1 =  mild, 2 =  m oderate, 3 =  severe) X 5 =
3. General well-being w eek ly
(0 =  good, 2 =  poor, 4 =  terrible) X  7 =
4 . Extraintestinal sym ptom s (fever, joint, eye, 
mucocutaneous, anal) each of these X  20 =
5. Diarrhoea abated on ly  w ith  opiates X  30 =
6. Abdominal mass
(0 =  absent, 2 =  questionable, 5 =  yes) X  10 =
7. Haematocrit: m ales <  47, fem ales <  42 X  6 =
8. B ody weight per cent below  standard weight X  1 =
T otal =
<  150 =  rstinge stage, 150— 350 m oderately active stage, >  350 =  seriously active stage
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prednisone —  depending on the sym ptom s —  were gradually decreased th en  discontinued. 
In  the lack o f a rem ission, w hen septic sym ptom s were dom inant, 7 to 10 day an tib io tic  therapy  
w ith  gentam ycin  or clindam ycin was introduced, w h ile  in  case the process w as torpid or 
persistent azathioprine w as adm inistered in  100— 150 m g daily doses. In  refractory cases 
colectom y was ind icated , depending on the clinical sta te .
According to  our therapeutical practice, th e  patien ts were kept in  h osp ita l during 
exacerbations. In  cases w ith  m oderate sym ptom s or in  rem ission, treatm ents w ere performed  
at the ou tp atien t clinic. U sually  clinical control w as done in every three m onth s. In  case 
o f long-lasting illnesses even  if  the patient w as asym p tom atic  we have insisted  on  an annual 
endoscopic control.
The diagnosis o f Crohn’s disease was based earlier besides the clinical sym p tom s on 
radiological find ings, surgical or histological results. R ecently , diagnosis is estab lished  by  
colonoscopy and biopsy.
The clinical a c tiv ity  o f the disease is evaluated  according to the index o f B est et al. [4] 
(Table II). In  conservative treatm ent of Crohn’s disease we usually followed th e  therapeutic  
schem e used in u lcerative colitis. In refractory cases w e occasionally adm inistered other drugs 
e.g . m etronidazole, disodium  crom oglycate, penicillam ine and levam isole. In  b o th  ulcerative  
colitis and Crohn’s disease, depending on the clinical sta te , drug therapy was com pleted  w ith  
dietary and sym p tom atic  treatm ent. Since for aspecific  colitis SASP was used constantly , 
its  side effects were registered continuously.
W ith the help o f other com ponent departm ents th e  patients suffering from  aspecific 
inflam m atory bow el disease were all collected in Borsod-Abaúj-Zem plcn County.
Results
During th e  20-year period 1963— 1982 we collected 557 p atien ts w ith  
aspecific ileocolitis from  different hospitals o f  Borsod-Abaúj-Zem plén County. 
D uring the first decade 240 cases of u lcerative colitis were d etected  and the 
num ber o f new cases was 3.1 per 100 000 yearly . In the second ten -year period  
the frequency w as the sam e. As to  Crohn’s disease, its incidence grew  tw ofold  
in the second ten -year period, so th at the incidence rate of the tw o  in flam ­
m atory bow el d iseases changed from 10 : 1 to  5 : 1 (Table III).
Table III
Ulcerative colitis and Crohn s disease patients 
in Borsod-A -Z  county during 20 years
1963— 1972 1973— 1982
772 000 inhabitants 800 000 inhabitants
Ulcerative 240 cases U lcerative 248 cases
colitis colitis
incidence: 3.1/100 000 incidence: 3.1/100 000
Crohn’s disease 23 cases Crohn’s disease 46 cases
incidence: 0.29/100 000 incidence: 0.58/100 000
R ate ~ 10 : 1 R ate ~ 5 : 1
In the past 20 years we treated 404 p atien ts w ith ulcerative co litis. Their 
m ean age at m anifestation  of the diseases was 37.2 years. In the second decade 
of our survey th e  in itial attack occurred 5 years earlier in average and there 
was a slight fem ale preponderance. The average follow-up tim e was 6.6 years.
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A ccording to  th e  site  o f  ulcerative co litis, in  52%  of the patien ts i t  was 
in  th e  rectosigm oid in  30.5%  the process ex tended  to  the left part o f th e  colon  
and in  15%  to  the whole large bowel. There m ay h ave been some un identified  
Crohn co litis patients h idden am ong th e  cases o f  segm ental in flam m ation  
w hich occurred in  2.5% .
A s to  its  clinical course in  66.5%  o f th e  patien ts the disease w as o f 
relapsing, in  20%  o f  chronic continuous and in  6.5%  o f acute fu lm inant typ e. 
7%  o f  th e  patients did n ot f i t  in  any o f the trad itional forms, therefore there  
m ay h a v e  been som e unidentifiable Crohn’s d isease cases in  this unclassified  
group.
A s to  the grade o f  clin ical severity  52.2%  o f  th e  patients could be classi­
fied  as m oderate, 22.3%  as severe, 19% as m ild and 6.5%  as fu lm inant.
A s to  therapy, 40%  o f  the patients could be treated with SA SP alone. 
74%  o f  all reacted to  SA SP plus steroid treatm en t. In 88% was clin ical im ­
p rovem en t achieved w ith  these drugs com plem ented  occasionally w ith  anti­
b io tics gentam ycin , clindam ycin  or in refractory patients w ith chronic aza­
th ioprine adm inistration. R efractory cases m ade up the other 12% . The 
23 operated  patients belonged to  the la tter group (F ig. 1).
S ign ifican t differences could be seen w hen analysing the patients accord­
ing to  th e  therapeutical periods (Table IV). U n til 1971 we m ostly used SA SP  
alone and occasional enem as. Perforation and other com plications m ade us 
ab sta in  from  system ic steroids. In  th at therapeutica l period the num ber of 
refractory cases reached 15% . From am ong th e  la tter  cases 8 p atien ts had  
to  be operated on, but considering the num ber o f  those who died a consider- 
ab ly  greater num ber ought to  have been operated .
Fig. 1. Sum m arized therapeutic results in  404 u lcerative  colitis patients
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Table IV
A  stepwise scheme showing the distribution o f  404 patients with ulcerative colitis 
observed and treated between 1963—1982
1963— 1971 
161 patients/9  years 
Therapy not evaluable: 11
R E FR A C T O R Y  
to therapy 22
II.
Operated 
from these
plus STE RO ID  
52 patients
I.
system ic
7
SASP
m onotherapy 
72 patients
local
45
100%
1972— 1982 
243 patien ts/11 years 
Therapy n o t evaluable: 0
6.6
14.7
—
7.8
34.7 15.6
— 34.6
50.6
35.4
R EFRA CTO RY  
to  therapy 16
Operated
from these 15
IH /b.
I + I I  plus
A Z A T H IO PR IN E  19
III/a.
I + 1 1  plus
ANTIBIOTICS 38
II.
plus ST E R O ID  
84 patients
system ic
59
local
25
SASP
m onotherapy  
86 patients
0%
D I E D
10 —  in basic disease 
5 —  am ong operated cases 
2 —  w ith colitis carcinoma
— 2 
— 1
— 3
Since 1972 we have been using SA SP alone m ostly in  th e  m oderate  
form s o f the disease or for m aintain ing a rem ission. In  cases o f  exacerbation  
w e adm inistered steroids sooner in  larger doses for a short tim e.
The num ber o f refractory cases w as successfully decreased to  approxi­
m ately  6% b y  adm inistering o f  com bined antibiotics in  septic form s and w ith  
azathioprine in  persistent processes. W hen conservative th erap y  had no 
satisfactory effect, surgery was indicated  sooner. As a result o f  these principles, 
since 1972 only tw o patients died; both  were unfit for operation.
Am ong th e  fulm inant u lcerative colitis cases leth ality  due to  th e  basic  
disease was 53.8% , in the m oderate or mild cases nil. The 6 colitis carcinom a
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p a tien ts  were m ostly from  th e  moderate group, th e  5 leth a l cases have already  
b een  reported [23]. O f th e  fulm inant cases during th e  first therapeutical 
period  only  one out o f  th e  12 patients recovered on drug treatm ent and one 
after surgery; 7 died during conservative th erap y  and 3 from among those  
w ho h ad  been operated on. D uring the second period, from  among 14 fulm inant 
cases 4 recovered on drug treatm ent and 7 as a result o f operation; 2 died  
during conservative th erap y  and 1 from am ong th e  operated patients.
In  the period 1963— 1982, 40 patients, 15 m en and 25 wom en were treated  
w ith  Crohn’s disease. The p a tien ts’ mean age at m anifestation  o f the sym p ­
tom s w as 27.7 and at d iagnosis 30.2 years.
The m ost frequent com plaints were spastic  abdom inal pains, loss o f  
w eig h t, diarrhoea and subfebrility . Articular com plaints and derm atological 
sym p tom s, among th em  SA SP  allergy were frequent. Bleeding occurred 
m o stly  in  distal processes. F istu la  and abscess could m ostly  be seen am ong  
th e  operated cases.
In  altogether 23 cases th e  changes affected  th e  ileocoecal region or the  
right part of the colon. In  3 cases the process w as lim ited  to the ileum , in  
12 cases to  the large b ow el, and in 2 cases to  th e  anorectal region.
In  13 cases the d iagnosis was m ade during surgery. Operation was 
in d ica ted  m ostly because o f  suspicion of appendicitis and som etim es because  
o f  sym ptom s of in testin a l obstruction. D iagnosis in 4 cases was based on  
X -r a y  and in 15 cases on endoscopic or b iopsy  fin d in gs. In  8 cases diagnosis 
cou ld  on ly  be made b y  com paring the data o f  d ifferent exam inations (X -ray, 
en d oscop y , biopsy and operation) and the clin ical course of the disease.
In  Crohn’s disease, S A S P  alone seem ed to  be efficient in a single case 
and steroid com bination in  5 cases. In 4 p atien ts antib iotics, in 7 cases aza­
th iop rin e and in 2 cases m etronidazole helped in  achieving a remission. W e 
occasionally  performed therapeutical trials w ith  5 am inosalicylic acid, SA SP  
en em a, crom oglycate, pen icillam ine, levam isole, etc.
E valuation  of th erap eu tica l interventions w as alm ost im possible b e­
cause 21 of the 40 p atien ts h ad  to be subjected to  bow el resection at one tim e. 
21 o f  the 40 patients are actually  w ell-balanced, 15 o f  them  have chronic 
com plain ts and 4 died o f  sep tic  com plications.
In  the patients w ith  ileocolitis we were n ever forced to discontinue the  
basic SA SP treatm ent ow in g  to  dose-dependent side effects. The not dose- 
d ependent sym ptom s according to frequency w ere pruritus, eruption, febrile 
reaction , urticaria, m ethaem oglobinaem ia, h aem olytic  anaem ia, toxic h epatitis  
and interstitia l pneum onitis. A s a result o f  such side effects in 11/222 patients 
w ith  ulcerative colitis and 5 /24  patients w ith  Crohn’s disease SASP had to  be 
discontinued. Salazopyridazine therapy often  caused itches and rashes; ad­
m inistration  of this drug h ad  therefore to be excluded  in 14 of the 182 patients  
w ith  ulcerative colitis and in  7 of the 33 p a tien ts w ith  Crohn’s disease.
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Discussion
In the last few  decades the incidence o f ulcerative colitis has not changed  
in  the English-speaking and Scandinavian countries. The num ber o f  new cases 
is 4 — 8 per 100 000 inhabitants yearly [20, 21]. During the 20 years of our 
study the incidence in  our region was also stationary, 3.1 per 100 000/yr. The 
frequency o f Crohn’s disease was gradually increasing and now its  incidence 
is 2— 4/100 000/yr abroad [5, 19]. The frequency in our region is now 
0.58/100 000/yr but w e should anticipate an increase.
The tw o diseases can be differentiated on th e  basis o f clinical, endoscopic, 
radiologic and pathologic findings in at least 80%  of the cases [11]. Differen­
tia tion  in 20% is how ever difficult or occasionally im possible even  b y  taking  
all aspects into consideration. It  is because neither disease has pathognom onic  
find ings present in every instance o f the one or absent in every in stan ce o f the 
other disease. The ty p e  o f  non-specific in flam m atory bow el d isease therefore 
rem ained unclassified , undeterm inated inspite o f repeated a ttem p ts in 28 
(6.9% ) of the 404 patien ts w ith ulcerative colitis and in 7 (17.5% ) of the 
40 patients suffering from Crohn’s disease.
The treatm ent o f aspecific inflam m atory bow el disease is a great problem. 
E stim ation  o f the therapeutic effect is d ifficu lt because of the ten d en cy  for 
spontaneous rem ission. On the basis o f our experience up to  now  SASP, 
steroids, azathioprine, m etronidazole and crom oglycate are more effic ien t than  
placebo. The application o f penicillam ine and o f aspecific im m unostim ulation  
(levam isole, BCG, transfer factor) is still in an experim ental stage.
The tactics o f  therapy are determ ined b y  separation o f u lcerative or 
granulom atous processes, the course o f the disease, its grade o f a c tiv ity , ana­
tom ical localization  and the com plaints.
A) U l c e r a t i v e  c o l i t i s
S A S P .  The orally adm inistered drug passes into the large bow el in 
85%  in unchanged form , where by a bacterial effect the azo-bond is split and 
the drug decom poses to  sulfapyridine and 5-am inosalicylic acid. In  the usual 
relapsing type o f  m ild or m oderate u lcerative colitis SA SP is sign ificantly  
more effective than  placebo [3, 6] but in  severe attacks the result is insignif­
icant and in the fu lm inant form o f the disease the drug is unsatisfactory.
Sulfapyridine has a lim ited  antibacterial effect and causes several side 
effects. According to  som e hypotheses it has the function o f veh ic le  on ly  [1, 
12, 39]. The 5-am ino-salicylic acid, considered to  be the efficien t com ponent, 
passes w ith the feces in  80%  unchanged and has m ostly a local effect. Its 
inflam m ation decreasing cytoprotective effect is probably based on the in­
hibition  of prostaglandin synthesis [33].
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T h e efficacy o f th e  drug in diarrhoea is sligh ter because o f  the short 
tran sit tim e  and because w h en  applying antib iotics, the SASP decom posing  
a c t iv ity  o f  the bacteria decreases. T hat is w hy there is a tendency for the  
p rod u ction  o f new sa licy late  com binations.
In  case of distal loca liza tion  and haem orrhagic proctosigm oiditis, local 
ad m in istration  of SA SP su p p ository  [32] and enem a [9, 15] proved to  be 
e ffic ien t. Side effects are frequent above a daily 4 g oral SA SP dose, therefore, 
i f  th ere  is  no im provem ent in  2 or 3 weeks, steroid adm inistration is advisable  
in stea d  o f  increasing the dose o f  SA SP.
In  th e  remission stage th e  relapse rate o f th e  disease w ithout treatm ent 
during a year-long observation  period was found to  b e around 75% [21] which  
could  b e decreased to 1/4 b y  continuously adm inistering 2— 3 g SA SP daily  
[7, 2 1 ]. In  order to prevent recurrences, lasting SA SP  therapy is necessary  
for a life tim e. Pregnant p a tien ts  can also be treated  w ith  SA SP or, i f  necessary, 
w ith  stero id  in the sam e w a y  as those who are n o t pregnant [22, 40].
S t e r o i d s .  System ic, q u ick ly  acting steroids are given  in the active stage, 
w hen th e  effect of SA SP is unsatisfactory  [14]. The optim al dose in  a m oder­
a te ly  a c tiv e  stage is 40 m g d a ily  [2], in  severe a ttack s it  is 50— 100 m g [37], 
and w ith  fulm inant sym p tom s it  is 100 [37]— 160 [13] mg daily. In  the last 
case parenteral alim entation , adequate replacem ent o f  flu id  and electrolytes, 
v ita m in s , protein and b lood is  an im portant part o f  therapy. I f  th e  septic  
sy m p to m s do not decrease on  th e  adm inistration o f antib iotics com bined w ith  
a b ig  dose o f steroid for 5— 7 days, then a surgical intervention should be 
in d ica ted  [37].
W h ile  the prevention o f  recurrences w ith sm all doses of steroid often  
fa ils, in  such cases 40 m g o f  prednisone should be g iven  every second day [15, 
16]. T h e efficacy of loca lly  applied  (suppository, enem a, foam) steroids in  
cases o f  proctosigm oiditis has been  known for long [36]. In  cases o f extensive  
p rocesses, oral therapy can successfu lly  be com bined w ith  the local adm in­
istra tio n  o f steroid.
A z a t h i o p r i n e .  In  th e  a cu te  stage its efficacy  has not been proved and 
it  does n o t seem to prevent recurrences [10]. In  th e  chronic active stage, 
h ow ever, it  decreases the steroid-dem and [29]. A zathioprine adm inistration  
seem s to  be reasonable i f  S A S P  or prednisone are in effic ien t or not tolerated.
T h e principles o f drug th erap y  for the treatm en t o f u lcerative colitis 
can b e seen  in Table Y.
B ) C r o h n 's  d i s e a s e
T h e therapy o f Crohn’s disease is in several aspects similar to  th at o f  
u lcera tive  colitis. They differ in  three characteristics [8].
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Table V
Drug therapy o f  ulcerative colitis
Anatomical localization
1. D istal process: local organs (suppository, enem a, foam )
2. E xtended form: system ic treatm ent
Course o f  disease 
1. Relapsing-rem itting: stopping of relapse (steroid +  SA SP) 
prevention of recurrence (perm anent SASP)
2. Chronic continuous: Azathioprine in case o f  active  stage besides SASP -f- stero id therapy
3. Fulm inant form: large dose of steroid, antib iotics, parenteral nutrition (if necessary, 
acute elective operation)
4. Non classifiable: Existence of Crohn’s disease m ust be cleared
Grade o f  severity and activity
1. Mild: SASP 3—4 g per day
2. M oderately severe: SASP, eventually tem porary steroid 30—40 mg per day
3. Severe: Steroid 40—100 m g per day +  antibiotics
4. Fulm inant: Steroid 100—150 m g per day -f* antibiotics 
total parenteral nutrition, substitution therapy
SA SP =  salicylazosulfapyridine
1. In  Crohn’s disease the in flam m atory process is o f more chronic nature  
and affects deeper parts o f the in testinal w all. The healing process is slow. 
A ntiinflam m atory treatm ent, including steroids needs consequently a longer  
period o f tim e.
2. A fter surgical resection o f a part o f  th e  bowel, there rem ains a sig­
nificant tendency for recurrence.
3. W hile in u lcerative colitis the increased bow el loss leads to  m etabolic  
deficiency, in  Crohn’s disease, because o f  the affection  of the sm all in testin e , 
we m ust count w ith  a dam aged absorptive function .
The disease has no generally accepted therapeutical strategy. T he basic  
principles can be gained from the present and future studies o f th e  N ation a l 
Cooperative Crohn’s D isease Study —  U .S .A . [35] and from the Europäische  
K ooperative Crohn Studie [17].
S A S P  a n d / o r  s t e r o i d .  In  case o f iso lated  colonic Crohn’s d isease SA SP, 
w ith  a process localized to  the sm all in testine m ain ly  steroid, and in  case of 
ileocolitis both  drugs are equally effective [16, 35]. Steroid is the more effective  
drug and its  com bination  with SASP is not favoured nowadays [16, 17, 34, 
35]. It w as observed th a t patients w ith cobblestone bowel contours reacted  
much better to  SA SP than  those w ithout such contours [35].
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S om e authors consider prolonged SA SP therapy beneficial in  th e  pre­
v en tio n  o f  recurrences. On th e  basis of controlled studies it  was how ever  
sta ted  th a t  neither SASP nor prednisone can protect against postoperative  
relapses [17, 34, 35]. T hat is w h y  it  is now  alw ays suggested to  m ake an 
a ttem p t to  prevent recurrences w ith  the continuous adm inistration o f the  
drug stero id  or SASP which seem ed to  achieve a rem ission [16].
A z a t h i o p r i n e .  Reports analysing small num bers o f patients show ed th a t  
azath iop rin e had an effect on th e  acute phase o f  Crohn’s disease. This was 
th en  p roved  in  a greater controlled patient m aterial [35]. In  chronic active  
processes th e  adm inistration o f  th e  drug’s m ain m etabolite, 6-m ercaptopurine, 
decreased sign ificantly  the steroid-dem and [27]. Therefore, for gaining tim e  
the q u ick ly  effective steroid is necessary till th e  slow ly  acting m ercaptopurine  
has ta k e n  effect.
C onsidering the prevention  of recurrence during a tw o-year-long aza­
th ioprine therapy, the recurrence rate in  com parison to placebo has not 
changed  sign ifican tly  [35]. On th e  other hand, in  patients in rem ission suspen­
sion o f  azathioprine therapy for a year sign ifican tly  increased the recurrence 
freq u en cy  [24], and so it  is probable th at in  a selected  patient m aterial react­
ing w ell to  azathioprine, perm anent adm inistration of the drug m ay success­
fu lly  p rev en t recurrences.
M e t r o n i d a z o l e .  D espite o f  its im m unosuppressive action m etronidazole  
seem s to  exert a therapeutic influence by its effect on the anaerobic flora. A l­
th ou gh  its  efficacy  in Crohn’s disease has not been  proved by the first controlled  
te sts , a m ulticentric study in  Sw eden has show n its  beneficial effect w hich is 
superior to  th a t of SASP [28 , 38]. In  perianal lesions often a dram atic im -
ТаЫе VI
Drug therapy o f  Crohn’s disease
A natom ica l localisation
sm all bow el —  steroid
ileoco litis  —- steroid plus SA SP
large bow el —  SASP, eventually  metronidazole
A cute stage
S A SP  3— 4 g/day  
P redn isone 0.5— 1.0 m g/kg/day  
M etronidazole 800 m g/day
Chronically active stage
P rednisone and/or azathioprine 2 m g/kg/day
Prevention o f  recurrence
T h erapy causing regression
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provem ent could be seen but in the case of isolated sm all bow el localization  
tlie efficacy was insignificant. As show n b y  crossed experim ents, in case of a 
failure o f  SA SP therapy, the change to  m etronidazole seems to  be beneficia l [38].
On the basis o f the literature and our own experiences th e  m ain guide­
lines in  the drug therapy — suggested in  case of Crohn’s disease — are summed 
up in Table V I.
Because of the wide spectrum  o f the clinical picture and th e  course of 
ulcerative colitis and Crohn’s disease the therapeutical approach m ust always 
be considered individually.
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THE EFFECT OF D-PENICILLAMINE 
IN DIFFERENT EXPERIMENTAL GASTRIC ULCER 
MODELS IN THE RAT
G. A. B á l i n t , V . V arró
F IR S T  D EPA R T M E N T OF M ED ICIN E, U N IV E R S IT Y  M ED ICAL SCHOOL, SZEG ED , H U N G A R Y  
(R eceived April 16, 1984)
Several su lfhydryl substances were found to protect the gastric m ucosa against 
th e  ulcerogenic effect o f  indom ethacin, w h ile  being ulcerogenic in  stress (restraint) 
ulcer. D -penicillam ine showed a dose depend en t antiulcerogenic effect in b o th  gastric 
ulcer m odels. This experim ental result has called attention to the tw o  m eth y l groups 
in  w hich the D-penicillam ine m olecule w as different from D -cysteine. I t  seem ed there­
fore th a t in contrast to cysteine the favourable effect o f D-penicillam ine in  stress ulcer, 
was due to  th is structural difference.
Keywords: gastric ulcer, ind om ethacin , stress, sulfhydryl com pounds.
Abbreviations : IN D : indom ethacin , STR: stress, DPA: D -pen icillam ine, U .I.: 
ulcer index.
Introduction
Szabó et al. [3] suggested th at the cytoprotective action m ay  be related  
to the presence o f sulfhydryl-groups, since th e  gastric mucus conta ins reduced  
glutath ione in high concentration. B álint and Varró [2] have show n su lfhydryl 
substances (glutathione, cysteine, cysteam ine and BAL) provided protection  
against the experim ental gastric ulcer induced  b y  IN D  while being ulcerogenic 
in STR  (restraint) ulcer.
D P A  (3 ,3 ,-d im ethyl-D -cysteine) is a chelating agent and an antidote  
for h eavy  m etal poisoning, capable o f ch em ica lly  binding various free radicals 
and thus to  in fluence the physical and chem ical properties o f  gastric m ucus. 
Therefore, we have investigated  its effect on different experim ental gastric 
ulcer m odels.
Materials and m ethods
T en groups o f 10 fem ale 190— 220 g W istar rats each were fasted for 24 hours prior 
to  the experim ent but were allowed water ad lib itum . The experim ental design , th e  ulcer 
m odels used and the m ode o f evaluation was published  elsewhere [1, 2].
W ith in  each group m ean values ±  SEM w ere calculated and analysed  sta tistica lly  
using S tu d en t’s i-test. Significant differences w ere assum ed when the probab ility  w as less 
than 5% .
D P A  (D -penicillam ine, Serva, 31710, research grade, Heidelberg, G FR ) w as dissolved  
in water and g iven  intraperitoneally in single doses o f  10, 50, 100 and 200 m g/kg . T he treat-
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m ents w ere carried out in  th e  ST R  nicer m odel at 0 m in, and in  the 6th, 12th and 18th hour  
o f the experim ental period, w hile in  the IN D  m odel a t 0 m in , and in the 2nd hour o f th e  in ­
vestiga tion .
Results
T he experim ental results are dem onstrated in  F ig . 1 and Table I.
Fig. 1. D ose-response curves o f D -penicillam ine in d ifferent gastric ulcer models in  th e  rat. 
R esu lts are shown as m ean ±  S.E .M . o f 10 values o f each poin ts. * =  P  <  0.05 v s Control 
(C). C =  control; STR =  stress-induced ulcers; IN D  =  indom ethacin-induced ulcers
Table I
Effect o f  D -Penicillam ine on Experim ental Gastric Ulcer
Group Indom ethacin ulcer Stress ulcer
U .I. X ±  S.E.M . ( J % )
Control 1 4 .4 ± 4 .3 9 (100.0) 10.0 ± 4 .5 4 (100.0)
D P A  10 m g/kg 1 3 .5 ± 3 .8 1 (93.8) 9 .4 ± 3 .1 7 (94.0)
D P A  50 m g/kg 5 .6 ± 1 .7 4 (38.9) 5 .4 ± 1 .6 6 (54.0)
D P A  100 m g/kg 1 .9 ± 0 .5 2 * (13.2) 3 .6 ± 0 .6 5 * (36.0)
D P A  200 m g/kg 2 .3 ± 0 .7 7 * (16.0) 4 .1 ± 1 .5 5 (41.0)
n  =  10 $/group 
* P  <  0.05 vs Control
Discussion
F rom  the results th e  follow ing conclusions h a v e  been drawn.
1. According to  our previous results [2], D P A  displayed a sign ifican t  
antiu lcerogenic property in  IN D -induced gastric u lceration  in a dose-dependent 
m anner.
2 . In  contrast to  our data  [2] D PA  show ed a strong, significant and dose- 
dependent antiulcerogenic effect on STR -induced gastric ulceration, too . This
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calls attention  to the structural difference existing betw een D P A  and its 
analogue, cysteine, i.e. to  the tw o m ethyl-groups in the D P A  m olecule. So far 
there are no data concerning the antiulcerogenic effect o f  su lfhydryl-com - 
pounds containing m ethyl-groups. In  our opinion the m ethyl-groups might 
in fluence the antiulcerogenic effect o f  D P A  in a favourable m anner. Further 
investigations seem  to  be needed along th is  line.
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IgM PARAPROTEIN IN THE SURRETINAL 
FLUID OF A PATIENT WITH RECURRENT 
RETINAL DETACHMENT AND WALDENSTROM’S 
MACROGLOBULINAEMIA
A. B e r t a 1, P. B e c k 2, J .  M i k i t a 2
'DEPARTMENT OF OPHTHALMOLOGY AND '2ND DEPARTMENT OF MEDICINE, 
UNIVERSITY MEDICAL SCHOOL, DEBRECEN, HUNGARY
(R eceived J u ly  9, 1984)
IgM paraprotein was detected b y  im m unoelectrophoresis and polyacrylam ide- 
gel electrophoresis in the subretinal flu id  (S R F ) of a patient suffering from  recurrent 
retinal detachm ent and W aldenstrom ’s m acroglohulinaem ia. Paraproteins in large 
qu antities m ay inh ib it fibrin form ation w hich in  turn m ay be an im portant agent in 
retinal reattachm ent and the starting poin t o f  scar form ation in the subretinal space. 
B y  th is case report th e  authors w anted to  support the assum ption th a t changes in  the  
protein  com position o f SR F m ight exp lain  th e  unsuccessful outcom e in  certain cases 
o f  retinal detachm ent when reattachm ent could not be achieved th ou gh  th e  diagnosis 
w as correct and the surgery performed correctly.
Keywords: IgM , paraprotein, subretinal fluid, retinal detach m en t, W alden­
strom ’s m acroglohulinaem ia.
Introduction
Subretinal flu id  (SR F) accum ulates betw een  the photoreceptor and the 
pigm ent epithelial layers o f the retina. The com position of the subretinal fluid  
depends on the pathogenesis and the duration o f detachm ent [5].
In  exudative detachm ents the S R F  is h ighly coagulable, turb id , yellow  
or even  brown in colour depending on th e  presence o f in flam m atory or haem ­
orrhagic elem ents. I f  m arked inflam m atory  changes are present, th e  protein  
con ten t o f the flu id  is high, it  contains im m unoglobulins, fibrinogen  and other 
serum  proteins o f  high m olecular w eight in large quantities [6, 11].
In  rhegm atogenous cases the S R F  is at first clear and non-coagulable, 
its com position  resem bles th at o f the vitreous. The protein con ten t increases 
w ith  th e  length  o f  th e  history and the changes o f the protein com position  
in  longstanding rhegm atogenous detachm ent are the result o f irrita tive  reaction  
o f the choroid vessels (vasodilatation  and increased perm eability [6, 11, 30]).
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F ib rin  form ation in  th e  S R F  m ay be an im portant factor in reattach- 
m en t o f  th e  retina [20]. I t  is considered to  be th e  starting point o f subretinal 
scar form ation; so it  probably contributes to  th e  success o f surgical procedures 
and prom otes the spontaneous resorption o f S R F  in  non-surgical cases [12]. 
F actors enhancing the change o f  fibrinogen to  fib rin  m ay help the process o f  
rea tta ch m en t. The inhib ition  o f  fibrin  form ation in  th e  subretinal space m ay  
lead to  recurrent detachm ents.
W aldenstrom ’s m acroglobulinaem ia is characterized by the accum ula­
tio n  o f  IgM  paraproteins in  th e  serum o f the p a tien t. The various sym ptom s 
o f th e  d isease are the result o f  disturbances in  m icrocirculation brought about 
b y  in creased  blood v iscosity . E xten sive  haem orrhages due to decreased p la te let  
fu n c tio n  and coagulability  changes are also present in  m ost patien ts. The 
la tter  are possib ly caused b y  com plex form ation o f IgM paraproteins w ith  
coa g u la tio n  factor У [24, 28].
T h e  ocular changes caused b y  W aldenstrom ’s m acroglobulinaem ia have  
recen tly  been  reviewed b y  T hom as et al. [27]. T hese changes include a d ila ta ­
tio n  an d  engorgem ent o f retinal vein s, retinal haem orrhages and oedem a, and  
serous detachm ent o f the m acula and the w hole retina  [19].
I n  th e  present work w e have studied th e  S R F  o f a patient suffering  
from  recurrent retinal detachm ent and W aldenstrom ’s m acroglobulinaem ia, 
w ith  th e  aim  to support the assum ption th a t changes in  the protein com posi­
tio n  o f  S R F  m ay hinder reattachm ent o f the retin a .
M aterials and m ethods
Case h isto ry
In tracapsular lens extraction  w as performed w ithou t loss o f  vitreous on both em m etropic  
eyes o f  th e  p atien t. One year after cataract operation retina l detachm ent developed in  his 
righ t e y e . R epeated  unsuccessful operations (scleral resection  and diatherm y) were perform ed  
in  an oth er  in stitu te . The patien t w as adm itted  to  our D epartm en t w ith  a fresh detachm ent 
of tw o  qu adrants w ith  a clearly v isib le  tear near th e  equator o f his left eye. Cerclage and 
d ia th erm y were performed. N o reattachm ent was observed in  the postoperative period. 
Cerclage reoperation  and the im planta tion  of a radial p lom b w as the next step in  surgical 
stra teg y . T hou gh  the SR F was drained, th e  retina rem ained detached after the second opera­
tio n , to o . Three m onths later the p a tien t was operated on again , cryopexy and air insu fflation  
were perform ed, w ithout success. B eside  retinal detachm ent th e  patient was suffering from  
d iab etes m e llitu s, rheum atoid arthritis, polyneuropathy, W aldenstrom ’s m acroglobulinaem ia  
and c o n sta n t tachyarrhythm ia due to  coronary sclerosis w h ich  needed special care before  
surgery u n d er  general anaesthesia.
Specim ens
S u bretina l fluid was obtained  in  th e  course o f th e  th ird  surgical procedure. The area 
around th e  proposed drainage site  w as carefully cleaned and dried. Im m ediately follow ing  
pu ncture  a  N o. 18 blunt needle on  a 2 m l syringe was held over the choroidal perforation site  
and th e  S R F  w as aspirated as it  em erged [15]. The sam ple w as centrifuged at 500 g for 10 m in. 
I t  w as p ra ctica lly  free o f cells. T he supernatant was stored a t — 20 °C until analysis w ith in  
48 hours after  the operation. Serum  from  venous blood w as drawn from the patient shortly  
before th e  surgical procedure. Tear sam ples were taken  after  th e  nasal instillation o f  80%  
eth an o l on e  hour before th e  operation  [3].
Acta Medica Hungarica 42, 1985
IgM PARAPROTEIN IN TH E RETINAL FLUID 181
A gar electrophoresis
Microscope slides (75 X  25 m m ) were cleaned thoroughly  and placed on a lev e l surface. 
2.0 m l o f 1% w /v  D ifco  “ Agar N oble”  solved in  barbitone buffer (pH 8.9, 0 .025 M) w as run 
even ly  over the surface o f each slide. After th e  gel had cooled and solified 1 m m  and 4 mm  
long troughs were cu t in  the m iddle o f each slide ex a ctly  perpendicular to  th e  ax is o f  the  
electrophoretic m igration. Sam ples o f 5 fd  were p u t in  each trough with the aid o f  a H am ilton  
m icropipette. R uns were carried out at 4 m A /slide for 4 hours at + 4  °C [14]. A  horizontal 
electrophoretic instrum ent (type 73, R eanal, B u d a p est, H ungary) and a DC pow er supply  
(typ e  O E-409, Labor Műszeripari M űvek, B u d ap est, H ungary) were used for electrophoresis 
in  th e  sam e barbitone buffer (pH  8.9, 0.025 M). F ollow ing  electrophoresis the slides w ere rinsed  
in  a 1 : 1 m ixture o f  m ethanol and acetic acid for 10 m inutes and dried betw een  filter  papers 
at room  tem perature. Protein bands were sta ined  in  1% aqueous solution o f  A m ido Black  
10 В for 10 m inutes. Slides were put in  7%  acetic  acid to  rem ove excess sta in  and allowed  
to dry.
P olyacrylam ide-gel (disc) electrophoresis w as performed according to  th e  standard  
procedure o f O rnstein [21] and D avis [9]. Gels w ere cast in  150 mm glass tu b e  w ith  an inner 
diam eter of 5 m m . T he spacer gel was 5 m m  and separation  gel 75 mm high. Separation  gels 
contained 5% acrylam ide m onom er. T R IS-g lycine buffer (pH  8.9) was used in  th e  electro­
phoretic instrum ent. Sam ples o f 5 fd were m ixed  w ith  50 /d  40% saccharose so lu tion  and 
applied directly on th e  top o f the spacer gel. A vertica l electrophoretic instrum ent (ty p e  69, 
R eanal, B udapest, H ungary) and a DC power su pp ly  (the same as for agar electrophoresis) 
were used for the electrophoresis. R uns were carried out at 2 m A/tube for 30 m in , and con­
tinued at 5 m A for 75 m in. Gels were stained b y  Coom assie Brilliant Blue R  250 according  
to  th e  m ethod of Crambach et al. [7].
Im m unoelectrophoresis was performed according to  Scheidegger [25] w ith  slight m odi­
fica tion . M icroscope slides (7 5 x 2 5  m m ) were cleaned and covered w ith 2 m l h o t buffered 
1% agar (D ifco “ Agar N oble”  solved in  barbitone buffer pH  8.9, 0.025 M) in  th e  sam e way  
as for agar electrophoresis. Two round wells w ere cu t in  the gel w ith a cutter  (1.5 m m  ex­
ternal diam eter) in  th e  m iddle o f the slide at 5 m m  distance from the edges. T he agar plug 
was rem oved b y  gentle  suction. The wells were filled  w ith  SRF or serum sam ples o f  5 fd. 
R uns were perform ed in a horizontal electrophoretic instrum ent (the same as for agar electro­
phoresis). The electrophoresis was performed at 8 m A /slide for 45 m inutes a t + 4  °C in barbi­
ton e  buffer (pH  8.9, 0.025 M). A t the end of th e  run a trough 60 mm long and  1 m m  wide 
was cu t in  the gel ex a ctly  parallel to  the axis o f  electrophoretic migration at 5 m m  from  the  
antigen  wells. The trough was filled w ith  antisera. The slides were kept in a m o ist cham ber 
at room  tem perature for 24 hours. The excess unprecip itated  protein was rem oved b y  washing  
in 0.9%  saline so lution  for 2 days. Slides were dried betw een  filter papers at room  tem perature. 
The precipitine lines were stained for 1 hour w ith  0.1%  Amido Black 10 В  d isso lved  in  a 
m ixture o f 90.0 m l m ethanol and 10.0 m l acetic acid [14]. The antisera used were, anti-hum an  
p olyvalen t horse serum , anti-hum an trivalen t (an ti IgA , anti IgG, anti IgM ) sheep serum, 
anti-hum an m onovalent (anti IgM) sheep serum , anti-hum an lam bda-specific horse serum, 
anti-hum an kappa-specific horse serum. The antisera were purchased from H um an Gödöllű, 
H ungary.
Stains and chem icals were of analytical grade, and were purchased, i f  n o t otherwise 
sta ted , from R eanal, Budapest.
Results
The paraproteinaem ia in our p a tien t w as diagnosed b y  agar electro­
phoresis. An in ten sive hand in the region o f globulins showed th e  presence  
of a paraprotein. The same characteristic band was dem onstrated b y  electro­
phoresis o f the S R F . The to ta l protein concentration  of SR F w as approxi­
m ately  one ten th  o f the serum protein concentration  therefore the com position  
o f S R F  was com pared w ith  that o f 10-fold diluted normal serum  (F ig . 1).
To m ake a precise com parison o f th e  protein com position o f  th e  two  
flu ids, polyacrylam ide-gel electrophoresis w as performed. P olyacrylam ide
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F ig. 1. A gar-gel electrophoretic patterns, l a  serum o f  p a tie n t suffering from W aldenstrom ’s 
m acroglobuliaem ia; b norm al serum; 2a  subretinal flu id  o f  patient; b tenfold diluted norm al 
serum  (1%  agar gel, B arbitone buffer pH  8.9, 0.025 M, sta in ed  w ith  Amido Black). T he arrows
I ind icate the paraprotein bands
gels contained 5% acrylam ide monomer, i.e . th e  pores o f the gels were w ide  
enough to  separate large m olecules like IgM  and its degradation products. 
An in ten sive  protein band was detected in  th e  m acroglobulin region o f b o th  
the p a tien t’s serum and SR F . This m acroglobulin fraction was absent from  
norm al serum and from  the tears of the p a tien t (F ig . 2).
The paraproteins w ere identified by parallel im m unoelectrophoresis o f  
th e  p a tien t’s serum , norm al serum, the p a tien t’s SR F  and tenfold d ilu ted
+
F ig. 2. P olyacrylam ide-gel electrophoretic patterns, a 10 //! subretinal fluid o f the p a tien t  
suffering from  W aldenstrom ’s m acroglobulinaem ia; b 10 /л1 tenfold diluted serum o f sam e  
p atien t; c 10 fű  tenfold d ilu ted  norm al serum; d 10 fA tears o f  sam e patient (O rnstein— D a v is  
system , 5%  acrylam ide-gel, T K IS-glycine buffer pH  8.9, sta in ed  by Coomassie B rilliant B lu e).
T he arrows indicate the paraprotein bands
Acta Medica Hungarica 42, 1985
IgM PARAPROTEIN IN THE RETINAL FLUID 1 8 3
F igs 3, 4 , 5. Im m unoelectrophoretic patterns, l a  serum o f patient suffering from  W alden­
strom ’s m acroglobulinaem ia; b norm al serum; 2a  subretinal fluid o f sam e p a tien t and anti­
hum an polyvalen t horse serum  on th e  first pair o f  slides (F ig. 3), w ith  anti-hum an trivalent 
(anti IgA , anti IgG, anti IgM ) sheep serum on th e  second pair o f slides (F ig . 4) and w ith  
anti-hum an m onovalent (anti IgM ) sheep serum on the third pair o f slides (F ig . 5). The slides 
were prepared according to  th e  m icroim m unoelectrophoretic m ethod o f  Scheidegger and
stained w ith  Am ido Black
norm al serum. The presence o f  paraprotein changed the appearance o f im m uno­
globulin precipitin lines in  the anodal part o f  the im m unoelectrophoretic  
patterns and SR F  (F ig . 3).
Im m unoelectrophoresis was performed w ith  trivalent im m une serum, 
too , which contained anti IgG , anti IgM and anti IgA  im m unoglobulins. The 
longest and m ost in ten sive  line in these im m unoelectrophoretic patterns was 
the line o f IgG. A nother short, d istinct and curved one corresponded to  IgM. 
The third very fa int precip itin  line close to  IgM belonged to  IgA . The presence 
o f paraproteins changed th e  form and place o f  IgM precipitin lines w hile the 
hands o f other im m unoglobulins were aneffected. The line o f  IgM  in  the 
p atien t’s serum and S R F  was h igh ly  curved and lay  very  close to  the arc 
o f IgG. This pattern was clearly different from the im m unoglobulins o f  normal 
serum and diluted norm al serum dem onstrated on the other side o f  the slides 
(F ig. 4).
Similar differences w ere detected b y  im m unoelectrophoresis w ith  m ono­
va len t (anti IgM) im m une serum. The precipitin lines o f IgM m olecules in  the 
serum  and the S R F  o f the patient were broad, curved and deform ed, support­
ing the fact that both  flu id s contained IgM m olecules o f paraprotein character
(F ig . 5).
Light chain analysis o f  the paraproteins w as also perform ed. Im m uno­
globulins in the serum and SR F  o f our patient produced long deform ed (double 
S shaped) precipitin lines w hen reacting w ith  anti-H  light chain im m une serum  
(F ig. 6). Such deform ities were not detected w ith  anti-A light chain antiserum  
(F ig. 7).
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F igs 6 , 7 . L ight-chain determ ination . Im m unoelectrophoretic patterns, l a  serum o f patien t 
su ffering  from  W aldenstrom’s m acroglobulinaem ia; b norm al serum; 2a  subretinal fluid of 
sam e p a tie n t  and b tenfold d ilu ted  norm al serum. The troughs were loaded w ith  anti-hum an  
k ap p a -sp ecific  horse serum on th e  f ir s t  pair o f slides (F ig. 6), and w ith  anti-hum an lam bda- 
sp ec ific  horse serum on the second p a ir  o f slides (F ig. 7). T he slides were prepared according  
to  th e  m icroelectrophoretic m eth o d  o f Scheidegger, were sta ined  w ith  Am ido B lack
T h ese electrophoretic p attern s dem onstrate th a t IgM paraprotein o f  the  
sam e ty p e  w ith  light chain character was present in  large quantities in  the  
serum  and SR F  of the p a tien t. T his com ponent w as clearly different from the  
im m unoglobulins present in  norm al and diluted norm al serum.
Discussion
T h e  protein content and com position o f  S R F  w as investigated  b y  several 
au th ors in  order to determ ine its origin in  exu d ative  and rheum atogenic  
cases [18 , 26, 23, 13]. I t  is agreed  th at in exu d ative  detachm ent the proteins 
are d erived  from choroidal v e sse ls  [4, 10, 17, 18, 2 2 ]. W hen there is a hole in  
th e  retin a , the vitreous is supposed  to penetrate through it  and to  lead to  
d eta ch m en t [8, 26, 30]. In  longstand ing  cases b oth  factors are at p lay b u t  
th e  share o f  the plasma increases w ith  the duration o f  detachm ent [5, 6, 18, 
30]. In  old  cases the proteins disappear from the S R F  w ith  the developm ent 
o f  choroidal atrophy [11].
T he SR F protein co n ten t has been related to  th e  outcom e o f surgery 
b y  sev era l investigators. T h e lev e l was sign ifican tly  lower after successful 
th a n  after  unsuccessful operations [1, 2, 12, 29]. There was a m arked increase 
in  th e  protein  content o f S R F  obtained from eyes w hich had undergone more 
th a n  one operation [12].
D eta iled  exam inations o f  S R F  by im m unoelectrophoretic techniques  
sh ow ed  th e  presence o f IgG  an d  IgA , but IgM  w as absent in  all specim ens 
stu d ied  so far [6, 8, 16, 17]. T hese findings were usually  explained b y  the  
lim ited  sem iperm eability o f  th e  endothelium  o f th e  choriocapillaries and o f  
B ru ch ’s membrane [6, 29].
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It is generally accepted th at studies o f  the protein com position offer 
a more reliable indicator o f choriocapillary dysfunction  than do to ta l protein  
estim ations [6].
The significance o f  fibrin form ation in S R F  in connection w ith  the result 
o f detachm ent surgery is not y e t quite clear. Orlowski [20] suggested  the 
in jection  o f plasm a or throm bin into the subretinal space after th e  aspiration  
o f the SR F . Good results were obtained b y  th is  m ethod in a few  cases. Sub- 
retinal fibrin  form ation m ay be an im portant factor in retinal reattachm ent 
but the process seem s to  be com plex and m ust be greatly influenced  b y  the  
concentration  o f all extrinsic pathw ay of coagulation. This problem  probably  
cannot be solved sim ply by introduction o f one or more coagulation  factors 
in to  the subretinal space.
Our case m ay be a good exam ple w hich shows the com plexity  o f the  
question. Paraproteins in  large quantities in h ib it fibrin form ation [24]. Para­
protein m olecules in the SR F  o f the patient m ay have hindered reattachm ent 
o f the retina in the early postoperative period. R esides, disturbances o f  micro- 
circulation due to  increased blood v iscosity  in  m acroglobulinaem ia m ay have  
played an im portant role in detachm ent o f  the retina and contributed to  
the developm ent o f the relapses.
The conclusions drawn from  the case were as follows.
1. The protein com position o f SR F shows great differences depending on 
the typ e, pathogenesis and duration o f the detachm ent, and m ay be affected by  
other diseases.
2. The protein com position  o f SR F m ay determ ine the result o f  retinal 
detachm ent operation. This m ay be one of th e  unknow n causes th a t explain  
th e  unsuccessful outcom e o f certain cases o f  retinal detachm ent, when both  
the diagnosis and surgery were correct.
3. S R F  estim ations m ay offer useful data  concerning the aetio logy and 
pathogenesis o f the detachm ent and the probable outcom e o f surgical in ter­
ventions. Such data m ay be useful in  determ ining the ty p e  and optim um  tim e  
o f operation.
4. Precise analysis o f a large num ber o f SR F-s is needed, the results 
m ust be correlated w ith  clinical findings, and the patients m ust be observed  
for a long period before these data can be really  used in the clinical care and 
m anagem ent o f  patients w ith  retinal detachm ent.
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THE EFFECT OF THROMBIN ACTIVATED 
FACTOR X III, THROMBIN AND PLASMIN 
ON THE CHEMILUMINESCENCE PRODUCED BY  
HUMAN NEUTROPHILS STIMULATED BY 
OPSONIZED ZYMOSAN (MANNOZYMR)
S .  S i p k a , G. Á b e l , L. C z i r j á k *, J. C s o n g o r * * ,  G. S z e g e d i * ,  J. F a c h e t
IN ST ITU TE OF PA TH O PH Y SIO LO G Y , T H IR D  D EPA R T M E N T O F M ED ICIN E*, AND CEN TRA L R E S E A R C H  
LABORATORY**, U N IV ER SITY  M EDICAL SCHO O L, D EB R EC E N , HUNGARY
(Received May 14, 1984)
Coagulation factor X III  formed by throm bin  activation  from zym ogen  factor  
X I I I  decreases the chem ilum inescence (CL) o f  hum an neutrophils stim ulated b y  opson­
ized zym osan (M annozym R). A t high concentrations, throm bin and p lasm in  also 
decreased the CL induced b y  opsonized zym osan. T he inhibitory effect o f  all th e  three 
enzym es was due to  their influence on the cell m em brane receptors (C3b and F c) and 
not to their direct effect on opsonized M annozym R. The potential clin ical role of 
factor X I II , throm bin and plasm a in the regu lation  o f neutrophil functions is assum ed.
Keywords: neutrophils, chem ilum inescence, factor X III , throm bin, p lasm in .
A bbreviations: CL: chem ilum inescence, OM: opsonized M annozym .
Introduction
N eutrophils engaged in  phagocytosis o f  opsonized zym osan em it a burst 
o f ligh t or chem ilum inescence as a result o f  generation of reactive oxygen  
including superoxide anions, hydrogen peroxide, hydroxyl radicals and singlet 
m olecular oxygen  [1, 3]. Since zym osan particles bind com plem ent com ponents  
and IgG  during opsonization  [2], the CL inducing  effect o f opsonized zym osan  
can be m ediated v ia  C3b and Fc receptors o f  neutrophils.
M annozym R (Serobacteriological In stitu te  “ H um an” , B u d ap est) is 
a 0.1%  suspension o f zym osan (glucom annan), a cell wall derivative o f  S acch a­
rom yces cerevisiae. O psonized M annozym R (OM) induces m ainly (ab ou t 80% ) 
C3b and to a less ex ten t (about 20% ) Fc m ediated  CL in human n eu troph ils. 
In anim al experim ents, M annozym R can be used as an im m u nopotentiating  
and antitum our agent [5, 16]. Like other ty p es o f  zym osan [2, 17], M anno-
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zy m R can  activate the alternative pathw ay o f  th e  com plem ent system  (Sipka  
et al. in  press) and increase th e  properdin lev e l [4].
T ransglutam inases cata lyse isopeptide-form ation resulting in  cross- 
linked , insoluble, polym eric proteins in m any cells types. The enzym e cross­
links p rotein s by form ing e-(y-glutam yl)-lysine cross-bridges [10]. R ecen tly , 
ev id en ce has been found o f th e  activation  o f “ tissu e”  transglutam inase during  
Fc m ed ia ted  phagocytosis o f  m acrophages [6, 9 , 15].
T h e zym ogen forms o f transglutam inases w hich are present in  various  
tissu es, organs and body flu id s are generally referred to as factor X I I I  [10]. 
The a c tiv e  enzym es form ed from  these zym ogen s by the proteolytic action  
o f th rom b in  and certain other proteases are called  factor X H Ia  (fibrin sta b i­
liza tio n  factor) [10, 13]. The role o f throm bin-activated  factor X I I I  was 
proved  in  cross-linking o f th e  fibrin clot and in  th e  postejaculatory clo ttin g  
o f rod en t sem inal plasm a [10].
S in ce th e  effect o f  tissue transglutam inase w as verified in the F c m ed i­
ated  a c tiv a tio n  and phagocytosis o f  m acrophages, the present stu d y  w as  
designed: (a) to  measure the effect o f throm bin-activated  human factor X I I I  
on th e  CL produced b y  hum an neutrophils; (b) to  te st the action o f throm bin  
and p lasm in  on CL induction  in  th is system ; (c) to  clarify the effect o f  a cti­
v a ted  factor X III , throm bin and plasm in on opsonized M annozym R.
Materials and m ethods
T op o sta sin  (human throm bin, H offm an-L a-R oche), plasm in (from hum an plasm a, 
Sigm a) and  FibrogamminR (F actor X III  concentrate from  hum an placenta, B ehring-W erke  
AG) w ere used.
O psonized M annozym R. M annozymR (1 m g) in  1 m l o f H anks’ balanced sa lt so lution  
(H B S S ) w as incubated w ith  1 m l o f  hum an serum at 37 °C for 30 minutes. A fter cen trifuga­
tion  a t 800 g  the  pellet was w ashed and resuspended in  1 m l of H BSS. This suspension was 
used as OM.
A c tiv a tio n  o f  factor X I I I .  30 IU  Fibrogam m inR and 30 IU  throm bin were incubated  
togeth er  in  3 m l H BSS supplem ented w ith  0.15 mol/1 o f  CaCl2 at 37 °C for 45 m inutes. The 
a c tiv ity  o f  transglutam inase w as tested  b y  14C-putrescine incorporation into casein  [10].
P repara tion  o f neutrophils. H eparinized blood w as diluted in 6% dextran in  saline  
(M acrodex, 70 000 m .w ., Pharm acia). The red cells w ere allowed to sedim ent for 45 m in  at 
room  tem perature. The leukocyte rich plasm a was th en  layered over Ficoll (Pharm acia-U ro- 
m iro B ranco  Ind. Chim.) gradient and centrifuged. T he p e lle t was treated w ith  0.83%  am m o­
nium  chloride in  order to lyse  th e  red cells. The rem ain ing leukocytes were neutroph ils in 
92— 9 9 % , viab le  in 99— 100% . T h ey  were washed tw ice  and resuspended in H B S S  [3].
M easurem ent o f chemiluminescence. 5 x l 0 6 neutroph ils were preincubated w ith  th rom ­
bin , throm bin-activated  factor X I I I  (containing equal ITJ-s) and plasm in at d ifferent con­
cen tra tion  at 37 °C for 45 m inutes. T he photon em ission  o f cells treated w ith  OM and o f  non- 
trea ted  controls was m easured by an Iso-Cap/300 liquid  scintillation  counter (N uclear Chicago, 
Searle In du str ies, Des P laines, U S A ) in th e  off coincidence mode (1). The to ta l num ber of  
p h o to n s m easured three tim es in f iv e  m inute intervals w as used as a characteristic va lu e  for 
a g iv en  sam ple.
T he CL induced b y  OM w as expressed in per cen ts compared to the value o f  OM-free 
cell su sp en sion , representing the basic CL, i.e. 100% . B efore measuring the CL, th e  sam ples 
and v ia ls  w ere preincubated at 37 °C. The inherent cellular light and not an am plified  ligh t 
sy stem  w as measured.
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Results
Preincubation o f hum an neutrophils w ith throm bin and throm bin  
activated  factor X I I I  at different concentrations (in both  system s the con­
centration o f throm bin was equal), resulted in a dim inished CL inducing effect 
o f OM in both system s. B u t a difference could be noted in th e  inh ib itory con­
centration of throm bin  activated  factor X I I I  and throm bin. N am ely , throm ­
bin  activated factor X I I I  was a p otent inhibitor o f CL already at such low  
concentrations o f  throm bin (being present in  the sam ple) at w hich  throm bin  
itse lf  (3 IU /m l) w as still ineffective (F ig . 1). Throm bin also decreased the CL 
generated by OM, b u t at concentrations higher than  10 IU /m l. B oth  throm bin  
and throm bin a ctiva ted  factor X III  resulted in  slight, non-sign ificant changes 
in  the “ spontaneous”  CL o f non-stim ulated  cells.
Preincubation o f cells w ith plasm in at concentrations higher than  
0.7 IU /m l was also inhibitory on the production of CL in neutrophils stim u- 
ated  by OM (F ig . 2).
F ig. 1. E ffect o f hum an throm bin and throm bin activated  factor X I I I  on  th e  chem ilum i­
nescence induced b y  opsonized MannozymR in hum an neutrophils. (M eans ±  S .D ., n =  4)
P la sm in  f IU /ml
F ig. 2. E ffect of hum an plasm in on the chem ilum inescence induced by opsonized M annozym^  
in hum an neutrophils. (M eans ±  S .D ., n. =  3)
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Fig. 3. E ffe c t  o f  preincubation o f opsonized  M annozym 1^  w ith  hum an plasm in, throm bin and 
throm bin activ a ted  factor X I I I  on th e  chem ilum inescence induced in hum an'neutroph ils.
(M eans ±  S .D ., n =  3)
Preincubation  of OM at d ifferent concentrations w ith  throm bin, throm ­
bin a c tiv a ted  factor X III  and p lasm in  and then , th e  m easurem ent o f its  CL 
inducing  effects on the neutrophils (Fig. 3) did not show  a significant inh ib i­
tion . (In  th e  case o f plasm in trea tm en t some slight b u t non significant e leva ­
tion  o f  CL induction was found.)
Discussion
M easuring the effect o f  throm bin  activated  factor X I I I ,  throm bin and 
plasm in  on the CL produced b y  OM in neutrophils, all the three enzym es 
decreased th e  phenom enon. W hereas throm bin and plasm in dim inished th e  
CL at rather high concentrations, activated  factor X I I I  was a potent inhibitor  
already a t such low  concentrations at which throm bin  itse lf  was not y e t  
e ffec tiv e . A ll the three enzym es acted  m ainly v ia  the cell mem brane receptors 
and n o t b y  m odifying the OM.
Our findings were in accordance with previous data  on the im portance  
o f transglutam inases in the regu la tion  of cell m em brane receptors [6, 8, 9, 11, 
12, 14, 1 5 ], especially o f  Fc receptors. Since the rate o f  F c m ediated com ­
p on en ts in  the tota l CL induced  b y  OM is not more than  about 20%  (as m en­
tion ed  in  th e  Introduction), and throm bin activated  factor X I I I  could result 
in an  a lm ost 50% decrease o f  to ta l CL, it m ay be supposed that beside Fc  
receptors [6, 9] and ß 2 m icroglobulin  [8], C3b receptors can also be targets  
of transglutam inases on the ce ll surface, and th a t zym osan induced CL of 
hum an neutrophils can be m od ified  not only b y  intracellular, but also b y  
throm bin  activated  transglutam inase.
I t  is likely  that the in h ib itory  effects o f throm bin and plasm in on the  
neutroph il functions at high concentrations have in v itro , a theoretical rather
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than practical im portance. A lthough, for exam ple, in chronic dissem inated  
intravascular coagulation  (DIC), where throm bin , throm bin activated  factor  
X I I I  and plasm in are generated sim ultaneously  in  the circulation [7], these  
three enzym es m ay even  worsen the clinical s ta te  by blocking th e  C3b and 
Fc m ediated functions o f R ES or other cell ty p es o f the im m une system .
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SERUM BETA-2-MICR0GL0BULIN IN CHRONIC 
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Serum -beta-2-m icroglobulin was m easured by radioim m unoassay in  25 patients 
w ith  chronic lym phocellular leukaem ia in  stages I I I —IV according to  th e  R ai classi­
fication . A significant positive correlation w as found between the absolu te lym phocyte  
count and the serum -beta-2-m icroglobulin level. No similar relationship w as observed 
betw een the score indicative o f organ in filtra tion  and the beta-2-m icroglobulin value.
On the evidence of the results, th e  increased production of beta-2-m icroglobulin  
is attributed in  the first place to the c ircu lating lym phocytes. The assay has been found 
to provide a reliable indicator, suitable for th e  m onitoring and evaluation  o f  therapy.
Keywords: Beta-2-m icroglobulin — CLL — organ infiltration  — absolute
num ber o f lym phocytes — therapy.
Introduction
H um an beta-2-m icroglobulin (B2M G ) is a protein o f low  m olecular 
w eigiit, first iso lated  by Berggârd and B earn  in  1968 (1). Its m olecular weight 
is 11 800 dalton, its  molecular radius 15 Â. Its  amino-acid sequence shows a 
close sim ilarity to the pattern o f the lig h t and heavy chains o f  IgG . Assim i- 
larity  has been found between B2MG and Bence-Jones protein as w ell [2,
3, 4, 5 , 6].
B2MG is found on the lym phocyte surface. According to present know l­
edge, its synthesis takes place prevalently  in  the lym phocytes. On th e  lym pho­
cyte surface it  is present in two m olecular form s, i.e. as part o f  th e  H L —-A 
antigen com plex and as a free m olecule. On the úuman lym p h ocytes there are 
3— 5 X 105 B2MG m olecules, roughly corresponding to fivefold o f  th e  num ber of 
H L — A antigens [5].
The biological function of this protein  has yet to be clarified. Increased  
levels were found in  m alignant lym phom a and certain infections, its  synthesis  
increases in response to the P H A -stim ulation  test.
The B2MG content o f the hum an B -lym p h ocyte surface exceeds th a t of 
the T -lym phocyte surface by 20%  [14]. T he cell membrene turnover provides 
the m ost im portant source of free B2M G o f blood-plasma and body-flu ids.
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A ccord in g  to  Am lot [3], th e  serum  B2MG levels correlate well w ith the tissu e  
in filtra tio n  o f lym phom a and m yelom a.
P rom p ted  by these considerations, we h ave checked the serum B2M G  
lev e l in  a num ber of our p a tien ts  w ith chronic lym p h oid  leukaem ia, w ith  a v iew  
to  th e  B2M G  level and the absolu te lym phocyte cou n t before and after tr e a t­
m en t, and  betw een the ex ten t o f  tissue in filtration  and the serum B2MG level-
P atients and m ethods
A  to ta l o f 25 patients, 18 fem ales and 7 m ales, o f  66.6 (49— 84) years average age were 
in clu ded  in  th e  study. A t the tim e o f  study  all patients w ere free from  infections and all had  
norm al ren al functions (average se-creatin ine, 88 p mol/1). Sam ples for B2MG estim ation were  
ta k en  in  th e  m orning hours. A t th e  tim e of the first sam pling none of the patients had y e t  
received  cy to sta tics . The second sam ple was taken after 4 w eeks o f combined chloram bucil- 
predniso lon e treatm ent, w ith  the exception  of 3 p atien ts w ho had been on com bined COP- 
schem e, and  were also checked during, as also after trea tm en t. B2M G was measured according  
to  th e  recom m endations o f E vrin  and  W ibell [9], using th e  P hadebas Beta-2-m icro T est (nor­
m al ra n ge , 1 .1— 2.4 mg/1). D iagnostic  criteria: absolute lym p h ocytosis in  peripheral b lood and  
lym p h oid  cell infiltration of the bone-m arrow.
Clinical staging was based on  th e  criteria proposed b y  R ai et al. [7]. According to  th is  
c lassifica tion , 11 patients were in  stage  II I , 14 in stage IV . Por the assessment o f organ in ­
filtra tio n  th e  Ellegaard-score system  w as applied before and after treatm ent [8] .
T h e  essentials o f the score sy stem  are seen in  T able I. E ach  patient scored a num ber  
according to  the infiltration o f  bone-m arrow , involvem ent o f  lym ph-nodes and size o f liver and  
sp leen , eva lu ation  was com pleted b y  linear regression analysis, using a H ew lett— Packard  
calculator.
T he response of the abso lu te  lym phocyte count and o f  the serum B2MG level to  chlor 
am bucil-prednisolone treatm ent and  to  the COP com bined cy to sta tic  scheme were exam ined-
ТаЫе I
The Ellegaard-score system
0 1 2 3
Bone-m arrow <  10% 10— 33% 3 3 - 6 7 % >  67%
lym phocytes lym phocytes lym phocytes lym phocytes
L ym ph-nodes not palpable one in  a single 
region
occasional lym ph-nodes multiregional large 
in different regions lymph-node m asses
L iver-Spleen not palpable <  5 cm  below costal 5— 10 cm  below  costal 
arch arch
> 1 0  cm below costal 
arch
Table II
Effect o f  chlorambucil-prednisolon treatment
Before treatm ent After treatm ent
Se B2M G , mg/1 4 .924+0.42 2.48 +  0.685 p >  0.05
A b solu te  lym phocyte count: G/L 30.3+ 2 .76 12.86 +  2.88 p >  0.05
Score Ó.8 +  2.6 3.8 +  0.8 p >  0.001
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Results
In  all but 2 of the patients the serum  B2M G level was increased and di­
rectly  related to  the absoluta lym p h ocyte cou n t (Fig. 1). A t 4 w eeks o f  treat­
m en t the correlation was less close than  at th e  beginning (F ig. 2). The response 
of th e  serum  B2MG level to  chloram bucil-prednisolone treatm ent the absolute
s
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ly m p h o cy te  count and o f the score is represented in  F ig. 3. The correlation  
betw een  serum  B2MG and score, as well as betw een  absolute lym p h ocyte  
count and  score, before and after treatm ent, is show n in  Figs 4— 7.
In  th e  three patients w ho had been on the com bined cytosta tic  COP- 
schem e th e  rosponse o f  the absolute lym phocyte count and o f the B2M G levels  
was s ig n ifica n t (Fig. 8).
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Fig. 7
D iscussion
The serum B2MG level is increased in  various malignant processes includ­
ing m yelom a and lym phom a, but high leve ls  h ave been reported in  in fectious  
m ononucleosis and in  carcinom a. Our p atien ts follow ed up and checked  repeat­
edly revealed high B2MG levels.
W e sought to id en tify  the factor responsib le for the increased B2MG  
level. In  the untreated  cases its value w as chlosely related to  th e  absolute  
lym p h ocyte count. On the other hand, therew as no positive correlation  bet- 
tw een the score reflecting organ in filtration  and the B2MG level. I t  seem s, 
therefore, ju stified  to  incrim inate the circu lating lym phocytes for th e  increased  
B2MG m etabolism . I t  was in  the first p lace th e  score indicative o f  organ in ­
filtration  w hich show ed a significant decrease in response to chloram bucil- 
prednisolone treatm ent, while the decline o f  th e  absolute lym p h ocyte  count 
and o f the serum B2MG level was not sign ifican t. In  the patients w ho had been  
on com bined cy tosta tic  COP-scheme, the serum  B2MG level also show ed a 
sign ificant fall, together w ith  the absolute ly m p h o cy te  count.
I t  has been concluded that in chronic lym p h ocytic  leukaem ia th e  serum  
B2MG level is closely related to the num ber o f  circulating lym p h ocytes. Mea­
surem ent o f serum  B2MG provides a useful gu ide for the assessm ent o f  therapy, 
but th e  absolute lym phocyte count is o f th e  sam e inform ative value.
The effect o f  chloram bucil-prednisolone treatm ent in the d van ced  stages  
o f  chronic lym p h ocytic  leukaem ia falls short o f  the desired therapeutic result. 
On the other hand, the parameters under s tu d y  showed a sign ifican t decline 
under the effect o f the com bined CO P-schem e. T his seems to give ju stifica tio n  
for th is form o f treatm ent in stages I I I — IV  o f  chronic lym phocytic leukaem ia.
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ZINK LEAD-INTERACTION IN THE RABBIT
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Subacute lead poisoning was performed in  a group o f rabbits b y  dissolving lead 
acetate (5 g/1) in  th e  drinking distilled water. A nother group o f rabbits w as left to  drink 
the same lead acetate solution  containing 0.435 g/1 acetate to  stu dy  the effects o f zinc 
on lead poisoning. A  third group drinking 0.435 g/1 zinc acetate so lution  alone was 
studied for com parison. In take of zinc caused a relative decrease o f blood , urine and 
faecal lead, significant activation  of the lead-inhibited erythrocyte delta-am inolaevulinic  
acid dehydratase (A L A D ) a ctiv ity  and a relative decrease of urinary delta-am inolaevu­
linic acid (ALA ) level. The analysis o f  several tissues for lead indicated th a t zinc caused 
biotransform ation o f lead from  blood to som e other tissues, leading to  excess storage in 
bone, kidney and liver and less exten t in the lung, brain and m uscle.
Keyword*! Zink lead-interaction, rabbit
Abbreviations : A LA  =  delta-am inolaevulinic acid A L A D  =  delta-am inolaevulinic acid 
dehydratase
Introduction
As a common contam inant of our environm ent, lead causes several ab­
norm alities in liv ing organism s o f these, a w idely  studied subject is tbe inhibi­
tion  o f heme syn th esis, resulting in anaem ia o f  the m icrocytic hypochrom ic  
ty p e . This anaem ia suggested  an alteration in  the nutritional and biochem ical 
roles o f  some essential m icronutrients especially  zinc and copper [24].
Lead poisoning in  hum ans and anim als is characterized b y  increased  
urinary excretion o f delta-am inolaevulinic acid (ALA) [6, 21] preceded by  
inhibition  of delta-am inolaevulinic acid dehydratase (A L A D ), E rythrocyte- 
A L A D  was fouud to  be inh ib ited  by lead in  hum an subjects [4, 11] and in  expe­
rim ental animals [5 ,1 0 ] . A lthough thiol com pounds can activate  th e  lead-inhi- 
ited  ALAD [17], various m etal ions especially  zinc [22] also activa te  the in-
* Perm anent address: D epartm ent of Chem istry, F acu lty  o f Science, M ansoura Univer­
sity , Mansoura, E gypt.
** Previous address: K ing Fahd Medical Research Centre, King A bdulA ziz U niversity, 
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h ib ite d  enzym e. Furtherm ore, zinc has been show n to  he involved in  the  
sy n th e s is  o f  ALAD [13].
Cerklewski and Forbes [5] found  that increasing dietary zinc decreased the  
se v e r ity  o f  lead toxicity  in  y o u n g  male rats. These and another authors [9] 
c la im ed  th a t these effects o f  z in c  were due to its  prevention  o f lead absorption  
at th e  in testin a l level. A lso, parenterally  adm inistered zinc in anim als provided  
p ro tec tio n  against the b io logica l effects of acute lead  poisoning [16].
T h e  activ ity  of eryth rocyte and liver A LA D  in you n g  rats was found to  be 
re la ted  d irectly  to the am ount o f  dietary zinc [2]. Furtherm ore, zinc at low  con­
cen tra tio n  activated the lead -in h ib ited  erythrocyte A L A D  of rats hut its  nor­
m al a c t iv ity  was not restored [14]. I t  could be restored to  norm al b y  zinc i n  
v i t r o  b u t  a t high zinc levels th e  enzym e was inh ib ited  [14]. In  healthy hum an  
su b jec ts , oral intake o f zinc resu lted  in an increase o f  erythrocyte A LA D  activ ­
ity  [1 ] .
T h e  excessive urinary excretion  of ALA accom panying lead poisoning in  
lea d -ex p o sed  workers was a lso  decrased by excess in take o f  zinc [8]. Túis 
d ecrease o f  urinary A LA  w as observed also in rats receiving lead and zinc 
h u t i t  w as claimed that blood lead  levels were n ot reduced [21].
I t  is apparent that th e  e ffec t o f  lead in tox ication  on the blood zinc level 
is n o t  clear. W e have therefore studied  the m utual effects o f zinc and lead in  
th e  ra b b it. The suggestion th a t  zinc m ight decrease th e  in testinal absorption  
of le a d  [5, 9] was also checked.
M aterials and methods
T hree groups of Swiss albino rabb its, 7 animals each w ith  bod y w eight abouts 5 kg/rabbit, 
w ere le f t  to  drink solutions o f 5 g/1 lead acetate (group I), 5 g lead acetate -f- 0.435 g zinc 
acetate/1  (group II) and 0.435 g/1 z in c aceta te  (group III) respectively , ad libitum  for a period of 
6 w eek s. B efore starting the experim en t all animals were to  drink distilled water for tw o weeks 
after  w h ic h  blood, urine and faecal sam ples were analysed for the specified param eters and the  
resu lts w ere considered base-line v a lu es. Thereafter, poisoning w as started blood, urine and 
faeca l sam p les were collected w eek ly  for 6 weeks. It was preferable to  give zinc in the drinking 
w ater s in ce  all previous investigators added zinc to the diet. Furtherm ore, the am ount o f zinc 
used in  th e  present study was far b e lo w  th e  concentrations causing intoxication  [17].
H eparinized blood sam ples w ere collected from the m arginal ear vein  by venipuncture  
usin g  d isp osab le  polypropylene syringes. Parts of the sam ples were directly assayed for ALA D  
a c tiv ity  [25] and the remainder w as prepared for lead and zinc estim ation 24-hour usine sam ples 
were co llected  and kept w ithout an y  added preservative in dark brown bottles in a refrigerator. 
24-hour faeca l samples were co llected  and prevented from contact w ith  urine by uring a sta in­
less s te e l nettin g  put on the sta in less steel cage floor ending in a polyethylene tube connected  
to th e  brow n  bottle in the refrigerator. Probable contam ination o f urine and faeces by lead or 
zinc, or b o th  from the drinking so lu tion  w as prevented by a special device.
B lo o d , urine and faeces were d igested  with concentrated H N 0 3 “ Analar”  as described  
p rev io u sly  [11]. After the 6th  w eek , th e  rabbits of all groups, in addition to  6 control rabbits, 
were k illed  and bones (tibia) as w ell as livers, kidneys, lungs, brains, hearts and the m uscles 
were w orked  up. Dried bone pow der w as prepared by the m ethod o f W ittm ers et al. [26] and 
the o th er  tissues were hom ogenized in bisdistilled water, and then digested w ith concentrated  
H N 0 3. B o n e  powders and tissues d ig ests  were dissolved in 0.8 M H N 0 3 for the estim ation of 
lead . B lo o d , urine and faeces lead and  zinc as well as bone and other tissues lead were estim ated
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Table I
Average concentrations (  +  S .D .) o f  lead in blood, urine and faeces o f  rabbits drinking solutions o f  5 gjl lead acetate (group I )  ; 5 g  lead acetate j 0.435 g  
zinc acetate/l (group I I )  and 0.435 gjl Zn (group I I I ) ,  during six weeks. The number o f  rabbits was 7 in each group except when otherwise staled
" D uration 
Test Base line + 1st Week 2nd Week 3rd Week 4th  Week 5th Week 6th  Week
Blood lead
(jUg/100 ml)
Group I 15 +  2.0 37 +  2.8 7 8 + 3 .5
(n =  6)
118 +  8.3 
(n =  6)
147 +  10.2 
(n =  6)
136 +  9.8 
(n =  6)
146 +  11.6 
(n =  6)
Group II 13 +  1.5 22 +  2.0 37 +  4.1 52 +  3.9 6 9 + 5 .2 84 +  6.6 102 +  7.4
Group III 1 4 + 3 .3 12 +  1.1* 9 +  0.6 7 +  1.0 5 +  0.3 4 +  0.5 2 +  0.1
Urine lead 
(m g/g creatinine)
Group I 1.52 +  0.34 2 .19+0.38** 2.30 +  0.61** 2.44 +  0.50 
(n =  6)
2.74 +  0.48 
(n =  5)
2.92 +  0.32 
(n =  5)
3.21 +  0.36 
(n =  5)
Group II 1.39 +  0.17 1.55 +  0.19* 2.10 +  0.17 2.19 +  0.15 2 .3 4 + 0 .0 9 2.48 +  0.17 2.86 +  0.14
Group III 1.44 +  0.41 1.39 +  0.36* 1.25 +  0.22* 1.08 +  0.25* 0.97 +  0.15* 0.98 +  0.17* 0.81 +  0.19
Faecal lead
G“g/g)
Group I 22 +  1.2 42 +  1.8 56 +  2.9 63 +  3.8 
(n =  6)
78 +  2.9 
(n =  5)
93 +  2.5 
(n =  5)
109+ 6.3  
(n =  5)
Group II 21 +  1.6 27 +  2.3 33 +  2.4 47 +  3.3 57 +  3.2 74 +  4.0 93 +  5.1
Group III 23 +  2.0 21 +  1.5* 16 +  0.9 11 +  0.7 8 +  1.1 5 +  1.3 2.1 +  0.5
+ Values after rabbits were kept drinking distilled water for 2 weeks before starting the experiment.
* N ot significant (P  >  0.05), * * significant (P  <  0.05) and all other values in the Table are highly significant statistically (P  <  0.001) 
as compared to the corresponding base line values.
£
Z
IN
K
 L
E
A
D
-IN
T
E
R
A
C
T
IO
N
 IN
 T
H
E
 R
A
B
B
IT
202 EL-W ASEEF, A., HASHIM, M. M.
q u a n tita t iv e ly  by a (Perkin E lm er) F lam e Atom ic A bsorption Spectrometer m odel 5000. 
U rinary  A L A  [23] and creatinine (2 0 ) were also estim ated. The results were analysed s ta t is t i­
ca lly  b y  standard methods [19].
Results
In  rabbits of groups I and  II , blood lead levels  were increased in th e  1st 
w eek  an d  continued increasing up to the 4th  w eek and remained con stan t  
th erea fter  but the values in  group II were alw ays less then  the corresponding  
v a lu es  o f  group I (Table I). T h e blood lead level low ering effect o f zinc w as  
m a n ifest in  rabbits drinking z in c  acetate solution  (group III) where the b lood  
lead  le v e l  in  the 6th w eek am ou n ted  to about one seven th  the base-line va lue. 
In  b o th  groups urinary and fa eca l lead levels were also increased but the va lu es  
in  group I I  were always low er th an  the corresponding values o f group I. T hese  
resu lts  in d ica te  a storage o f  lea d  in  some body tissues caused by zinc and excess  
storage w as found in b on es, k id n eys and livers and less in  the lungs, brains, 
and m u scles (Table II).
Table II
Concentrations o f lead (ßgjg) (m ean  ±  S .D .)  in tissues o f  rabbits drinking distilled water (control), 
5 g ß  lead  acetate (group I ) ,  5 g lead acetate +  0.435 g zinc acetateß (group I I )  and 0.435 g ß  zinc  
acetate (grou p  I I I )  after the 6th week o f  the experiment. Each group includes 6 rabbits
G roup Control
Tissue
Group I G roup I I Group I I I
Bone 59.6 + 5 .3 5 159.0 ±24 .59* 252.9 ± 4 5 .4 0 * 90.0 ± 1 1 .4 0 *
Liver 0.92 +  0.44 10.4 ±3 .28* 21.0 ± 8 .7 5 * 1.2 ± 0 .2 2 r!-s-
K id ney 0.90 +  0.29 61.7 ±19.19* 87.7 ± 1 7 .2 6 * 0.90 ± 0 .2 3 n s -
Lung 1 .33+0.12 4.5 ±0 .91* 6.4 ± 2 .2 8 * 3.4 ± 1 .3 0 *
Brain 0.27 +  0.05 1.3 ± 0 .40* 1.6 ± 0 .2 2 * 0.28 ± 0 .0 6 n s -
H eart 0.21 +  0.09 0 .1 7 ± 0 .0 2 n s- 0 .5 2 ± 0 .4 2 n s - 0 .2 2 ± 0 .1 1 л 4-
Muscle 0 .05+0.03 0 .0 7 ± 0 .0 4 n s- 0.48 +  0.22** 0.13 +  0.06**
* H igh ly  significant (P  <  0.001). 
** Significant (P <  0.01). 
n-s- N o t  significant (P  >  0.01).
B lo o d  zinc levels were e lev a ted  in groups II  and I I I  during the period  
o f s tu d y  and the values in  group III  were higher th an  their corresponding  
va lu es in  group II. In group I (no zinc intake) b lood  zinc concentration w as 
sig n ifica n tly  (P <  0.01) increased  in  the 2nd and 3rd w eeks (Table III). U rinary  
zinc w a s increased in groups I I  and III  but faecal zinc was elevated on ly  in  
group I I I .  In  group I, how ever, urinary zinc w as higher significantly (P  <  
<C 0 .001) decreased during th e  6 week period while faecal zinc was decreased  
on ly  a fter  the 3rd week (T able III ) .
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Blood A LA D  activ ity  was sign ifican tly  inhibited in group I in  the 2nd  
week and thereafter (Table IV). Intake o f  zinc w ith lead (group II)  decreased  
th e  inhibitory effect o f  lead on ALAD to  a great extent. Intake o f  zinc alone 
(group III) gradually activated  the norm al blood ALAD (Table IV ).
Urinary ALA, known to be increased in  lead poisoning w as sign ifican tly  
decreased by zinc in take. Furtherm ore, zinc intake alone (group I I I )  reduced  
the normal excretion o f ALA to  a m inim um  (F ig. 1).
Fig. 1. Urinary ALA in rabbits drinking zinc acetate or lead aceta te
D iscussion
The present results have confirm ed those of previous authors [1, 5, 9] 
who found in other anim al species th at oral zinc intake alleviated  m an y  toxic  
effects o f  lead. This was evident from th e  decrease of blood lead  concentra­
tion , relative activation  of lead-inhibited  erythrocyte ALAD and a relative  
decrease o f urinary ALA. It m ust be m entioned  that although the sam e anion 
(acetate) was used for lead and zinc in th e  present work due to  th e  h igh solu­
b ility  o f these salts in water and in order to  prevent any precip itation  o f either 
m etals, previous authors [7] found th a t th e  antagonistic effects o f  zinc are 
solely  due to zinc itse lf  and not to  the anion.
The decrease in  blood lead level due to  zinc intake is caused b y  b iotrans­
form ation o f lead from blood to  otúer tissu es, especially to  the b on e, kidney  
and liver, and was not due to a prevention o f  lead absorption from  th e in testin e  
as thought previously [5, 9]. I f  zinc prevented  the in testinal absorption of 
lead then  faecal lead would be raised. A ctu a lly , the faecal lead lev e l w as highly  
sign ificantly  (P  <  0.001) elevated  in groups I and II during the 6 w eek  period 
(Table I) but the level in  group I I  (zinc in tak e) was always lower than  in  group I. 
In  other words, zinc m ay accelerate in testin a l lead absorption b u t at th e  same
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Table III
Average ( +  S.D.J concentrations o f zinc in blood, urine and faeces o f  rabbits drinking solutions o f 5 g/l lead acetate (group I )  ; 5 g  lead acetate +  0.435 g  
zinc acetateß (group I I )  and 0.435 g ß  zinc acetate (group I I I )  during six  weeks. The number o f  rabbits is 7 in  each group except when otherwise staled
D uration
Test Base line + 1st Week 2nd Week 3rd Week 4 th  Week 5 th  Week 6th  Week
Blood zinc 
fog/100 ml)
Group I 5 0 + 6 .1 6 0 + 7 .8 * 6 8 + 7 .0 7 8 + 4 .9  
(n = 6 )
74 +  9.8 
(n =  5)
76 +  8.7 
(n =  5)
72 +  5.3 
(n =  5)
Group II 4 7 + 5 .8 68 +  9.0 74 +  4.9 8 0 + 6 .6 83 +  7.0 8 4 + 5 .8 88 +  7.1
Group III 5 3 + 5 .0 7 5 + 4 .9 79 +  7.0 83 +  5.9 9 0 + 6 .0 9 6 + 6 .9 10 6 + 9 .9
Urine zinc 
(m g/g creatinine)
Group I 1.23 +  0.25 0 .7 2 + 0 .1 5 0 .3 6 + 0 .0 4 0 .2 4 + 0 .0 3  
(n =  6)
0 .1 3 + 0 .0 2  
(n =  5)
0 .06+ 0 .02  
(n =  5)
0 .04+ 0 .01  
(n =  5)
Group II 0.97 +  0.17 0 .90+ 0.12* 0.82 +  0.14* 0 .6 2 + 0 .1 2 0 .4 4 + 0 .0 7 0.35 +  0.03 0 .28+ 0 .08
Group III 0.85 +  0.26 1.36 +  0.45**- 2.88 +  0.84 5 .5 6 + 1 .4 4 11.33 +  2.08 2 1 .73+ 4 .05 53 .35+ 7.98
Feces zinc
M e )
Group I 2 .3 6 + 0 .6 4 2 .17+ 0 .60* 1.98 +  0.58* 1.53 +  0.61* 
(n =  6)
1.29+0.65**  
(n =  5)
1.15 +  0.61 
(n =  5)
0.91 +  0.49 
(n =  5)
Group II 2.45 +  0.55 2.36 +  0.52* 2.26 +  0.49* 2 .14+ 0 .45* 2 .05+ 0 .42* 1 .93+0.40* 1 .84+0.38*
Group III 2.25 +  0.68 3.88 +  0.89 6 .0 3 + 1 .0 7 7 .80+ 0 .91 9 .2 9 + 0 .4 7 10 .44+ 0 .99 12 .37+1.17
S
f t
+ У alues after rabbits were kept drinking distilled water for 2 weeks before starting the experiment.
■+ N ot significant (P  >  0.05), ** significant (P  <  0.05) and all other values in the Table are highly significant statistically (P  <  0.001) 
as compared to the corresponding base line values.
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tim e accelerates its  storage in som e tissues and accordingly decreases the blood 
lead concentration, w hich was actually  the case. This was further confirmed by  
the finding that in  rabbits o f  group III  (intake o f zinc alone) the faecal lead 
level decreased gradually reaching about one ten th  its baseline value at the  
end o f the 6th w eek w ithout any significant elevation  o f blood or urinary lead 
levels. N ot only th is  but also the blood lead level was m arkedly decreased in 
th is  group. This m eans that the norm ally absorbed lead w as directed to other 
b od y  tissues b y  th e  zinc intake.
Blood, urinary and faecal zinc levels were increased in  rabbits o f group III  
(Table III) and th e  blood zinc level was elevated  also in group I I . Surprisingly 
the blood zinc level w as further elevated  in rabbits o f group I (lead intake only) 
w ith  a concom itant decrease of the urinary and faecal zinc levels , a finding  
not reported before. Zinc absorption and transfer to  túe vascular system  are 
related to the synthesis o f m etallothionine (in the en terocytes), the synthesis 
o f which is proportional to  the dietary in take o f zinc [18]. M etallothionine is 
know n to bind d iva len t m etals such as copper, cadm ium  and possibly lead  
[1] and, accordingly, excessive lead absorption w ill interfere w ith  the formation  
o f th e  zinc-m etallotúionine com plex. This m ay explain the observed elevation  
o f th e  blood zinc le v e l in lead-poisoned rabbits. I t  is believed th a t the elevated  
blood  zinc level is associated with increased erythrocyte protoporphyrin which 
has lon g  been know n to  accom pany lead poisoning [11]. This is consistent with
Table IV
Average ( f S . D . )  activities o f  blood 6-aminolaevulinic acid dehydratase (u n its* ) o f  rabbits drinking 
solutions of 5 g /l lead acetate (group I ) ,  5 g  lead acetate 0.435 g zinc acetate/l (group I I )  and 
0.435 g/l zinc acetate (group I I I )  during six  weeks. The number o f  rabbits is  7 in  each group except
when otherwise slated
D uration Group I Group I I G roup I I I
Base lin e++ 41.9 +  12.78 39.9 +  15.01 39.5 + 11.15
1st W eek 40.0+11 .19* 37.1 +  14.18* 52.2 + 5.62**
2nd W eek 3 2 .1 +  7.60** 34.2 +  13.00* 61.7 + 4.36
3rd W eek 2 1 .6 +  8.90 
(n =  6)
32.0 +  12.41* 74.5 + 6.72
4th Week 9 .8 +  3.32 
(n =  5)
30.1 +  10.14 82.5 + 6.60
5th W eek 7 .5 +  3.15 
(n =  5)
2 4 .6 +  6.40** 9 0 .8 + 7.35
6th W eek 5 .1 +  3.09 1 8 .7 +  5.07 100.3 + 9.64
+ One ALAD un it is the am ount of enzym e necessary to convert 1 jumol/ml/minute of 
O-aminolaevulinic acid to porphobilinogen per m l of red blood cells.
++ Values after rabbits were kept drinking distilled water for 2 weeks before starting the 
experiment.
* Not significant (P  >  0.05), ** significant (P  <  0.05) and all other values in the table are 
highly significant (P  <  0.001) as compared to the corresponding base line values.
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the recen t finding that more th a n  h a lf of the protoporphyrin accum ulated in  
ery th ro cy tes  o f lead-poisoned hum ans and animals is present in  the form  o f  
zinc-protoporpúyrin com plex [3, 15].
A c tiv a tio n  of lead-inhib ited  A L A D  by zinc is qu ite clear from  the difference 
betw een  it s  values in groups I  and  I I  (Table IV). In  zinc-treated  rabbits (group  
III) A L A D  activ ity  was more th a n  tw ice it base-line va lue. This m echanism  is 
rather obscure. However, as th e  enzym e is zinc-dependent and carries a large  
num ber o f  SH  groups [17], zinc can  com pete w ith lead  for the enzym e leading  
to its  a c tiv a tio n . The rapid increase in  the activ ity  o f  th e  enzym e from  erythro­
cytes in cu b a ted  with zinc i n  v i t r o  [12] suggest an activa tion  o f the ex isting  
enzym e rather than de novo syn th esis .
Z inc intake caused a decrease o f the elevated  urinary A LA  in  lead- 
poisoned  rabbits (Fig. 1). A lso in  rabbits drinking zinc aceta te  alone, urinary  
ALA  grad u a lly  decreased in d ica tin g  th at this effect m ust be secondary to  the  
a c tiv a tio n  b y  zinc of A LA D . H ow ever, none of the rabbits drinking lead  +  
-f- zinc a ce ta te  solution (i.e. h igh  blood lead levels) was having a norm al uri­
nary A L A  level. In other w ords, w hen the blood lead level is high, even  during 
zinc in ta k e , the urinary ALA le v e l is still high. This is not consistent w ith  results 
of T h a w ley  [21] who reported norm al urinary ALA in  som e lead-poisoned rats 
after o ra lly  administering excess zinc, and this p lacing considerable doubt on  
the v a lid ity  o f the urinary A L A  screening test for determ ining lead exposure. 
I t  seem s th a t the difference b etw een  the present results o f  T haw ley [21] lies 
in th e  w a y  o f expressing ALA  va lu es in urine. T haw ley expressed his results as 
w eight A LA /24-hour urine vo lu m e while in the present stu d y  ALA was ex ­
pressed in  m gig creatinine. In exam in ing  the m echanism  o f decreasing urinary  
A LA  b y  zinc, the finding th a t in h ib ition  by lead o f  rabbit red cell A LA D  is 
an tagon ized  by zinc [16] leads one to  hypothesize th a t a lead-zinc in teraction  
m ay occu r in  developing red cells as w ell as on residual A LA D  present in  m ature 
red ce lls .
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E. S. V i z i , K .  M a g y a r  (E ds): Regulation o f  T ransm itter Function: B asic and C lin ica l Aspects.
Price: H ung. F t. 690.—
Proceedings of the F ifth  M eeting of European Society  for Neurochem istry, held  in  B udapest, 
H ungary, 21— 26 A ugust 1984. Joint edition published by Akadémiai K iad ó , B u d ap est and 
E lsevier Science Publishers, A m sterdam  1984. X V  +  571 pages, w ith  111 figures and
58 tables. Price: . . .
The hook contains 92 papers by 248 participants from 20 countries. T he top ics o f the  
proceedings are arranged in  th irteen sections: 1. m echanism s of neurotransm itter release, 
2. transm itter receptors: m olecular m echanism s and functional im plications (E S N -E N A  joint 
sym posium ), 3. new developm ents in dem yelination  and m ultiple sclerosis, 4 . m etab olism  of 
neuropeptides, 5. Alzheim er’s disease, 6. transm itters and neuroendocrine reg u la tio n , 7. trans­
m itter im m unocytochem istry, 9. gangliosides and neuronal plasticity, 10. benzod iazep in e  and 
G ABA receptors, 11. cell surface m olecules and cell interaction, 12. neurochem istry  o f  cholin­
ergic neurons, and 13. m onoam ines in  invertebrates.
T he proceedings are a very im portant source o f up-to-date inform ation o n  th e  current 
state  o f neurochem ical research and its relevance to  neurological and p sy ch ia tr ic  disorders. 
The book contains more than  one thousand full references published since 1978. T he volum e  
concludes w ith an author index  and a subject ind ex .
The proceedings are h igh ly recom m ended to  pharmacologists, b io ch em ists , physi­
ologists, neurologists, psychiatrics and gerontologists who are interested in  th e  recen t develop­
m ents o f the regulation o f transm itter function.
F .  V a r g a
The H um an Environment —  Past, Present and Future. Eisenbud, M. N C R P , B eth esd a , MD
1983. 44 pages, 6 figures, 6 photos
This useful publication o f the N ational Council on Radiation P ro tectio n  deserves 
a favourable reception. Its author has m anaged to  give a comprehensive, y e t  concise view  
o f th is w idely  involved subject, w ith  a keen eye for th e  essentials, but w ith  due consideration  
to  th e  necessary details. In  th e  introduction he enlarges on the m axim  “The P a st is Prologue” 
and approaches the problem s o f the interrelations between man and environ m en t in  this 
spirit. H e m ight have taken a retrospective look  far into the preindustrialized era, b u t this 
would have been outside the purpose of the book , since the tremendous up sw in g  o f science 
and technique affecting our environm ent dates back not more than two centuries.
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T he m ost current issues o f  th e  subject are dealt w ith  under seven headings. F irst th e  
role o f  grow th acceleration and its  involvem ent in th e  changing environm ent are discussed, 
a d efin itio n  of environm ent being  g iven . After the n ex t part entitled  Hierarchy of E nviron­
m en t, various questions of environm ental pollution receive m o st interesting coverage. T his  
chapter reveals some rem arkable fa c ts . For instance, according to  a WHO report issued in  
1964, environm ental factors are som ehow  involved in  a proportion  as high as 60 to  90%  o f  
th e  to ta lity  o f cancer cases. A  further fact of adverse sign ifican ce is the gradual increase in  
C 0 2 in  th e  atmosphere. T he problem s of the world’s burgeoning population and of the need  
for en ergy  are discussed in  all th e ir  aspects. In the chapter “ W hat is our E nvironm ental 
F u tu re? ” th e  author faces th e  essen tia l problems o f th e  fu tu re  w ith  remarkable luc id ity , 
keep in g  his predictions w ith in  th e  realities.
T he book closes w ith  a lis t  o f  th e  essential references.
L .  C s e i .k ó
N ew  A pproaches to Health E ducation  in  Prim ary Health Care. T echnical Report Series N o. 690.
WHO, G eneva 1983. 44 pages, 1 figure. P rice: Sw. Fr. 4.—
T is publication contains th e  subject matter o f a m eetin g  held by the WHO E xpert 
C om m ittee  on the above su bject in  Geneva from 12 to  18 O ctober, 1982.
P art I, by w ay of in tro d u ctio n , quotes the d eclaration  o f the Conference organized  
b y  U N IC E F  and WHO in A lm a -A ta , USSR, 1978, th a t “ peop le  h ave the right and d u ty  to  
p a rtic ip a te  individually and c o llec tiv e ly  in the planning and im plem entation of their hea lth  
care and  th a t “ education concerning prevailing health problem s and th e  methods of prevent­
ing  and  controlling them ” belonged  to  the essential a c tiv it ie s  o f  primary health care. P arts  
2 and 3 outline the issues and p o in t ou t the concepts in  th e  spirit o f the Alma-Ata D eclara­
tio n , stressing the im portance o f  education. Part 4 g ives th e  characteristics o f the new  a p ­
proaches to  health education in  prim ary health care under th e  following headings: People- 
orien ted  health technology; L ay  resources in health care; N ew  approaches concerned w ith  
hu m an  ecology; New role for h ea lth  care providers. T his ch apter is concise but none th e  less 
w ell-su ited  for practical im plem entation . Part 5 points to  im plications for health education  
p ra ctice , giving close guidelines on  planning and m anagem ent, ethical issues, inform ation and  
com m u nication , training, ev a lu a tio n  and lines of research. T he book closes w ith Part 6 , in  
w h ich  an excellent sum m ary on  th e  objectives and fu tu re ta sk s  is found.
L. Cselkó
Research fo r  the Reorientation o f  N ational Health System s. T echnical Report Series N o. 694.
W H O , G eneva 1983. 71 pages. Price: Sw . Fr. 7 .—
T he subject-m atter o f  th e  m eetin g  of a WHO stu d y  group held in Geneva from  27 S ep ­
tem b er to  1 October, 1983, is su m m ed  up in this booklet.
P art 1 introduces th e  n atu re  o f  health system  research (H S R ), its subjects and m ethods. 
P a rt 2 discusses the subjects o f  H S R  in  depth, giving special coverage to the aspects o f soc iety , 
h ea lth  needs, production and d istr ibu tion  of resources, organizational structures o f health  sy s­
te m s, m anagem ent, com m unity  participation. Part 3 deals w ith  th e  performance of H SR , poses 
q u estion s for research, considers, th e  infrastructure o f organization  and the im plem entation  
o f  research findings. Part 4 o u tlin es the role of W HO, w hich  is  to  direct, to support H SR  and  
to  correlate the activities o f  th e  m em ber states. Part 5 su m s up th e  conclusions and recom ­
m endations in three groups (T he va lu e  of health system  research; Subjects for health sy stem
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research; Performance of health  system  research). The tasks are set out clearly, point by  
point. This part will be o f  particular practical use. In  the Sum m ary the essentials are briefly 
recapitulated.
L .  C s e l k ó
Evaluation o f Certain Food A dditives and Contaminants. Technical Report Series No. 696.
W H O , G eneva 1983. 47 pages. Price: Sw. Fr. 5 .—
The joint FAO /W H O  E xpert Committee on Food A dditives held its  27 th  m eeting in 
Geneva, 11— 20 April, 1983, on food additives and contam inants. The subject-m atter has 
now been published.
Part 1, the introduction, outlines the objectives o f  the m eeting. A fter general con­
siderations, Part 2 discusses various aspects o f the subject (toxicological evaluation , intoler­
ance to  food additives, alterations caused by polyols, e tc .) and gives a revision  o f  som e specif­
ications. Part 3 “ Com m ents on Specific Food A dditives and Contam inants” , provides detailed 
inform ation on additives (antioxidants, extraction solvents, flavouring agents, food colours, 
preservatives, sw eetening and thickening agents, e tc .) and on contam inants (m etals, xeno- 
biotics, anabolic agents). In  parts 4 —6 specifications are revised, future task s are outlined, 
recom m endations to  FAO and W HO are given. The publication closes w ith  three annexes: 
the first gives a survey o f earlier m eetings held on th is subject, the second lists th e  acceptable 
daily intakes, the third poin ts to  future lines o f toxicologic research.
L .  C s e l k ó
M ass Catering. C h a r l e s , R . H. G. Regional Publications, European Series N o. 15. W HO, 
Copenhagen 1983. 70 pages, 8 figures. Price: Sw. fr. 13.—
W ith the developm ent of industrialization, urbanization and tourism  th e  m ass catering 
system s have to m eet increasing dem ands in industrialized, as well as in develop ing, countries. 
This book gives an authoritative, y e t readable, survey on the current questions o f th e  subject.
The brief introductory notes are followed b y  Chapter 1, which deals w ith  various 
practical issues (bacterial and other contam inations, prem ises serving for catering purposes, 
raw m aterial supplies, m anpower, sanitary requirem ents, etc.) Chapter 2, General Methods 
o f Control, covers questions o f planning, licensing, m anagem ent, supervision , general and 
personal hygiene, water problem s, laboratory tests, epidem iological hazard analysis critical 
control point (HACCP). Chapter 3 is on new technologies (cook-freeze and cook-chill, slow 
cookers, m icrowave cooking, convenience foods, electronic therm om eters, anaerobic packing). 
Chapter 4 deals w ith train ing. Chapter 5 discusses th e  pertaining problem s o f  institutional 
and welfare catering, including hospitals, old people’s hom es and clubs, m eals-on-wheels. In 
Chapters 6— 8 catering in canteens o f factories and other com m ercial establishm ents, open- 
air catering (disasters, festiva ls , tourist hotels, holiday cam ps) are considered. Chapters 9— 10 
provide information o f particular interest on travel catering (aeroplanes, ships, other vehicles). 
Chapter 11 is on banqueting. The book closes w ith a sum m ary in Chapter 12.
L .  C s e l k ó
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P lan n in g  the Finances o f the H ealth Sector. M a c h , E. P ., A b e l - S m i t h , B. W H O, G eneva 1983.
124 pages w ith  1 figure and 21 tables. Price: Sw. Fr. 14.—
M any countries, particularly th e  developing ones, are seeking to  orientate their health  
services tow ards a more equitable and efficient utilization o f  resources. A  detailed analysis 
o f th e  fin a n c in g  of health services is an im portant step in  such an undertaking.
T h is  m anual sets out a m eth od o logy  for carrying out an analysis, suggesting w ays of 
co llecting  and  organizing data on expend iture and financial sources. I t  also suggests how  this 
in form ation  m ight be utilized in  p o licy  form ulation, to  m ake a m aster plan for the future use 
o f all f in a n c ia l and material resources. Particular attention  is paid to  prim ary health  care in 
view  o f  i t s  h igh  priority in  current hea lth  policies. A  series o f  tables presents m odels that 
provide a n  analytical framework for national planning, and sum m arizing tables have been 
devised  for  th e  use of policym akers.
T h e  m anual is aimed at p lanners, econom ists, statistic ians, accountants and researchers 
in th e  h e a lth  and health-related sectors in  developing countries, and at th e  sta ff o f  inter­
nationa l an d  bilateral agencies concerned w ith  developm ent aid.
B y  th is  manual comprizing 8 chapters, a list o f 30 references and 2 annexes, the author 
has p ro v id ed  workers o f developing countries w ith an excellent guide, m ore o f practical than  
o f th e o r etica l orientation.
L. C s e l k ó
P rim a ry  H ealth Care —- The Chinese Experience. W HO, G eneva 1983. 105 pages, 9 tables 
12 figures, 17 photos. Price: Sw. Fr. 14.—-
A n  Inter-regional Seminar on  Prim ary H ealth Care to o k  place in China, from  13 to  
26 J u n e  1982. Jointly organized and  financed by U N D P , N IC E F , the W orld B ank , and 
W H O , w ith  th e  support o f the M inistry o f  Public H ealth o f  th e  People’s R epublic, it  w as held  
at th e  W H O  Collaborative Centre for Prim ary H ealth Care in  Y exian  County, Shandong  
P rovince.
T h e  objectives of the sem inar were:
a )  to  explore some aspects o f  experience in primary health  care in  China, w ith  partic­
ular a tten tio n  to
—  th e  three-level network o f  th e  health  care system
—  th e  people’s involvem ent in , and m anagem ent of, hea lth  care
—  h ea lth  manpower developm ent
-— financing of health care,
b )  to  draw conclusions applicable to  the developm ent o f prim ary health care in  other 
countries.
T h e  book  comprizes 4 chapters and an appendix. Chapter 1 introduces th e  subject of 
th e  sem inar and provides detailed inform ation on China. Chapter 2 “ A n Introduction  to  
R ural H ea lth  Services in China’’, deals w ith  the health situation  in  th e  rural areas. This is the  
m ost in terestin g  part of th e  book , in  v iew  of the fact th a t m ore th an  80% of th e  Chinese 
p op u la tion  o f  more than a thousand m illions, live under rural conditions. The len gth  o f Chap­
ter 3, “ A sp ects  of Primary H ealth  Care in  China” is in  proportion to  the im portance o f its 
subject. T h e  following subdivisions are o f particular interest: The three-level netw ork o f the  
health  care system ; The people’s in v o lvem en t in and m anagem ent of, health  care; H ealth  
m anpow er developm ent; Financing rural health  care. Inform ation provided b y  these  sections 
brings th e  hea lth  situation prevailing in  China into due prom inence. Chapter 4, presenting  
th e  conclu sions of the seminar, opens w ith  the following general considerations:
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China has dem onstrated a trem endous political com m itm ent to th e  ta sk  o f changing 
th e  quality  o f life o f all its  people and especially  o f th e  rural population. H ea lth  goals have 
been given very high priority. This political com m itm ent permeates all leve ls o f  governm ent 
and all social and m ass organizations ensuring sustained popular support.
The reorganization o f the country’s econom ic and social structure, and in  particular 
the high level o f decentralization has perm itted  th e  integration of the hea lth  sector w ith all 
aspects o f econom ic and social developm ent and has facilitated the people’s involvem ent in 
th e  financing as well as th e  m anagem ent o f  hea lth  care.
Concerted action  in  m any sectors has contributed  to  raising the leve l o f  hea lth  of the 
people. Sufficient increase in  income and its equitab le distribution to perm it m inim ally ad­
equate shelter, cloth ing and, above all, essential food  a t affordable prices, th e  expansion of 
literary and m ass education  (particularly prim ary education), the provision o f  public services 
such as water supplies and transport, the policies and programmes related to  fa m ily  planning, 
etc., have all contributed to  this im provem ent o f  th e  health status.
Perhaps th e  m ost im portant factor in  th e  developm ent of the health  care system  has 
been th e  participation o f th e  people in th e  provision  o f health services, in  th e  m anagem ent 
o f the system , and in  m ass campaigns. The people have  contributed to  th e  in tegration  and 
better coordination o f health  programmes and to  intersectoral collaboration o f  health  pro­
gram m es and to intersectoral collaboration at all levels.
E very step in  developm ent of th e  Chinese hea lth  care system  in the p a st— starting with  
m ass m obilization for prevention, followed b y  th e  developm ent of cooperative hea lth  centres, 
th e  em ergence o f th e  “ barefoot doctor” , the com bined use of traditional Chinese m edicine and 
w estern m edicine, th e  developm ent of the com m une and brigade network w ith  its cooperative 
m edical insurance schem es and of the whole supp ortive  health care network at higher levels, 
etc ., is a concrete and liv ing  expression of w h at constitu tes appropriate tech n o logy . In this 
chapter som e further aspects o f primary hea lth  care possibilities and task s involved by 
participation  of the population, utilization o f financia l resources, developm ent o f  manpower, 
are also discussed. The A nnex contains num erical and other data, supported b y  m aps.
The book contains such an im m ense w ealth  o f  inform ation that any a ttem p t at con­
densing it into a review , even in the form o f  referring to  its bare essentials, w ould  be futile.
L . C.SET.KÓ
Effects o f  Nuclear W ar on Healths and H ealth Services. W HO, Geneva 1984. 178 pages, 37 
tables, 21 figures. Price: Sw. Fr. 20.—
T he 1981 W H O  A ssem bly adopted th e  resolu tion  that, in the spirit o f  th e  W H O  Con­
stitu tion  th a t the health  o f all peoples is fundam ental to  the attainm ent o f peace and security  
and in view  of the involvem ent of physicians and other health workers in  th e  task s connected  
w ith  th is goal, an International WHO C om m ittee o f  Experts m et on 14— 18 April 1982, 
2— 4 Novem ber 1982 and 10— 11 February 1983, in order to discuss the hea lth  problem s of 
nuclear war. This book presents a global report o f  th ese  m eetings. It opens w ith  th e  following 
conclusions em erging from  th e  reports and discussions:
1. “ C onventional” wars are continually becom ing more destructive. H ow ever, the 
introduction of nuclear weapons has added to ta lly  new  dimensions to warfare.
2. A single therm onuclear bomb can ha v e  an  explosive power of a m illion  tim es the  
largest conventional bom bs and the present stockp iles o f  nuclear weapons h a v e  an explosive  
power thousands o f tim es greater than all th e  exp losives detonated during th e  Second World 
W ar. In  addition to  th e  effects of blast and h eat, th e  radiation and nuclear fa llou t o f  a nuclear 
explosion can have devastating effects, both  im m ed iate  and long-term.
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3. T he Com m ittee has considered three possible scenarios:
1. T h e  detonation of a 1-m egaton  bom b over a large c ity  w ould kill more than 1.5 m il­
lion p eo p le  and  injure as m any.
2. “ L im ited ” nuclear war w ith  sm aller tactical nuclear w eapons totalling 20 m egatons, 
aim ed a t  m ilitary  targets in a re la tiv e ly  densely populated area, would exact a to ll o f  about  
9 m illion  dead  and seriously injured, o f  w hom  more th an  8 m illion  would he civilians.
3 . A n  all-ou t nuclear war usin g  at least half o f th e  estim ated  present stockpiles o f  
nuclear w ea p o n s (an approxim ate to ta l o f  10 000 m egatons) w ou ld  result in more than 1000 m il­
lion in jured  people.
4. I t  is  obvious that no h ea lth  service in any area o f th e  world would be capable o f  
dealing a d eq u a te ly  w ith the hundreds o f  thousands o f people seriously injured by b last, h ea t  
or ra d ia tion  from  even a single 1-m egaton  bomb. E ven , th e  d eath  and disability th a t could  
result from  an  accidental explosion o f  one bomb from  am ong th e  enormous stockpiles o f  
w eapons cou ld  overwhelm  national m edica l resources.
5. I t  is  d ifficult to  com prehend th e  catastrophic consequences and the human suffering  
th at w o u ld  resu lt from the effects o f  nuclear explosions in  th e  second and third scenarios 
th a t are considered . W hatever rem ained o f the medical services in  th e  world could not a llev iate  
the d isa ster  in  any significant w ay.
6. T o th e  im m ediate catastrophe m ust be added th e  long-term  effects on the environ­
m ent. F a m in e  and diseases would b e  widespread, and social and economic system s around  
the w orld  w ou ld  be totally  disrupted .
7. T herefore, the only approach to  the treatm ent o f th e  health  effects o f nuclear e x ­
plosions is  prim ary prevention o f su ch  explosions, th a t is, th e  prevention of atom ic war.
8. I t  is  not for the Com m ittee to  outline the political step s by which this threat can  
be rem oved  or the preventive theraphy to be im plem ented.
9. H ow ever, WHO can m ake im portant contributions to  th is  process by system atica lly  
distr ibu tin g  inform ation on the hea lth  consequences o f atom ic warfare and by continuing and  
expand ing  international cooperation in  th e  field  of health.
P a r t I contains introductory com m ents. Part II , “ P h ysica l Characteristics o f  N uclear  
E x p lo sio n s and their E ffects” g iv es insigh t into various asp ects o f  the subject, including  
p h en om en a occurring when nuclear w eapons are exploded, fo llow ed  b y  details, such as e ffects  
o f size o f  b om b s and height o f exp losion , electrom agnetic pu lse, effect o f nuclear detonation  
on h u m a n  beings (blast wave, therm al w ave, initial rad iation , local and global radioactive  
fa llou t, e ffec ts  o f radiation on th e  b o d y . In the same chapter three predicted scenarios o f  
a nuclear w ar are presented, viz.
Scenario  1. London was chosen as an example. In both  varieties a bomb of 1 Mt (m ega­
ton) w a s supposed  to detonate, the f ir s t  in  the altitude o f H irosh im a, i.e. at 580 m, th e  second  
in an a lt itu d e  o f  2500 m. The casualties for the two altitudes are largely identical, i.e. 1 800 000  
dead, 1 700 000 injured for low a ltitu d e , 1 600 000 dead, 1 600 000 injured for high altitude. 
In su m  25%  o f  th e  population w ou ld  be killed and another 25%  wounded.
Scenario  2. Local use o f nuclear weapons. Here m ilitary targets in Central Europe are 
assum ed to  be attacked w ith ta c tica l nuclear weapons o f 100— 200 k t (kiloton). In th is  case  
th e  e x p lo siv e  power of the tactical nuclear weapons would add up to  20 Mt which, according  
to  th e  ca lcu la tion s, would result in  9 m illion dead and th e  sam e number of severe injuries 
and a b o u t th e  sam e number o f less severe injuries.
Scenario  3, all-out nuclear ivar. In  th is case 10 000 M t nuclear bombs would be e x ­
ploded a ll over th e  world, 90%  in  E urope, Asia and N orth  A m erica, 10% in Africa, L atin  
A frica, L a tin  America and O ceania. The result o f such a war would be 1 150 000 
deaths an d  1 100 000 000 injuries. H a lf  o f th e  world’s entire population  would be im m ediate  
victim s.
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In Part III , on th e  m anagem ent o f casualties, the scope o f the problem  is outlined 
and guidelines on treatm ent are offered. For th is part, as well as for P art IV , on th e  short­
term  and long-term  effects o f nuclear war, supplem entary inform ation is provided in the 
A nnexes. Part VI, Conclusions, is followed b y  a glossary and a selected b ib liography.
This inform ation is condensed into th e  first 37 pages of th e  book . T he remaining, 
considerably larger, part is occupied by 9 annexes which contain a v a st b o d y  o f  h igh ly im­
portant factual inform ation on therm onuclear w eapons and nuclear war, inclu d ing  the short­
term  and long-term  effects o f therm onuclear w eapons on individuals and h ea lth  services, the 
effects o f medium- and long-range weapons, carcinogenic, teratogenic, gen etic  involvem ents, 
and the possibilities o f the health services in th e  case o f a nuclear war. In  A nnexes 4 and 5 
w e find detailed inform ation on th e  health effects on individuals and h ea lth  services o f the 
Hiroshim a and Nagasaki bom bs.
In view  of its high significance th e  book deserves to  be translated in to  various languages, 
s о as to be m ade accessible to  physicians and health  workers all over th e  world.
L. C s e l k ó
A partheid  and Health. W H O, G eneva 1983. 258 pages, 29 tables, 2 figures. Price: Sw. Fr. 29.—
This book claim s particular interest. Its subject, dealt w ith in tw o  p arts, is very tim ely. 
B y  taking a look at th e  health  problem s posed b y  apartheid, it gives plenti o f  food  for thought 
and discloses appalling facts.
Part I. Report o f  an international conference held at Brazzaville, People's Republic of 
the Congo, 6-—20 November, 1981
Chapter 1, serving as introduction, is follow ed by the opening sta tem en ts from the 
follow ing participants: C. A. A. Quenum E, R egional Director for A frica, W H O ; A. Nzo, 
Secretary-General o f the African N ational Congress; I. N . Pokela, Chairman o f  th e  Pan Afri­
canist Congress o f Azania; I. Idongo, Secretary o f  H ealth , South W est Africa P eop le’s Organi­
zation; and H. Mahler, Director General, W H O. Chapter 3 is centred on th e  m ain  them es of 
th e  Conference which m ay be listed w ithout further com m entary: H eath  or Apartheid? 
A nalysis o f the child care delivery system  in apartheid South Africa; A partheid  and maternal 
and child health; Apartheid and worker’s health; Apartheid and m ental health . The dis­
astrous effects o f racial discrim ination on the health  situation of the b lack population are 
highlighted by all sta tem en ts and com m ents. The recom m endations in Chapter 4 span a wide 
range and extend to direction, coordination and m anagem ent, health sy stem  infrastructure 
as w ell as technology. In Chapter 5, th e  m ain lines o f the strategy for “ h ea lth  for all by  the 
year 2000” in the African R egion and action against racial discrim ination are pointed out. 
This is followed by a detailed  plan o f action. I ts  structure is consistent w ith  th e  m ain lines 
o f W H O-s general program m es. Chapter 6 contains the Brazzaville D eclaration  in  its full 
te x t. Section I closes w ith  tw o annexes connected w ith  the programme o f th e  Conference.
Part II is an analytical report to  the Conference on the health  im plications of racial 
discrim ination and social inequality . E xplanatory com m ents upon som e d efin ition s are given. 
Chapters 1— 2 give inform ation on th e  nature o f apartheid, backed by sta tistica l figures and 
th e  origins o f South African society , and its hea lth  care system . Chapter 3 deals w ith the 
liv ing  conditions and pattern  of disease; it  presents general and special m orb id ity  and m ortality  
figures reflecting a sadly disadvantageous situation  of the black versus w h ite population . Some 
appalling exam ples: there were 16-tim es more deaths due to infectious d iseases am ong the 
coloured than am ong th e  w hite population. Tuberculosis accounted for 1/3 o f  th ese  deaths. 
The death rate of infectious diseases is 12-tim es as high in the coloured th a n  in th e  white
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p op u la tion  o f advanced age-groups, an d  tuberculosis is responsib le for 80% of these deaths. 
T he figu res o f  maternal and child h ea lth  fare in no w ay b etter . Other diseases also show a 
str ik ing prevalence in the coloured population . Similarly alarm ing figures emerge from Chap­
ter 4 w h ich  deals w ith the ex ten t a n d  effect of m alnutrition. T his is also true for Chapters 
5— 6, d iscussing the im pact o f  apartheid  on psychosocial develop m en t and occupational health  
and d iseases. The aspects o f th e  s itu a tio n  outlined above are reflected  in  the health services 
dealt w ith  in  Chapter 7, giving a su rv ey  o f the politics o f h ea lth  care. In conclusion, the s itu ­
ation  o f  disease and health care in  S o u th  Africa is view ed in th e  ligh t o f the Constitution o f  
th e  W orld  H ealth Organization.
L. C s e l k ó
R. H . B a n n e r m a n n , J . B u r t o n , C h ’e n  W e n -C h i e h : T rad itiona l M edicine and Health Care 
Coverage. W H O , Geneva 1983. 342 p ag es, 4 tables, 1 figure, 22 photos. Price: Sw. Fr. 35.—
T his book has the invaluab le  m erit o f providing clear, com prehensive and thorough­
going inform ation in 28 well-arranged chapters on the various ty p es  o f  traditional m edicine  
w hich are still in practice on a larger or lesser scale in various parts o f  the world.
P a rt I takes a general look at th e  system s and practices in  traditional medicine. Chapter 
1 g iv es an excellent introduction in to  the new discipline o f “ ethnom edicine” . In Chapter 2, 
w hich deals w ith traditional m ed icin e  in  Africa, the role o f th e  traditional healers and the  
variou s practices o f traditional m ed icin e  are given due consideration . Chapter 3, on trad i­
tio n a l m ed icine in Latin Am erica, cen tres on two subjects: hum oral theory and therapy, in  
w hich c o n te x t  the meaning o f “ H o t”  and “ Cold” are exp lained , and on spiritism. Chapter 4 
exp la in s th e  various aspects o f  A y u verd ic  medicine, w hich has spread from the Indian sub­
co n tin en t. T he doctrine of m edical astrology is also given  consideration . Chapter 5 provides 
in form ation  on the basis concepts and  practice of the U nani sy stem  o f health, referred to  also 
as G raeco-A rab, or Arab m edicine. T h is system  had its roots in  th e  Arab civilization and its  
practice  has been revived in th e  In do-P ak istan  subcontinent. Chapter 6 takes a look at th e  
p ast and  present o f traditional Chinese m edicine and view s it  in  th e  framework of the present 
hea lth  system . Acupuncture and m oxibustion  are dealt w ith , and th e  lines of research in  
acupu ncture are pointed out in  Chapter 7. Chapter 8, on trea tm en t o f fractures and so ft  
tissu e  in juries by integrated m eth o d s o f  traditional Chinese and W estern Medicine claim s 
particu lar interest. Chapter 9 rev iew s th e  history, types and organization  of modern allopathic  
m edicine and public health, and ad v o ca tes a closer in tegration  o f  traditional m edicine w ith  
a llop ath y . In  Chapters 10— 13 we f in d  information of exem plary objectiv ity  on hom eopathy, 
n a tu ro p a th y , divination and E xorcism , and Hypnosis. Chapter 14 is on practices of yoga and  
m ed ita tio n . Chapter 15 describes th e  practices of traditional m idw ifery and contraception, 
poin tin g  to  lines of research and to  w a y s of integration w ith  m odern health services. In Chap­
ter 16 se lected  individual therapies such as antroposophical m edicine, autogenic train ing, 
breath in g , biofeedback, hydrotherapy, etc., are considered.
P a rt II  deals w ith herbal m edicines and herbal pharm acopoeias. Chapter 17 covers 
th e  endangered plants used in tra d itio n a l medicine, providing a l is t  o f  these  plants. Chapter 18 
is on  th e  N A PR A L E R T  system . T his is  a computerized data  b a se  on th e  chem istry and phar­
m aco lo g y  o f  natural products and h as been given th e  acronym  N A PR A L E R T  (N atural 
P rod ucts A L E R T ) Chapter 19 ta k e s  a look at the s itu aation  o f phytopharm acology and  
p h y to th era p y , medical plants, p lan t drugs and utilization o f loca l p lant resources in prim ary  
health  care.
P art II I , in Chapters 20 to  25 , g ives a profile o f th e  trad ition al practices in the W H O  
regions, i.e . in the six principal reg ions, w ith close details on  th e  situation  in the individual 
countries.
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Part IV covers th e  organizational and legal aspects o f traditional m edicine. In Chapter 
26, the organizational task s are outlined. In  Chapter 27, legal aspects, patterns o f legislation  
concerning traditional m edicine and policy options in regulating the practice o f traditional 
m edicine are discussed in  close detail. Chapter 29 g ives a brief but none the less interesting, 
closing review of the place o f traditional m edicine in  prim ary health care.
L. C s e l k ó
Smoking Control Strategies in  Developing Countries. Technical Report Series No. 695. W HO, 
G eneva 1983. 92 pages, 1 figure. Price: Sw. Fr. 8.—
The m eeting held b y  the W HO E xpert C om m ittee on Sm oking Control Strategies in  
D eveloping Countries in Geneva from 22 to  27 N ovem ber is reported in this publication.
Part 1, the Introduction , gives an exhaustive explanation  of th e  reasons for discussing 
the sm oking problem  of th e  developing countries a t a h igh level. Though th e  book is prim arily  
addressed to developing countries, the problems and task s it deals w ith also apply to  developed  
countries.
Part 2, entitled The rationale for sm oking control, contains a w ealth of inform ation  
on the epidem iological and econom ical aspects, the prevalence of sm oking including th e  tradi­
tional and other tobacco habits and their high r isks, as also on the constituents o f smoke. 
The growth of tobacco industry is seen against the background of declining food consum ption  
in som e of the developing countries, thus raising b lu n tly  the alternative, “ food or tobacco” . 
It has been further found th a t smokers have higher annual dem ands on m edical services than  
non-smokers. On th e  evidence of a W H O -study, in  Canada, the health care costs connected  
with sm oking could be estim ated for a certain tim e interval at U S S 24 000 m illion, to  which  
another 15 000 m illion due to  loss of productivity and absenteeism  from work has to  be added. 
In the framework o f Part 3, entitled Sm oking Control in Developing Countries, th e  objectives 
are defined, the control programmes outlined, guidelines for data-collection are affered, public  
inform ation and public education programmes are provided, th e  role o f m edia being em pha­
sized. The necessity for and th e  chances of, restrictive m easures and legislation  are pointed  
out. The activities serving the primary goal, the cessation  o f sm oking are sum m ed up. Part 4 
points to  the lines o f research. In Part 5, on international action, the activ ities o f W HO as 
well as o f other organizations are considered. Part 6 sum s up th e  recom m endations. The book  
closes w ith a list o f  118 references. There are tw o annexes. The first recapitulates th e  recom ­
m endations of previous W HO expert com m ittees on sm oking. The second sum s up the counter­
ing argum ents against th e  control o f smoking.
L. C s e l k ó
M. J. S u e s s , J. W. H u i s m a n s : Management o f  H azardous Waste. W HO R egional Publications, 
European Series N o. 14. W H O, Copenhagen 1983. 101 pages, w ith 4 tables, 2 figures. Price:
Sw. Fr. 10.—
“ During the past decade, the public has becom e increasingly aware o f one o f  th e  major 
consequences o f industrial developm ent —  the q u an tity  and diversity o f th e  hazardous w aste  
it  generates. At th e  sam e tim e, awareness has been growing that certain disposal m ethods 
used for such w aste m ay pose risks to hum an health  and the quality o f environm ent. Several 
countries have m ade efforts to  develop effective technologies and adm inistrative procedures 
for hazardous w aste m anagem ent.”
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T he brief introduction of th is  very tim ely  book is follow ed by policy guidelines in 
Chapter 1, in  which general princip les and som e specific aspects are pointed out. Chapter 2, 
w hich defin es th e  problem and sets criteria, falls into  th e  following subdivisions: Criteria for 
id en tify in g  hazardous waste; E x clu sive  and inclusive lis t o f hazardous waste; W aste hazard­
ous in  o n ly  part o f  the m anagem ent cycle; E xam ples o f hazardous waste; Other w aste-arisings. 
Chapter 3 form ulates the legal and adm inistrative requirem ents. In  Chapter 4 th e  basic lines 
o f p lan n in g  are set out. Chapter 5 deals w ith  the tasks of collection, transport and storage, 
and C hapter 6 w ith those o f m anagem ent, treatm ent and disposal. Chapter 7 gives recom ­
m end ation s for enforcement, Chapter 8 offers guidelines for transfrontier transport. A n nex  1 
gives th e  essentia l references. A n nex  2 lists th e  non-hazardous w astes, A nnex 3 gives exam ples 
o f hazardous w aste. In A nnex 4 there is a lis t o f th e  typ es o f solution and w aste-w ater from  
m etal fin ish in g . In Annex 5 we fin d  th e  conclusions and recom m endations o f th e  W orking  
Group on  Guidelines for the Control o f  T oxic and other H azardous Chemical W aste, Garmisch- 
P artenk irch en , 17— 20 March, 1981.
O n e  o f  th e  principal m e r its  o f  th e  b o o k  is  i t s  clear, lo g ica l arran gem en t. I t  p ro v id es  
in v a lu a b le  g u id elin es for th e  m a n a g e m e n t o f  hazard ou s w a ste .
L .  C s e l k ó
R ecom m ended Health-based L im its in  Occupational Exposure to Pesticides. Technical R eport 
Series N o . 677. W HO, G eneva 1982. 110 pages, 16 tab les, 1 figure. Price: Sw. Fr. 8 .—
T h is is a report of a m eeting o f  th e  W HO Stu dy Group held in  G eneva from  15 to  
22 J u n e, 1981.
In  P a rt 1 serving as in troduction , th e  purpose o f th e  report is outlined and th e  proce­
dures, ev a lu a tio n  of the studies, th e  relationships o f  exposure-effect and exposure-response  
are d iscussed , and conversion factors applied to express th e  concentrations o f th e  vapours 
o f  th e  su bstances in the air in  term s o f  m illigram m s per cubic m etre are given. E xp erts are 
in v ited  to  provide WHO w ith  an y  additional data th a t m ay  serve for re-evaluation o f  th e  
recom m ended health-based exposure-lim its o f the four substances m alathion, carbaril, BH C  
(L indane) and dinitro-o-cresol, w h ich  form  the actual subject o f th e  report. Parts 2— 5 cover  
these  four pesticides in close detail, discussing invariab ly in  the sam e order their properties, 
uses, h e a lth  hazards, assessm ent o f  exposure, relationship betw een exposure and effect, con­
c lusions, recom m endations, research possibilities. These four chapters contain essentia l in ­
form ation  for specialists engaged in  th is field . Part 6 gives recom m endations for research, 
em phasisin g  th e  health of agricultural workers, th e  need for epidem iological data , anim al 
exp erim en ts, m etabolic studies, proper surveillance and th e  special problems o f developing  
countries.
E a ch  chapter is exhaustively  referenced. The te x t  is backed by clear, instructive tables.
L. C s e l k ó
H orm onal B iology o f Endometrial Cancer. E dited by G. S. R i c h a r d s e x  and D. T. M a c L a u g h l i n .
G eneva 1978. 187 pages.
In  th is  volum e the results o f  research were discussed at a conference held under the  
sponsorship o f UICC in Geneva betw een  6 and 10 February, 1978, and the conclusions have  
been in tegrated  by the editors into  a coherent whole. The topics o f th e  conference were str ictly  
confined to  th e  hormonal aspects o f  endom etrial hyperplasia and cancer.
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I t  begins w ith  introductory notes on the risk factors of endom etrial cancer, including  
th e  prevalence o f oestrogenic effects, the possible role o f androgens, and on  th e  progression  
o f  endom etrial hyperplasia, as well as o f  th e  m alignant processes o f epithelial origin. I t  deals 
exhaustively  w ith  the intracytoplasm ic proteins o f high specific horm one-binding affin ity , 
w ith  th e  quantitative changes in th e  receptors and w ith  oestradiol-17-beta dehydrogenase  
induction , considering also the m olecular m echanism  o f action of oestrogen and progesterone  
and the form ation of potentia lly  steroid-specific products.
T he quantitative changes of th e  receptors and their characteristics in  case o f  hyper­
plasia and carcinoma are described in detail. I t  is poin ted  out that oestrogenic a c t iv ity , unless 
interrupted by progesterone, will result in  hyperplasia or carcinoma. P rogesterone inhibits 
oestrogenic a c tiv ity  by blocking the function  o f th e  receptor system  on th e  one h an d , and b y  
inducing th e  a ctiv ity  o f the enzym e oestradiol-dehydrogenase, on the other. This effect m ay 
result in a rapid regression, or a com plete disappearance, of hyperplasias, dysp lasias, even  
o f carcinom as, particularly o f  those o f differentiated type. It is also em phasized th a t the  
gestagens, despite their benefits, provide no com plete solution to the therapeutic  problems 
o f endom etrial cancer.
Cervical carcinoma responds to  progesterone in  one third of the cases and th e  responsive  
tum ours are prevalently o f w ell differentiated types. Undifferentiated tum ours respond in no 
m ore than 15% o f the cases. For th is reason additional use o f progesterone is advocated  by  
th e  authors in all cases in w hich chem otherapy is justified .
T he trends o f future research are pointed out in th e  closing chapter.
The monograph gives an excellent sum m ary o f  the successive stages o f  th e  process 
resulting in  endom etrial cancer, covering also the horm onal aspects o f  th is tum ou r, as also 
the results of, prevalently biochem ical, research atta ined until 1978 in this field . I t  com m ends 
itse lf  b y  its clear arrangement, its easy  and readable language, its exhaustive  references, as 
w ell as by the large number o f its  instructive tables, to  research workers and to  all those  
seeking inform ation on the subject.
S . C s ö m ö r
Second Cancer in Relation to R adia tion  Treatment fo r  Cervical Cancer. E ditors N . E . D ay 
J. D . B o i c e  J r . Lyon 1983. Price: £ 17.50
This volum e published by an international working party of W HO on th e  irradiation  
therapy of cervical carcinoma is the 52nd num ber o f th e  serial publications o f  IA R C  (Inter­
national A gency for Research on Cancer).
This international study  o f th e  radiation therapy of cervix carcinom a is centred on 
irradiation carcinogenesis. The aim  o f  th e  program m e is to provide qu antitative  inform ation  
o f  m axim um  accuracy on th e  prevalence o f new , dose-related carcinomas form ed in other 
organs, thu s contributing to  th e  understanding o f irradiation carcinogenesis. W ith  th is  objec­
t iv e  a group of patients a num ber o f whom  had been exposed to known irradiation  doses 
were follow ed up in order to find out w hether new prim ary tumours had form ed in  other organs, 
and if so at which sites and after w hich therapeutic schem es. The observations w ere supported  
by dosim etry, pathologic evaluation  and chrom osom al studies. The findings o f new  tum ours 
were checked against the predicted prevalence of th e  respective tum ours for th e  sam e age- 
groups.
T he book comprizes an introduction, a list o f th e  participants in the stu d y , description  
of m ethods, data of some cancer registers providing the basis for the study, rad iation  exposure 
o f other organs involved by irradiation o f the uterine cervix, a sum m ary and appendix  with 
com prehensive data in a tabulated  form.
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T he data  of 15 cancer registers have been studied separately  and also on a com parative  
basis. In  consideration of th e  differences between the various form s of treatm ent, the patients  
were d iv ided  into tw o groups according to whether or n o t  th e y  had received radiotherapy. 
In  v iew  o f  th e  inconsistency o f  stag in g  during the long fo llow -up  period, only “ invasive” and 
“ n on -in vasive” groups were d istin gu ished . The tim e of produ ction  o f the second, new  prim ary  
carcinom a was correlated to  th e  t im e  of diagnosis o f  th e  cervical carcinoma. I f  no second  
carcinom a had been form ed, th e  t im e  of death or of th e  la st follow -up was considered. The 
data lis ted  in  a tabulated form  o f  consistent arrangement form  th e  bulk of the book. A histor­
ical rev iew  of the recording system s and of data-collecting accom panying the tables m akes 
the interpretation  of bare data  easier and the book m ore readable.
From  th e  chapter provid ing  a comprehensive rev iew  i t  emerges that the data o f more 
th an  180 000 patients w ith  cerv ica l cancer have been analysed . The process of 91 000 had 
attained th e  invasive stage and 87 000 of these patients had  received radiotherapy. Carcinoma 
in  situ  w as found in 84 000 cases. T he years o f follow -up of th e  irradiated patients to ta lled  
approxim ately  625 000, and 10 years after diagnosis o f  th is tum our the total figure was 
180 000 years. The average period o f follow-up was 7.1 years. In  th e  patient m aterial studied  
th e  production  of a second carcinom a w as observed in  3 324 o f th e  irradiated cases, as against 
the predicted  number o f 3 063 in  an age-matched population . I t  was a tumour of th e  lung, 
o f gen ita l regions, of bladder and rectum  which accounted in  th e  first place for the difference, 
but th e  differences for th e  occurrence o f tumours of oral ca v ity , oesophagus, small in testine, 
pancreas, for m esenchym al tum ou rs and for acute and chronic leukaem ia were also significant. 
I t  was prim arily breast cancer w h ich  had an incidence low er than  predicted. P ulm onary  
cancer w as of equally high incid en ce in  the non-irradiated and in  th e  irradiated cases, as also 
in th e  ease o f carcinoma in situ . Interpretation of th e  figures requires caution, since in the  
production  o f pulm onary carcinom a other carcinogenic factors (e.g. sm oking) m ay also be 
involved .
I t  is concluded from  th e  resu lts that the risk of a second carcinom a involved by irradia­
tion  o f  th e  cervic scarcely exceed s th e  predicted incidence o f  th e  respective tum ours; in  other  
words, th e  high radiation exposure in  cervical cancer scarcely  adds to the hazard o f a second  
carcinom a. T he sites o f production  o f  a new carcinoma, as w ell as the tim e elapsed since the  
irradiation, m ight be com patib le  w ith  a possible role o f  earlier radiotherapy in ind ividual 
cases. I t  is em phasized, how ever, th a t  exposure to m oderate or major radiation doses (over  
100 rad) carries an increased hazard o f a second carcinom a, particularly o f bladder, rectum , 
bones, connective  tissue, u ter in e  corpus, ovaries, sm all in testin e , kidney, as also of m ultiple  
m yelom a. Ovarian irradiations ha v e  reduced the risk o f breast cancer before the age o f 40 b y  
60%  and even  beyond the age o f  50 b y  20%.
T he authors present h ig h ly  challenging aspects w ith o u t th e  claim of solving th e  prob­
lem s at issue. I t  is felt th a t th e  possib le role of radiation doses, sm oking, history, social sta tu s  
and o f other factors in  the produ ction  o f a second carcinom a has to  be established in  th e  light 
of further studies.
T he book will be o f particu lar interest to oncologists and gynaecologists.
S. C s ö m ö r
Directory o f  On-going Research in  Cancer Epidem iology. E d itors C. S. M u i r , G. W a g n e r .
L yon  1984. Price: £ 18.—
This volum e, the 62nd num ber in this series is a jo in t  publication by the W H O -spon­
sored International A gency o f  Cancer Research and th e  Germ an Cancer Research Centre.
I t  falls into two d istin ct parts. The first provides concise inform ation, rem iniscent o f 
the sty le  o f  E xcerpta M edica, on  1213 fields o f research, condensed into 466 pages. I t  also
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considers the keywords, th e  sites o f the respective tum ours, the start and possible completion 
o f  the studies.
From  the statistical figures given in the introduction it em erges th a t in  the framework 
o f research in 1984 the new subjects have attained a proportion o f 16.5% , th is figure having 
shown a declining tendency since 1980. Between 1976 and 1980 new subjects o f  research were 
increasing in number. This part gives a global review representing th e  research teams of 
61 countries.
In the second part w hich for the reader is no less im portant, inform ation is grouped 
under the following aspects: nam e of authors in  alphabetic order, keyw ords, sites of the 
tum ours, chemical com pounds under study, m ethods used, occupations under review. Sub­
sequently the research team s of the various countries, th e  addresses o f  th e  cancer-registers 
based on various populations are listed for th e  facilitation of contacts betw een  the research 
centres all over the world.
This well-arranged, carefully edited book m eets its objective: it w ill be indispensable 
to  all those seeking overall inform ation on international research in cancer epidemiology. 
To-day there are certain ly reliable inform ative services organized b y  th e  various centres 
engaged in cancer research, but this volum e, as an aid on the bookshelf, is unique in its own 
kind.
S. C s ö m ö r
Laboratory Decontamination and Destruction o f Carcinogens in  Laboratory. W astes: Some 
Hydrazines. IARC Scien tific  Publications No. 54. Lyon 1983. 87 pages. Price: £  7.95
Some hydrazines have  carcinogenic, som e others, antineoplastic properties. The wastes, 
even  though of sm all qu antity , formed in th e  course of laboratory operations, m ust be decon­
tam inated before disposal. In  the pertinent literature we find but sparse inform ation on the 
destruction of carcinogenic w astes, and even the published procedures lea v e  som e doubts 
about the reliability o f testing . The procedures discussed in th e  book h ave been developed 
for small quantities, but are adaptable to m assive w astes as well.
Hydrazine, m onom ethylhydrazine (MMH), 1 ,1-dim ethylhydrazine (U D M H ) and 
1,2-dim ethylhydrazine (SM DM ) have been found carcinogenic to  laboratory anim als (dogs, 
m ice). They are tox ic  to hum ans, but their carcinogenecity has not been confirm ed. Pro­
carbazine has been studied for carcinogenecity in mice.
After a review of th e  analytical procedures the degradation techniques are described. 
The explosion hazards obviously  exclude the use of ashing m ethods. For th e  elim ination of 
hydrazine wastes th e  follow ing treatm ents are recommended.
1) potassium  hydroxide solution of a nickel-alum inium  alloy;
2) sulphuric K -perm anganate;
3) K-iodate;
4) hypochlorite.
All procedures are described in detail. The efficiency o f all these  procedures attains
99% .
The annexes list the chem ical and physical constants o f the hydrazines, give the details 
o f the essential biological and chem ical procedures for the degradation o f hydrazine and pro­
v ide a bibliography.
The publication will be o f use, in addition to research workers dealing w ith  products 
o f  this kind, also to those being in charge o f the disposal o f such m aterials.
K. J o b s t
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L aboratory  Decontamination and D estruction  o f Carcinogens in  Laboratory W astes: Som e N- 
N itrosam id es. IARC Scien tific  P ub lica tion s No. 55. L yon 1983. 65 pages. Price: £  6.95
B io log ica l and biochem ical investigation s concerned w ith  th e  pathom echanism  of  
carcin ogen esis have made ex ten siv e  u se  o f N-nitrosam ides. In  th e  publication dealing w ith  
th ese  com poun ds (IARC SP  N o . 43) variou s m ethods have been  recom m ended for the decon­
ta m in a tio n  o f laboratory w astes, an d  th ese  methods were expected  to  be practicable w ith  
N -n itrosam id es as well. The experim en ta l results have, how ever, show n th a t th e  procedures 
in  q u estio n , though being su ited  for th e  degradation of N -n itrosam ides, g ive  rise at th e  sam e 
t im e  to  th e  formation of harm ful m utagen ic  compounds. This m akes direct application of 
th e  m e th o d  unsafe, even in  th e  case  o f  related compounds.
T h o u g h  it is uncertain w h eth er  and how far the N -n itrosam ides under stu dy  occur in 
our en v iron m en t, some of their rep resentatives are used in  diazoalkane synthesis [(N-nitroso- 
N -e th y lu rea  (N N U ), N -n itroso-n -m ethylurea (NM U)], in  cancer therapy or in biological 
research (bischloroethylnitrosourea an d  l(2-chloroethyl)3-cyclohexyl-1-nitrosourea).
M N U  and E N U  if applied in  adequ ate  doses produce tum ours in  practically  all organs 
of la b o ra to ry  animals. I t  is typ ica l o f  th ese  compounds to  produce tum our in  the brain and  
th e  n erv o u s system  and prevalently  to  a ffec t young animals. T he carcinogenicity o f N-nitroso- 
N -m eth y lu reth a n e  (MNUT) and o f  N -n itroso-N -ethylurethane (E N U T ) has been also dem on­
stra ted . I t  is not known w hether th e  N-nitrosam ides are carcinogenic to  hum ans as well.
D egradation  of the N -n itrosam ides w ith  acid or alkaline so lutions is unadvisable be­
cause o f  th e  production of to x ic  carcinogen ic gases (diazom ethane). The recom m ended proce­
dures m a y  b e  summed up as fo llow s.
1) so lutions of sulphanylic acid  hydrochloride;
2) hydrochloric iron filings;
3 ) acid  potassium  perm anganate;
4 )  denitrosilation w ith  brom ohydrogen.
E a c h  procedure is described in  detail. Destruction o f N -n itrosam ide contained in  the  
sam p les a tta in s 99.5% . The d egradation  products of som e o f th e  com pounds exam ined are 
m u ta g en ic  to  strains TI530 and T I535  o f  Salmonella typh im urium , depending on the decon­
ta m in a tio n  m ethod used.
T h e  Appendix lists th e  nom enclature of the m ost com m on N -nitrosam ides, their 
p h y sica l and  cmical properties and g iv es a list of references relating  to  th e  biological and 
chem ical decontam ination m ethods.
T h e  publication is essential to  b io logists engaged in  experim ental oncology, as well as 
to  ch em ists  and laboratory workers dea lin g  w ith N -nitrosam ides.
K .  J o b s t
Acta Medica Hungarica 42, 1985
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American Cancer Society
Eleanor Roosevelt
International Cancer Fellowships
The International Union A gainst C ancer, with funds provided by the  A merican 
C ancer Society, will aw ard fellow ships for research on cancer.
The aw ards will be gran ted  to experienced  investigators who have dem onstrated  
the ir ability for independent researc h  and who wish to broaden the ir experience 
by a period of study at a single institution in another country.
Fellowships will be gran ted  only to  perso n s  on the staff of universities, teaching 
hospitals, research  laboratories or sim ilar institutions.
Awards will be m ade to investigators who are  devoting them selves e ither to the 
experimental or the clinical a sp e c ts  of ca n cer research.
Fellowships will not be  g ran ted  to  p ersons  who wish to  perfect the ir training in 
m ethods of cancer detection  o r in therapeu tic  techniques, o r who wish to  visit 
briefly several institutions ab road .
The duration of fellowships will be one year but in special c ircum stances this 
period may be longer or shorter.
The stipend will be based  on the  cu rren t salary of the applicant and the salary of 
an investigator of com parable experience  in the place where the  applicant 
expects to study.
An allowance will be m ade tow ards the co s t of travel of the fellow and  of those 
dependan ts who will accom pany him.
The deadline for receiving applications and supporting documents Is 1 October. 
Successful applicants may begin their Fellowship at any time during the twelve 
months’ period beginning 1 May.
Application forms and additional inform ation may be obtained from:
International Union Against Cancer
3, rue du Conseil-Général 
1205 Geneva 
Switzerland
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The Yamagiwa-Yoshida 
Memorial International 
Cancer Study Grants
T h e  Y a m a g i w a - Y o s h i d a  M e m o r i a l  I n te r n a t io n a l  C a n c e r  S t u d y  G r a n t s  a r e  f u n d e d  b y  t h e  
J a p a n  N a t i o n a l  C o m m i t t e e  f o r  t h e  U I C C  w h ic h  r e c e iv e s  s t r o n g  f i n a n c i a l  s u p p o r t  f r o m  th e  
O l y m p u s  O p t i c a l  C o m p a n y ,  L td , in  T o k y o .  T h e s e  S t u d y  G r a n t s  a r e  a d m in i s t e r e d  b y  th e  
I n t e r n a t i o n a l  U n io n  A g a i n s t  C a n c e r .
T h e y  a r e  d e s i g n e d  to  e n a b l e  in v e s t i g a t o r s  o f  a n y  n a t io n a l i ty  t o  g a i n  e x p e r i e n c e  in , o r  m a k e  
c o m p a r a t i v e  s t u d i e s  o f , s p e c i a l  t e c h n i q u e s  in  b o th  t h e  b io l o g i c a l a n d  c l i n iq u e  a s p e c t s  o f  
c a n c e r  r e s e a r c h .
T h e  s t u d y  g r a n t s  w ill n o t  b e  a w a r d e d  f o r  t h e  p u r p o s e  o f  v is i t in g  a  n u m b e r  o f  in s t i tu te s  o r  
o f  s o l e l y  p a r t i c i p a t in g  in  c o n g r e s s e s ,  c o n f e r e n c e s ,  a n d  s y m p o s i a .
T h e y  w ill b e  a w a r d e d  fo r  p e r i o d s  n o t  e x c e e d i n g  9 0  d a y s .
E a c h  g r a n t e e  w ill r e c e iv e  a  t r a v e l  a l l o w a n c e  to w a r d s  t h e  c o s t  o f  a  t o u r i s t / e c o n o m y  a i r  f a r e ,  
a n d  a  l iv in g  a l l o w a n c e  to w a r d s  t h e  c o s t  o f  b o a r d  a n d  l o d g i n g .  N o  a l l o w a n c e  w ill b e  p a id  
f o r  d e p e n d e n t s .
T h e  c l o s i n g  d a t e s  f o r  r e c e i p t  o f  a p p l i c a t i o n s  w ill b e  3 0  J u n e  o r  3 1  D e c e m b e r  o f  e a c h  y e a r .
S u c c e s s f u l  a p p l i c a n t s  w ill b e  n o t i f i e d  w i th in  9 0  d a y s  o f  e a c h  c l o s i n g  d a t e .  S tu d y  G r a n t s  
m u s t  b e  a c t iv a t e d  w ith in  1 8 0  d a y s  o f  t h e  d a t e  o f  n o t i f ic a t io n .
A p p l i c a t i o n  f o r m s  â n d  a d d i t io n a l  i n f o r m a t i o n  m a y  b e  o b t a i n e d  f r o m :
INTERNATIONAL UNION 
AGAINST CANCER
INTERNATIONAL UNION AGAINST CANCER 
UNION INTERNATIONALE CONTRE LE CANCER
Fellowships and Personnel Exchange
S ynopsis  of the three p ro jec ts  
adm in istered  by the U ICC
— American C ancer Society-Eleanor Roosevelt 
International Cancer Fellowships
— Yamagiwa-Yoshida Memorial International 
C ancer Study Grants
— International C ancer Research Technology 
Transfer Project (ICRETT)
A d d itio n a l in fo rm a tio n  an d  ap p lica tio n  fo rm s  m ay  be o b ta in e d  fro m  :
In te rn a tio n a l U n ion  A gain st C ancer - 3, rue du C onseil-G énéral - 1 2 0 5  G eneva (S w itze rlan d ) 
T e lep h o n e  (41 22) 20  18 11 T elex  4 2 9  7 2 4
International Cancer Research 
Technology Transfer Programme
(ICRETT)
i*
/O'I
DATA BANK 
(ICROB)
!
t
The International Union Against Cancer, with funds partly provided 
by the International Cancer Research Data Bank (ICRDB) of the 
National Cancer Institute of the United States of America, and partly 
by the International Union Against Cancer, will award “International 
Cancer Research Technology Transfer” grants for research on cancer.
The purpose of this programme is to promote direct and rapid person- 
to-person transfer of information about new or improved techniques or 
methods between investigators located in different countries who are 
working in areas of basic, clinical or behavioural research in order to 
further the progress of cancer research.
The available funds are designed to permit investigators of any 
nationality* to visit a research centre or centres abroad for a period 
not exceeding 28 days. The grant will be allocated towards travel and 
living expenses.
The selection of applicants will be on a continuous basis and the results 
will be communicated as rapidly as possible.
Additional information and application forms may be obtained from:
accordance with US Federal Regulations, this Programme is not open to employees of US Government
INTERNATIONAL UNION AGAINST CANCER
rue du Conseil-Général 3, 1205 Geneva
Switzerland
Agencies.
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UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
D E PA R T M E N T  OF RADIOLOGY
RADIOLOGY POSTGRADUATE EDUCATION
PRELIMINARY PROGRAMS FOR COURSES
IN T E R V E N T IO N A L , MRI A N D  N EU R O R A D IO L O G Y  
January 13 — 17, 1986 — Fairm ont H otel, San Francisco
DIAG NO STIC RADIOLOGY SE M IN A R S  
January 20 — 21, 1986 — Camino R eal, Ix ta p a , Mexico
DIAG NO STIC RADIOLOGY SE M IN A R S  
February 24 — 28, 1986 — Park City, U tah
DIAG NO STIC IM AGING: 1986
March 9 —14, 1986 — W aiohai H otel, K auai, Hawaii
A DVANCES IN  URO RADIO LO G Y
March 22 — 23, 1986 — Fairm ont H otel, San Francisco
THORACIC IM AGING U PD A TE 1986
April 17 - 1 9 ,  1986 — H yatt R egency H otel, M onterey
P R IN T E D  IN  H U N G A R Y  
A k adém iai K iadó és N yom d a, B udapest
IN FO R M A TIO N  FOR AUTH O RS
Acta M edica H ungarica  is published under the auspices o f the H ungarian Academ y o f  Sciences. 
Manuscripts and editorial correspondence should he sent to the editorial office: Й -1450 B ud a­
pest 9, P .O . B o x  67.
Original articles dealing with clinical and experim ental m edicine will be accepted w ith  the  
understanding th at th ey  have not been and will not be published elsewhere and are subject  
to editorial revision.
Form  o f  m anuscripts
Two copies o f the manuscript typew ritten  double-spaced w ith  margins at lea st 4 cm  
wide should be subm itted . Pages should be numbered consecutively. The first page should  
contain (1) the title  o f the paper (2) the in itia ls and first nam e(s) o f  the author(s), (3) nam e o f  the  
institu tion  where the work was done, (4) nam e and address o f the author to whom  correspon­
dence and offprint requests should be addressed — this will appear as a footnote; (5) an abstract 
not exceeding 250 works which states the purposes of the study, the m ain findings and principal 
conclusions. B elow  the abstract provide 3 to 10 keywords that will assist indexers in  cross­
indexing the article.
The tex t o f  the paper should be d iv ided  into sections w ith  the headings: In trod uction , 
Materials (P atien ts) and Methods, R esu lts, D iscussion, References.
Unusual abbreviations should be identified in an alphabetical list typed after  th e  ab­
stract and keywords.
Drugs m ust be referred to by their W HO code designation (Recom m ended In tern a tio n ­
al Nonproprietary Nam es); use o f proprietary nam es is unacceptable.
The international system  of un its (SI) should be used for all measurem ents.
References
These should be cited in the te x t  as numbers in square brackets. The list o f  references 
should contain in alphabetical order o f  the first authors’ nam es the following: auth ors’ last 
nam es w ith initials; for journal articles the title  o f the paper(lower case), journal title abbreviated  
according to the sty le  used in Index M edicus, volum e number, inclusive page num bers, year  of 
publication in parentheses; for hooks the title  (upper and lower case), publisher, place and date  
o f publication. O nly manuscripts accepted for publication m ay be included in th e  reference  
list.
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1. Stagg, B. H .,T em p erly , J. M., W yllie, J . H.: The fate o f pentagastrin. Gut 12, 825 — 829 (1971)
2. Falkner, F .: Prevention in Childhood o f H ealth Problem s and A dult Life. W H O , G eneva
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H andbook o f  Physiology. Am erican Physiological Society, W ashington 1963, pp. 65 — 79.
Tables
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w ith  Rom an num erals and have a brief specific  title. The data presented in the tab le m u st be 
logically and clearly organized and should be self-explanatory. O m it internal horizontal and 
vertical rules. Cite each table in the te x t and indicate its approxim ate ph.ee on the m argin.
Illustrations
Figures should be subm itted in  duplicate. They m ust be num bered consecutively  w ith  
arabic numerals. All figures should bear the nam e of the first author, the figure num ber and an 
arrow indicating the top. Cite each figure in the tex t and indicate its  approxim ate place on  the  
margin. I f  a figure has been published, acknowledge the original source and subm it w ritten  
perm ission from th e  copyright holder to  reproduce the material. Figure captions should  be 
subm itted typed double-spaced on a separate sheet.
Proofs and reprints
The first authors will receive (1) com m ents and suggestions o f the Editorial B oard for 
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